Bri1 gene-related dementias; A morphological and biochemical study. by Lashley, T.
280891460X 
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS
Degree  ^   Year  ,2 ^   ^   ^   Name of Author
COPYRIGHT
This is  a thesis accepted for a  Higher Degree of the  University of London.  It is  an 
unpublished typescript and the copyright is held by the author.  All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIG HT DECLARATIO N
I recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from  it or information derived from  it may be published without the 
prior written consent of the author.
LOANS
Theses may not be lent to individuals, but the Senate House Library may lend a copy 
to  approved  libraries  within  the  United  Kingdom,  for  consultation  solely  on  the 
premises  of  those  libraries.  Application  should  be  made  to:  Inter-Library  Loans, 
Senate House Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University  of  London  theses  may  not  be  reproduced  without  explicit  written 
permission from  the  Senate  House  Library.  Enquiries  should  be addressed  to the 
Theses Section of the  Library.  Regulations concerning  reproduction vary according 
to the date of acceptance of the thesis and are listed below as guidelines.
A.  Before  1962.  Permission granted only upon the prior written  consent of the
author.  (The Senate House Library will provide addresses where possible).
B.  1962-1974.  In many cases the author has agreed to permit copying upon
completion of a Copyright Declaration.
C.  1975 - 1988.  Most theses may be copied  upon  completion  of a Copyright
Declaration.
D.  1989 onwards.  Most theses may be copied.
This thesis comes within category D.
I  I  This copy has been deposited in the Library of    (L
□
This  copy has  been  deposited  in the Senate  House  Library,  Senate  House, 
Malet Street, London WC1E 7HU.
C:\Documents and Settings\lproctor\Local Settings\Temporary Internet Files\OLK8\Copyright - thesis (2).docBRI2 gene-related dementias; a 
morphological and biochemical study.
By Tammaryn Lashley
Thesis submitted for the degree of Doctor of 
Philosophy at the University of London
Department of Molecular Neuroscience
Institute of Neurology 
Queen Square House 
Queen Square 
London 
WC1N 3BG
1UMI  Number:  U5922B4
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did  not send a complete manuscript 
and there are missing  pages, these will be noted.  Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI  U592234
Published  by ProQuest LLC 2013.  Copyright in the Dissertation  held  by the Author.
Microform  Edition © ProQuest LLC.
All rights reserved.  This work is protected against 
unauthorized copying  under Title  17, United States Code.
ProQuest LLC 
789  East Eisenhower Parkway 
P.O.  Box  1346 
Ann Arbor,  Ml  48106-1346Abstract
Aspects of the neurodegenerative mechanism in AD remain unknown; therefore studies 
on alternative models of cerebral amyloidosis, such as familial British dementia (FBD) 
and familial Danish dementia (FDD) may contribute to a better understanding of the 
neurodegenerative process.  FBD and FDD are neurodegenerative disorders caused by 
mutations in the BRI2 gene. Both mutations cause elongation of the precursor proteins, 
the furin-like  cleavage  of which results  in the  formation  of amyloidogenic  peptides, 
ABri in FBD and AD  an in FDD.
Extensive  morphological  examinations  of  FBD  and  FDD  were  undertaken  using 
antibodies  recognising  ABri  and  ADan,  establishing  a  regional  distribution  of CNS 
peptide  deposits  in  either  amyloid  or  pre-amyloid  configuration  in  both  diseases, 
including cerebral amyloid angiopathy (CAA) formation.
Amyloid  associated  proteins  (AAP)  are  able  to  modify  Ap  aggregation  and  are 
implicated  in  AD  pathogenesis.  Establishing  whether  AAPs  are  implicated  in  the 
pathogenesis of other cerebral amyloidoses, AAP deposition was investigated and found 
associated  with  ABri  and  ADan  amyloid  and  preamyloid  parenchymal  lesions. 
Inflammatory mechanisms, including activation of the complement pathways, initiated 
by  Ap  deposition  strongly  are  implicated  in  AD  pathogenesis.  The  presence  of the 
complement pathways were shown in FBD and FDD,  highlighting the importance of 
chronic  inflammation  in  the  neurodegenerative  diseases.  Biochemical  analysis  of 
extracted ABri and ADan species indicates that as solubility of the deposits decrease 
heterogeneity  and  complexity  of  extracted  peptides  increases,  including  post- 
translational modification of glutamate to pyroglutamate.
2The production and cellular origin of the precursor proteins and the localisation of furin 
expression were  investigated.  Evidence  is presented that BRI2  mRNA and  furin  are 
found  in  neurons  and  glia,  suggesting  that  cleavage  of the  wild  type  and  mutated 
precursor  proteins  can  take  place  in  these  cells.  The  absence  of BRI2  mRNA  in 
cerebrovascular cells indirectly supports the drainage hypothesis of CAA.
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Chapter 1  Introduction.
1.1  Cerebral amyloidosis and neurodegeneration
Amyloidosis  is  a  term  that  covers  many  disorders  involving  abnormal  protein 
conformations  leading  to  aggregation  and  fibrillization.  A  diverse  group  of proteins 
which  are  normally  present  as  soluble  precursor  proteins  are  able  to  assemble  into 
amyloid  fibrils  by  adopting  a  p-pleated  sheet  conformation,  producing  insoluble 
deposits.  To date there are over 25  different proteins identified that are able to form 
amyloid fibrils (Westermark et a l, 1999; Revesz et al., 2003). Although these amyloid 
forming proteins are the product of normal genes, several amyloid precursors do contain 
abnormal amino acid substitutions causing an unusual potential for self-aggregation. Of 
all  the  identified  amyloid  proteins,  less  than  half are  known  to  result  in  amyloid 
deposition in the central nervous system (CNS), which can result in cognitive decline, 
dementia and stroke.
Cerebral amyloid angiopathy (CAA) is a term used to define the deposition of amyloid 
within the walls of leptomeningeal and cortical arteries,  arterioles and less frequently 
capillaries and veins (Vinters,  1987),  commonly  associated with Alzheimer’s  disease 
(AD) and Down’s syndrome (DS). Familial conditions in which amyloid is deposited as 
CAA  include  hereditary  cerebral  haemorrhage  with  amyloidosis  of Icelandic  type 
(HCHWA-I),  familial  CAA  related  to  mutations  of the  APP,  PS1  or  PS2  genes 
including hereditary cerebral haemorrhage with amyloidosis of Dutch type (HCHWA- 
D),  transthyretin-related  meningocerebrovascular  amyloidosis,  gelsolin  related  CAA 
and  the  recently  described  BRJ2  gene-related  dementias  in  the  British  and  Danish 
kindreds which form the subject of this thesis.
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CAA in AD may go beyond a contribution of ischaemia to the clinical and pathological 
manifestations of the disease, suggesting that CAA may be involved in the development 
of plaques and tangles, the pathological hallmarks of AD (Weller et a l,  1998). Clues to 
the  relationship  between  amyloid  and  neuronal  dysfunction  may  well  arise  from 
research  involving  other  mutant  peptides  in  addition  to  Ap.  Particularly  the  novel 
molecules ABri and ADan which originate from different mutations in the BRI2 gene 
and were not previously known to be related to human neurological disorders. Therefore 
different amyloid peptides are able to trigger similar neuropathological changes leading 
to neuronal loss and dementia, supporting the notion that amyloid peptides may be of 
primary importance in the initiation of neurodegeneration.
1.2  Familial British dementia (FBD)
1.2.1  Clinical features of FBD
FBD  was  first  described  by  Worster-Drought  and  colleagues  as  a  familial  presenile 
dementia with spastic paralysis (Worster-Drought et al.,  1944; Worster et al.,  1940). In 
subsequent studies FBD was referred to as an example of atypical AD (Aikawa et a l, ), 
Gerstmann-Straussler syndrome  (GSS)  (Masters et al.,  1981;  de Court & Mandybur, 
1987; Keohane et a l, ) or as a form of primary CAA and classified together with the 
Icelandic and Dutch types of HCHWA (Vinters,  1987). It was also considered to be a 
form of hereditary spastic paraparesis (Baraitser, 1990).
Following the original pedigree studied by Worster-Drought et al (Worster et a l, 1940), 
a number of additional families have been described.  Griffiths et al (1982) described 
two siblings with pathological changes that were identical to those observed in the cases 
described by Worster-Drought et al. Plant et al (1990) discovered that the two families
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were part of the same larger pedigree, by reference to a house physicians family history 
in the archive case notes of a patient seen at the National Hospital  for Neurology in 
1924.  In  1982  a  case  of  ‘familial  cerebellar  ataxia  with  amyloid  angiopathy’  was 
published by Love and Duchen.  It has long been suspected that this patient suffered 
from the same disease despite there being no report of dementia. This case has also been 
linked to  the  main Worster-Drought  family  (Mead  et al.,  2000).  A pedigree  of 372 
individuals has so far been assembled from the Worster-Drought pedigree (Mead et al.,
2000)  (figure 1.1).
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Figure 1.1: Worster-Drought pedigree (Mead et al 2000)
A second pedigree, reported in abstract form by Doshi et al  1996, has been studied in 
detail  in  an  attempt  to  find  a  common  ancestor with  the  Worster-Drought pedigree 
(figure 1.2). Only two members are affected. The family was traced back to a generation 
bom  in  1840s  but  a  link  has  not  yet  been  found.  A  third  pedigree  has  also  been
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identified  recently  with  typical  clinical  presentation  and  the  BRI2  gene  mutation  in 
affected  members.  Although  it  cannot  be  traced  at  present  to  the  Worster-Drought 
pedigree, ancestors of this and the Worster-Drought family are believed to have lived in 
the same village (unpublished data).
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Figure 1.2: Familial British Dementia - second pedigree (Mead et al 2000)
Analysis of clinical  details of 6  living  affected patients  and 35  historical  cases have 
shown a median age of onset of clinical symptoms is 48 years (range 40-60) and the 
median age of death 56 years (range 48-70) (Plant et al.,  1990) (table 1). Psychometric 
assessment early in the course of the disease has shown marked impairment of memory 
ultimately  progressing  to  global  dementia.  Many  of the  cases  developed  personality 
change  as  an  early  manifestation.  Spastic  paralysis  is  characteristic  and  is  far more 
profound  than  is  seen  in  GSS  or  in  variant  AD.  All  patients  have  progressed  to  a 
mutism,  unresponsiveness,  quadraplegia  and  incontinence  and  finally  to  a  chronic 
vegetative state.
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Case
(Worster-Drought)
Sex Age at onset of symptoms 
(years)
Age at death 
(years)
m F 40 53
m F - -
mi F - 52
m2 M 57 60
m3 F 44 54
III4 F 48 53
III5 F 48 66
III6 F 48 50
IV1 M 40+ 53
IV2 F 42 52
IV3 F 46 56
IV6 M 45 51
IV9 F 50 56
IV12 F 44 54
IV13 M 46 54
IV15 F 44 56
IV17 F 43 -
V2 F 57 63
V4 F 54 61
V7 M 50 56
V15 M 45 51
V28 F 50 55
V32 M - 52
V33 M 48 50
V41 F 56 65
V45 F 42 64
Table 1: Age of onset and age o f death of individuals affected by FBD
(Plant et al 1990)
1.2.2  Neuropathology of FBD
The neuropathological changes have been reported in detail in six historical cases of this 
condition  (Worster-Drought  et  al'.,  1944;  Worster  et  a l 1940;  McMenemey,  1952; 
McMenemey,  1970; Griffiths et al.,  1982; Love & Duchen,  1982; Plant et al.,  1990). 
The  brains  are  of  normal  or  slightly  reduced  overall  weight  with  leptomenigeal 
thickening  and  mild to  moderate  diffuse  atrophy  of both the  cerebral  and  cerebellar 
hemispheres. The cerebral cortex is relatively well preserved in slices of the fixed brain 
but the white matter is reduced in bulk, diffusely discoloured and contains small cystic 
infarcts.  The brain  stem and  spinal  cord appear normal  to the naked  eye.  The main 
histological finding is severe and widespread amyloid deposition in the walls of small
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leptomeningeal arteries and arterioles of gray and white matter.  In addition, there are 
numerous parenchymal amyloid plaques together with ischaemic white matter damage 
and  the  presence  of  numerous  neurofibrillary  tangles  (NFTs),  particularly  in  the 
hippocampus (Plant et a l,  1990).  CAA affects vessels of small  size usually less than 
100pm  in  diameter.  The vessels  affected  by  CAA  are  narrowed  or occluded  and  a 
significant  proportion  of them  show  concentric  fibrotic  thickening  of  their  wall, 
fragmentation  of the  elastic  lamina  or  the  morphological  phenomenon  of  double 
barrelling.
Two types of amyloid plaques are found: a) large plaques are about 150pm in diameter 
with a central congophilic core with radiating spicules of amyloid emerging from it and 
a finely fibrillar rim: b) small plaques with appearances similar to the core of the large 
plaques without the rim (Plant et al,  1990).  Some of the large plaques are related to 
capillaries.  The large plaques are most numerous in the dentate fascia, CA3  and CA4 
regions of the  hippocampus,  presubiculum  and  basolateral  nucleus of the amygdala. 
Perivascular  plaques  occur  chiefly  in  the  cerebral  and  cerebellar  cortex  and  white 
matter,  while  small  plaques  are  numerous  in  CA1  and  part  of CA2  regions  of the 
hippocampus and less common in the granular cell layer of the cerebellar cortex (Mead 
e ta l, 2000).
NFTs are seen in most of the remaining pyramidal neurons of the hippocampus and are 
also observed in the subiculum, entorhinal cortex, amygdala and occasionally elsewhere 
in the cortex and in the basal  nucleus of Meynert.  In the cerebellar cortex neuronal 
axonal  torpedoes,  neuronal  cell  loss  and  severe  gliosis  are  observed.  The  dentate 
nucleus also shows neuron loss and deep cerebellar white matter ischaemic lesions. In 
the  medulla there  is  long  tract  degeneration  in  the  pyramids  and  inferior  cerebellar 
peduncles,  neuron  loss  and  gliosis  in the  inferior olive  and  in the  medial  accessory
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olive. The spinal cord shows pallor of myelin staining in all columns of white matter, a 
few large amyloid plaques in grey and white matter and amyloid containing vessels.
The  white  matter  changes  are  considered  to  be  secondary  to  CAA  in  arterioles 
penetrating through the cortex to supply the white matter. The white matter changes are 
thought to contribute to the dementia. The plaque formation, NFTs and neuron loss in 
the hippocampus are sufficient to account for amnesia; cerebellar plaques and ischaemic 
lesions for the ataxia and cerebral deep white matter and spinal cord pathology for the 
spasticity  (Mead  et  a l,  2000).  Although  the  pathological  changes  were  originally 
thought to be confined to the CNS deposition of the amyloid protein in systemic organs 
has been added to the list of morphological abnormalities that occur in FBD (Ghiso et 
al, 2001).
1.3  Familial Danish dementia (FDD)
13.1  Clinical features of FDD
Stromgren  (1981)  described  9  cases  from  3  generations  of an  autosomal  dominant 
inherited disorder. The family originated from the Djursland peninsula Northwest of the 
city of Aarhus in Denmark with most members now living in Aarhus. Previously known 
as heredopathia ophthalmo-oto-encephalica (Stromgren et al.,  1970; Stromgren,  1981) 
then as familial CAA with deafness and ocular haemorrhage (Danish type). The clinical 
picture of FDD is unique with early cataract formation (around the age of 20) followed 
by deafness (around the age of 30) and progressive ataxia and dementia beginning in the 
fifth and sixth decades. Progression to death occurs within ten years following the onset 
of neurological symptoms. The ages at onset of the different symptoms are summarized 
in Table 2 (Stromgren, 1981).
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Designation in 
pedigree
Ages at onset of disturbances Age at 
death Visual Auditory Neurological Psychiatric
n-2 <46 None ? ? -73
m-i -20 -43 ? 53 62
III-2 48? 47 60 59 60
III-3 32 42 56 56 58
III-5 27 42 <50 <55 57
III-6 Congenital <28 <20 56 57
III-7 27 ? ? ? 34
IV-2 <19 25 40 <42 7
IV-5 10 28 37 54 60
Table 2: Ages of disturbance onset in FDD
An  up  to  date  pedigree  of the  family  with  FDD  is  shown  in  figure  1.3.  Case  3 
corresponds to HI-6 and Case 2 corresponds to IV-5 in table 2.  Cases 1, 2 and 3 shown 
in figure 1.3 were available for the study presented in this thesis.
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Figure 1.3: FDD pedigree (Holton et al 2002)
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1.3.2  Neuropathology of FDD
The published report by  Stromgren in  1981  described  accumulation of iipid’  in the 
blood vessel walls and parenchyma but subsequent studies have shown the presence of 
CAA in FDD (Stromgren,  1981),  in the cerebrum,  cerebellum,  spinal cord and retina 
(Bek,  2000).  The  disease  is  neuropathologically  characterized  by  a  uniform  diffuse 
atrophy of all parts of the brain and very severe chronic diffuse encephalopathy mostly 
in the cerebellum, cerebral cortex and white matter.  The presence of plaques and NFTs 
is the major histopathological finding in the hippocampus, whereas the cerebral white 
matter also shows some ischemic lesions (Stromgren et a l, 1970; Stromgren, 1981).
1.4  Genetic alteration of BRI2 in FBD and FDD
1.4.1  Identification of ABri protein and ABriPP
In 1995 Ghiso et al investigated a case of FBD with immunohistochemical techniques 
using antibodies to  known amyloid  proteins and  suggested that the disease  'familial 
cerebral amyloid angiopathy (British type),  might be due to the deposition of a novel 
amyloid  protein  (Ghiso  et  al.,  1995).  The  identification  of the  amyloid  protein  was 
achieved  by  using  a  combination  of  formic  acid  solubilization  and  gel  filtration 
chromatography from isolated leptomeningeal blood vessels (Vidal et al.,  1999).  MS 
analysis  indicated  the  presence  of a  peptide  of Mr  3,935.  Analysis  of the  protein 
sequence also revealed that the amyloid protein was a fragment derived from a larger 
precursor molecule in which the longest open reading frame predicted a protein of 266 
amino acids with a calculated Mr of 30,329.05 and a theoretical pi of 4.86. Hydropathy 
analysis  indicated the presence of a putative  single transmembrane  spanning domain 
between  amino  acids  52  and  74,  indicating  that  the  molecule  is  a  type-II  integral
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transmembrane protein with the C-terminal part being extracellular and a potential N- 
glycosylation site identified at asparagine 170.
gcgagatccctaccgcagtagccgcctctgccgccgcggagcttcccgaa  -  119
cctctcagccgcccggagccgctcccggagcccggccgtagaggctgcaatcgcagccgg  -  59
gagcccgcagcccgcgccccgagcccgccgccgcccttcgagggcgccccaggccgcgcc  -  1
atggtgaaggtgacgttcaactccgctctggcccagaaggaggccaagaaggacgagccc  60
M V K V T  F N  SALAQKEAKKDE P  
1  20
aagagcggcgaggaggcgctcatcatcccccccgacgccgtcgcggtggactgcaaggac  120
KSGEEALI I  PPDAVAVDCKD 
21  40
ccagatgatgtggtaccagttggccaaagaagagcctggtgttggtgcatgtgctttgga  180
PDDVVPVGQRRAWCWCMCFG 
41  60
ctagcatttatgcttgcaggtgttattctaggaggagcatacttgtacaaatattttgca  24 0
1  A  F   M   L   A   G   V  I  LGGAYLYKYFA 
61  80
cttcaaccagatgacgtgtactactgtggaataaagtacatcaaagatgatgtcatctta  300
LQPDDVYYCGIKYIKDDVIL 
81  100
aatgagccctctgcagatgccccagctgctctctaccagacaattgaagaaaatattaaa  360
NEPSADAPAALYQTIEENIK 
101  120
atctttgaagaagaagaagttgaatttatcagtgtgcctgtcccagagtttgcagatagt  420
I  FEEEEVE F I  SV PV PE F A D S  
121  140
gatcctgccaacattgttcatgactttaacaagaaacttacagcctatttagatcttaac  4  80
DPANIVHDFNKKLTAYLDLN 
141  160
ctggataagtgctatgtgatccctctgaacacttccattgttatgccacccagaaaccta  54 0
LDK CYVI PLNTSIVMPPRNL 
161  180
ctggagttacttattaacatcaaggctggaacctatttgcctcagtcctatctgattcat  600
LELLINIKAGTYLPQSYLIH 
181  200
gagcacatggttattactgatcgcattgaaaacattgatcacctgggtttctttatttat  660
EHMVITDRIENI DHLGFFIY 
201  220
cgactgtgtcatgacaaggaaacttacaaactgcaacgcagagaaactattaaaggtatt  720
RLCHDKETYKLQRRETIKGI 
221  240
cagaaacgtgaagccagcaattgtttcgcaattcggcattttgaaaacaaatttgccgtg  780
QKREASNCFAIRHFENKFAV 
241  260
gaaactttaatttgttct- n?.acagtcaagaaaaacattattgaggaaaattaatatcac  84 0
E  T  L  I  C   S  -  
261  266 
agcataaccccaccctttacattttgtgcagtgattattttttaaagtcttctttcatgt 
aagtagcaaacagggctttactatcttttcatctcattaattcaattaaaaccattacct 
taaaatttttttctttcgaagtgtggtgtcttttatatttgaattagtaactgtatgaag 
tcatagataatagtacatgtcaccttaggtagtaggaagaattacaatttctttaaatca 
tttatctggatttttatgttttattagcattttcaagaagacggattatctagagaataa 
tcatatatatgcatacgtaaaaatggaccacagtgacttatttgtagttgttagttgccc 
tgctacctagtttgttagtgcatttgagcacacattttaattttcctctaattaaaatgt 
gcagtattttcagtgtcaaatatatttaactatttagagaatgatttccacctttatgtt 
ttaatatcctaggcatctgctgtaataatattttagaaaatgtttggaatttaagaaata 
acttgtgttactaatttgtataacccatatctgtgcaatggaatataaatatcacaaagt 
tgtttaactagactgcgtgttgtttttcccgtataataaaaccaaagaatagtttggttc 
ttcaaatcttaagagaatccacataaaagaagaaactattttttaaaaattcacttctat 
atatacaatgagtaaaatcacagattttttctttaaataaaaataagtcattttaataac 
taaaccagattctttgtggatactattaaagtaacatttaagcctcaaccttg
Figure  1.4:  Nucleotide  sequence  and  predicted  amino-acid  of  BriPP.  Single 
transmembrane spanning domain highlighted in red  A potential N-glycosylation site 
identified at Asp 173 indicated in blue.  The normal stop codon located at 267 indicated 
in green.
40Chapter 1- Introduction
The BRI2  transcript  was  mapped  to  human  chromosome  13  by  fluorescence  in-situ 
hybridisation (FISH)  analysis  (Vidal  et al,  1999).  Measurements of chromosome  13 
also showed that the BRI2 gene is located 34% of the distance from the centromere to 
the  telomere  of chromosome  13q  corresponding  to  the  band  13ql4.  The  predicted 
nucleotide sequence of the BRI2 gene, contains six exons is shown in figure 1.4 (Vidal 
et al.,  1999).  Hybridisation of the clone of the  human precursor protein to Northern 
blots identified a major mRNA transcript of -2.0 kb and a second transcript of 1.6 kb 
which  were  expressed  in  most  regions  of the  human  brain  as  well  as  in  several 
peripheral tissues (Vidal et al, 1999).
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Figure 1.5: Nucleotide sequence of the British mutation
Nucleotide sequence analysis of the BRI2 gene revealed a single nucleotide transition (T 
for A) at position 267 resulting in the presence of an arginine residue instead of the 
normal  stop  codon,  producing  an  open  reading  frame  33  nucleotides  longer  and  a 
precursor protein of 277 amino acids instead of the wild type 266 (Vidal et al,  1999) 
(figure 1.5).
This nucleotide substitution is associated with FBD and is not seen in unaffected family 
members  or  individuals with unrelated  neurological  disorders.  Furthermore,  the  stop 
codon  that  is  altered  in  the  British  family  is  conserved  in  the  murine  homolog,
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indicating  that  the  nucleotide  substitution  is  a  pathogenic  mutation  rather  than  an 
innocent polymorphism.  Once the identity of the amyloid protein had become known 
polyclonal  antibodies were  raised against the  last ten residues  of the ABri  sequence 
(Vidal et a l,  1999) and such antibodies (anti-ABri) were shown to recognise amyloid 
deposits in FBD. This immunoreactivity co-localized with Congo red staining showing 
that the anti-ABri antibody was in fact staining the amyloid material.
1.4.2  Identification of ADan protein and ADanPP
Using  the  same  strategy,  as  in  FBD,  the  amyloidogenic  protein  was  isolated  from 
leptomeningeal  blood  vessels  in  FDD  and  demonstrated to  have  homology to  ABri 
(Vidal et al., 2000b). Genetic analysis of the BRI2 gene in the Danish kindred showed 
that the genetic defect is different from that found in FBD.  In FDD there is a  10-nt 
duplication insertion, (TTTAATTTGT) between codons 265 and 266, one codon before 
the normal stop codon at 267. This causes a frame shift mutation, which abolishes the 
normal stop codon generating an 11  amino acid longer precursor protein. The amyloid 
subunit  (ADan)  is produced,  similar to  ABri,  by  cleavage  of the  last  34  C-terminal 
amino  acids  of the  mutated  precursor  protein  (figure  1.6).  However  the  twelve  C- 
terminal amino acids of the peptide are different from those of ABri. Using MS analysis 
a peak was found at 4,046 Da for ADan, which corresponded to the estimated mass of 
the peptide.  Another major peak was  also  found  at  3,883.7  Da,  which  matched  the 
molecular mass of the amyloid  molecule extending from residues  1-33  with a cyclic 
pyroglutamate at the N terminus and a detyrosinated C-terminus. Other peaks were also 
found which matched peptides starting at position 3  and extending to residues 28, 33 
and 34.
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Figure 1.6: Nucleotide sequence of the Danish mutation
From  the  discovery  of  the  amyloidogenic  peptide,  ADan,  a  polyclonal  antibody 
(Ab5282)  was  raised  using  a  synthetic  peptide  homologous  to  residues  22-34 
(CFNLFLNSQEKHY) of the ADan peptide,  which is mutation specific (Vidal et a l, 
2000b).  A limited immunohistochemical  study was carried out using Ab5282 and the 
amyloid and preamyloid lesions were visualized for the first time. Ab5282 was found to 
label  Congo  red  positive  structures  including  parenchymal  and  vascular  amyloid 
lesions.  In addition Congo red negative,  Ab5282 positive deposits were also found in 
the brain tissue of FDD  cases.  Tau  immunoreactive  structures were numerous in the 
hippocampus where abnormal neurites, mostly around affected blood vessels, NFTs and 
neuropil threads (NTs) were seen in large numbers (Vidal etal., 2000b).
1.4.3  Generation of ABri and ADan by proteolytic processing
The mechanism of cleavage of both the wild-type and mutated precursor proteins has 
been investigated using in vitro studies in cell cultures. These have shown a furin-like 
cleavage of the wild-type BriPP between Arg243 and Glu244, generating a C-terminal 
23 amino acid fragment. ABriPP and ADanPP, the mutated precursor proteins, are also
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cleaved at the same site producing the amyloidogenic peptides ABri and ADan (Kim et 
a l,  1999; Kim et a l, 2002) (figure 7). The processing of ABriPP has been shown to be 
greatly  increased  compared  to  the  wild-type  BriPP,  suggesting  that  the  carboxyl 
terminal eleven amino acids in ABriPP enhance furin mediated proteolysis (Kim et a l,
1999).
Furin is one of seven members of the calcium dependent serine proteases,  also called 
proprotein  convertases  (PCo).  PCos  have  a  general  recognition  motif  sequence 
(R/R)xn(R/K) where n=0,2,4,or 6 and X is any amino acid except Cys and rarely Pro 
(Seidah & Chretien,  1999).  Furin,  a type  1  transmembrane protein,  is synthesized as 
profiirin  and  during  progression  from  the  endoplasmic  reticulum  to  the  trans-Golgi 
network, undergoes activation by two sequential autoproteolytic cleavages, the second 
of which  permits  dissociation  of the  propeptide  providing  the  final  step  in  enzyme 
activation (Thomas, 2002; Nakayama,  1997). Furin has been shown to be essential for 
embryonic development as gene knockout results in death between embryonic days 10.5 
and  11.5  (Roebroek et a l,  1998).  Several  studies  have  shown that furin  has a wide 
tissue distribution (Seidah & Chretien,  1994;  Schalken et al,  1987; Hatsuzawa et al, 
1990) and in-situ hybridisation studies using rat brain have demonstrated the presence 
of furin mRNA in neuronal cells (Cullinan et a l,  1991; Day et al,  1993). Furin protein 
expression has been confirmed immunohistochemically in hypothalamic nuclei (Dong 
etal, 1997).
Furin is  involved  in the processing of a wide variety of precursor proteins including 
serum proteins, growth factors, receptors, extracellular matrix proteins, bacterial toxins 
and  viral  coat  proteins.  In  addition,  it  has  been  associated  with  the  proteolytic 
processing of the precursors of molecules associated with cerebral amyloid deposition. 
These include B ACE, which cleaves A|3PP to produce the N-terminus of the Ap peptide
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in  AD;  AD AMI 0  and  AD  AMI 7 which  have  been  implicated in  a-secretase activity 
leading to the cleavage within the Ap  sequence of ApPP (Lopez-Perez et al'.,  2001); 
gelsolin, the precursor protein for the amyloidogenic peptide AGel, deposition of which 
results in a form of familial CAA.
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Figure 1.7: Mutations in the BRI2 gene. Mutations in FBD and FDD are situated on 
chromosome 13 which encodes the 266 amino acid long precursor protein BriPP. Both 
mutations extend the  open reading frame resulting in novel 277 amino acid proteins, 
ABriPP and ADanPP.  The amyloidogenic peptides ABri and ADan are derived by furin- 
like proteolytic cleavage of the C-terminal 34 amino acids.
1.4.4  The BRI gene family
The BRI gene belongs to a multigene family comprising at least three homologues in 
both mice  and  humans, BRI1,  BRI2  and BRI3.  Which  have also  been referred to  as 
ITM2A, ITM2B and ITM2C, or E25A, E25B and E25C respectively (Deleersnijder et al., 
1996; Pittois et al.,  1998; Vidal et al.,  1999; Vidal et al., 2001). BRI gene homologues
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have also been found in other vertebrate and non-vertebrate animals suggestive of an 
evolutionary conserved gene family (Deleersnijder et al.,  1996; Sanchez-Pulido et al., 
2002;  Vidal  et  al.,  2001).  Each  of the  family  members  was  mapped  to  a  different 
chromosome by fluorescence in-situ hybridisation: the human BRI  I gene is located on 
chromosome X (Pittois et al.,  1999): BRI2 gene on the long arm of chromosome  13 
(Vidal et al.,  1999)  and BRI3 gene on chromosome 2 (Vidal et al.,  2001).  The gene 
expression  pattern  of the  human  isoforms  is  strikingly  dissimilar.  Whereas  BRI2  is 
highly ubiquitous, BRI1 and BRI3 show limited expression profile. BRI1 is particularly 
restricted to the mouse osteogenic and chondrogenic tissues (Pittois et al,  1998). BRI1 
is  also  expressed  in  CD34(+)  hematopoietic  progenitor  cells  (Mao et al,  1998)  and 
upregulated  in  T-cell  development  with  enhanced  expression  during  thymocyte 
selection  and  T-cell  activation  causing  CD8  downregulation when  overexpressed  in 
CD4/CD8  double positive thymocytes  (Kirchner  &  Bevan,  1999).  BRI3  is  localised 
primarily  in the  brain (Vidal et al,  2001;  Choi  et al.,  2001),  with highest  levels  of 
expression in the cerebral cortex, medulla,  amygdala hippocampus, thalamus,  caudate 
nucleus and spinal cord.
The BRI2 gene locus is on the long arm of chromosome  13,  specifically at  13ql4, as 
demonstrated by  fluorescence in-situ hybridisation analysis (Vidal  et a l,  1999).  It is 
broadly expressed in peripheral organs, with high levels of expression in heart, kidney, 
pancreas, liver, placenta as well as brain, where it shows a more abundant distribution in 
the  hippocampus  and  cerebellum  compared  with  cortex  (Vidal  et a l,  1999).  In-situ 
hybridisation of human cells in culture showed BRI2 mRNA is widely distributed in 
different  cerebral  cell  populations  and  its presence  can be  demonstrated  in  neurons, 
astrocytes and microglial cells, as well as smooth muscle and cerebral endothelial cells.
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No in  vivo in-situ hybridisation data on the expression of BRI2 mRNA within human 
brain has been shown to date.
1.4.5  The BRI proteins
At the protein level the human and mouse BRI isoforms share over 90% homology with 
the  same  isoform in the  other species, with a less pronounced amino acid similarity 
among  the  different  isoforms  within  each  species.  Very  little  is  known  about  the 
physiological functions of the BRI proteins. Database scans for possible functional roles 
revealed  a  BRICHOS  domain,  a  conserved  motif common  to  members  of the  BRI, 
ChM-I, SP-C and CA11 protein families (Sanchez-Pulido et al., 2002). The conserved 
BRICHOS  domain  is  located  within the  pro-peptide  region,  which  is removed after 
proteolytic  processing  by  pro-protein  convertases  and  which  includes  a  pair  of 
conserved cysteine residues that most likely form a disulphide bridge, with the blocks or 
sequence  conservation  located  predominantly  around  these  cysteines.  It  has  been 
postulated that this domain may be involved in the targeting of the respective proteins to 
the secretory pathway or in intracellular processing. Although all the proteins described 
as possessing the BRICHOS motif are dissimilar in proposed functions they share two 
common features:  1) they are all type II transmembrane proteins and 2) they are all 
processed by furin-like endoproteases.
Studies aimed at determining the brains topographical distribution of BRI2 in humans 
demonstrated  its presence  in normal  pyramidal neurons  in the  CA3  and CA4 of the 
hippocampus as well as in Purkinje cells in the cerebellar cortex (Akiyama et al., 2004). 
In pathological conditions, BRI2 was detected in dystrophic neurites in senile plaques 
and around ischemic lesions derived from axons and dendrites in AD tissues, and it was 
highly  positive  within  Lewy  neuritis  in  dementia  with  Lewy  bodies  and  PD  cases
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(Akiyama et al., 2004). Although this study did not look at normal controls or FBD and 
FDD cases.
Although the function of BRI2 remains unknown, its cellular distribution throughout the 
brain  and  its  presence  in  dystrophic  neuritis  in  various  neurodegerative  conditions 
(Akiyama et al., 2004), along with its morphological distribution within neuronal cell 
bodies and axons and its axonal localisation in BRI2 transfected neurons (Choi et al.,
2001)  suggest a role in transport along neuronal processes and a putative role in nerve 
terminals.
1.5  Alzheimer’s disease
1.5.1  Introduction
AD is the most common form of CAA. Therefore, FBD and FDD closely mimic the 
morphological features of AD and will therefore be compared with AD throughout the 
thesis.  In  1907,  Alois  Alzheimer  a  German psychiatrist,  using  the  newly  developed 
Bielschowsky’s silver impregnation method, described the occurrence of NFTs in the 
brain of a 55  year old woman dying  after a 4 year history of progressive  dementia. 
Almost a century later AD is recognized as a leading cause of disability and decreased 
quality of life among the elderly (Kawas & Brookmeyer, 2001).
The clinical diagnosis of AD depends on the inclusion and exclusion of certain features, 
an  extensive  clinical  workup  is  performed  including  clinical  history,  physical 
examination,  neuroimaging,  neuropsychological  evaluation  and  analysis  of  CSF. 
Despite extensive clinical evaluatation, the final definite diagnosis of AD depends upon 
the neuropathological evaluation.
Gross anatomical changes are observed in AD; cortical atrophy noted at autopsy varies 
between  AD  cases  and  may  correlate  with  cognitive  decline  (Mouton et  al.,  1998).
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Atrophy exemplified by narrowing of the gyri and widening of the sulci is observed in 
the frontal, temporal and parietal lobes also revealed by tissue sections, while relative 
sparing  of  the  occipital  cortex  is  common.  Another  feature  of  AD  is  often 
disproportionate enlargement of the temporal  horns of the lateral ventricles,  together 
with severe atrophy of the hippocampus and amygdala.
1.5.2  Histology, immunohistochemistry and electron microscopy of AD
1.5.2.1  Neurofibrillary tangles
One of the major histopathological hallmarks of AD are NFTs, intracellular inclusions 
often occupying the cell body of the neuron. NFTs are not specific to AD and are found 
in  aged  individuals,  progressive  supranuclear  palsy  (PSP)  (Li  et  a l,  1998),  GSS 
(Ishizawa  et  a l,  2002)  and  DS  (Wegiel  et  a l,  1996).  NFTs  are  an  important 
pathological feature of AD as they correlate with cognitive decline and remain a key 
diagnostic  feature  of AD.  Although NFTs  may  be  apparent  on H&E  staining  other 
stains  are  required  for their  optimal  visualisation,  which  include  a variety  of silver 
impregnations  e.g  Galiyas  or  Bielschowsky’s  method  or  by  immunohistochemistry 
using antibodies raised against hyperphosphorylated tau.
The general shape of NFTs differs depending on the neuron within which it is formed. 
For example tangles in the pyramidal neurons of the Ammon’s horn in the hippocampus 
are usually  flame  shaped.  Whereas  in the  rounder neurons of the  nucleus  basalis of 
Meynert or locus coeruleus they have a more globose appearance. NFTs, particularly in 
the  CA1  of the  hippocampus  and the  entorhinal  cortex,  may  survive  long  after the 
neurons  have  died  and  lost  their  cell  membranes.  These  are  termed  ‘ghost’  or 
‘extracellular  tangles’  and  are  still  detectable  on  silver  stains  or  by  tau 
immunohistochemistry.
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It has been  seen with EM that tangle bearing  neurons exhibit  a progressive change. 
Early  stages  show accumulation of perinuclear aggregates of paired helical  filaments 
(PHF)  and other filaments.  These changes progress to  a densely  compacted  mass of 
PHFs  within  the  cell  body  and  apical  dendrite  impinging  upon  the  nucleus  and 
cytoplasmic organelles. PHFs have been extensively studied and have been shown to be 
composed  of two  filaments  measuring  around  20nm  in  diameter.  Although  initially 
thought to represent twisted tubules (Terry et a l,  1964), this observation changed with 
Kidd’s finding that PHFs consisted of two filaments wound  in a double helix (Kidd, 
1964). Phosphorylated tau protein was shown to be a major constituent of PHFs within 
NFTs,  plaque-related  neurites  and  NTs  (Delacourte  &  Buee,  1997).  PHFs  contain 
epitopes  spanning  the  entire  length  of tau  (Iwatsubo  et  al.,  1994a)  and  multiple 
phosphorylation sites have been identified.
The topographical distribution of neuropathological changes has been studied in AD by 
several groups (Braak & Braak,  1991; Delacourte et al,  1998). It has been found that 
NFTs  tend  to  occur  most  frequently  in  the  amygdala,  hippocampal  formation, 
parahippocampal gyrus and the temporal, frontal and parietal cortices. NFTs generally 
occur in a predictable laminar distribution, with some laminae being severely affected 
while others are spared. For example in the entorhinal cortex NFTs are always present 
in neurons of layers II and IV, whereas layers III, V and VI have relatively few NFTs. 
In the association cortex, the pyramidal  neurons  in  layers II,  HI and V are  similarly 
affected.  In  general  NFT  bearing  cells  are  large  pyramidal  neurons,  primarily 
glutamatergic  and  frequently  marked by  antibodies to phosphorylated neurofilaments 
(Schmidt et al,  1996) and in contrast other neuronal populations appear to be spared. 
Braak  and  Braak  in  1991  observed  that  the  progression  of neurofibrillary  changes 
follows  a  predictable  pattern  (Braak  &  Braak,  1991).  From  examining  brains  of
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demented  and  non-demented  individuals,  they  found  a  characteristic  distribution  of 
NFTs  and  NTs.  This  allowed  the  differentiation  of  six  stages  exemplified  by 
progression from the transentorhinal to the isocortex. The first two stages involve NFTs 
in  the  entorhinal,  transentohinal  and  CA1/  subicular  portions  of the  hippocampal 
formation.  In stages ID and IV increasing numbers of NFTs accumulate in the limbic 
system and stages V and VI in isocortical areas.
1.5.2.2  Neuropil threads
NTs are thread like structures in the neuropil distributed widely in the grey matter in 
AD. The frequency of NTs correlates with the severity of dementia and the numbers of 
NFTs.  They  are  also frequently  associated  with  ghost or extracellular tangles  in the 
hippocampus  (Yamaguchi  et  al.,  1991b).  Although  observed  near  dendrites  of NFT 
bearing neurons (Braak & Braak,  1988), threads may also involve distal dendrites or 
axons in the amygdala or entorhinal cortex unassociated with local tangle-bearing cell 
bodies (Schmidt et al, 1993).
Like NFTs,  NTs  are  also  observed  in  other disorders;  including PSP  (Probst  et  al, 
1988),  corticobasal  degeneration  (CBD)  (Ksiezak-Reding  et  a l,  1994)  and  Pick’s 
disease (Cochran et al, 1994).
1.5.2.3  Senile plaques
The other major histopathological  hallmark of AD are senile plaques which are near 
spherical structures ranging in diameter from 4 to 200pm. The amyloid portion of senile 
plaques  is  apparent  in  many  silver  stains  but  may  also  be  distinguished  from  other 
substances  using  Congo  red  stain  or  the  fluorescent  dye  thioflavine-S. 
Immunohistochemical  preparations  using  Ap  antibodies  also  highlight  the  senile
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plaques along with diffuse plaques.  Although plaques  have been classified based  on 
their  morphological  appearance,  A {3  immunohistochemistry  does  not  distinguish 
between the conformational state of the AP peptide.
1.5.2.3.1  Neuritic plaques
Neuritic plaques display clusters of abnormally distended, radially orientated, neuronal 
processes often surrounding well-formed extracellular Ap cores found in the limbic and 
association cortices. The fine structure of neuritic plaques highlights their complexity, 
with amyloid cores surrounded by radiating spikes of fibrillar amyloid. Amyloid is often 
seen in coated vesicles within the cytoplasm (Roher et a l, 1993) suggesting a process of 
receptor mediated  endocytosis.  Lamellar or dense bodies  are a  major component  of 
plaque  neurites  and  have been  shown to  contain  acid phosphatase (Suzuki  &  Terry, 
1967) suggesting a lysosomal origin.  These structures co-exist in varying proportions 
with  clusters  of PHFs.  Astrocytes  and  microglia  are  often  seen  surrounding  neuritic 
plaques and entwined within the extracellular amyloid.  This relationship between glial 
cell and plaques is not yet fully understood.
The Ap contained within the neuritic plaques tends to be the species ending at amino 
acid 42 (AP42). This longer, more hydrophobic form is prone to aggregation. However, 
the Ap species ending at the amino acid 40 (AP40) which is normally more abundantly 
produced by cells than AP42 usually co-localises with AP42 within the plaques.
1.5.2.3.2  Diffuse plaques
In  contrast  to  neuritic  plaques,  diffuse  plaques  or  pre-amyloid  plaques  are  more 
amorphous and lack the thickened neurites and well-defined amyloid cores (Ikeda et a l,
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1989; Yamaguchi et a l,  1989) of neuritic plaques. In fact diffuse plaques have little or 
no ultrastructurally detectable fibrillar amyloid (Yamaguchi et al., 1991b). They are not 
or weakly  detected with  silver stains,  and  show very weak  staining with fluorescent 
amyloid dyes, but show immunoreactivity with AP antibodies.
Many investigators believe that the diffuse plaques, often seen before the occurrence of 
neuritic plaques, represent earlier stages of plaque development and eventually evolve 
into  neuritic  plaques  (Dickson  et  al.,  1988).  This  notion  may  be  supported  by  the 
observation  that  the  distribution  of the  diffuse  plaques  is  similar to that  of neuritic 
plaques  i.e.  limbic  and  association  cortices.  An  alternative  hypothesis  is  that  the 
individual plaque types develop independently of each other (Armstrong,  1998). From 
immunohistochemical  studies it was determined that the Ap peptides deposited in the 
diffuse plaques are AJ342 and no or little AP40 immunoreactivity was found. This is in 
contrast to the mixed deposits generally found in neuritic plaques.
1.5.3  Amyloid cascade hypothesis
With the deposition of two aggregated proteins in AD there continues to be a debate 
about  which  of the  two  lesions  might  precede  the  other  and  has  a  primary  role  in 
neurodegeneration.  Many  studies  support  the  hypothesis  that  amyloid  fibrils  drive 
neurodegeneration in AD, known as the amyloid cascade hypothesis (Hardy & Selkoe,
2002). The hypothesis raised by Hardy et al (1992) suggested that the deposition of Ap, 
whether it is due to overproduction or insufficient clearance,  is the causative agent of 
AD  pathology  and  that  the  NFTs,  cell  loss,  vascular  damage  and  dementia  are 
consequences of this.
The initial step in this proposed pathway (Figure  1.8) is the accumulation of Ap  into 
amorphous  deposits.  The  longer  AP  peptide  (1-42)  is  the  most  amyloidogenic  and
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earliest  peptide  species to  deposit.  This  initial  deposition  acts  as  a  seed  for  further 
deposition  of the  shorter  less  amyloidogenic  peptide  AJ3  1-40.  With  the  toxic  Ap 
peptides  accumulating,  an  inflammatory  response  is  triggered.  Amyloid  associated 
proteins may also play an indirect role in this process by accelerating amyloid filament 
formation.  The  amyloid  deposits  induce tangle  formation,  neuritic  degeneration  and 
ultimately neuronal loss. These final steps in the pathogenesis of AD remain undefined 
since the mechanisms for neurodegeneration and neuronal death in AD are still not fully 
understood.
Several  developments  have  supported the  amyloid  cascade hypothesis  including:  the 
identification of rare cases of familial AD caused by mutations in the APP, PS1 or PS2 
genes and the production of transgenic mice exhibiting some AD like pathology. On the 
other  hand  mutations  found  within  the  tau  gene  do  not  lead  to  AD.  Instead  these 
mutations  are  associated  with  frontotemporal  dementia  and  parkinsonism  linked  to 
chromosome 17.
54Chapter 1- Introduction
Autosomal  Dominant  Forms of AD Sporadic  Forms of AD
Missense mutations in the APP or Presemlin 1  
or 2 genes
Failure of Ap  clearance mechanisms 
(e.g  inheritance of ApoE4: faulty Ap  degradation!
Increased Ap production throughout life Gradually rising A042 levels m the bran
Accumulation and oligomerisation of Ap 42  in limbic and associated cortices
Subtle effects  of Ap  oligomers on synaptic efficacy
Gradual deposition of Ap 42  oligomers as  diffuse piaques
Microglial and astrocytic activation 
Altered neuronal ionic homeostasis;  oxidative injury
Altered kinase phosphatase activities
Widespread neuronl synaptic dysfunction and some neuronal loss with neurotransmitter deficits
Onset of symtoms of DEMENTIA
Figure 1.8: Amyloid cascade hypothesis (Selkoe et al 2002)
Although the amyloid cascade hypothesis offers the framework to explain AD there are 
still details lacking.  A long-standing controversy surrounds the relative contribution of 
plaques to the loss of neuronal function, because there is a relatively poor correlation 
between the numbers of plaques and the degree  of cognitive decline (Hyman,  1992; 
Berg et a l 1998).  A  significant  correlation between  soluble  Ap  levels  in  the  brain 
parenchyma  and  the  severity of the  disease  has  been  shown  (McLean et al.,  1999), 
which is in contrast to the total Ap load appearing to only signify the presence of the 
disease.
Although the amyloid cascade hypothesis is a framework of events that try to explain 
the mechanism behind AD, the same cascade could be implicated in FBD and FDD. 
Both hereditary diseases have an accumulation of a peptide capable of forming amyloid 
deposits,  both  have  NFTs  present.  Whether  the  intermediate  steps  proposed  in  the
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amyloid  cascade  hypothesis  are  present,  for  example  microglial  and  astrocytic 
activation, is part of the focus of this study.
1.5.4  ApPP processing and the generation of AP
Ap is derived from its large precursor protein APPP. The APP gene is composed of 18 
exons and can be alternatively spliced to create 10 isoforms ranging from 563 to 770 
amino acid residues (Coulson et al, 2000).
ApPP  is  a  type  1   integral  membrane  protein  with  a  large  ectodomain,  a  single 
membrane  spanning  domain  and  a  short  cytosolic  domain  (Kang  et al,  1987).  The 
ectodomain  consists  of an  N-terminal  region  that  forms  an  extracellular  globular 
structure which is followed by a sequence rich in positively charged residues (acidic 
domain) and a glycosylated region.
ApPP  is  co-translationally  translocated  into  the  endoplasmic  reticulum  (ER)  via  its 
signal peptide. Then post-translationally modified through the secretory pathway.  The 
a-secretase was identified as the first proteolytic cleavage site located 12 amino acids 
N-terminal  to  the  transmembrane  domain  of ApPP  between  residues  687  and  688, 
releasing a large soluble N-terminal fragment a-APP into the lumen/ extracellular space 
with retention of the 83-residue C-terminal fragment in the membrane.
This is followed by cleavage around residue 712 by a y-secretase,  releasing the non- 
pathogenic  fragment  p3  fragment.  Although  this  pathway  is  considered  to  be  non- 
pathogenic p3 has been shown to be present in amyloid plaques (Higgins et al,  1993). 
This  sequence  of events  does  not  lead  to  the  generation  of AP,  as the  a-secretase 
cleaves within the Ap domain itself. To initiate the formation of Ap the ApPP molecule 
is  cleaved  by  a  P-secretase  that  cuts  28  residues  from  the  transmembrane  domain,
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between residues 671 and 672, releasing a smaller derivative, p-APP, and retaining a 99 
residue  fragment within the membrane.  This  is  followed by the y-secretase  cleavage 
yielding Ap. The key to this pathway is the y-secretase. If it cleaves at residue 712 then 
Ap 1-40 is produced, but if it cleaves after residue 714 then Ap 1-42/43 are produced. 
Efforts have been directed towards the identification of a-, p-, and y-secretases involved 
in  the  processing  of  ApPP.  The  a-secretase  cleavage  corresponds  to  a  secretory 
pathway,  which  predominates  in  all  non-neuronal  cells  including  mammalian  cells 
(Sisodia et al.,  1990). ADAM 10, ADAM 17, MDC-9 and TACE, all of which belong to 
the  family  of  disintegrin  metalloproteases  have  been  proposed  as  a-sectretase 
candidates in mammalian cells (Buxbaum et al.,  1998; Koike et al,  1999; Lammich et 
al.,  1999).  P-secretase  cleavage  constitutes  the  first  step  in  the  formation  of  Ap 
peptides, its action leaves the Ap peptide anchored to the membrane with its N-terminus 
free.  Five  groups  independently  identified a  candidate  for the  P-site  ApPP  cleaving 
enzyme BACE1  (Vassar et al.,  1999; Yan et al.,  1999;  Sinha et al.,  1999; Lin et al.,
2000). The BACE polypeptide sequence contains two conserved motifs that form the 
active  site  of aspartic  proteases  of the  pepsin  family.  BACE  is  an  unusual  aspartic 
protease because it has a C-terminal transmembrane domain and is therefore membrane 
bound.  Extensive studies by the five groups demonstrated that BACE exhibits all the 
characteristics of P-secretase; firstly it is expressed in all tissues, but at higher levels in 
neurons of the brain; BACE is localized within acidic intracellular compartments; over­
expression  of  BACE  in  cells  increases  p-secretase  cleavage  products;  anti-sense 
inhibition of BACE in cells decreases  p-secretase cleavage; purified forms of BACE 
cleave  APP  substrates  in  vitro  with  correct  p-secretase  specificity.  Soon  after  the 
discovery of BACE, a homologous gene BACE2 (also called Aspl or Memapsinl) was
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also identified (Solans et al., 2000). BACE1 and BACE2 share 64% homology and both 
have  a  C-terminal  transmembrane  domain.  The  BACE1  gene  is  localised  to 
chromosome  llq23.3  a locus not yet seen to be associated with AD, while BACE2 is 
localised to chromosome 21 (Solans et a l, 2000). Recent work has shown that although 
BACE2  can  cleave  APPP  at  the  P-secretase  site,  the  enzyme  cuts  more  efficiently 
within the Ap domain and therefore may limit the production of pathogenic AP species 
(Farzan et al., 2000).
Activity of y-secretase is required  to release both Ap  and p3  peptides from the cell 
membrane.  y-Secretase  can  cleave  at  multiple  positions  generating  AP  peptides  of 
different  lengths.  y-Secretase  cleavage  occurs  within  the  predicted  transmembrane 
domain of ApPP requiring the enzyme to either cleave within the lipid bilayer or change 
the conformation of the C99 fragment (Selkoe,  1999). It has been recently reported that 
a  large  complex  exhibits  y-secretase  activity  on  C99  like  substrates  and  that  this 
complex catalyses both 40 and 42 cleavage at a ratio similar to that found in intact cells. 
It has been shown that the activity of the complex is inhibited by y-secretase pathway 
inhibitors.  Antibodies raised against PS1  inhibit soluble y-secretase activity, indicating 
that PS1 protein is physically associated with the y-secretase enzyme complex (Li et a l,
2000). These data can be explained by the hypothesis that PS1 and PS2 are themselves 
y-secretase (Wolfe et al, 1999).
1.5.5  Amyloid conformational states
A number of proteins are able to undergo specific aggregation into amyloid fibrils in 
vivo,  leading to different pathological disorders.  The Ap amyloid found in AD, under 
normal physiological conditions, is a soluble protein (sAp). Due to unknown factors the 
soluble protein forms insoluble fibrils with a P-pleated sheet conformation.  In the last
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decade the leading hypothesis in AD has been that dementia derives from neurotoxins 
comprising self-associated Ap peptides (Selkoe, 2001). After a decade of investigation 
into amyloid toxicity the question of which specific neurotoxic structures derived from 
Ap self-association contributed to AD pathogenesis still has to be answered.
It has been shown that amyloid fibrils are not the only neurotoxic species derived from 
Ap monomers (Klein et al., 2001). Neurotoxicity was found in ADDLs (Ap- derived 
diffusible ligands) these are globular oligomers  of Ap formed from Ap42 monomers 
ranging in  size from trimers to 24-mers (Chromy et al.,  2003).  They are able to kill 
differentiated  CNS  neurons  with  the  toxicity  being  cell  type  specific.  Neurotoxic 
activity has also been found in assemblies known as protofibrils (Hartley et al.,  1999; 
Walsh et al.,  1999).  Protofibrils were identified several years ago as intermediates in 
fibrillogenesis (Harper et al.,  1997; Walsh et al,  1997), they are rod like rather than 
globular in structure,  10 times the size of ADDLs, with diameters of ~5nm and often 
display a beaded appearance. For protofibrils to form they need high concentrations of 
Ap  monomers.  It  is  unknown  whether  these  different  conformational  states  of Ap 
interconvert freely. The idea that AD pathogenesis has less to do with the amyloid fibril 
but more with the non-fibrillar conformational  states is consistent with the imperfect 
correlation between amyloid plaque burden and dementia.  The amyloid fibril may be 
the end stage of a process in which the key pathological events have occurred earlier 
mediated by intermediated conformational states of the Ap peptide.
It has been proposed that mutations already known to affect the ApPP gene cause the 
soluble Ap to aggregate to a greater extent than in normal individuals. Other factors that 
may affect or initiate this process are post-translational modifications, concentrations of 
soluble Ap, low pH, tissue factors, metal ions and amyloid associated proteins (AAPs).
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The  pathway  involved  in  fibril  formation  is  not  unique  to  Ap.  Among  others,  the 
formation of soluble oligomers, protofibrils and then amyloid like fibrils of ABri can 
also be produced experimentally (El Agnaf et al., 2001; Kim et a l,  1999b). Although 
ABri and Ap have no sequence homology the key features of their neuropathology and 
fibril assembly pathways are similar. There is, as yet, no biochemical evidence of non- 
fibrillar  forms  of  ADan:  however  immunohistochemical  evidence  of  non-fibrillar 
(ADan positive and Congo red negative) material in FDD, suggests the presence of pre- 
amyloid  conformational  states.  The  similarity  between  the  two  peptides  (ABri  and 
ADan),  with  identical  22  amino  acid  N-terminal  sequences  and  the  potential  for 
identical disulphide bonding suggests that ADan and ABri may, or are likely to, follow 
a similar pathway to fibril formation.
1.6  Genetics of familial Alzheimer’s disease.
The prevalence of inherited forms of AD has been documented to be around 5% of all 
cases, with three genes found to be associated with familial AD; ApPP, PS  I and PS2. 
Furthermore the apolipoprotein E (ApoE) gene has been shown to be a risk factor for 
sporadic AD and  some early onset familial  AD.  Studying the mutations within these 
genes may provide an insight into the mechanism of AD by examining genotypic to 
phenotypic relationships.
1.6.1  Mutations in the ApPP gene
The  location  of mutations  within  the  ApPP  gene  and  their  genotype-to-phenotype 
relationship  have  provided  critical  insights  into  the  pathogenesis  of AD  and  CAA. 
Mutations in ApPP are clustered around the three-secretase cleavage sites; immediately 
before the P-secretase site; after the a-secretase site or C-terminally to the y-secretase
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site.  The mutations exert their pathological effects through different mechanisms and 
often  have  characteristic  clinical  and  pathological  phenotypes.  The  double  Swedish 
mutation [KM670/671NL] affects the two residues located just before the N-terminus of 
Ap,  immediately  preceding  the  p-secretase  cleavage  site  (Johnston  et  al.,  1994; 
Axelman et al.,  1994)  (figure  1.9),  producing Ap plaques  as well as  extensive NFT 
pathology (Bogdanovic et al., 2002). This mutation induces increased cleavage by the 
p-secretases generating more Ap40 and Ap42, although the main species deposited in 
this disease is Ap42 (Mann et al.,  1996). Mutations occurring around the y-secretase 
cleavage site, including the London mutation (V717I) and the Florida mutation (1716V) 
enhance the production of Ap42 (Hardy, 1997; Selkoe, 2001). The phenotypes of these 
mutations  are  that  of  classical  AD  including  extensive  NFT  pathology.  Whereas 
mutations that occur in the middle of the Ap sequence between residues 21  and 23 are 
associated with a clinical presentation that includes heamorrhagic and ischemic strokes 
and a pathological presentation of severe CAA. The first of these latter mutations to be 
described was HCHWA-D.
The other known mutations that occur around the same region of the Ap protein include 
Flemish  (A692G),  Italian  (E693K),  Arctic  (E693G)  and  Iowa  (D694N)  mutations 
(figure  1.9).  As  well  as  the  mutations  within  the Aj}PP  gene,  an  extra  copy  of the 
structurally normal ApPP owing to elevated gene dosage in DS leads to the premature 
occurrence of classical AD neuropathology (Holtzman & Epstein, 1992).
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Figure 1.9: Mutations in the APP gene that cause AD like phenotypes. Mutations in the 
APP gene are clustered around the three secretase cleavage sites.  The above diagram 
illustrating the orientation of the Ap peptide in the ApPP peptide and its orientation 
across  the  membrane.  The  three-secretase  cleavage sites  are  highlighted on  the Ap 
peptide and the mutations shown on the Ap peptide sequence.
1.6.2  Genetic risk factors for AD
Mutations in the PS1, PS2 and AfPP genes are known to cause familial AD. It has also 
been shown that the possession of an e4 allele of the ApoE gene is a genetic risk factor 
for  late  onset  AD,  being  over  represented  in  subjects  with  AD  compared  with  the 
general population. A strong association between the inheritance of the Apo e4 and both 
sporadic AD and late onset familial AD has also been described (Corder et al.,  1993; 
Strittmatter et al., 1993a). ApoE is a single gene located on chromosome 19q 13.2, and 
has three major allelic variants (s2, e3 and s4) encoding three protein isoforms (Emi et 
al.,  1988).  There  are  six  possible  genotypes  e2/2,  e2/3,  s2/4,  e3/3,  e3/4,  e4/4  and 
compared with people without the e4 allele individuals with one copy of the Apo e4
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allele (e2/4, e3/4) have approximately a 2- to 3- fold greater risk of developing AD and 
those with two copies (e4/4) an 8- to 10- fold greater risk. Additionally, inheritance of 
one or two Apo e2 alleles is associated with a reduction in the risk for developing AD 
and thus may constitute a protective factor (Lippa et al., 1997).
1.7  Cerebral amyloid angiopathy
1.7.1  History of cerebral amyloid angiopathies
CAA is defined by the presence of congophilic fibrillar protein deposits in the media 
and  adventia  of  leptomeningeal  and  cortical  arteries  and  arterioles  and  rarely  in 
capillaries and veins. After the first description by Divry in 1941 of amyloid deposition 
in senile plaques in AD, came the recognition by Scholz in Germany that amyloid can 
also be found in cerebral blood vessels in the brains of elderly patients.  The earliest 
English language description of CAA was by Worster-Drought et al in 1940 when they 
first  described FBD.  In the  1970’s  it was  recognised that  CAA  is  a major  cause  of 
cerebral  haemorrhage in the elderly,  ischemic lesions and dementia,  as well as being 
associated with cerebral  haemorrhage,  CAA has also been documented as one of the 
pathological hallmarks in AD (Frangione et al., 2001).  The fibrillar deposits found in 
CAA of AD,  DS  and  normal  elderly  subjects  are  composed  of Ap.  As well  as the 
deposition of the Ap protein in blood vessel walls in sporadic AD,  CAA can also be 
severe in variants of familial AD caused by mutations of the AJ3PP or PS1 genes. Other 
proteins are also involved in familial CAAs, including mutated cystatin C in hereditary 
cerebral  haemorrhage  with  amyloidosis  of  Icelandic  type  (HCHWA-I),  variant 
transthyretins  in  meningo-vascular  amyloidosis,  mutated  gelsolin  in  familial 
amyloidosis of Finnish type and ABri and ADan in the BRI2 gene-related dementias.
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The  cellular  mechanisms  involved  in  CAA  which  result  in  the  degeneration  of the 
microvessel wall  are poorly understood.  It is also unknown whether the mechanisms 
involved in various types of CAAs are similar or unrelated.
1.7.2  Morphological appearances
Amyloid  deposition  most  frequently  affects  leptomeningeal  and  cortical  small  and 
medium sized arteries and arterioles, resulting in an acellular thickening with a smudgy 
appearance of the blood vessel wall. As a rule capillaries and veins tend to be less often 
affected than arterial blood channels. Amyloid laden blood vessels show positivity with 
Congo red, with an apple green birefringence when viewed under polarized light and 
green fluorescence when stained with thioflavine-S. Both stains are highly specific, for 
they are dependent on the p-pleated sheet conformational state of the amyloid peptides. 
The deposition of amyloid within blood vessels is a multistep process. Amyloid initially 
appears in the basement membrane around smooth muscle cells in the abluminal area of 
the media and adventia (Vinters,  1992). This phase is followed by a progressive loss of 
smooth  muscle  cells  and  the  appearance  of  vascular  degenerative  changes.  The 
preservation  of endothelial  cells  is  usually  a  feature.  A  grading  system  has  been 
proposed  by  Vonsattel  et  al  (1991)  which  may  be  useful  for  both  diagnostic  and 
research  purposes  (Vonsattel  et a l,  1991).  Briefly  if amyloid  is  seen  in  the  media 
without significant destruction of smooth muscle cells it is classified as ‘mild’  CAA. 
The smooth muscle cells are mainly absent in ‘moderate’ CAA, while together with the 
loss of smooth muscle cells and the presence of degenerative changes such as double 
barrelling,  microaneurysm formation,  fibrinoid necrosis and leakage of blood through 
the blood vessel walls constitutes ‘severe’ CAA.
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Ultastructural examination of blood vessels in cases of AD has shown that randomly 
orientated amyloid fibrils are first laid down in the abluminal aspect of the basal lamina 
around smooth muscle cells, which gradually spread towards the internal elastic lamina 
of arteries  and  the  endothelium  of arterioles.  As these  deposits  increase  in  size the 
luminal  smooth muscle cells may  show degenerative features.  In capillaries amyloid 
fibrils are found within the basal lamina with larger deposits extending into the adjacent 
neuropil.  In  HCHWA-D  immunoelectron  microscopy  demonstrated  that  the  initial 
phase of A(3 deposition the basal lamina shows increased electron density and reticular 
structures with amyloid fibrils being observed in more advanced lesions.
1.7.3  Sporadic cerebral amyloid angiopathy
The majority of CAA is sporadic and is found in elderly individuals with or without 
morphological  evidence of AD.  CAA can also be associated with other neurological 
manifestations  including transient  neurological  symptoms,  CAA-associated vasculitis 
and  it  has  also  been  suggested to  be  a  cause  of dementia (Greenberg et al.,  2000). 
Recent epidemiological studies have been shown to support vascular factors playing a 
role in the pathomechanism of dementia in AD (Pfeifer et al., 2002). Further studies are 
needed to elucidate the pathogenic mechanisms by which CAA affects cognition, but it 
seems  likely  that  ischemia  related  to  CAA  plays  a  significant  part  in  this  process 
(Cadavid  et  al.,  2000;  Winkler  et  al.,  2001;  Natte  et  al.,  2001).  This  proposal  is 
supported by clinicopathological  studies demonstrating that the presence of extensive 
CAA alone is sufficient to cause dementia in some cases of HCHWA-D (Natte et al,
2001).
The overlapping biology of sporadic  CAA and  AD  suggests that the two conditions 
share common risk factors.  With the occurrence of both diseases steadily increasing 
with age, the incidence of CAA may be as high as 46% in elderly individuals over the
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age  of 70  (Bergeron  et  al,  1987;  Esiri  &  Wilcock,  1986;  Glenner  et  al,  1981). 
Compared with non-AD cases the presence of AD further increases the frequency and 
severity of CAA pathology and vascular amyloid deposition can be observed in more 
than 80% of all AD cases.  CAA is of moderate degree in about a quarter of all  such 
cases (Ellis et al,  1996).  The ApoE e4 allele that has been identified as an important 
risk factor in AD, has also been related to sporadic and AD related CAA (Greenberg et 
al,  1995; Premkumar et al, 1996). Increasing doses of ApoE e4 have been shown to be 
associated with increasing amounts of Ap40 per affected cortical blood vessel without 
increasing the proportion of amyloid laden blood vessels (Alonzo et al,  1998). From 
these  observations,  the  hypothesis  was  proposed  that  ApoE  e4  enhances  the 
accumulation of AP40 in blood vessels previously seeded by AP42. The ApoE s2 allele 
has  been  demonstrated  to  be  associated  with  CAA  related  cerebral  haemorrhage  in 
which,  through  an  unknown  mechanism,  amyloid-laden  blood  vessels  undergo 
vasculopathic changes leading to their rupture (Nicoll et al, 1997).
1.7.4  Cerebral amyloid angiopathy in familial AD
1.7.4.1  Mutations in AfiPP
Familial AD  is the single most important hereditary condition that is associated with 
CAA.  Mutations located in the middle of the Ap protein between residues 21  and 23 
cause severe CAA. In the autosomal dominant condition HCHWA-D (E693Q) patients 
develop strokes including cerebral haemorrhage and white matter changes (Bomebroek 
et al,  ).  Some patients present with dementia  in the presence or absence of strokes 
suggesting that  severe CAA associated with this  mutant has a  significant role in the 
dementing  process  in  these  individuals.  In the  Italian  (E693K)  and  Arctic  (E693G)
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(Nilsberth et al., 2001) variants in which the mutations affect the same site severe CAA 
has also been described. Carriers of the Flemish mutation (A692G) develop early onset 
AD  or  cerebral  haemorrhage,  and  their  pathological  phenotype  is  unique  in  that  it 
includes  neurofibrillary degeneration and  AD type  Ap  plaques with  a  large amyloid 
core (Kumar-Singh et al., 2000). The Iowa mutation (D694N) has been described with a 
clinical phenotype characterized by dementia and pathological changes including severe 
CAA (Grabowski et al, 2001). Abundant NFTs and dystrophic neurites, often occurring 
around amyloid-laden blood vessels are present. Sparse parenchymal plaques of diffuse 
morphology, composed of AP40 have been described (Grabowski et al, 2001).
Despite  the  close  localization  of  these  mutations  with  similarities  in  the  clinical 
presentation, experimental studies suggest that the Dutch and Iowa mutations exert their 
pathological effects through a mechanism that is strikingly different from that found in 
the Flemish  mutation.  Neither the Iowa nor the Dutch  mutations  seem to  affect the 
processing of A(3PP, but instead have an effect on the aggregation and toxicity of these 
modified  peptides.  In  contrast,  the  main  affect  of the  Flemish  mutation  is  that  it 
interferes with the normal processing of APPP and leads to an increased production of 
Ap by the P-secretase homologue BACE2 (Farzan et al, 2000).
1.7.4.2  Mutations in the PS1 and PS2 genes
As well as mutations found within the ApPP gene some mutations associated with the 
PS1 and PS2 genes cause severe CAA. A recent study has suggested that PS  I mutants 
in  which  mutations  are  located  after  codon  200  have  more  severe  CAA than those 
located  before  codon  200  (Mann  et al,  2001a).  In  cases  with  A9  and  A183/AM84 
mutations  of the  PS  I  gene  the  clinical  phenotype  can  include  spastic  paraparesis
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(variant AD) and the neuropathological changes include cotton wool plaques together 
with extensive and severe CAA (Crook et al., 1998; Steiner et al., 2001; Houlden et al., 
2000). CAA has also been identified to be a prominent feature and in at least one case 
cerebral haemorrhage was documented in a Volga-German family with familial AD due 
to the N14II mutation in the PS2 gene (Nochlin et al., 1998; Levy-Lahad et al., 1995).
1.7.4.3  Ap in sporadic and familial AD
Ap species deposited in the blood vessel walls in sporadic AD and familial AD related 
CAAs are pathogenic variants of a constitutive host protein,  sAp.  Ap and sAp have 
identical primary  sequences but have  different  secondary  structures,  which could be 
responsible for their different physiochemical properties, including the generation of p- 
pleated sheet conformations resulting in aggregation and formation of insoluble amyloid 
fibrils. The Ap species deposited in the blood vessel walls show both C and N-terminal 
heterogeneity, as well as post-translational modifications that can be demonstrated with 
specific  antibodies.  Both  immunohistochemically  and  biochemically  Ap40  has  been 
shown to be predominantly deposited in the blood vessel walls in both sporadic and 
familial AD as well as in HCHWA-D (Levy et al.,  1990a). Pathological observations 
reported  in  both  humans  and  transgenic  animals  suggest  that  the  first  AP  species 
deposited  in  the  blood  vessel  wall  ends  at  position  42  which  seeds  the  subsequent 
deposition of Ap40 (Lemere et al.,  1996). The N-terminal heterogeneity of AP with a 
potential of such N-terminally truncated species for enhanced aggregation has also been 
documented (Iwatsubo et al., 1996; Pike et al., 1995; Tekirian et al., 1998).
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The biochemical and toxicological properties of the Ap peptide deposited in HCHWA- 
D  and  other  variants  have  been  extensively  studied.  In  HCHWA-D  the  amyloid 
deposited as CAA is composed of both variant (E22Q) and wild-type Ap (Prelli et al., 
1990). Compared with wild-type Ap both the Dutch and Iowa Ap40 synthetic peptides 
rapidly assemble to form fibrils in solution, while the Flemish Ap40 peptide does not 
(Wisniewski et al., 1991; Van Nostrand et al., 2001). A further feature of the Dutch and 
Iowa  synthetic  peptides  is  that  they  induce  robust  pathologic  responses  in  cultured 
human  cerebrovascular  endothelial  cells  and  are  also  toxic  to  smooth  muscle  cells 
(Miravalle et al, 2000). Similar to Ap parenchymal lesions, vascular Ap deposits are 
also  associated  with  deposition  of AAPs,  including  complement  components,  serum 
amyloid  P  component  (SAP),  ApoE,  a-l-antichymotrypsin  (ACT), 
glycosaminoglycans,  extracellular matrix proteins  and complement inhibitors  such as 
ApoJ  and  vitronectin.  Whether  these  unrelated  proteins  are  key  elements  for  the 
mechanism of fibre formation or represent innocent bystanders is not known.
1.7.5  Other hereditary cerebral amyloid angiopathies
1.7.5.1  Acys in HCHWA-I
HCHWA-I  also known as hereditary cystatin C amyloid angiopathy (HCCAA)  is an 
autosomal dominant condition with an early onset (Ghiso et al., 1986). Individuals may 
clinically  present  with  a  cerebral  haemorrhage,  followed  by  cognitive  decline  and 
dementia.  Pathological  examination  shows  severe  CAA  of leptomeninges,  cerebral 
cortex, basal ganglia, brainstem and cerebellum (Gudmundsson et al.,  1972; Jensson et 
al.,  1989).  In addition, amyloid deposits can be  found in peripheral tissues including 
skin, lymphoid tissues, salivary glands and testes (Benedikz et al., 1990; Lofberg et al,
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1987).  The  amyloid  deposited  is  an  N-terminal  truncated  degradation  product  of 
cystatin C bearing a single glutamine for leucine substitution, due to an A for T point 
mutation at codon 68 of the cystatin C gene, located on chromosome 20pl 1.2 (Levy et 
al.,  1989; Ghiso et al.,  1986;  Schnittger et al.,  1993). In patients with HCHWA-I the 
CSF  levels  of cystatin  C  were  found to  be  higher than those  of healthy  individuals 
(Bjamadottir et al., 2001). The structural differences between the variant (L68Q) and 
wild-type cystatin C account for the susceptibility of the variant protein to unfolding, 
proteolysis and fibrillogenesis (Calero et al., 2001).
1.7.5.2  Transthyretin
Amyloidoses due to mutations of the transthyretin (TTR) gene, located on chromosome 
18, are late onset autosomal dominant systemic diseases in which the deposition of one 
of the many variant transthyretin proteins (TTR) takes place in multiple organs (Benson, 
1996; Nilsberth et al., 2001; Ghiso et al., 1994). The TTR molecule has an extensive 1 3- 
structure, the TTR monomer has eight (3-strands arranged in anti-parallel configuration 
in two planes. It has also been suggested that single amino acid substitutions predispose 
TTR to fibril formation as they destabilize it by lowering the energy requirement for 
tetramer dissociation (Koo et al.,  1999). The most common phenotype associated with 
mutations in TTR gene is a condition identified as familial amyloidotic polyneuropathy 
(FAP).  The  systemic  organs  most  commonly  affected  by  amyloid-TTR  (ATTR) 
deposition  are  heart,  eye  and  kidney  and  can be  affected  individually  or  in  various 
combinations with the involvement of the peripheral nerve. Involvement of the CNS is 
exceptional,  but  a  few  variants  are  known.  A  Hungarian  kindred  carrying  a  D18G 
mutation has been reported  (Garzuly  et al.,  1996)  in which  affected  individuals  are
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reported to have memory loss,  decreased hearing and signs of cerebellar involvement 
and pyramidal dysfunction.
1.7.5.3  Gelsolin
Gelsolin  related  amyloidosis  or  familial  amyloidosis,  Finnish  type  (FAF)  is  an 
autosomal  dominant  condition  characterized  by  systemic  deposition  of the  amyloid 
protein gelsolin (AGel).  This disease  has been documented worldwide (Kiuru,  1998) 
with the majority of cases being found in Finland.  The major clinical presentation of 
FAF  includes  ophthalmologic,  dermatological  and  neurological  symptoms  (Kiuru, 
1998).  Two  point  mutations  are  known  within  the gelsolin  gene,  either  G654A  or 
G654T. In all Finnish patients studied the G654A mutation has been found, whereas the 
G654T mutation is found in pedigrees from Denmark and Czechoslovakia (Haltia et a l, 
1990; Levy et al,  1990b; de la et al,  1992). Gelsolin is a unique protein which occurs 
in a cytoplasmic 80kDa form and a plasma 83kDa form, both of which are generated by 
alternative  transcriptional  initiation  sites  and  mRNA  processing  from  a  single  gene 
located on chromosome 9 at q32-34 (Kwiatkowski et al,  1986).  The two forms differ 
from  one  another by  the presence  of an N-terminal  25  amino  acid  extension  in  the 
secreted plasma form (Yin et al,  1984).  AGel deposited in tissues of FAF patients is 
composed of internal proteolytic fragments of the mutated proteins spanning positions 
173-243 or 173-225 of the secretory form of gelsolin (Ghiso etal., 1990; Maury, 1991). 
Gelsolin itself appears to have a low amyloidogenic potential, indicated by secondary 
structure predications (de la et al,  1992). In contrast, substitution of the charged amino 
acid  aspartic  acid  (187)  by  an  amino  acid  with  an  uncharged  (asparagine)  or 
hydrophobic side chain (tyrosine) creates an amyloidogenic sequence,  suggesting that 
residue  187 is a critical site for amyloidogenesis (Maury et al,  1994). Because of the
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charge change in the gelsolin molecule it is postulated the susceptibility to proteases 
alters thereby rendering the molecule amyloidogenic. The deposition of AGel amyloid 
in  most tissues with  a predilection for blood vessel  walls  and basement membranes 
takes place. The prominent amyloid angiopathy involves arteries of nearly every organ 
including the CNS.  Small and medium sized arteries and arterioles and capillaries are 
mainly  affected,  but  veins  show  only  occasional  involvement.  The  production  of 
gelsolin by vascular smooth muscle cells is of specific interest, as it may relate to one of 
the  most  characteristic  pathological  findings  in  FAF  the  prominent  and  widely 
distributed amyloid angiopathy.
\
1.7.6  CAA in BRI2 gene related dementias
FBD has been documented as showing severe and widespread CAA (Plant et al.,  1990; 
Revesz  et  al.,  1999).  Widespread  deposition  of  amyloid  in  the  cerebral  arteries, 
arterioles and capillaries has been found,  but amyloid deposition rarely affects veins. 
Establishing the pattern and distribution of ABri deposition forms part of the subject of 
this study. Despite the severe CAA significant cerebral haemorrhage is relatively rare 
(Mead et al., 2000; Plant et al,  1990) unlike in HCHWA-D and HCHWA-I in which 
cerebral haemorrhage is a common clinical manifestation. In FDD the only information 
available suggests that ADan is deposited in both blood vessels and parenchyma (Vidal 
et al.,  2000b).  However,  no  systematic  investigation has been previously carried out 
about ADan deposition in FDD CAA. Co-deposition of AP in FDD has been described 
briefly  within  ADan  positive  vascular  amyloid  mainly  in  the  form  of perivascular 
plaques (Vidal et a l, 2000b).
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1.7.7  Mechanisms of CAA: Systemic verses local origin
The  origin  of the  different  amyloid  proteins  in  cerebral  blood  vessels  is  not  fully 
understood and a number of hypotheses have been proposed, which mainly deal with 
the  origin  of Ap  in  sporadic  and  AD  related  CAAs.  As  most  cell  types  are  able to 
produce ApPP several theoretical possibilities can be considered for the origin of the 
Ap deposits in cerebral blood vessels.
1)  AP  depositing  in  cerebral  blood  vessels  may  be  derived  from  the 
circulation. In support of such a hypothesis is the observation that ApPP is expressed by 
megakaryocytes,  is present in platelets and  sAP is present in plasma (Gardella et al 
1992; Mackic et a l,  1998; Zlokovic et a l,  1993). Furthermore there is a bi-directional 
receptor-mediated transport across the blood brain barrier (BBB), and exchanges of Ap 
between  the  CNS,  blood  and  CSF  play  an  important  role  in  determining  Ap 
concentration in the CNS (Zlokovic,  2002).  A number of receptors including RAGE 
(receptor for advanced glycation end products), LRP-1 (low-density lipoprotein receptor 
related protein-1), SR (scavenger receptor) and megalin receptors have been implicated 
in this process (Mackic et al,  1998; Shibata et al, 2000; Zlokovic et al, 1996). RAGE- 
mediated AP transport is present at the luminal side of the BBB facilitating Ap transport 
in  a  luminal  to  abluminal  direction  and allowing  a significant  influx of Ap  into the 
brain.  In contrast the LRP-1  receptor mediated transport is initiated at the abluminal 
side and has a role in eliminating AP from the cerebral interstitial fluid. It is of note that 
one of the modulators of this process is the LRP-1 ligand ApoE, which is also one of the 
risk factors of CAA and sporadic AD (Zlokovic, 2002).
Another source of AP  in CAA could be the CSF where it is present in both normal 
individuals  and  AD  patients.  The  arguments  against  a  blood  borne  derivation  of 
cerebrovascular Ap include the finding that Ap is first detectable morphologically in the
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abluminal basement membrane of blood vessels (Yamaguchi et al.,  1992).  The more 
common involvement of arteries than veins and smaller arteries than larger ones in the 
subarachnoid space are arguments against a CSF origin of AP in CAA (Weller et al., 
1998).  Furthermore  systemic  overexpression  of a C-terminal  fragment  of the  human 
APPP in transgenic mice, which has high levels of sAP in the plasma, does not result in 
CAA or deposition of AP in brain parenchyma (Tamaoka et al, 1998).
2)  The  vascular  hypothesis  proposes  that  Ap  may  derive  from  cerebrovascular 
cellular  elements  and  this  proposition  is  supported  by  morphological  observations 
showing that AP  deposits are closely associated with cerebrovascular smooth muscle 
cells (Kawai et al.,  1993; Vinters et al,  1996). Furthermore it has been demonstrated 
that isolated cerebral microvessels and meningeal blood vessels are able to produce Ap. 
Arguments  against  the  vascular  hypothesis  include  the  finding  that  Ap  deposits  in 
capillaries, which lack smooth muscle cells, and also that of larger arteries, which have 
several layers of smooth muscle cells are less affected (Wisniewski & Wegiel, 1994).
3)  The drainage hypothesis proposes that Ap, produced primarily by CNS neurons, 
is  drained  along  the  periarterial,  perivascular  spaces  of the  brain  parenchyma  and 
leptomeninges and CAA occurs due to deposition of Ap along these drainage pathways 
(Weller  et  al,  1998).  Degenerative  changes  that  commonly  affect  aged  individuals 
could  have  a  deleterious  effect  on  the  perivascular  flow  of  interstitial  fluid  and 
contribute to vascular deposition of Ap. The presence of CAA in some of the transgenic 
animal  models  of AD  in  which  ApPP  is  expressed  by  neurons  could  support  the 
drainage hypothesis (Van Dorpe et al., 2000).
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Data  suggest  that  some  of the  amyloid  peptides  implicated  in  familial  CAAs  for 
example ACys, ATTR and AGel may derive from the circulation as they all deposit in 
systemic organs (Kiuru, 1998; Olafsson etal., 1996; Garzuly et al., 1996), but the origin 
of ABri  and  ADan deposited  in the brain parenchyma  and cerebral  blood  vessels  is 
unknown. The possibilities include that they are derived from the circulation like some 
other amyloid  forming peptides,  are produced  solely by cellular elements within the 
CNS, which is similar to that found with ApPP in AD, or that both mechanisms may be 
present.  Observations to date have shown that ABri is found in the circulation and is 
deposited  systemically in FBD  (Ghiso et al.,  2001),  which raises the possibility that 
peripherally produced ABri species could also be a source of CNS amyloid deposits. 
Although the familial forms of CAA are usually rare disorders, some of these disorders 
such as the BRI2 gene-related dementias might provide an insight into the link between 
cerebral vascular and parenchymal amyloid deposition and neurodegeneration.
1.8  Tau
1.8.1  Tau protein and normal function
Tau,  a  microtubule-associated  proteins  (MAPs),  functions  to  stabilize  microtubules 
within  cells.  Microtubules  have  two  general  functions  1)  they  form  the  primary 
structural component of the mitotic spindles and 2) organise the cytoplasm.
1.8.2  Tau deposition
Insoluble tau isolated from neurodegenerative diseases is hyperphosphorylated and does 
not bind to microtubules (Lovestone & Reynolds,  1997;  Grundke-Iqbal et al.,  1986; 
Morishima-Kawashima et al., 1995). The major effect of tau hyperphosphorylation may
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be the destabilization of microtubules.  Tau knock-out mice develop  almost normally 
indicating that loss of tau function may be compensated by other MAPs (Harada et al., 
1994). Hyperphosphorylated tau is able to bind normal tau and other MAPS leading to 
microtubule disruption (Alonso et al,  1996). A number of protein kinases and protein 
phosphatases have been implicated in the abnormal phosphylation of tau. These include 
a number of stress activated protein kinases.
NFTs  develop  intracellularly  and  consist  of  PHFs  which  are  formed  by 
hyperphosphorylated tau. With time the neurons containing PHF tau die leaving behind 
extracellular  ghost  tangles  (Bancher  et  al,  1989;  Braak  et  al,  1994).  Various 
components  have  been  associated  with  these  extracellular  ghost  tangles  including 
growth factors (Tooyama et al, 1993), proteoglycans (Alonso et al,  1996; Snow et al, 
1992) and complement components (McGeer et al, 1989; Schwab et al, 1996b).
1.9  Role of complements in cerebral amyloid diseases
Evidence  suggests  that  cerebral  inflammation  is  associated  with  AD  pathogenesis 
(Akiyama etal., 2000) and inflammatory mediators, immunologic factors and activators 
of the complement pathways have been implicated in this process (Berkenbosch et al, 
1992). Complement proteins have been shown by previous studies to be associated with 
Ap plaques (Head et al,  2001;  Stoltzner et al, 2000;  Webster et al,  1997) amyloid­
laden blood vessels (Verbeek et al,  1998) and NFTs (Alonso et al,  1996; Shen et al, 
2001; Schwab et al, 1996b) in vivo. AP has been shown to bind to Clq and activate the 
classical pathway (Afagh et al, 1996; Rogers et al, 1992b) and the alternative pathway, 
through  the  hydrolysis  of C3  (Bancher  et  al,  1987;  Pangburn  &  Muller-Eberhard, 
1983).
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1.9.1  Introduction to the complement cascades
Complement  proteins  are  a  group  of serum  and  cell  surface  proteins  that  interact 
together  and  with  other  immune  system  molecules  in  a  highly  regulated  manner, 
providing many of the effector functions of humoral immunity and inflammation. There 
are two complement pathways; one is the phylogenetically older ‘alternative’ pathway, 
which is initiated on microbial  surfaces without the requirement for specific immune 
responses.  The second pathway,  called the ‘classical’  pathway,  is usually initiated by 
binding  of  complement  proteins  to  antibody-antigen  complexes.  Both  pathways 
converge to a common final pathway generating the assembly of the membrane attack 
complex (MAC) (figure 1.10).
The functions of the complement pathways fall into two broad categories 1) cell lysis by 
the MAC and 2) biological effects of proteolytic fragments of complement. It has been 
described how complement activation on cell surfaces leads to the insertion of the MAC 
into lipid bilayers causing osmotic lysis of the cell. Many other effects of complement 
in  immunity  and  inflammation  are  mediated by  the  proteolytic  fragments  generated 
during  complement  activation.  These  proteolytic  fragments  may  remain  membrane 
bound to the  same cell  surface to where complement  has been  activated  or may  be 
released into the fluid phase (blood or extracellular).
1.9.1.1  Classical pathway
The ‘classical’ pathway is activated principally by the binding of Cl to the Fc portion of 
antibody  molecules  that  have  bound  antigens.  There  are  stringent  requirements  for 
antibody mediated Cl activation that ensures the pathway is activated only under certain 
conditions.  Activation  of  Cl  requires  specific  regions  of  certain  antibodies,  with 
examples including the Cy2 domains of IgG or C|i3  domains of IgM.  Furthermore a
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single Cl molecule must bind simultaneously to at least 2 Fc portions of Ig to induce a 
conformational change in the Cl  molecule,  inducing enzymatic activity.  Cl  is a large 
multimeric protein complex ~750kDa,  composed  of Clq,  Clr and Cls subunits.  The 
catalytic  functions  of Cl  are  mediated  by  Cls-Clr-Clr-Cls  tetramer  that  is  non- 
covalently associated with the Clq subunit. Clr and Cls are serine esterases that remain 
inactive until the Cl molecule binds to an immune complex
Factor B Alternative Pathway Factor D
C3a
C3 converts se C5 convertase
C3bBb C3 C3b
Microbial surfaces 
polysaccharides
C5b C3b  C5 C5b-9
C3a C4a
C4bl C4b2a C4b2a3b
C3 convertase C5 convertase
C2b
Classical Pathway
Artigen-Anbbody
complex
Figure 1.10: Alternative and classical complement pathways.  The diagram shows how 
the alternative pathway is activated by microbial surfaces and the classical pathway by 
antigen-anti  body complexes.  Both pathways converge by catalysing the conversion of 
C5 to C5b and the formation of the MAC complex.
Once bound Clr is enzymatically activated, this then cleaves and activates Cls. Which 
in turn acts on the next two components of the classical pathway, C4 and C2. C4 is the 
next serum complement protein to be activated in the classical pathway, participating in 
the formation of the C3  convertase.  In addition,  it  is critical  for keeping  subsequent 
activation steps localized to the initial site where the antibody is bound. C4 consists of 3 
polypeptide  chains  a, (3   and  y.  The a  chain  contains  a  thioester bond  similar to  C3 
keeping the C4 molecule localized to the antigen-antibody binding site. The a chain of
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the soluble C4 is cleaved by the active Cls component yielding a large short-lived, C4b 
molecule and a small C4a fragment that diffuses from the cell surface. C4b contains a 
thioester bond in the a  chain and is highly susceptible to nucleophilic attack. Most C4b 
molecules are inactivated by rapidly reacting with water.
C2 is the third soluble serum component of the classical pathway. It is involved in the 
formation of the C3 convertase. It is a single chain polypeptide that binds to cell surface 
bound C4b molecules in the presence of Mg++. Once bound to C4b, C2 is cleaved by a 
nearby Cls molecule to generate a soluble C2b fragment of unknown significance. The 
larger C2a fragment that is produced remains associated with C4b on the cell surface, 
resulting in the formation of the C4b2a complex, known as the classical pathway C3 
convertase.
C3  is the fourth soluble serum component in the classical pathway,  but also a central 
component of the alternative pathway.  C3  convertase removes a small  C3a fragment 
from the a-chain of C3  generating C3b, which contains unstable thioester bonds that 
react with water yielding inactive C3b (iC3b). Around  10% of the C3b formed forms 
covalent  bonds  with  cell  surfaces  or  with  Ig  to  which  the  C3  convertase  is  bound 
resulting in the formation of C4b2a3b known as the classical pathway C5 convertase. 
C5 convertase catalyses the cleavage of C5, which intiates the formation of the MAC. 
Proteins involved in the terminal pathway include C5, C6, C7, C8 and C9. This part of 
the process is initiated by the cleavage of C5 by either of the C5 convertases from the 
alternative  or  classical  pathway.  Further  steps  in  these  pathways  do  not  involve 
enzymatic degradation, but require the binding and polymerisation of intact proteins. C5 
is then cleaved into a small C5a fragment that is released and a two chain C5b fragment 
that remains bound to the cell  surface.  C6, C7, C8, and C9, which are the remaining 
components  of  the  cascade,  are  structurally  related  proteins.  C5b  maintains  its
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conformational shape ready to bind C6 and the stable C5b-6 complex is produced and 
remains  loosely  associated  with  the  cell  surface.  Once  C7  is  bound  the  resulting 
molecule becomes highly lipophilic and is inserted into the hydrophobic lipid bilayer of 
cell  membranes.  Once  inserted  into  the  membrane  one  C8  molecule  is  bound.  The 
formation of the highly lytic and microbicidal MAC is accomplished by binding of C9. 
C9  is  a  monomeric  serum  protein that  polymerises  at the  site  of the  bound  C5b-8. 
MACs with just four C9 molecules bound have full lytic capabilities.
1.9.1.2  Alternative pathway
The alternative pathway is activated in the absence of antibodies and is, therefore,  a 
mechanism  of innate  immunity.  This  pathway  is  in  a  continuous  state  of low-level 
activation due to the reactivity of soluble C3 with water. This fluid phase activation is 
sometimes called C3 tickover, which then goes on to promote solid phase activation. 
The  fluid  phase  activation  is  initiated  when  the  internal  thioester  bond  of C3  is 
hydrolysed by water to form an unstable intermediate called C3i, which binds to the 
alternative  pathway  protein  factor B.  Once  bound  to  C3i  factor B  is  susceptible  to 
proteolysis by factor D, a serine protease that circulates at very low concentration in the 
serum. Factor D proteolytically cleaves bound factor B, releasing a small fragment (Ba), 
leaving  a  larger  fragment  Bb  attached  to  C3i.  This  C3iBb  complex  is unstable  and 
rapidly decays unless it is bound to properdin. Properdin may also bind to C3i before 
factor D,  and  promote the  binding  of factor B.  The  stable  complex  formed  by  the 
binding of both properdin and factor B is the initial alternative pathway C3 convertase, 
where the Bb fragment functions as a serine protease capable of cleaving C3.
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1.9.2  Regulation of pathways
The complement  cascades have evolved to permit rapid,  self-amplified activation on 
microbial  surfaces,  which  is  necessary  for  effective  defence  against  infection.  The 
requirement for tight regulation of both pathways is needed, without which complement 
activation could lead to deleterious consequences. About half the protein components of 
the  complement  system  function  as  regulatory  molecules,  showing  how  tightly  the 
system  is  controlled.  As  complement  activation  involves  both  the  fluid  phase  and 
localized membrane events, the regulatory mechanisms have evolved to include both 
soluble  and  integral  membrane proteins.  The  majority of regulatory  mechanisms  are 
directed toward the  C3  convertase  activity,  which  is the  central  feature  of both the 
classical and alternative pathways.
Inhibition  of the  initiation  of the  classical  pathway  is  undertaken  by  Cl  inhibitor 
(C1INH).  C1INH functions  by  presenting  a  ‘bait’  sequence that  mimics the  normal 
substrates of Clr and Cls. Most of the Cl found in the blood is non-covalently bound to 
C1INH (which is present at seven times the molar concentration of Cl). However, once 
Cl binds to antigen-complexed antibody, via the Clq subunit the C1INH is released and 
the classical pathway can proceed.
If the  classical  and  alternative  pathways  are  activated,  they  have  the  potential  to 
generate millions of C3b molecules by the action of the C3 convertases. Several of the 
proteins involved in C3/C5 convertase regulation are members of a family of proteins 
called  regulators  of complement  activation  (RCA).  All  these  proteins  also  share  a 
structural feature, the presence of multiple copies of a 60 amino acid long, cysteine-rich 
module called a complement control protein repeat (CCPR). Molecules involved in this 
regulation include Factor I, which is a plasma serine protease that cleaves C3b and C4b 
preventing their insertion into the convertases. Factor H and C4-binding protein are two
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RCA  members  that  serve  as  important  cofactors  for  Factor  I-mediated  proteolysis. 
Factor H and C4BP work in a similar fashion by binding to the fluid phase C3b and C4b 
respectively,  and  inhibiting the  formation  of the  C3  convertases.  The  second  major 
mechanism in the regulation of C3/C5 convertases is the destabilization of the enzyme 
complexes  themselves.  The  major  host  cell  membrane  bound  protein  is  decay- 
accelerating  factor  (DAF),  which  is  also  a  member  of the  RCA  family.  DAF  is 
expressed on most blood cells, endothelium and epithelial cells, being covalently linked 
to the outer leaflet of the plasma membrane by a phosphatidyl-inositol linkage. DAF 
functions by binding either C3 convertases and causing rapid release of Bb from C3b, or 
C2a from C4b.
Even after the formation of the convertases, excessive complement mediated cell lysis is 
prevented by a number of proteins that act at the level of MAC. The presence of MAC 
inhibitory molecules on host cells distinguishes them from most microbes and protects 
cells against lysis. In addition, at the C5b-7 stage, the growing MAC complexes have 
the ability to insert into neighbouring cell membranes besides the membrane on which 
they were generated. Therefore, inhibitors are needed in the host cell membranes and at 
the  plasma  level  to  ensure  innocent  bystander  cell  lysis  does  not  occur.  A  major 
membrane inhibitor of MAC is CD59 (membrane inhibitor of reactive lysis). It is also, 
like DAF inserted into the membrane by a phosphatidylinosital linkage. CD59 works by 
inserting itself into the growing MAC  complex after the  insertion of C5b-8,  thereby 
inhibiting C9  membrane  insertion.  Soluble inhibitors of MAC  include vitronectin (S 
protein)  and  ApoJ  (Clusterin,  SP40-40).  Vitronectin  functions  by  binding  C5b-9 
complex  preventing  their  insertion  into  the  cell  membrane.  Like  vitronectin,  ApoJ 
inhibits  MAC  formation  by  binding  to  soluble  C5b-7  complexes  and  preventing 
membrane insertion.
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1.9.3  Vitronectin
Vitronectin (Vn) is a multifunctional protein that has been reported to have roles in cell 
adhesion,  regulation of complement cascades and blood coagulation.  It  is present  in 
serum at 200-400  pg/ml,  and is also present in  many tissues as a component of the 
extracellular  matrix.  As  a  complement  inhibitor  it  can  bind  to  the  nascent  C5b-7 
terminal  complement  pathway  components  therefore  preventing  the  insertion  and 
assembly of the C5b-9 membrane attack complex into cellular membranes. Vn generally 
localizes at the site of complement activation and has also been visualized in AD brains, 
in which it co-localizes with Ap containing plaques and NFTs. It is bound to cells that 
express a group of integrin receptors that recognises the Arg-Gly-Asp amino acid motif. 
Although  primarily  produced  in  the  liver  other  tissue  cells  can  express  Vn  mRNA 
including  brain,  heart,  and  skeletal  muscle  and  cerebellar Purkinje  cells  (Walker  & 
McGeer, 1998).
1.10  Amyloid Associated Proteins (AAPs)
The amyloid  structures found in the neurodegenerative diseases mentioned above are 
not a result of the accumulation of the amyloid proteins alone, but such structures also 
contain a number of other components, generally referred to as AAPs.  Attention was 
first placed on the senile plaques found in AD and the presence of a variety of proteins 
associated with such lesions was documented (Wisniewski & Frangione,  1992).  These 
included complement factors and their inhibitors, acute phase proteins,  proteoglycans 
and ApoE and it was proposed that most of these proteins are deposited as a result of 
amyloid deposition.
There  are two  possible  roles  for the  AAPs  in the pathogenesis  of Ap  deposition  in 
plaques and/or CAA. They may trigger or facilitate AP deposition and/or fibrillization
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(Ghiso & Frangione, 2002), or, as a secondary effect, increase Ap induced cytotoxicity 
and tissue damage. Theoretically, it is also possible that they do not have any biological 
effect.
1.10.1  Apolipoprotein £
ApoE is a 34-kDa product of a 4 exon gene located on the long arm of chromosome 19, 
and is central to cholesterol metabolism (Mahley,  1988).  It is classed as a very low- 
density  lipoprotein,  which  is  synthesized  primarily  by  the  liver.  In  addition  to 
cholesterol metabolism it is also important in local  circuits of lipid turnover that are 
involved in  membrane repair.  In humans, the ApoE gene is polymorphic,  leading to 
three major ApoE isoforms (E2, E3 and E4). ApoE3, the most common isoform, has a 
cysteine at position  112 and an arginine at position  158;  ApoE2 is the least frequent 
isoform, with cysteine at both positions, whereas ApoE4 presents arginine at both sites 
(Mahley,  1988).  The  role  of ApoE in the  pathogenesis  of AD  is unclear,  given the 
multiple functions of ApoE that are already known.  It has been proposed that ApoE 
functions as a ‘pathological chaperone’  in AD (Wisniewski & Frangione,  1992).  This 
term  describes  a  process  in  which  a  protein  binds  to  another,  inducing  and/  or 
maintaining an altered or intermediate folding state that leads to an incorrect fate in 
vivo. ApoE has also been shown to be present in systemic amyloid deposits, which are 
not related to Ap, therefore ApoE most likely has a general role in amyloidogenesis. 
ApoE binds to Ap only after it has been cleaved from ApPP and acts as a glue to foster 
plaque  maturation,  making it resistant to  degradation.  Such a role  is consistent with 
immunohistochemical studies on ApoE distribution among different types of amyloid 
deposits (Sheng et al,  1996; Gallo et al,  1994). There have been several studies that 
have shown ApoE is able to enhance AP polymerisation and aggregation. (Sanan et al,
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1994;  Ma  et al.,  1994).  The  different  isotypes  have  been  shown to  bind  to  Ap  at 
different  rates  (Yang  et  al.,  1997),  with  the  ApoE3/ApoE2  isoforms  binding  more 
avidly to  Ap than the  ApoE4  isoform.  Furthermore the  density  of Ap  deposition  is 
directly related to the inheritance of an 84 allele (Schmechel et al.,  1993), therefore the 
inability of ApoE4 to bind Ap efficiently may result in the accumulation of Ap leading 
to its deposition.
Transgenic  mice  carrying  the ApPP^1 1 7 1 *   mutation  show  large  fibrillar  AP  deposits 
surrounded by plaque-associated dystrophic neurites.  In the ApPPV717F apo E-/- mice 
extensive  nonfibrillar  Ap  deposits  were  observed  and  the  neuritic  degeneration was 
relatively rare,  suggesting that the presence of ApoE is required for the formation of 
amyloid  plaques.  However  when  astrocyte-specific  expression  of human  apoE3  or 
apoE4  was  introducted  in  such  animals,  fibrillar  Ap  deposition  could  be  restored 
(Holtzman et al, 2000a). ApoE has also been shown to be a ligand for LRP-1 (Beisiegel 
et al.,  1989), and is also a constituent of high-density lipoproteins which are associated 
with soluble Ap in the CSF (Koudinov et al.,  1996) and bind to LRP-1  (Fagan et al.,
1996).  It  has  been  shown  that  Ap  is  internalized  via  a  pathway  that  shows  close 
relationship to the metabolism of ApoE-containing lipoproteins,  via LRP-1  and other 
lipoprotein receptors (Urmoneit et al., 1997).
1.10.2  Apolipoprotein J
ApoJ is a multifunctional disulfide linked heterodimeric glycoprotein composed of two 
-40 kDa subunits, named a- chain and P- chains (de Silva et al., 1990a). The final ApoJ 
structure is generated by post-translational cleavage at peptide bond Arg 205- Ser206 and 
stabilized by five interchain disulfide bonds. A single gene on chromosome 8 produces
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a single mRNA that codes for a 449 amino acid chain containing a leader sequence and 
the a and (3  subunits (Kirszbaum et al,  1989).  ApoJ mRNA is found within almost all 
mammalian tissues (Collard & Griswold, 1987) as well as in all body fluids (Aronow et 
al,  1993).  ApoJ is mainly a secreted glycoprotein although an intracellular form has 
been described (Jin & Howe, 1997). It was first isolated from ram rete testis and named 
clusterin because of its ability to elicit clustering of Sertoli cells (Blaschuk et al,  1983; 
Fritz et al,  1983).  Since then this multifunctional ubiquitous protein has been purified 
from several tissues where it apparently exhibits different functional properties.  ApoJ 
has  been  implicated  in  the  following  normal  functions;  as  a  phagocyte  recruitment 
signal (Buttyan et al, 1989); it promotes aggregation and adhesion of cells (Silkensen et 
al,  1995); involoved in spermatogenesis (Hermo et al,  1994); development (French et 
al, 1993); complement inhibition (Jenne & Tschopp, 1989) and lipid transport (de Silva 
etal, 1990b).
The  CNS  is  a  major  site  of ApoJ  mRNA,  although  regional  differences  have  been 
observed (Danik et al,  1993). High levels are found in neuron rich layers including the 
granular cell layer of the hippocampal formation, whereas the cortical layers show ApoJ 
mRNA is also expressed by astrocytes.
In pathological conditions, such as AD, an increase of mRNA and protein expression is 
observed  (Duguid  et  al,  1989).  Immunohistochemical  staining  for  ApoJ  has  been 
shown to co-localise with amyloid lesions in the brain and peripheral organs, including 
many diffuse lesions found in the cortex of AD and DS cases (McGeer et al,  1992). It 
has also been shown that ApoJ immunoreactive, NFT-free neurons appear to be 
relatively resistant to neuronal death in AD, suggesting a neuroprotective role for Apo J 
in AD (Giannakopoulos etal, 1998).
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1.10.3  Serum amyloid P component
SAP  component  was  named  because  of  its  amyloid  binding  capacity.  SAP  is  a 
component of all amyloid deposits including those of AD. SAP is known as a pentraxin 
because of its capacity to aggregate in a non-covalent fashion into flat pentameric discs. 
Pentraxins are also able to activate the classical complement pathway in an antibody 
independent manner (Hicks et al.,  1992).  It has been presumed that SAP is primarily 
produced by liver hepatocytes (Gabay & Kushner,  1999) and that the presence of SAP 
within  cerebral  amyloid  lesions  is  due  to  a  damaged  BBB  (Kalaria  et  a l,  1991). 
However, this proposition has been disputed by some (Caserta et al.,  1998) as it has 
been shown that SAP mRNA is present several organs (Yasojima et al., 2000), and was 
also found in other cell types  such as macrophages and neurons.  SAP has also been 
reported to be a normal constituent of basement membranes and it may have a normal 
physiological role as well as being a response protein in pathological situations (Zahedi,
1997).  Its  strong binding to glycosaminoglycans would  explain  its appearance  in  all 
forms of amyloid but would not explain its association with pathological structures such 
as NFTs (Schwab et al'.,  1997). Immunohistochemical staining of SAP usually mirrors 
that seen for C4d (McGeer et al.,  1991), but its deposition on NFTs has been found to 
precede the appearance of C4d (Schwab et al., 1997).
Using immunoelectron microscopy SAP has also been shown to be associated with Ap 
fibrils (Holm et al, 2000). Positivity for SAP was seen on the surface of in vitro formed 
mature AP42 fibrils,  whereas protofibrils,  representing earlier stage in fibrillogenesis 
did not show any positive immunoreactivity.
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1.10.4  a-l-antichymotrypsin
ACT is an inhibitor of chymotrypsin-like serine protease and is normally produced in 
the liver as part of the acute phase response to inflammation. ACT is overexpressed in 
astrocytes in brains of AD  patients (Pasternack et al.,  1989).  With the deposition of 
ACT in amyloid laden blood vessels and plaques the question can be raised whether 
inflammation was merely a response to the disease or whether it was an essential cause 
of the disease. In situ hybridisation studies in AD brain revealed that ACT is produced 
mainly by reactive astrocytes located around senile plaques (Abraham, 2001). Virtually 
all  plaque  types,  including  the  diffuse  ones,  are  stained  with  antibodies  to  ACT, 
suggesting that  ACT  first appears  in  early  diffuse plaques.  Rozemuller et  al  (1991) 
found  that  ACT  immunoreactivity  was  associated  with  congophilic  plaques  and  in 
amorphous  plaques  and  resembled  the  staining  pattern  of  Ap.  They  also  found 
infrequent staining of NFTs. An antibody directed against an inactive form of ACT was 
found to be negative on pathological structure and vascular amyloid was negative with 
all the ACT antibodies.
Amino acids 1-12 of AP closely resemble the conserved active site of serine proteases, 
the natural target for protease inhibitors  such as  ACT.  In contrast to  ACT,  ApoE is 
found to be associated with all cerebral and systemic amyloids, apparently reflecting a 
more general  affinity  for the  P-pleated  sheet  conformation  characteristic  of amyloid 
filaments.  ACT was not detected in amyloid deposits occurring  in other amyloidoses 
studied so far, raising the possibility of a special interaction between ACT and Ap. This 
can be tested in the two novel diseases, FBD and FDD with ABri and ADan amyloid 
lesions respectively
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1.10.5  Cystatin C
Cystatin C, also known as y-trace protein, is an alkaline protein composed of one non­
glycosylated  120 residue polypeptide chain (Grubb & Lofberg,  1982), belonging to a 
group  of potent,  non-covalent,  competitive  inhibitors  of cysteine  proteinases  of the 
papain superfamily and is present in all body fluids with the highest concentrations in 
the  CSF  and  seminal  fluid  (Bobek  & Levine,  1992).  It  has  a  molecular weight  of 
~14KDa  and  mRNA  levels  of cystatin  C  were  found  at  varying  levels  in  different 
tissues with highest expression levels in pancreas, testis and brain. The human cystatin 
C gene has been mapped to chromosome 20pl 1.2 (Abrahamson et a l 1989; Schnittger 
et a l,  1993). Mutant cystatin C is associated with HCHWA-I (see section 1.7.5.1) and 
the possibility that cystatin C may have a role in the pathogenesis of other amyloidosis 
was raised by the observation that it is present in Ap parenchymal and vascular amyloid 
lesions in AD (Levy et a l, 2001). Furthermore, a polymorphism in the cystatin C gene 
may confer a greater risk of developing AD (Crawford et al, 2000; Finckh et al, 2000).
1.10.6  Heperan sulphate proteoglycans (HSPGs)
HSPGs are a small subgroup of the larger group of proteoglycans (PG). PG molecules 
are composed of proteins and carbohydrates and are distributed throughout the body. 
Being  found  intracellularly,  on  cell  surfaces  and  in  the  extracellular  matrix.  By 
definition a PG is a molecule where at least one glycosaminoglycan (carbohydrate) side 
chain is covalently attached to the protein core of the molecule. EM studies have shown 
that PGs have a bottlebrush-like structure, with  the ‘bristles’ non-covalently attached to 
a filamentous hyaluronic acid backbone and are composed of a core protein to which 
glycosaminoglycans are covalently linked.  To date there have been 25  different core 
proteins found in the rat brain (Herndon & Lander, 1990).
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The carbohydrate moieties of PG are called glycosaminoglycans  (GAG).  They are  a 
group of polysaccharides of major structural importance in vertebrate animals. All are 
unbranched polymers composed of repeating disaccharide units,  in which one of the 
sugars is either N-acetylgalactosamine or N-acetylglucosamine.  The major GAGs are 
chrondroitin sulphate, dermatan sulphate,  keratan sulphate and heperan sulphate.  The 
extended  structures  of PGs  together with  their  polyanionic  character  of their  GAG 
components cause them to be highly hydrated.
Protein
Family
Name ~MW
core protein
GAG type Cellular origin Tissue
location
Lecticans Aggrecan 225-250 CS in brain Unclear Cartilage
Versican 400 CS Neurons (chick) Connective
tissue
Neurocan 245 CS Neurons Glia CNS
Brevican 140 soluble CS Glia CNS
Syndecans Syndecan-1 50 HS/CS Not known Cerebellum
Syndecan-2 48,90 HS Neurons
Syndecan-3 120 HS Neurons
Glypicans Glypican-1 64 HS Neurons CNS
Others NG2 300 CS Glia CNS
Perlecan 400 HS(CS) Blood  vessels, 
glia
Basement
membrane,
cartilage
Agrin 220 HS Neurons Basement
membrane
Table 3: Table of  HSPG’ s Showing cellular origin and tissue location; CS- chondroitcm 
sulphate, HS- Heperan sulphate, MW-Molecular weight
PGs  can  be  split  into  different  categories (table  3),  large  extracellular PG’s  include 
aggrecan, versican, neurocan and brevican. Cell-associated PGs form a variable group 
of molecules with many functions, which include syndecans and phosphatidyl inositol 
anchored proteoglycans. Nervous tissue proteoglycans include NG2, agrin and perlecan. 
One  important  feature of PGs  is their ability to form  non-covalent  interactions with 
other proteins through their GAGs.  One  such protein that PGs  have been  shown to 
interact with is A(3. Binding of sulphated GAG to Ap has been found to decrease AP
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degradation and this process is thought to be catalysed by insulin degrading enzyme. Ap 
has also been shown to bind to the core protein of HSPGs (Buee et al.,  1993). This is 
mediated by a heparin binding consensus sequence (VHHQKL) located towards the N- 
terminal end of the Ap peptide (Snow et al.,  1995). Ap easily self-aggregates to form 
amyloid fibrils in vitro and the binding of HSPGs to Ap (11-28 and 1-28) enhances this 
aggregation (Fraser et al., 1992).
GAGs and PGs have been found to be present in senile plaques and CAA in AD, and it 
has been suggested that they might enhance the polymerisation of Ap into fibrils. Such 
fibrils  would become  resistant to  proteolytic  cleavage  and  could therefore  stimulate 
further  deposition  of Ap.  It  has  been  suggested  that  oligomeric  and  protofibrillar 
intermediates  of  Ap,  which  are  said  to  be  highly  neurotoxic,  may  preferentially 
associate  with  sGAG  resulting  in  the  formation  of dense  filamentous  inclusions  in 
which  Ap  molecules  are  prevented  from  interacting  with  neuronal  membranes. 
According to this hypothesis the generation of senile plaques in AD would be a partially 
protective response aimed at reducing Ap neurotoxicity.
Several PGs and sGAGs have previously been shown to be associated with pathological 
lesions in AD. Syndecans and glypicans reside in the cell membrane but differ in core 
protein  structure  and  type  of  attachment  to  the  cell  membrane.  Syndecans  are 
transmembrane PGs and have a cytoplasmic domain, whereas glypicans are anchored to 
membrane lipids via glycosylphosphatidyl inositol molecules. Members of both families 
have been shown to be associated with senile plaques  and CAA related to Ap depostion 
(van Horssen et al., 2001), although differences were seen between members of each 
group. There are six members in the glypican family (GPC1 to GPC6), which have been 
identified in mammals (Veugelers et al., 1999). The size of the core protein is similar in
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all (60-70 kDa) and the homology is moderate. All  14 cysteine residues are conserved 
so therefore all may have a similar structure.
Agrin and perlecan are HSPGs associated with the extracellular matrix and have been 
studied  in  relation  to  AD.  Perlecan  was  first  isolated  from  the  Englebreth-Holme- 
Swarm tumor in 1980, and consists of a large core protein carrying 3 heparan sulphate 
side chains (Costell et al.,  1997). It is a major HSPG present in basement membranes 
and cartilage and was originally reported not to be present in the CNS.  Some studies 
have shown it to be present in normal CNS vessels but not in CAA or SP (van Horssen 
et a l, 2001), while others have suggested that it is present in amyloid-laden vessels and 
plaques  (Snow  et al.,  1994).  Agrin,  with  a molecular weight  of 500  kDa  (200KDa 
protein core) is a major basement membrane derived extracellular HSPG of the brain 
and has  an important role  in  synaptogenesis  at the  neuromuscular junction  (Cole  & 
Halfter, 1996). In vitro studies, using sGAG, have shown that they are important for the 
enhancement of Ap fibril formation (Castillo et al.,  1999) and that the deposition and 
accumulation of other PG’s/GAGs at sites of Ap deposition may also participate in the 
enhancement of Ap fibrillogenesis. Agrin has also been shown to contain nine protease 
inhibiting domains and may therefore, protect the protein aggregates in senile plaques 
against extracellular proteolytic degradation leading to the persistence of these deposits 
(Verbeek et al., 1999).
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1.11  Hypothesis
There  are  common  pathogenic  events  occurring  in  cerebral  amyloid  diseases 
irrespective  of the  amino  acid  sequence  of the  amyloid  peptide.  Therefore,  my 
main  hypothesis  investigated  in  this  thesis  is  that  FBD  and  FDD  provide 
alternative models of AD.
1.12  Questions and approaches
To investigate the main hypothesis of this thesis and issues related to FBD and FDD 
which had not been addressed previously in the literature as outlined in the introduction. 
The questions raised and the approaches taken are summarized below;
A)  What are the pathological features of FBD and FDD?
Al) What is the distribution of ABri fibrillar and nonfibrillar lesions in FBD and 
what is  their  relationship  to  neurofibrillary  pathology,  astroglial  and  microglial 
responses?
To address these questions in this study of FBD cases the topographical distribution and 
patterns of ABri deposition were studied by immunohistochemistry. To determine the 
conformational state of the protein deposits ABri immunohistochemistry was combined 
with  thioflavine-S  and  evaluated  by  confocal  microscopy.  The  distribution  and 
relationship of neurofibrillary degeneration to ABri deposits were investigated with tau 
immunohistochemistry  alone  and  in  combination  with  Ab338.  The  astrocytic  and 
microglial responses to ABri deposits were studied by a double immunohistochemical 
approach. The ultrastructural characteristics of the ABri protein deposits were studied 
by immunoelectron microscopy.
A2) What is the distribution and conformational patterns of ADan deposition in 
FDD and their relationship to neurofibrillary pathology, astroglial and microglial 
responses?
The  topographical  distribution  of ADan  deposition  was  studied  in  FDD  cases  using 
immunohistochemistry. To determine the conformational state of the protein deposits, 
ADan  immunohistochemistry  was  combined  with  thioflavine-S  and  evaluated  by
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confocal microscopy. The distribution and relationship of neurofibrillary degeneration 
to ADan deposits were investigated by tau immunohistochemistry. The astrocytic and 
microglial responses to ADan deposits were studied by a double immunohistochemical 
approach.  The  ultrastructural  characteristics  of the  ADan  deposits  were  analysed by 
immunoelectron microscopy.
B) What other protein components are associated with ABri and ADan lesions?
Bl)  Are  ‘amyloid  associated  proteins’,  which  are  known  to  co-localise  with Ap 
deposits  in  AD  and  some  other  cerebral  and  systemic  amyloidoses,  present  in 
amyloid and pre-amyloid lesions in FBD and FDD?
As the presence of AAPs in Ap lesions in AD has been linked to the process of Ap 
fibrillogenesis, this study aimed to establish whether such proteins are also associated 
with ABri and ADan lesions thus raising the possibility of a more general role for these 
proteins  in  amyloid  fibril  formation.  This  question  was  addressed  by  an 
immunohistochemical study investigating the distribution of Apolipoprotein E (ApoE), 
Apolipoprotein  J  (ApoJ),  a-l-antichymotrypsin  (ACT),  serum  amyloid  P  component 
(SAP),  cystatin  C  and  various  heparan  sulphate  proteoglycans  (HSPGs),  including 
agrin, perlecan, glypican-1 and syndecans.
B2) Are the complement pathways activated and complement products implicated 
in the pathogenesis of FBD and FDD?
In  relation  to  Ap  deposition  activation  of  the  complement  pathways  has  been 
documented with implications for fibrillogenesis, host response and the mechanism of 
neurodegeneration. This study investigates the presence of complement components of 
both  the  classical  and  alternative  pathways  and  complement  inhibitors  in  FBD  and 
FDD, and seeks to establish whether the binding of the recognition protein Clq to ABri 
and ADan is dependent on the conformational state of these amyloid proteins. For this 
Clq  immunohistochemistry was  combined with thioflavine-S  stain and  evaluated by 
confocal microscopy.
C)  Is  there  biochemical  heterogeneity  of  the  ABri  and  ADan  peptide  species 
deposited in the morphologically different lesions?
As correlation exists between the N- and C- terminal heterogeneity of the Ap peptide 
species and different lesion types in AD, the question was addressed whether similar
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heterogeneity occurs in FBD and FDD. In this study, ABri and ADan species deposited 
in  blood  vessels  and  parenchymal  lesions  were  isolated  and  biochemically 
characterised.  In  addition,  the  heterogeneity  of the  Ap  species  co-deposited  in  the 
parenchyma and CAA in FDD was also studied by immunohistochemistry, utilising a 
panel of antibodies specific for N- and C-terminally modified Ap species.
D)  What is the origin of ABri and ADan proteins in FBD and FDD?
Understanding  the  origin  of  the  ABri  and  ADan  peptide  could  provide  further 
information about the evolution of the parenchymal and vascular lesions.  To test the 
hypothesis  that  the  brain  is  a  major  source  of these  amyloid  peptides  a  study  was 
undertaken  to  establish  the  cerebral  distribution  of  BriPP  and  the  enzyme  (furin) 
implicated in its processing. For this study in-situ hybridisation, immunohistochemistry 
and biochemical methods were used.
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Chapter 2 —  Material and Methods 
2.1  Tissue Processing
2.1.1  Paraffin embedded tissue
Representative areas of formalin fixed brain and spinal cord tissue were processed as 
shown in table 4.
Step Reagent 3 Day Time
1 70% alcohol 6.00 hrs
2 90% alcohol 6.00 hrs
3 90% alcohol 6.00 hrs
4 Absolute alcohol 6.00 hrs
5 Absolute alcohol 6.00 hrs
6 Absolute alcohol 6.00 hrs
7 Absolute alcohol 6.00 hrs
8 Chloroform 6.00 hrs
9 Chloroform 6.00 hrs
10 Wax 6.00 hrs
11 Wax 6.00 hrs
12 Wax 6.00 hrs
Table 4: Processing of  paraffin tissue. Reagents and times used
After  processing  tissue  was  embedded  in  paraffin  wax  and  stored  until  required. 
Paraffin sections were cut using a Leica sledge microtome at  7pm,  placed onto 30% 
alcohol  solution  and  floated  out  onto warm water.  The  sections  were  picked  up  on 
superfrost slides (BDH) or Vectabond coated slides (Vector), and left to dry at 37°C for 
several hours followed by an overnight incubation at 60°C.
2.2  Immunohistochemistry on paraffin embedded tissue
Sections were  deparaffinized  in  three  changes  of xylene  for  5  minutes,  followed  by 
rehydration using graded alcohols (100%, 95% and 70%). For all immunohistochemical 
staining the endogenous peroxidase activity was blocked using 0.3% H2O2 in methanol
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for  10 minutes followed by washes in distilled water for at least 5  minutes.  Sections 
were subjected to various pretreatment protocols depending on the antibody used (see 
section 2.2.1).  Non-specific protein binding was blocked using  10%  non-fat  milk  in 
PBS (0.05M pH7.2) by incubating the sections for 30 minutes at room temperature. The 
milk was then replaced with the required primary antibody and incubated for 1  hour at 
room temperature or overnight at 4°C (table 5) depending on the primary antibody used, 
followed by two washes in PBS. Incubation with the relevant secondary antibody was 
carried out for 30 minutes at room temperature, followed by washing in distilled water 
and  two  changes  of PBS.  Sections were  incubated  in  avidin-biotin  complex  (ABC, 
Dako) for 30 minutes at room temperature, followed by washes in distilled water and 
two  changes  in  PBS.  The  antigen-antibody  reaction  was  visualized  using  di- 
aminobenzidine (DAB,  Sigma) as the chromogen.  Sections were placed in a 500pg / 
100ml PBS DAB solution that was activated with 32pl H2O 2 (30% solution, BDH) for 4 
minutes and the colour intensity checked. Sections could also be replaced into the DAB 
solution  if darker  colour  intensity  was  required.  Sections  were  counterstained  with 
Mayers  haematoxylin  (BDH)  for  10  seconds,  washed  in  distilled  water  and  finally 
dehydrated through 70%, 95% and absolute alcohol before being cleared in two changes 
of xylene and permanently mounted with Depex (BDH).
2.2.1  Pretreatments used for paraffin embedded tissue sections
Different pretreatments were used for the retrieval of various antigens that may have 
been obscured by fixation or processing of the tissue.  The pretreatments were carried 
out after the endogenous peroxidase was blocked with methanol (see section 2.2). The 
following pretreatments were used with the different antibodies as appropriate (see table 
5);
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•  Formic acid (FA) -  Sections were placed in 99% FA for 10 minutes followed 
by several washes in distilled water.
•  Pressure cooking (PC) -  Sections were placed in boiling citrate buffer pH 6.0 
for 10 minutes once maximum pressure is reached.
•  Trypsin -  Sections were placed in distilled water at 37°C for 5  minutes,  and 
then transferred to 0.1% trypsin (Sigma): 0.1% CaCh (BDH) solution in distilled 
water for 10 minutes at 37°C.
•  Microwave -  Sections were placed in citrate buffer pH 6.0 for 20 minutes on 
high power in a 900W microwave.
•  Formic acid and pressure cooking (FA + PC) -  Sections were first pretreated 
in FA as above, washed in distilled water for 10 minutes. This step was followed 
by pretreatment as described above in the pressure cooker.
2.2.2  Double immunohistochemistry for light microscopy
Double immunohistochemical staining was carried out on paraffin sections and frozen 
sections using  both  a  monoclonal  antibody and  a polyclonal  antibody,  or using two 
polyclonal antibodies. The protocol was followed as in section 2.2 or 2.4 depending on 
whether paraffin or frozen sections were used.  The antibody was visualized with the 
glucose oxidase method as described in section 2.14.7. This was followed by incubation 
with the second primary antibody overnight at 4°C.  The relevant secondary and ABC 
were applied as in section 2.2 and the antibody visualized with Novored (Vector) for 2 
minutes at room temperature. Sections were then washed in distilled water, dehydrated, 
cleared in xylene and mounted in DEPX (BDH).
99Antibody Source Cone. Species Pretreatments Incubation Period
CR3/43 Dako 1:200 M PC One hour
Amyloid P Novacastra 1:200 P FA + PC Overnight at 4°C
Apo E Autogen Bioclear 1:200 M FA + PC One hour
Apo J Santa Cruz 1:600 P FA + PC One hour
a-1  -antichymotrypsin Neomarkers 1:500 P PC Overnight at 4°C
a-1  -antichymotrypsin Novacastra 1:500 P PC Overnight at 4°C
Vitronectin Quidel 1:300 M FA + PC One hour
IC3b Quidel 1:1500 M FA + PC One hour
Cystatin C Gift from Dr Ghiso 1:200 P FA + PC Overnight at 4°C
AT8 Autogen Bioclear 1:600 M Microwave One hour
A3-40 Autogen Bioclear 1:100 P FA + PC One hour
AP-42 Autogen Bioclear 1:100 P FA + PC One hour
5282 Gift Dr Ghiso 1:1000 P FA One hour
338 Gift Dr Ghiso 1:2000 P FA One hour
CD-68 Dako 1:150 M Trypsin One hour
GFAP Dako 1:1000 P Trypsin One hour
A4 Dako 1:100 M FA + PC One hour
Clq Dako 1:100 P Trypsin / free floating Overnight at 4°C
Apl-16 Biosource 1:4000 M FA + PC One hour
A317-26 Biosource 1:4000 M FA + PC One hour
Table 5: Antibodies used on paraffin sections. M-Mouse monoclonals; P- Rabbit polyclonals; FA- Formic acid; PC- Pressure cook.Chapter 2- Material and methods
23  Immunohistochemistry of free floating sections
Paraffin  sections  were  cut  on  a  Leica  sledge  microtome  at  30jj.m  and  collected  in 
Eppendorf tubes until required. The sections were dewaxed in xylene and rehydrated in 
graded  alcohols  (100%,  95%  and  70%).  Sections  were  blocked  for  endogenous 
peroxidase  in  0.3%  H2O2  in  methanol  for  10  minutes.  Followed  by  the  required 
pretreatment needed  for the antibody used (see  section 2.2.3)  and blocking  for non­
specific  protein  binding  by  incubating  the  tissue  in  10%  non-fat  milk  at  room 
temperature. Incubation with the primary antibody in 10% non-fat milk containing 0.1% 
Tween-20 (BDH) was carried out overnight at 4°C. The tissue was washed in PBS on a 
shaker for  1   hour with 6  changes of PBS,  followed by  incubation with the relevant 
secondary antibody for 1   hour at room temperature, and extensive washes in PBS (6 x 
10 mins).  The tissue was placed in ABC (Dako) for 45 minutes at room temperature, 
followed by extensive washes in PBS. The antigen was visualized as above with DAB 
(see section 2.2).
2.4  Immunohistochemistry on frozen sections
Frozen sections were cut at lOfim from either flash frozen or slow frozen material, using 
a  cryostat  (Bright),  and  mounted  onto  either  superfrost  slides  (BDH)  or  vectabond 
coated slides (Vector), depending on the size of the sections collected. Sections were air 
dried for 30 minutes, frozen at -80°C and stored until needed.  Sections were removed 
from the freezer and placed on foil and air dried for 10 minutes, post-fixed in either 4% 
paraformaldehyde, or acetone depending on the antibody used (table 6) for 30 minutes 
at room temperature. This was followed by washes in distilled water and two washes in 
PBS.
101Antibody Antigen Source Cone. Species Post fixation
338 ABri Dr Ghiso 1 1000 P 4% Para
5282 ADan Dr Ghiso 1 1000 P 4% Para
340 ABriPP Dr Ghiso 1 500 P 4% Para
Furin Furin Affinity Biochemicals 1 50 P Acetone
NeuN NeuN Chemicon 12000 M Acetone/ 4% Para
GFAP GFAP Chemicon 1 1000 M Acetone/ 4% Para
Sc5b-9 Membrane attack complex Quidel 1 50 M Acetone
C5b-9 Membrane attack complex Quidel 1 50 M Acetone
C4d C4d Quidel 1 1000 M Acetone
C3d C3d Quidel 1 50 M Acetone
Bb Bb Quidel 120 M Acetone
JM72 Agrin Ref; Verbeek 1 500 M Acetone
BI31 Agrin Ref; Verbeek 1 750 G Acetone
1948 Perlecan Ref; Verbeek 1 500 R Acetone
3G10 Pan-HSPG Ref; Verbeek 1300 M Acetone
JM13 Heparan sulphate side chains Ref; Verbeek 1 100 IgM Acetone
JM403 Heparan sulphate side chains Ref; Verbeek 1300 IgM Acetone
10H4 Syndecan 2 (ectodomain) Ref; Verbeek 1300 M Acetone
2E9 Syndecan -1,-3 (cytoplasmic domain) Ref; Verbeek 1 500 M Acetone
1C7 Syndecan-3 (ectodomain) Ref; Verbeek 1 100 M Acetone
SI Glypican-1 (core protein) Ref; Verbeek 1 50 M Acetone
Table 6: Antibodies used on  frozen tissue. M- Monoclonal; P- polyclonal; G- goat polyclonal; R- Rat polyclonal.Chapter 2- Material and methods
The endogenous peroxidase activity was blocked using 0.3% H2O2 in methanol for 10 
minutes  followed  by washes  in  distilled  water  and  two  changes  of PBS.  The  non­
specific  protein  was  blocked  using  10%  non-fat  milk  for  30  minutes  at  room 
temperature. The sections were incubated with the primary antibody for 1  hour at room 
temperature and the remaining protocol was followed as described in section 2.2.
2.5  Highman’s Congo red staining.
Highman’s  Congo  red  stain  was  used  to  demonstrate  protein  deposits  in  amyloid 
conformation.  Sections were dewaxed, rehydrated in graded concentrations of alcohol 
and then placed in water (section 2.2).  Staining with Congo red solution (0.5% Congo 
red  (BDH)  in  50%  alcohol)  was  carried  out  for  10  minutes  and  differentiated with 
alcoholic potassium hydroxide solution (0.2% KOH in 80% alcohol) for 3-10 seconds, 
followed  by  washing  in  distilled  water.  Nuclei  were  counterstained  with  alum 
haematoxylin  (BDH)  and  the  sections  placed  in  running  tap  water  for  5  minutes. 
Sections  were  then  dehydrated  in  graded  alcohol  solution,  cleared  in  xylene  and 
mounted using Depex (BDH). Congo red staining was viewed under a polarized light.
2.6  Thioflavine-S staining
2.6.1  Single staining with thioflavine-S.
Sections  were  dewaxed  and  rehydrated  as  described  in  section  2.2,  and  stained  in 
aqueous 1.0% thioflavine-S (Sigma) solution for 7 minutes. Sections were differentiated 
with 70% ethanol for 5 minutes and left to wash overnight in PBS before cover slipping 
in  aqueous  mountant  (BDH)  and  viewed  under  a  fluorescent  microscope  (Zeiss 
Axioskop MC80DX).
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2.6.2  Double staining with thioflavine-S and immunohistochemistry
Sections  were  dewaxed  and  rehydrated  as  described  in  section  2.2. 
Immunohistochemistry was carried out on the sections before the thioflavine-S staining. 
Single fluorescent staining was carried out as described in section 2.7.1 and the antigen 
visualised was using the tetramethylrhodamine kit (NEN) to give a red  fluorescence 
against the green fluorescence of the thioflavine-S. If FA pretreatment was required for 
the immunohistochemical staining then only a 70% solution was used for 10 minutes, as 
in control experiments using tissue sections with known amyloid deposits, higher FA 
concentrations abolished specific staining with thioflavine-S.
2.7  Fluorescence immunohistochemistry
Fluorescence immunohistochemistry was carried  out using a number of antibodies to 
demonstrate  the  co-localization  of  specific  antigens.  Single  and  double 
immunohistochemistry was undertaken and the methods are described below;
2.7.1  Single staining
Paraffin sections were prepared as described  in  section 2.1.1.  Immunohistochemistry 
was carried out as described in section 2.2 up to the washing step following the ABC 
incubation. The sections were incubated for 10 minutes at room temperature with either 
tetramethylrhodamine  kit  (1:500:  NEN)  to  give  the  red  fluorescence  or  the 
tetramethylfluorescein kit (1:200: NEN) to give the green fluorescence and viewed on a 
fluorescence microscope (Zeiss Axioskop MC80 DX).
2.7.2  Double Staining
Double fluorescent  staining was carried out on paraffin  sections  and frozen  sections 
using both a monoclonal antibody and a polyclonal antibody, or using two polyclonal
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antibodies. The protocol was followed as in section 2.7.1 for single fluorescent staining. 
The antibody was visualized with tetramethylrhodamine (1:500, NEN) for 10 minutes at 
room temperature. This was followed by incubation with the second primary antibody 
overnight at 4°C. From this point forward all sections were kept in the dark to avoid the 
first fluorescent chromogen fading. The relevant secondary and ABC were applied as in 
section 2.7.1 and the antibody visualized with tetramethylfluorescein (1:200, NEN) for 
10 minutes at room temperature. Sections were then washed in distilled water, mounted 
in  aqueous  mountant  (BDH)  and  viewed  under  a  fluorescent  microscope  (Zeiss 
Axioskop MC80 DX).
2.7.3  Confocal microscopy
Fluorescent immunohistochemistry was carried out as described above (sections 2.7.1 
or 2.7.2). Sections were then viewed with a Leica TCS4D confocal microscope using a 
3-channel scan head and argon/krypton laser (UCL confocal imaging unit).
2.8  Immunoelectron microscopy
2.8.1  Tissue processing for electron microscopy
Tissue  specimens  were  fixed  overnight  at  4°C  in  buffered  gluteraldehyde  (2.5%  in 
0.05M  sodium  cacodylate  buffer).  After  fixation  tissue  was  cut  into  1-2  mm  thick 
blocks, rinsed in 0.1M sodium cacodylate buffer, transferred to  1% osmium tetroxide 
and left for 3 hours at 4°C.  The osmium was discarded and the blocks were placed in 
fresh  0.1M  sodium  cacodylate  buffer.  The  tissue  was  dehydrated  by  being  placed 
through increasing grades of alcohol, 70% alcohol for 10 minutes, 90% for 10 minutes 
and finally 3 changes of absolute alcohol for 10 minutes. For each alcohol change the 
tissue was agitated on a rotator.
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While continuing to be agitated the tissue was transferred to propylene oxide for two 15 
minute incubations.  The tissue was then placed in a  1:1  mixture of propylene oxide: 
epoxy resin for 1  hour, followed by an overnight incubation in neat epoxy resin rotating 
in the fume hood. The epoxy resin was prepared in the following way; 20ml of Araldite 
CY212 (Resin: Agar) is mixed with 25ml DDSA (Hardener: Agar) in a plastic beaker, 
followed  by  0.8ml  DMP30  (accelerator:  Agar).  The  whole  mix  is  then  thoroughly 
mixed with a wooden tongue depressor. When the colour changed from pale yellow to a 
deeper orange, a magnetic stirrer was placed in the beaker and the mixture was mixed 
on a warm plate for approximately 20 minutes. When mixed sufficiently the resin was 
ready for processing and the tissue was embedded in epoxy resin and left in a 60°C oven 
in a fume cupboard for 48 hours in order to achieve polymerization.
2.8.2  Immunoelectron microscopy for ABri
2.8.2.1  Ab338 immunohistochemistry on semi-thin sections
Resin  blocks  were  trimmed  and  semi-thin  sections  (2pm)  were  cut  using  an 
ultramicrotome (Du pont MT6000),  collected onto  superfrost glass  slides (BDH) and 
left to dry on a hotplate for at least 30 minutes.  Sections were etched with saturated 
sodium ethoxide (15.25g NaOH/ 200ml Absolute alcohol) solution for 1   hour at room 
temperature, rinsed in three changes of absolute ethanol followed by three changes of 
distilled water. The sections were then placed in 4.7% sodium periodate solution for 1  
hour at room temperature, followed by four changes of distilled water. The endogenous 
peroxidase was blocked with 0.3% H2O2 solution in methanol for 10 minutes followed 
by  10  minutes  rinse  in  PBS.  Sections  were  pre-treated  in  99%  FA  for  10  minutes 
followed by three washes in distilled water, followed by incubation for 30 minutes in 
10% non-fat powdered milk in PBS to block non-specific protein binding. The primary
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antibody Ab338 was applied  at  1:3000 and  incubated at 4°C  overnight,  followed by 
washes in distilled water for at least 30 minutes. Biotinylated anti-rabbit (1:200 Dako) 
secondary antibody was applied, for 30 minutes followed by washing in distilled water 
for 30 minutes. ABC (Dako) was applied for 30 minutes and sections were washed in 
distilled water for 30 minutes. The chromogen was then developed using DAB (Sigma) 
for 4 minutes to give a brown precipitate.
2.8.2.2  Ab338 immunohistochemistry for electron microscopy
Sections were cut at 0.88pm from the main blocks using an Ultramicrotome (Du pont 
MT6000) with a diamond knife (Diatome) and mounted onto pre-prepared nickel grids 
(400  mesh thin bar,  Agar  Scientific).  The nickel  grids were prepared by  soaking  in 
chloroform for 10 minutes, transferred to 20% glacial acetic acid in pure distilled water 
for 2 minutes, washed in 95% ethanol for 2 minutes and allowed to dry. The sections 
were incubated at room temperature in 4.7% sodium metaperiodate (BDH) for  1   hour 
and rinsed twice in Tris-buffered saline (TBS, 0.5M pH7.4) containing  1% Triton X- 
100, followed by rinsing the grids in TBS-BSA  (TBS containing 1% BSA and 0.05% 
sodium azide).  The grids were incubated for 60 minutes at room temperature in  10% 
normal  goat  serum  in  TBS-BSA  buffer,  then  transferred  onto  Ab338  antibody 
(1:20,000)  overnight  at  4°C.  The  grids were  then  washed  on  droplets  of TBS-BSA 
before incubation with goat anti-rabbit IgG gold conjugate (1:15 in TBS,  Sigma) with 
particle size of 20nm at room temperature for 60 minutes.  This was followed by four 
washes in TBA-BSA buffer. The grids were then post-fixed in 2.5% gluteraldehyde in 
sodium cacodylate buffer for 10 minutes, washed in distilled water and allowed to dry. 
Sections were counterstained with uranyl acetate (25% uranyl acetate in methanol) for 3 
minutes followed by three washes in methanol/ distilled water washes. The grids were
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dried on clean fiber-free paper, stained in lead citrate (see appendix) for 10 minutes at 
room temperature, washed in three changes of filtered distilled water and dried on fiber- 
free paper.
2.8.3  Immunoelectron microscopy for ADan
2.8.3.1  Ab5282 immunohistochemistry on semi-thin sections.
The blocks were trimmed, cut and prepared as described in section 2.8.2.1. The primary 
antibody Ab5282 was applied at 1:1000 to the sections and left at 4°C overnight. The 
sections were washed in distilled water and the protocol was followed as described in 
section 2.8.2.1.
2.8.3.2  Ab5282 immunohistochemistry for electron microscopy
Ultrathin  sections  were  cut  and  mounted  onto  nickel  grids  as  described  in  section 
2.8.2.2. The grids were etched as described in section 2.8.2.2, once blocked they were 
transferred onto droplets of Ab5282 (1:50) for 72 hours at 4°C.  The grids were then 
washed on droplets of TBS-BSA and transferred onto droplets on biotinylated  swine 
anti-rabbit secondary (1:200, Dako) for 30 minutes at room temperature, then washed in 
TBS-BSA.  The  grids  were  incubated  for  30  minutes  at  room  temperature  in  ABC 
complex (Dako) followed by three changes of TBS-BSA buffer, followed by incubation 
in biotinylated tyramide (1:200, NEN) for 10 minutes at room temperature and washed 
in three changes of TBS-BSA buffer.  The grids were incubated with anti-biotin gold 
(20nm, Agar) for 1  hour at room temperature and washed thoroughly in TBS-BSA.
108Chapter 2- Material and methods
The  grids  were  then post-fixed  for  10  minutes  with  2.5%  gluteraldehyde  in  sodium 
cacodylate buffer. Washed in distilled water and allowed to dry and counterstained with 
uranyl acetate and lead citrate as previously described in section 2.8.2.2.
2.8.4  Immunoelectron microscopy for Ap
2.8.4.1  Ap immunohistochemistry on semi-thin sections
The  protocol  was  followed  as  described  in  section  2.8.2.1  for  Ab338 
immunohistochemistry on semi-thin sections up to the incubation step with the primary 
antibody. The primary antibody Ap 17-26 (Biosource International) was used at 1:4000 
and the sections left at 4°C overnight. The sections were then washed in distilled water 
for  30  minutes.  Biotinylated  anti-mouse  (1:200  Dako)  was  applied  for  30  minutes 
followed by another 30 minutes wash in distilled water. ABC (Dako) was then applied 
for 30 minutes. Sections were again washed in distilled water for 30 minutes. DAB was 
used as described previously to visualize the antigen.
2.8.4.2  Ap immunohistochemistry for electron microscopy
The protocol was followed as described in section 2.8.2.2 up to the point of incubation 
with  the  primary.  The  grids  were  transferred  onto  Ap  17-26  antibody  (Biosource 
International  1:100) and incubated overnight at 4°C.  The grids were then washed on 
droplets of TBS-BSA before incubation with goat anti-mouse IgG gold conjugate (1:15) 
with particle size of lOnm for 60 minutes at room temperature (Sigma). The grids were 
then  washed  again  in  TBA-BSA  buffer  and  post  fixed  for  10  minutes  with  2.5% 
gluteraldehyde in sodium cacodylate buffer, washed in distilled water and allowed to 
dry. The grids were then counterstained with uranyl acetate and lead citrate as described 
in section 2.8.2.2.
2.8.5  Double immunoelectron microscopy for Ap and ADan
For double staining with Ab5282 and Ap 17-26, the protocol above for single staining 
with Ap was followed up to the incubation with the gold conjugate. After that step the 
grids were incubated on droplets of Ab5282 (1:50) for 72 hours at 4°C.  The rest for the 
protocol was followed as in section 2.8.2.2 for single staining with Ab5282. The grids 
were also post-fixed and counterstained as previously described.
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2.9 Evaluation of immunohistochemistry
2.9.1  Evaluation of pathological analysis of CAA
The  presence  and  frequency  of parenchymal  deposits  and  CAA  were  evaluated  in 
different anatomical regions using a semi-quantitative approach. For CAA a four tiered 
scoring  system was used  such that  score  0  was  given  for unaffected areas;  *+’  if a 
proportion of the arterioles/ small arteries were affected, but no or only an occasional 
capillary  was  stained;  *++’  if the  majority  of arterioles  as  well  as  minority  of the 
capillaries were positive; and ‘+++’ for areas in which the majority of the arterioles and 
capillaries were positive for either ABri or ADan.
2.9.2  Evaluation of pathological analysis of parenchymal deposits
For the quantitation of parenchymal deposits, Ab338  or Ab5282 positive,  Congo red 
positive and thioflavine-S positive structures with or without an associated blood vessel 
were  considered  to  represent  amyloid  deposits  (plaques).  Diffuse  deposits  were  ill- 
defined, Ab338 or Ab5282 positive, Congo red negative structures, which were weakly 
stained if at all with thioflavine-S. Using a x  10 objective plaques and diffuse deposits 
were scored separately in each case following a principle similar to that recommended 
by  ‘The  Consortium  to  Establish  a Registry  for Alzheimer’s  disease’  (CERAD)  for 
quantitating neuritic plaques in AD. Score 0 described the absence of either plaques or 
diffuse deposits,  score  *+’  corresponded to  sparse,  score  ‘++’  to moderate  and score 
*+++’ to frequent plaques or diffuse deposits.
2.9.3  Evaluation of tau pathology
The  severity  of NFT,  NT  and  AN  pathologies  was  evaluated  separately  in  a  semi- 
quantitative manner using a xlO objective; score 0 was used if the pathological change 
was absent, *+’ was used if it was sparse, ‘++’ moderate, and  ‘-H-+’  if the change was 
severe.
2.9.4  Controls for immunohistochemistry
To  demonstrate  the  specificity  of the  immunohistochemistry  used  in  the  following 
chapters various controls were included.  Firstly all primary antibodies were ommited 
from the protocols and replaced with PBS (pH7.4). This method was used to determine
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whether  secondary  antibodies  were  binding to  any  antigens  in  the  tissue.  Secondly, 
where the primary antibody was not obtained from a commercial supplier (where it was 
assumed rigourous quality control checks would have been carried out) the  antibody 
was absorbed with the immunising peptide.  This approach is expected to reduce any 
specific staining (see section 8.2.3). Preimmune serum from the same animals used to 
produce the antibodies was also used as a control.
2.9.5  Methods of consistency for semi-quantiative analysis
Several methods of assessing the consistency of the immunohistochemical staining and 
the  semi-quantitative  methods  were  used  in  these  studies.  In  every 
immunohistochemical  experiment to be used for  semi-quantitative  analysis  a control 
section (FBD material) was stained with Ab338 and evaluated for the intensity of the 
DAB staining. The intensity of the staining was therefore standardised for this section 
so  that  sections  stained  in  different  immunohistochemical  runs  could  be  analysed 
together.
Scores  were  assigned  to  the  different  immunohistochemical  stains  according  to  the 
scoring systems described in 2.9.1, 2.9.2 and 2.9.3. The scores given were obtained by a 
consensus  agreement  between  3  observers  (two  neuropathologists  and  TL),  the 
consistency of which was further verified with repeat evaluation with a minimum of 
75% of the slides stained.
In a pilot study scores were established in a manner similar to that recommended for 
determining Ap plaque density by CERAD (Mirra SS et al 1991).
2.10 Protein extraction
2.10.1  Crude protein extraction
Approximately lg tissue of sample, from fresh frozen tissue, was dissected from various 
cerebral regions.  Separating white and gray matter and recording the weight of each 
individual sample. Any visible blood vessels were collected separately. To each sample 
lOmls  of  Tris  buffer  saline  (20mM  Tris-HCl/150  mM  NaCl,  pH  7.4)  containing 
protease  inhibitors  (protease  inhibitor  cocktail  tablets-  Roche)  was  added  and 
homogenized  by  hand,  to  limit  disruption  of the  blood vessels.  Blood  vessels  were 
collected, by filtration through a 53pm mesh, from the gray and white matter and pooled
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together with larger blood vessels collected from earlier dissection of the same region. 
The blood vessel samples were washed in Tris buffer containing protease inhibitors and 
centrifuged for 10 minutes at 4°C at 4,000 RPM (Beckman J-6B). The supernatant was 
discarded and the pellet homogenized with a mechanical homogeniser to disrupt all the 
blood vessels. Samples obtained were centrifuged for 1  hour at 35,000 RPM (112,500 x 
g) at 4°C in a Beckman XL-lOOk ultracentrifuge using a 70.1 Ti rotor.
The  supernatant  (SI)  was  collected  and  stored  at  4°C  for  further  analysis  by 
immunoblotting  and mass  spectrometry.  The pellet was  homogenized  in  collagenase 
buffer (50mM Tris,  lOmM CaCb, 3mM NaN3) and subjected to collagenase digestion 
(0.3mg/ml Collagenase EC.3.4.24.3;  Sigma) for  16 hours  at 37°C. The samples were 
then placed on ice for 10 minutes followed by centrifugation for 1  hour at 35,000 RPM 
(112,500 x g) at 4°C. The supernatants (S2) were collected and stored at 4°C for further 
analysis. Using a mechanical homogeniser the pellet was resuspended in 20mM Tris/ 
2%  SDS.  The samples were  centrifuged for  1   hour at 35,000 RPM (112,500 x g) at 
10°C.  The  supernatant  (S3)  was  removed  and  kept  at 4°C  for  further  analysis.  The 
pellets were then washed with three changes of Tris buffer to remove any excess SDS 
before re-suspending in 500pi of 20mM Tris buffer. The samples were centrifuged at
14.000 RPM (21,000 x g) for 30 minutes at 4°C in Eppendorf tubes using an Eppendorf 
centrifuge 5417R. The buffer was removed and discarded and 400pl of 70% FA was 
added to the pellets, which were left overnight at 4°C. The samples were centrifuged at
14.000 RPM for 15 minutes, the supernatant (S6) removed and kept at 4°C for further 
analysis.
To verify generation of undesired degradation products due to reagents included in the 
protocol, parallel experiments were carried out under similar experimental conditions 
were the collagenase step was omitted.
2.10.2  Protein purification from supernatants SI, S2 and S3.
Two different methods were used to purify supernatants SI, S2 and S3 for further mass 
spectrometry  and  sequence  analysis:  1)  reverse-phase  batch  purification  and  2) 
immunoprecipitation.
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2.10.3  Reverse-phase batch purification
C18 beads (25mg; Millipore) were placed in an Eppendorf tube; 90% acetonitrile (AcN) 
was added to the beads to wet them before centrifugation for 3 minutes at 14,000 RPM. 
The 90%  AcN was  removed  and this  step was  repeated once.  The beads were then 
washed in 60% AcN followed by 20% AcN / 0.1% trifluoroacetic acid (TFA), 900pl 
aliquots of SI  and S2 were placed into separate Eppendorf tubes, to which  lOOpl  1% 
TFA and 200pl of 20% AcN was added. The samples were then added to the Eppendorf 
tubes containing the C18 beads and left overnight at 4°C to allow the proteins to attach 
to the beads.  The samples were centrifuged at  14,000 RPM for 3  minutes to form a 
pellet of beads with conjugated protein. The beads were then washed 5 times with 0.1% 
TFA/ 5% methanol to remove any tissue debris. The bound proteins were eluted from 
the beads with 300pi of 0.1% TFA/ 90% AcN.  The absorbance for each sample was 
read at 280nm to confirm the presence of protein and estimate recovery.  For the  S3 
samples the SDS was first removed using SDS-out sodium dodecyl sulfate precipitation 
kit (Pierce). Briefly, to 1ml of sample we added 50pl of SDS-out reagent and placed on 
ice for 20 minutes. The sample was transferred to a microfilter and centrifuged at 4,000 
RPM for 10 minutes. The protein was then extracted from the supernatant as described 
above.
2.10.4  Immunoprecipitation experiments
Fifty microliters of paramagnetic beads coated with either goat anti-rabbit IgG or anti­
mouse IgG (Dynabeads M-280; Dynal) were allowed to interact for  12 hours at 4°C 
inder constant end-to-end rotation with 6pg of purified IgG from either antiserum 338 
or  5282  or  with  a  combination  of  3gg  each  of  4G8  and  6E10  for  the 
immunoprecipitation of ABri, ADan and Ap, respectively. After washing three times in
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PBS, beads were blocked in 0.1% (w/v) bovine serum albumin in PBS. Antibody-coated 
beads  were  incubated  with  either  20|ul  (-4%  of the  total  fraction)  of FA-extracted 
amyloid previously neutralized in ~800  pi of 0.5 M Tris-base, pH  11,  or 20% of the 
total  volume  of each PBS-soluble  or  SDS-extracted  fractions  (SI-S3).  As  indicated 
above for the case of the SDS-extracted fractions,  SDS was mostly removed prior to 
immunoprecipitation  with  SDS-out  SDS  precipitation  reagent  employing  the  same 
conditions. Elution of the bound material from the beads was performed by different 
methods,  according  to  the  technique  used  for  the  studies  that  followed.  For  mass 
spectrometry analysis, beads were subsequently washed three times with PBS and three 
times with water,  and the bound peptides were eluted  in 5  pi  of a 4:4:1  mixture of 
isopropyl alcohol/water/formic acid. For Western blot analysis, beads were suspended 
in  20  pi  of  Tris-Tricine  SDS  sample  buffer  (Bio-Rad)  containing  10%  (v/v)  p- 
mercaptoethanol (Sigma) and directly applied onto the 16% Tris-Tricine gels for SDS- 
PAGE analysis. In some cases, 5 pi of 1  M dithiothreitol (Sigma) was used for sample 
reduction instead of P-mercaptoethanol.
2.11  Mass spectrometry
Mass  analysis  of the  isolated  material  was  carried  out  using  matrix-assisted  laser 
desorption  ionization  time-of-flight  MALDI-TOF  mass  spectrometry.  Extracted 
peptides from PBS, SDS, and FA fractions SI, S2,  S3 and S6 were subjected to direct 
mass spectrometry analysis using 5-10 pi of sample or subjected to further purification 
by immunoprecipitation, as described above. Due to the abundance of ABri, ADan and 
Ap,  the  use  of  immunoprecipitation  was  not  always  necessary  in  FA  fractions. 
However,  for  the  PBS  and  SDS  fractions,  it  was  a  required  step  for  proper  mass 
spectrometry  identification;  the  combination  of  low  peptide  recovery  (due  to  low
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availability) with high dilution of the samples resulted in a concentration that, for direct 
assessment, was below the sensitivity of the MALDI-TOF. In some cases, particularly 
for  the  FA  extracts,  samples  were  further  purified  by  micro-reverse-phase 
chromatography using Zip-TipC4 (Millipore) according to the manufacturer’s protocol. 
Briefly, tips were first wet by aspirating and dispensing 60% AcN three times into the 
tip. The tip was then equilibrated by washing three times with lOpl equilibration buffer 
(0.1% TFA). The samples were passed through the tips by pipetting and dispensing the 
sample (10  pi)  10 times  into the tip,  allowing the attachment of the peptides to the 
reverse-phase.  After  washing  5  times  with  20pl  of a  mixture  of 0.1%  TFA/  5% 
methanol, retained peptides were eluted using 5pi of 90% AcN/ 0.1% TFA.  MALDI- 
TOF mass  spectrometry analysis was performed at the New York University Protein 
Analysis Facility.  Samples were analyzed in a  10 mg/ml a-cyano-4-hydroxycinnamic 
acid matrix (Sigma) prepared in 50% acetonitrile and 0.1% trifluoroacetic acid (feasible 
for  -10,000-Da  mass  range)  using  a  Micromass  Tof-  Spec-2E  MALDI-TOF  mass 
spectrometer  in  linear  mode  using  standard  instrument  settings.  Under  these 
experimental  acidic conditions,  which also render noncovalent binding unobservable, 
mostly  monomeric  species  of ABri,  ADan  and  Ap  were  detected.  Internal  and/or 
external calibration was carried out using human adrenocorticotropic hormone peptide 
18-39 (average mass 2,465.68 Da) and insulin (average mass 5,733.49 Da) as standards. 
FindPept tool from the ExPASy Proteomics server (www.us.expasy.org/tools) was used 
to assign the experimental mass values to specific peptide sequences and to search for 
the presence of posttranslational modifications.
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2.12  Western blot analysis of amyloid peptides
For western blots, samples obtained after immunoprecipitation (see section 2.10.2.2) or 
from  the  direct  SI,  S2,  S3  and  S6  extracts  (lOpl  previously  lyophilized  and 
reconstituted in 40pl of Tricine sample buffer) were used for the experiments. Five pi of 
dithiothreitol  (DTT),  the  reducing  agent,  was  added  to  each  sample  and  they  were 
boiled for 3 minutes in a water bath.  Samples, control peptides (synthetic ABri, ADan, 
or Ap) and a molecular mass standard (rainbow marker, Amersham Pharmacia Biotech) 
were loaded onto a 16.5% Tris-Tricine acrylamide gel and electrophoresed overnight at 
50V.  After  electrophoresis,  proteins  were  transferred  onto  methanol/water  pre-wet 
polyvinylidene difluoride (PVDF,  Millipore)  membranes using  3-cyclohexylamino-l- 
propanesulphonic acid pH 11 buffer (CAPS), containing 10% (v/v) methanol for 1  hour 
at 400 mA. After blocking non-specific binding sites for 1  hour at RT with 5% low-fat 
dried  milk  in  PBS  /0.1%  Tween,  membranes  were  incubated  with  the  pertinent 
antibodies in the appropriate dilution overnight at 4°C (Table 7). After 4 washes of 10 
minutes  each  with  PBS  /  0.1%  Tween,  membranes  were  incubated  in  horseradish 
peroxidase-labeled goat anti-mouse or anti-rabbit 1:3000 (Amersham) depending on the 
primary used. Antibody binding was visualized using an enhanced chemiluminescence 
(ECL) detection kit and exposed to Hyperfilm ECL (Amersham).
Antibody Antigen Source Concentration Species
Ab338 ABri Dr J Ghiso 1:5000 Polyclonal
Ab5282 ADan Dr J Ghiso 1:4000 Polyclonal
4G8 A3 17-24 Signet 1:2000 Monoclonal
6E10 AP 1-17 Signet 1:2000 Monoclonal
Table 7: Antibodies usedfor western blot analysis of amyloid  peptides.
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2.13  Northern blot analysis
2.13.1  Gel preparation
In a sterile conical flask 1.5g agarose, 109ml DEPC water and 15ml xlO MOPS-acetate- 
EDTA buffer (pH 7.0, Sigma) were mixed and boiled to dissolve the agarose. When the 
solution  was  hand  hot  27ml  formaldehyde  was  added,  mixed,  poured  into  the  gel 
apparatus  and allowed to  set.  Once  set the  apparatus  was  filled with gel  buffer (lx 
MOPS-acetate-EDTA buffer pH 7.0 buffer in DEPC water) to completely submerge the 
gel.
2.13.2  RNA extraction for northern blot analysis
For RNA extraction approximately lg of flash frozen tissue was weighed out and used. 
The RNA was extracted following a published protocol (Chomczynski & Sacchi, 1987). 
In brief the samples were homogenized in 4M guanidium thiocyanate, 25mM sodium 
citrate, pH 7, 0.5% sarcosyl and 0.1 M 2-mercaptoethanol  (solution D) in 10 times the 
homogenate weight. Samples were homogenized using an electric homogeniser for 10 
seconds  at  a  time  and  cooled  on  ice  in  between  homogenizing.  3.6ml  aliquots  of 
homogenate were transferred to  15ml sterilized Falcon tubes,  0.36ml  sodium acetate 
(2M; pH4), 3.6ml of water saturated phenol and 0.72ml of chloroform: isoamyl alcohol 
were  added mixing well  before  each  addition.  The  tubes  were  capped and the  final 
suspension was vigorously shaken for  10 seconds, and cooled on ice for  15  minutes. 
The samples were then centrifuged at 10,000g for 20 minutes (at 4°C).
The  aqueous  phase  was  carefully  transferred  to  a  sterile  Eppendorf tube  avoiding 
contamination with the DNA interface and an equal volume of isopropanol (-20°C) was 
added.  Each tube was  shaken vigorously and left at -20°C  overnight.  Samples were 
removed from the freezer, thawed and centrifuged at 10,000g for 20 minutes (4°C). The 
supernatant was decanted and the tube blotted to remove excess liquid. The pellet was 
then dissolved in 0.3ml solution D and transferred to a sterile Eppendorf tube.  After 
adding  an  equal  volume  of  isopropanol  the  Eppendorf  tubes  were  then  shaken 
vigorously, and then placed at -20°C for > 1   hour. The samples were sedimented in a 
microcentrifuge, the supernatant removed and the pellet left to air dry. The pellet was 
washed in 1ml 75% ethanol (-20°C) and recentrifuged. This washing step was repeated 
and the pellet allowed to dry. The pellet was redissolved in 0.5% SDS at 65°C for 15 
minutes with periodic mixing.
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2.13.3  Spectrophotometric standardization
The RNA samples obtained from section 2.13 were diluted with DEPC water, vortexed 
and  read  absorbance  at  260nm  and  280nm.  Blanks  were  0.5%  SDS  treated  in  an 
identical manner to the sample. The spectrophotometer was zeroed at 280nm and the 
blanks read at 260nm before reading samples. The general rule was followed that the 
ratio A260/A280 is an indication of the purity of the preparation and that the higher the 
ratio,  ideally  around  two,  the  better  the  quality  of RNA.  Since  RNA  solutions  of 
40|xg/ml give an A260 value of 1   AU, the concentrations of unknown RNA’s can be 
calculated as shown below:
Unknown RNA concentration (pg/pl) = A260 x 40 x (dilution factor/1000)
2.13.4  Sample preparation and electrophoresis
The  RNA  samples  were  mixed  with  a  sample  mix  (lOx  MOPS,  formaldehyde, 
formamide) before being loaded onto the gel. To 48pl of sample mix,  12pl of RNA 
sample (diluted to give the required pg) was added. The RNA size marker (Invitrogen, 
section 2.14.5) was prepared by mixing 7pi with 5 pi 0.5% SDS and 48pi sample mix. 
Samples and size markers were heated at 55°C for 15 minutes, and then placed on ice. 
6 pi gel loading solution (Invitrogen) was added to each sample, mixed and 40 pi loaded 
into each well. RNA size markers and samples were loaded in adjacent wells. The gel 
was run at 60V until the bromophenol blue of the gel loading solution had migrated 
approximately 8cm.
2.13.5  Northern transfer: capillary blot
A glass Pyrex dish was  filled with  1   litre of saline-sodium phosphate-EDTA buffer 
(SSPE, 0.2M phosphate buffer, pH7.4, 2.98M NaCL and 0.02M EDTA)  and a glass 
platform was placed within the dish to elevate the gel above the buffer within the Pyrex 
dish. The platform was then covered with a wick (Whatman paper) and saturated with 
SSPE buffer. The surface of the wick was flattened using a clean pipette. The gel was 
removed from the gel apparatus and one comer cut to identify the orientation of the gel. 
The gel was placed onto the wick with the RNA side (bottom of the gel) facing up. The 
gel was surrounded with cling film to prevent short-circuiting of the blotting buffer. 
Hybond-N plus nylon membrane was used for the transfer and cut to the same size as
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the gel. The membrane was pre-wet in SSPE buffer, then gently placed on top of the gel 
avoiding air bubbles. The same comer was cut as was cut on the gel. Three sheets of 
Whatman paper were cut to the same size as the membrane, pre-wet with SSPE buffer 
and placed on top of the membrane; again avoiding any air bubbles. A stack of hand 
towels were cut to the same size and placed on top of the filter paper, followed by a 
glass plate and a 0.5kg weight. The capillary transfer was allowed to proceed overnight. 
The towels and filter papers were removed and the membrane was exposed to UV light 
to allow cross linking of the RNA and then air dried for at least 1  hour.
2.13.6  RNA integrity
To  16|xl of sample mix containing ethidium bromide (EtBr); 4pl of sample (diluted in 
0.5% SDS to give approx.  1.5|xg/|xl) was added. This was then heated at 55°C for 15 
minutes and placed on ice. 2|xl gel loading solution was added, mixed and 20pi loaded 
into wells. The agarose gel (section 2.14.1) was run at 100-120 V for 0.5 -1 hour.
2.13.7  RNA marker
A 0.24-9.5 Kb RNA ladder (Invitrogen) was used as the RNA marker, which contains a 
mixture of six synthetic poly (A)-tailed RNA’s which gives bands at 0.24,  1.35, 2.37, 
4.40, 7.46 and 9.49kb.
2.13.8  cDNA probes used for northern blot analysis
The  cDNA  probes  used  for  the  northern  blot  analyses  were  obtained  from  whole 
plasmids  containing  the  BRI  sequence  (Dr  Jorge  Ghiso)  and  a  separate  plasmid 
containing the GAPDH sequence (Dr Drew Hope). The cDNA was amplified using the 
PCR method described in section 2.16.3, and ran on a gel as described in sections 2.16.4 
and 2.16.5. The primers used for both the BRI and GAPDH amplifications are shown in 
table 8
Transcript Sense Antisense bp
BriPP CGTTCAACTCCGCTCTGGC GCAAACTCTGGGACAGGCACAC 378
GAPDH* ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 433
Table 8: PCR primers used in analysis of BriPP gene transcription. Primers marked 
with * are based on previously published data (Lee et al 2002).
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2.13.9  Labelling of cDNA probes
cDNA probes were labelled using 35S and a High Prime kit (Roche).  The cDNA was 
prepared to 25ng/pl.  1  pi of the cDNA was taken and the volume was made up to 11 |xl 
using sterile water. This was then denatured by heating in boiling water for 10 minutes 
and chilling on ice. High Prime was mixed according to the manufacturers instructions 
and  then  4pl  was  added  to  the  denatured  DNA,  followed  by  5pi  50pCi  35S  and 
incubated for 20 minutes at 37°C. The reaction was stopped by adding 2pi 0.2M EDTA 
(pH 8.0).
2.13.10  Separation of labelled probes on Sephadex G50
The  labelled probe was placed on  a  Sephadex column to remove  any unicorporated 
deoxyribnucleoside  triphosphates.  Sephadex  G50  was  prepared  in TE pH  8.0  buffer 
(lOmM Tris, l.OmM EDTA). A 2ml syringe was lightly plugged with baked glass wool 
and then loaded with Sephadex solution to a total volume of 2ml and this was allowed 
to settle. The column was washed gently with 2x 1ml of TE (lOmM Tris, l.OmM EDTA 
pH8.0) buffer. The labelled probe in TE buffer was loaded on top of the column and the 
eluate collected until the drops stopped (fraction 1). The column was then washed with 
2x 200pl of TE buffer and the eluate was collected separately (fractions 2 & 3). This 
was followed by further washing with 2 x 400pl TE buffer and samples were collected 
as  separate  fractions  (fractions 4  &  5),  these  two  fractions  will  contain  70%  of the 
labelled  probe.  Further  washes  were  done  with  2  x  200pl  TE  buffer  and  separate 
fractions were collected (fractions 6 & 7). 1  pi was taken from each fraction and counted 
using a scintillation counter to locate the labelled probe.
2.13.11  Methylene blue staining
A  1% methylene blue stock solution was made (0.5g methylene blue dissolved in 50 
mis of 0.5M sodium acetate) and kept in the dark. A 0.04% working solution was made 
from  the  stock  solution  (0.4mls  of stock  solution  diluted  into  96  mis  0.5M  sodium 
acetate) when needed.  The membrane obtained from the northern blot capillary transfer 
(section  2.14.3)  was  soaked  in  5%  acetic  acid  solution  for  15  minutes  at  room 
temperature and transferred to the working solution (0.04% methylene blue solution) for 
5-10 minutes.  Excess dye was rinsed out by soaking the membrane  in sterile water. 
Sharp distinct bands should be seen corresponding to the RNA bands.
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2.13.12  Hybridisation of membranes
Before hybridisation the bands that were shown with the methylene blue were marked 
with  a  pencil  along  with  the  RNA  marker  so  they  could  be  lined  up  later  in  the 
procedure. The membranes were placed in a sterile hybridisation cylinder and wet with 
2x SSC by filling the cylinder. After two minutes the 2x SSC was replaced with lOmls 
of the pre-hybridisation solution (SSPE, Denhardts solution, formamide,  SDS, DEPC 
water).  The cylinder was placed on a rotating wheel in the hybridisation oven for 30 
minutes at 42°C. The pre-hybridisation buffer was then replaced with the hybridisation 
buffer (5mls: pre-hybridisation buffer) containing 800pl the labelled probe and left to 
hybridise overnight at 42°C in the hybridisation oven.
2.13.13  Washing of membranes
The  hybridization buffer was  removed  from the hybridization cylinder and replaced 
with pre-heated 2x SSC solution containing 0.1% SDS. The membranes were washed 3 
x 10 minutes in this solution and 2 x 15 minutes in 0.5x SSC containing 0.1% SDS at 
55°C.
2.13.14  Visualisation of RNA
The membranes were transferred to a cassette containing x-ray film and exposed for 10 
days. The cassette also contained an intensifying screen (Amersham) that concentrated 
the  signal  omitted  from  the  labelled probe.  The  film  was  then  developed  using  an 
automated x-ray film processor (Kodak, Radiography department, NHNN).
2.14  In-situ hybridisation
2.14.1  Tissue samples
Flash frozen tissue was removed from the -80°C freezer and mounted onto cork pieces 
using OCT (BDH) in a class 1   micro-cabinet. The mounted blocks were then placed in 
the  cryostat  (Bright)  at  -20°C  and  left  for  several  hours  for  the  temperatures  to 
equilibrate before cutting.  Sections were cut at  15pm and placed on sterile superfrost 
(BDH) or Vectabonded (Vector) slides and dried on a hot plate for about 30 minutes 
before  storing at -80°C  until  required.  In between each tissue  sample the blade was
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cleaned with three changes of absolute alcohol to avoid cross contamination of mRNA 
between the different samples.
2.14.2  Probes
Three  oligonucleotide  sense  probes  (Invitrogen)  were  used  corresponding  to  three 
different  regions  of the  BRI2  gene.  Table  9  shows  the  region  of  the  BRI2  gene 
recognized by each probe.
Probe Region  of 
cBRI gene
Sequence bp
1 28-68 CCGCTCTTGGGCTCGTCCTTCTTGGCCTCCTTCTGGGCCAG 40
2 609-648 ACCCAGGTGATCAATGTTTTCAATGCGATCAGTAATAACC 39
3 802-836 T  ATTAATTTT  CCTC  AAT  AAT  GTTTTTCTT  G  ACTGT 34
Table 9: BRI2 probes used  for in-situ hybridisation
2.14.3  Labelling of probes
The  above  oligonucleotides  were  labelled  using  the  DIG  oligonucleotide  3’-  end 
labelling kit (Roche).  lOOpmol of oligonucleotide were added to sterile double distilled 
water to a final volume of lOp.1 in a reaction vial. The reaction buffer, CaCh solution 
and DIG ddUTP solution were added to the oligonucleotides according to manufactures 
directions and vortexed.  2pl of terminal transferase was added to the mix and left to 
incubate at 37°C for 1  hour. The oligonucleotides were placed on ice and 4pl of EDTA 
pH8.0 was added to stop the reaction.
2.14.4  Hybridisation.
All  solutions used in the  hybridisation method were  sterile  and  all procedures  were 
carried out at room temperature unless otherwise stated. The slides were removed from 
the freezer and allowed to air dry for up to 10 minutes face up on a sheet of aluminum 
foil. The sections were then fixed in 4% paraformaldehyde in PBS for 5 minutes. Slides 
were washed twice in PBS for 2 minutes per wash and then washed in sterile saline for 
1   minute  to  remove  any  phosphates  deposited  by  the  PBS.  Sections  were  then 
dehydrated by immersion in 60%,  80% and 95% EtOH in DEPC treated water for 2
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minutes each, then removed from the alcohol and allowed to air dry for a minimum of 
30 minutes. The hybridisation buffer was allowed to warm to room temperature before 
the probe was added. Sections were incubated with the DIG-labelled probe diluted in 
hybridization buffer (Sigma) to a concentration of 200ffnol/jil, with 0.1 mg/ml salmon 
sperm (Invitrogen) added. 50pl of diluted probe was added to each slide and covered 
with parafilm to prevent the slides drying out. They were then hybridised overnight at 
37°C, in a humidified chamber.
2.14.5  Post-hybridisation washes
A  water bath  was  heated  to  55°C  and  4-5  liters  of  lx  SSC  in  distilled  water was 
prepared.  All  solutions  for post hybridisation  steps  could be  made up  in non-sterile 
water. Four glass troughs were placed into the water bath, filled with 1  litre of lx SSC 
and warmed to 55°C. Three glass containers were prepared for floating off the parafilm. 
All three were filled with lx SSC solution; the first was used for floating the parafilm 
carefully  off the  glass  slide  and  to  remove  the  majority  of the  hybridisation buffer 
followed by two quick rinses in the other two glass troughs. Once all the slides have had 
the  parafilm  removed  the  rack  of slides  was  placed  in  the  first  55°C  wash  for  15 
minutes. This procedure was repeated 3 x  15 minutes at 55°C, followed by two more 
washes in lx SSC at room temperature for 30 minutes and in distilled water, to remove 
the remaining salts.
2.14.6  Immunohistochemistry to visualize the probes
Once washed the sections were ready to visualize. First blocking was carried out in 10% 
non-fat  milk /  PBS  for  30  minutes  at  room  temperature,  followed  by  an  overnight 
incubation  with  the  primary  anti-DIG  antibody  (Roche  1:250)  at  4°C  overnight, 
followed by several changes of PBS. The sections were then incubated in biotinylated 
anti-mouse antibody (Dako  1:200) for 30 minutes at room temperature followed by a 
30-minute incubation in ABC. The sections were washed several times in PBS. Finally 
visualization was carried out using the G.O.D method described in section 2.15.7.
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2.14.7  Glucose oxidase nickel DAB method
Sections were washed in 0.1 M PBS for 30 minutes, rinsed in 0.1 M acetate buffer (pH 
6.0) and incubated in the reaction solution as follows:
•  0 .1M acetate buffer pH6
•  0.05% DAB
•  0.04% ammonium chloride
•  2.5% nickel ammonium sulphate
•  0.25% |3-D-glucose
•  0.001% Glucose Oxidase
Sections were incubated in the reaction solution for around  15 minutes and placed in 
PBS to stop the reaction. Sections could be returned to the reaction solution and left for 
a longer period if a darker precipitation product was required.
2.14.8  0.1% Nuclear fast red counter stain
5g aluminum sulphate was dissolved in  100ml H2O and O.lg nuclear fast red (BDH) 
was added. Sections were immersed in a filtered solution for 1   minute then washed in 
running water, dehydrated in graded alcohol solutions, cleared and mounted.
2.14.9  Controls used for in-situ hybridisation
To verify that the  sense probes used in the in-situ hybridisation experiments  several 
control experiments were undertaken. Anti-sense probes were labelled and used in the 
same manner as the sense probes described in section 2.14.3. Excess unlabelled probe 
was added to the DIG labelled sense probe (1:100 dilution) which competed with the 
labelled  probe  and  significantly  reduced  the  amount  of positive  staining  observed. 
Control experiments were also carried out for all the steps of the immunohistochemical 
method used to visualise the probe. For that the anti-DIG and biotinylated secondary 
antibodies were replaced with PBS in consecutive experiments. All control experiments 
carried out provided negative or significantly diminished positive staining.
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2.15  Western blot analysis of BriPP and furin
2.15.1  Sample preparation from tissue
Approximately lg of tissue was weighed and homogenised in lOmls PBS/ Complete 
(Protease inhibitor, Roche), and kept on ice. The samples were aliquoted into 1ml 
Eppendorf tubes and centrifuged at 14,000rpm for 5mins. Excess samples were stored at 
-80°C until required.
2.15.2  Gel electrophoresis
To  13(4.1  of the  supernatant  from  the  sample  obtained  in  section  2.15.1,  5pi  of 4x 
NuPAGE  LDS  sample  buffer  (Invitrogen)  was  added  along  with  2pi  of NuPAGE 
reducing agent (0.5M DTT, Invitrogen). The samples were vortexed and heated to 70°C 
for  lOmins.  The  samples  were  then  loaded  onto  NuPAGE  Bis-Tris  pre-cast  gels 
(Invitrogen) and the manufacturers instructions followed. In brief, the 20pl of sample 
were  loaded  into  the  wells  of the  gel  and  the  gel  was  run  at  a  constant  200V  for 
approximately 35mins. To allow for maximum separation at the lower molecular weight 
end MES  running buffer (Invitrogen)  was used.  A  SeaBlue marker (Invitrogen) was 
used with every gel run.
2.15.3  Gel transfer
The sponge pads, and pre-cut filter paper (cut to the same size as the gel) were pre­
soaked  in  NuPAGE  transfer  buffer  (Invitrogen)  containing  methanol  according  to 
manufacturers instructions. A PVDF membrane was cut to the gel size and pre-wet in 
methanol for 30 seconds before being transferred to the NuPAGE transfer buffer. Once 
the gel had run for 35mins, it was removed from the pre-cast mould and placed between
125Chapter 2- Material and methods
the sponge pads, filter paper and membrane according to the manufactures instructions. 
The transfer then took place at 30V for 2 hours.
2.15.4  Development of blots
The  membranes  were  removed  from the  transfer chamber and rinsed twice  in PBS, 
followed by incubation in 10% non-fat milk for 1  hour at room temperature. Incubation 
with the relevant primary antibody (Table 42 section 8.2.2) took place overnight at 4°C, 
taking care that the membranes did not dry out. The membranes were then washed for 1  
hour  in  5  changes  of PBS-Tween  (0.1%),  followed by  incubation with  the  relevant 
HRP-conjugated  secondary  antibody  (Invitrogen,  1:1000)  for  1   hour  at  room 
temperature.  The  membranes  were  again  washed  in  PBS-Tween  (0.1%)  for  1   hour 
before the antibody binding was visualized using enhanced chemiluminescence (ECL) 
detection kit and exposed to Hyperfilm ECL (Amersham).
2.16  Polymerase chain reaction (PCR)
2.16.1  Reverse transcription of RNA
Production of single  stranded cDNA  from RNA template was  achieved using Avian 
Myeloblastosis  Virus  (AMV)  reverse  transcriptase  (RT).  The  RNA  pellets  were 
dissolved in 10pl of a solution containing ImM dNTPs and 50pg/ml Oligo dT primers, 
and incubated at 65°C followed by at least 1  min at 4°C, allowing the primers to anneal 
to the poly-A tails of mRNA in the samples. This was followed by the addition of 4pl 
5x AMV RT buffer (Promega), 4pl 25mM magnesium chloride and 40 units RNasin 
(Promega) and the mixture was heated to 42°C. Finally  10 units AMV RT (Promega) 
were  added,  and  the  incubation  continued  at  42°C  for  50  mins.  The  reaction  was 
stopped by incubating at 70°C for 15 minutes. The cDNA was then treated with 10 units 
RNase H (Sigma-Aldrich) for 30 mins at 37°C to remove the RNA template, and then 
the reaction was inhibited by 70°C incubation for a further 10 min. cDNA preparations 
were stored at -20°C and used as templates for PCR reactions.
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2.16.2  RT-PCR
Single stranded cDNA templates were prepared by reverse transcription as described in 
section 2.16.1.  Primers were  designed for specific  amplification of cDNA fragments 
from  genes  of  interest,  with  glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH) 
being used as a house keeping gene control. The samples were prepared for RT-PCR by 
mixing with various other components as described in table 9.
Product Source Quantity
Sample - lpl
lOx PCR buffer Promega 5 pi
25mM MgC12 Promega 1.5pl
Sense primer Invitrogen lpl
Anti-sense primer Invitrogen lpl
lOmM dNTP mix Promega lpl
Taq DNA polymerase Promega 0.4pl
Q solution Invitrogen 3 pi
Table 9: Quantities used  for RT-PCR reaction.
As templates were of low concentration the PCR method was modified to enhance their 
amplification by using ‘touch-down’  annealing temperatures. After an initial 5 min at 
95°C, cycling with 30s at the annealing temperature, 30s at 72°C and 30s at 95°C was 
performed. The annealing temperature for the first cycle was 60°C and was reduced by 
0.5°C in each subsequent cycle until reaching 50°C at the twentieth cycle. Subsequent 
cycles utilised 50°C as the annealing temperature. The PCR products were separated by 
1% agarose  gel  electrophoresis (section 2.16.5)  and densitometrically analysed using 
Kodak ID software (Labtech International).
2.16.3  Gel preparation for RT-PCR
In a sterile conical flask  lg agarose and  100ml TAE buffer (40mM Tris-HCL pH8.0, 
20mM  acetic  acid,  ImM  ethylenediamine  tetracetic  acid  (EDTA)  were  mixed  and 
boiled to dissolve the agarose. When the solution was hand hot 1  pi of ethidium bromide 
was  added,  mixed,  poured  into  the  gel  apparatus  and  allowed  to  set.  Once  set  the 
apparatus was filled with lx TAE buffer to completely submerge the gel.
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2.16.4  Primers used for RT-PCR
The primers used for the RT-PCR reactions for BRI2 and GAPDH are shown in table 
10.
Transcript Sense Antisense bp
BriPP CGTTCAACTCCGCTCTGGC GCAAACTCTGGGACAGGCACAC 378
GAPDH* ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 433
Table 10: PCR primers used in analysis ofBriPPgene transcription. Primers marked 
with * are based on previously published data (Lee et al 2002).
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Chapter 3
Regional distribution of  ABri amyloid 
and preamyloid deposition and its 
relationship with neurofibrillary
degeneration in FBD.
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Chapter 3 -  Hypothesis and specific questions
In this chapter, I wished to investigate the hypothesis that deposition of the ABri 
amyloid peptide is closely related to the neurodegenerative process in FBD. The 
specific questions I wished to concentrate on were:  1) What is the distribution of 
ABri  fibrillar  and  nonfibrillar  lesions  in  FBD;  2)  What  is  their  relationship  to 
neurofibrillary pathology, astroglial and microglial responses?
To address these questions in this study of FBD cases the topographical distribution and 
patterns of ABri deposition were studied by immunohistochemistry. To determine the 
conformational state of the protein deposits ABri immunohistochemistry was combined 
with  thioflavine-S  and  evaluated  by  confocal  microscopy.  The  distribution  and 
relationship of neurofibrillary degeneration to ABri deposits were investigated with tau 
immunohistochemistry  alone  and  in  combination  with  Ab338.  The  astrocytic  and 
microglial responses to ABri deposits were studied by a double immunohistochemical 
approach. The ultrastructural characteristics of the ABri protein deposits were studied 
by immunoelectron microscopy.
3.1  Introduction
The  neuropathological  hallmarks  of  FBD  include  extensive  CAA,  cerebellar 
degeneration and parenchymal amyloid plaques as described in section 1.2. The unique 
mutation  involved in FBD  has  led to  the generation  of a  specific  antibody (Ab338) 
produced  using  a  synthetic  peptide  comprising  the  last  ten  residues  of the  ABri 
sequence  (Vidal  et  al.,  2000b).  Ab338  is  therefore  able  to  recognise  both 
conformational  states  of  the  ABri  peptide,  amyloid  and  preamyloid.  Pathological 
analysis carried out prior to the identification of ABri only gave a limited insight into 
the distribution of the ABri lesions (Griffiths et al,  1982; Plant et al.,  1990; Worster et 
al.,  1940).  Previous  pathological  anaylsis  using  Bielschowsky  silver  impregnation 
showed the majority of the hippocampal plaques to be non-neuritic, but the presence of 
smaller amyloid plaques associated with abnormal neurites was also noted (Revesz et 
al.,  1999). Therefore using the ABri specific antibody the topographical distribution of 
the ABri lesions within the CNS could now be asscessed.
One of the central issues of AD research is to establish a possible relationship between 
Ap deposition and formation of NFTs. Neurodegeneration in AD with the formation of
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NFTs, NTs and ANs is generally considered to be secondary to Ap deposition, which 
has been  shown to produce  a toxic  environment (Selkoe,  1994).  A  close  anatomical 
relationship between hippocampal amyloid plaques and cytoskeletal changes has been 
noted in FBD, suggesting that mechanisms documented in AD may also be present in 
this condition. However, with the anti-ABri antibody available it would now be possible 
to study the relationship between ABri and tau deposition in depth.
The  importance  of  activated  microglia  in  AD,  which  produce  pro-inflammatory 
cytokines,  reactive  oxygen  species  and  other  potentially  toxic  substances  has  been 
reported  (Dickson,  1997;  Dickson  et  al.,  1993).  Evidence  in rodents  indicates  that 
microglia  can  be  activated  by  neuronal  degeneration,  suggesting  that  microglial 
activation  may  be  secondary  to  neurodegeneration.  This  indicates  that  microglial 
activation in AD may be secondary to neurodegeneration and, once activated, microglia 
may  participate  in  a  local  inflammatory  cascade  promoting  tissue  damage  and 
contribute to amyloid formation. Prominent astrocytic response has been shown to be 
associated with amyloid deposits in FBD (Revesz et al.,  1999).  A close relationship 
between microglia and astrocytes has been shown within AD, suggesting that astrocyte 
derived growth factors may promote microglial growth (Lee et al.,  1994). In addition, 
astrocytes are the source of other important substances contributing to neuronal damage 
including ApoE and ApoJ (Boyles et al., 1985).
The  purpose  of this  study  was  to  investigate  the  distribution  of ABri using  Ab338 
immunohistochemical  techniques  and  gain  a  detailed  pathological  analysis.  The 
conformational  state  of ABri  lesions,  as  to  whether  amyloid  or  pre-amyloid  were 
present,  was  also  assessed  with  double  anti-ABri  immunohistochemistry  and 
thioflavine-S fluorescent staining to examine the correlation between the lesion type and 
the conformation of the protein present.
The distribution of NFTs, NTs and ANs was investigated immunohistochemically with 
anti-tau antibody AT8. Double immunohistochemistry was also carried out to establish 
their distribution in relation to different ABri lesions, using Ab338 and AT8.
To establish the extent of glial response to ABri lesions glial fibrillary acidic protein 
(GFAP)  and  microglial  response  using  CD68  and  CR3/43.  Double 
immunohistochemistry was also carried out using the glial cell markers with Ab338 to 
determine the presence of the glial cells within ABri deposits, followed by staining with 
thioflavine-S to investigate the glial response with the conformational state of ABri.
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3.2  Material and Methods
3.2.1  Tissue
Brain and spinal cord from five cases of FBD, five sporadic AD cases and three age- 
matched controls were used for these studies.  The pathological diagnosis of AD was 
made using standard criteria (Mirra et a l, 1991). FBD cases 1-3 were from the original 
pedigree  (Worster  et  al,  1940)  (we  thank  Professor  Margeret  Esiri  for  providing 
material  from  case  3),  case  4  from  a  second  pedigree  with  identical  clinical  and 
pathological features (Mead et al, 2000a) and case 5 is from a recently identified third 
family  with  typical  clinical  presentation  and  mutation  of the BRI gene  in  affected 
members (Table 10) (Mead etal, 2000a).
Case Age Sex Cause of death Diagnosis
1 56 F Not recorded FBD
2 65 F Bronchopneumonia FBD
3 N/A N/A N/A FBD
4 60 M Cardiac failure FBD
5 68 F Bronchopneumonia FBD
6 69 F Acute tracheobronchitis AD
7 92 F Pneumonia AD
8 88 M Bronchopneumonia AD
9 89 F AD AD
10 85 F Acute tracheobronchitis AD
11 56 M Cardiac failure Control
12 33 M Acute bronchopneumonia Control
13 75 F Head injury Control
Table 10: Cases used in FBD pathology study
For immunoelectron microscopy (iEM) selected tissue samples from the hippocampal 
formation (cases 1  and 5) and temporal neocortex (case 5) were fixed in 3% buffered 
gluteraldehyde.
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3.2.2  Antibodies and immunohistochemistry
The antibodies used for this study are listed in table 11. Immunohistochemical analysis 
was carried out at the light microscopy level using the standard protocol (section 2.2). 
To  determine  the  relationship  between  protein  deposition  and  amyloid  formation 
sections were double stained with Ab338 and thioflavine-S, as described in section 2.6.2 
or double stained with Ab338 and Congo red as described in section 2.5. Tissue sections 
from  the  hippocampal  formation,  amygdala,  and  cerebellum  including  the  dentate 
nucleus, cerebral cortex and white matter were used for double staining with Ab338 and 
either GFAP or CD68  (section 2.7.2). iEM was carried out using Ab338 to establish 
whether ABri was of fibrillar or non-fibrillar nature in the different structures (section 
2.8).
Antibody Source Species Pretreatment Dilution
338 Dr J Ghiso Polyclonal Formic acid 12000
338 Abs Dr J Ghiso Polyclonal Formic acid 12000
338 PI Dr J Ghiso Polyclonal Formic acid 12000
AT8 Autogen Bioclear Monoclonal Microwave 1600
GFAP Dako Polyclonal Tyrpsin 1 1000
CD68 Dako Monoclonal Trypsin 1200
Table 11: Antibodies used  for the pathological study o f  FBD. Abs: Antibody 
preabsorbed with synthetic peptide used  for immunisation, PI: Pre-immune.
3.2.3  Evaluation of Ab338 and AT8 immunohistochemistry
3.2.3.1  Semi-quantitation of CAA
The presence  and frequency of Ab338 positive plaques  and CAA were evaluated in 
different anatomical regions using a semi-quantitative approach (section 2.9.1).
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3.2.3.2  Semi-quantitation of parenchymal deposits
The presence of Ab338 positive parenchymal plaques were defined as Ab338-, Congo 
red-, and thioflavine-S positive structures with or without an associated blood vessel, 
whereas diffuse deposits were often ill-defined, Ab338 positive, Congo red- negative 
structures, which were only weakly stained, if at all, with thioflavine-S. The method of 
quantitation was followed as described in section 2.9.2.
3.2.3.3  Semi-quantitation of tau pathology
The  severity of NFT, NT and AN pathologies were  evaluated  separately in a  semi- 
quantitative manner as described in section 2.9.3.
3.3  Results
3.3.1  Distribution of ABri in parenchymal amyloid lesions
Amyloid plaques, defined as Congo red and thioflavine-S positive structures, were seen 
in many of the CNS areas. Importantly Ab338 stained all plaques types described by 
previous studies using silver impregnation techniques (Griffiths et al., 1982; Plant et al., 
1990; Revesz et al.,  1999). Such plaque types included the large and small plaques of 
the hippocampal formation (figure 3.1 A - C) and also the parenchymal amyloid plaques 
in the cerebellum (figure 3. IE) and dentate nucleus (figure 3. IF). In the majority of the 
hippocampal  and cerebellar amyloid plaques there was a very good overlap between 
Ab338  and  thioflavine-S  double  staining  (figure  3.2A-F).  Ab338
immunohistochemistry,  Congo  red  and  thioflavine-S  methods  combined  with  semi- 
quantitative evaluation, showed little variation between cases; therefore they will all be 
described together (tables  12  -  14).  The hippocampus and cerebellum were the most
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severely  affected regions by  amyloid plaques, but considerable  numbers  of amyloid 
plaques were present in structures such as the hypothalamus, amygdala, locus coeruleus, 
inferior olive and the cerebellar dentate nucleus.  Between the hippocampus and third 
temporal  gyrus  Ab338  positive  deposits  affected  all  allocortical  areas  and  also  the 
isocortical  fusiform gyrus.  An anatomically determined sharp transition between two 
staining patterns was noted at the junction between the subiculum and presubiculum. 
The subiculum contained a significant number of Ab338, Congo red, and thioflavine-S 
positive amyloid plaques. In many cerebral and cerebellar areas and also in the spinal 
cord Ab338  stained  subpial deposits,  which were variably positive  on Congo red or 
thioflavine-S  preparations.  Clearly defined fibrillar staining was  also  seen associated 
with the basolateral aspect of the ependyma (not shown).
3.3.2  Distribution of Ab338 parenchymal pre-amyloid structures
Examples  were  found  where  Ab338  positivity  was  observed  without  corresponding 
thioflavine-S  or Congo red staining,  suggesting that the protein conformational  state 
was  pre-amyloid  (non-fibrillar)  (figure  3.2G-I,  arrow).  This  was  also  seen  in  the 
cerebellum, particularly in the granular cell layer of the cerebellar cortex, where Ab338 
often stained structures more extensively and/or intensely than thioflavine-S and Congo 
red  did.  This  staining pattern  was  also  apparent  in  a proportion  of the  perivascular 
protein  deposits  (figure  3.2J-L,  arrow).  Diffuse  deposits  were  also  noted  in varying 
numbers in other areas such as the entorhinal cortex, tectum, periaqueductal gray, the 
medullary  pyramids,  spinal  cord  gray  and  white  matter  and  neocortex  where  they 
appeared randomly distributed throughout the cortical laminae. In the cerebral cortices 
loosely arranged diffuse  deposits were  also  seen to  surround neurons,  often with an 
accentuation of staining adjacent to the perikaryon.
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Figure  3.1:  Distribution  of  ABri  in  FBD  shown  by  Ab338
immunohistochemistry.  A:  There  are  numerous  structures  outlining  the 
anatomical regions of the hippocampus. B: Large plaques are mainly found in the 
CA4 and granular cell layer (GCL). C: Small plaques are characteristic in CA1. D: 
Diffuse deposits are present in the parvopyramidal cell clusters (PVC) of the pre- 
and parasubiculum. E: The cerebellar cortex is severely affected by ABri plaques 
often  forming  confluent  deposits F:  ABri  plaques  outline  the  cerebellar  dentate 
nucleus (arrows) G: Vessels are affected by ABri deposition throughout the CNS 
often  showing  degenerative  changes  such  as  double  barrelling  (arrow).  H: 
Perivascular parenchymal  ABri  deposits  were  frequently found (arrows).  Bar  in 
panel A represents  1000pm in A,  500pm in E, 250pm in panels B,C and D and 
100pm in F,G and H.
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Figure 3.2:  ABri  and  thioflavine-S  fluorescent  immunohistochemistry  (ABrirred; 
thioflavine-S:  green;  C,F,I,L and O combined images):  A-C, D-F, M-O:  The good 
overlap  of ABri  with  thioflavine-S  (A  and  B,  M  and  N)  suggests  that  most  of the 
parenchymal,  including  perivascular  and  vascular  ABri  deposits  are  in  amyloid 
conformation (fibrillar). G-I; J-L: However, parenchymal (G-I, arrow) and perivascular 
(J-L: arrow) preamyloid (non-fibrillar) deposits are also present. Original magnifications 
A-C x 10 and D-O x 20.
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This phenomenon was found at several other locations, including in the pyramidal and 
granular cell layers of the hippocampus, around Purkinj e-cells, anterior horn cells of the 
cord, and neurons of the inferior olive.
A delicate membranenous staining pattern highlighting neuronal cell margins was noted 
most  readily  in  hippocampal  pyramidal  cells.  In  the  CA1  region  and  subiculum  a 
number of less compact NFTs, not associated with visible neuronal nucleus or plasma 
membrane (extracellular tangles) were stained with Ab338 and a few such structures 
seemed to  have  been  incorporated  into  amyloid  plaques.  The  presubiculum  and the 
parasubiculum  had  an  ill-defined  diffuse  staining pattern.  The  size and shape of the 
Ab338  positivity  closely  matched  the  anatomical  boundaries  of the  pre  and  para 
subicular  parvopyramidal  cell  islands.  In  the  entorhinal  cortex  the  deposits  were 
predominantly of the diffuse type with a striking bilaminar distribution.  There was an 
inner wide band, occupying the deeper cortical laminae, with an ill-defined, confluent 
staining  pattern  and  a  narrower outer band  composed  of often  better  circumscribed 
deposits.  The outer Ab338 positive band closely overlapped with the Pre-a neuronal 
clusters  and  with  the  Pre-a  neurons  themselves  gradually  descended  in  the 
transentorhinal  cortex to form a  single band of well-defined  Ab338  positive,  mainly 
diffuse deposits in the deeper laminae of the fusiform gyrus.
Ab338 also stained subependymal areas around the ventricles and cerebral aqueduct in a 
diffuse pattern.  The cerebral,  cerebellar,  and spinal cord white matter showed mostly 
diffuse deposits although perivascular amyloid plaques were also noted.
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3.3.3  Regions unaffected by ABri deposition
The  striatum,  globus pallidus,  substania  nigra and pontine  raphe,  which also  lacked 
CAA, were entirely unaffected by parenchymal deposits whereas the degree (none to 
mild) of thalamic involvement varied between cases.  Other areas including the optic 
chiasm, pontine base and sacral cord lacked any parenchymal deposits but were affected 
by CAA (tables 12-14).
3.3.4  Control  immunohistochemistry
No  staining  of vascular amyloid,  plaques  or diffuse deposits  of the FBD  cases was 
observed  in  controls  using  the  pre-immune  serum,  the  Ab338  pre-absorbed  with 
synthetic  peptide  or when the  primary  antibody  was  omitted.  Immunohistochemical 
staining with Ab338 of brain tissues from individuals with AD or normal controls were 
also negative.
3.3.5  Distribution of ABri staining of CNS blood vessels.
All affected blood vessels stained with Congo red and thioflavine-S were also Ab338 
positive (figure 3.2M-0). Furthermore on preparations double stained with Ab338 and 
thioflavine-S there was generally a good overlap between the different staining patterns, 
although  a  smaller  proportion  of  affected  blood  vessels,  especially  those  with 
perivascular plaques were more extensively stained with Ab338 (figure 3.1H). Many of 
the  leptomeningeal  and  parenchymal  small  arteries  (figure  3.1G),  arterioles  and 
capillaries  were  stained  throughout  the  CNS,  although  the  severity  of CAA  varied 
considerably in the different areas; the striatum, globus pallidus,  and substantia nigra 
were  entirely  unaffected,  in  the  thalamus  and  pontine  base  CAA  was  of moderate 
severity, whereas in other areas such as the hippocampus and cerebellar cortex it was
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severe.  In the cerebellum there was a difference in the  staining pattern of the blood 
vessels of the deep white matter in that, with the exception of those found in the vicinity 
of the  dentate nucleus, they were more rarely  stained with Ab338  than those of the 
white matter in the cerebellar folia.
The  majority  of the Ab338  positive blood vessels were  arterial, but a proportion of 
venous  channels  were  also  affected.  These  latter  was  more  frequent  in  the 
leptomeninges, but were also found in the parenchyma. Although small arteries with a 
diameter of up to 1mm were stained with the Ab338, the majority of the affected blood 
vessels were smaller than 300pm. The larger vessels were usually less affected in that 
Ab338  primarily  stained  the  abluminal  aspect  of the  media  and  the  adventitia.  In 
contrast,  in  many  of  the  small  arteries  and  arterioles  Ab338  positivity  was  seen 
throughout the  full thickness  of the wall,  often with  severe  disruption of its normal 
structure and sometimes occlusion of the lumen. An accentuation of the staining in the 
outer perimeter of some small arteries and arterioles was noted.
Longitudinal  sections  of affected  arterioles  and  capillaries  showed that Ab338  often 
stained blood vessels walls in a linear manner although the full length was not always 
affected. Other staining patterns included the presence of globular deposits along blood 
vessel  walls  or  fine  Ab338  positive  spicules  radiating  from  the  walls  of  affected 
arterioles and capillaries.  In all regions the glia limitans around many affected blood 
vessels was stained with an extension into the adjacent parenchyma, often giving rise to 
plaques like structures previously described as perivascular plaques.
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TYPE OF LESION
Plaques,
including
perivascular
Diffuse deposits CAA NFT AN NT
Olfactory bulb + + + +  + + + + + +
Retina + + + + 0 0 0
Optic nerve + + + + + N/A 0 0
Optic chiasm 0 0 + N/A 0 0
Optic tract + + + N/A 0 0
Hippocampus + + + + + + + + + + + + + + + + + +
Amygdala basal +  +  + +  +  + +  +  + +  +  + 4- +  + +  +  +
Amygdala lateral + +  +  + +  + + + +  +
Uncus +  + + + + + + + + + + + + +
Entorhinal cortex + + + + + + + + + + + + +
Fusiformgyrus + + + + + + + + + 0 + + +
1st, 2nd, 3 
temporal gyri
+ + + + + 0 +
Frontal cortex 0- + + + + 0 0 0
Cingulum + + + + + 0 +
Insular cortex + + + + + + + + +
Parietal cortex + + + + 0 0 0
Occipital cortex 0 + + + 0 0 0
Cerebral white 
matter
+ + + ++-+++ N/A 0 0
Hypothalamus + + + + + + 0 0 0
Striatum 0 0 0 0 0 0
Globus pallidus 0 0 0 0 0 0
Claustrum + + + + + + 0 +
Meynert nucleus 0 + + + + 0 +
Thalamus 0-+ 0-+ + 0 0 0
Subthalamus + + + + 0 0 0
Table 12: Distribution of the different ABri lesion types and tau pathology in FBD.
CAA- cerebral amyloid angiopathy; NFT- neurofibrillary tangle; AN- abnormal 
neurite; NT-  neuropil thread; N/A -  not applicable
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TYPE OF LESION
Plaques,
including
perivascular
Diffuse
deposits
CAA NFT AN NT
Tectum 0 + + + + + 0 0
Periaqueductal gray + + + + + 0 +
Midbrain raphe 0 + + + 0 +
Substantia nigra 0 0 0 + 0 +
Red nucleus + + + + + + + 0 0 0
Cerebral peduncle + + + + + N/A 0 0
Locus coeruleus + + + + + + + + + + 0 0
Pontine raphe 0 0 0 + + 0 + +
Pontine base 0 0 + 0 0 0
Inferior olive + - + + + - + + + + 0 0 0
Pyramid 0 + - + + + + N/A 0 0
Cerebellar cortex + + + + + + + + 0 0 0
Cerebellar white m. 0- + 0 + + N/A 0 0
Dentate nucleus + + + + + + + 0 0 0
Table 13: Distribution of the different ABri lesion types and tau pathology in FBD.
CAA  -  cerebral amyloid angiopathy;  NFT -  neurofibrillary  tangle;  AN -  abnormal 
neurite; N T- neuropil threadLC - lateral column; PC - posterior column;  VC - ventral 
column; GM - gray matter.
TYPE OF LESION
Plaques,
including
perivascular
Diffuse
deposits
CAA NFT AN NT
Cervical cord LC 0- + + + + + + N/A 0 0
Cervical cord PC 0- + + - + + + + N/A 0 0
Cervical cord VC 0- + 0 - + + + - + + N/A 0 0
Cervical cord GM + + - + + + + 0 0 0
Thoracic LC + + + + + + N/A 0 0
Thoracic PC + + + N/A 0 0
Thoracic VC 0 0- + + N/A 0 0
Thoracic GM 0 0- + + 0 0 0
Lumbar LC 0 0 + N/A 0 0
Lumbar PC + 0- + 0- + N/A 0 0
Lumbar VC 0 0- + + N/A 0 0
Lumbar GM 0- + + + ++-+++ 0 0 0
Sacral LC 0 0 + N/A 0 0
Sacral PC 0 0 + + N/A 0 0
Sacral VC 0 0 + N/A 0 0
Sacral GM 0- + + + + + 0 0 0
Table  14:  Distribution  of the  different ABri  lesion  types and tau pathology  in FBD 
spinal cord.
CAA  -  cerebral amyloid angiopathy;  NFT -  neurofibrillary  tangle;  AN -  abnormal 
neurite; NT - neuropil thread; LC - lateral column; PC - posterior column;  VC - ventral 
column; GM - gray matter
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3.3.6  Distribution of ABri within the retina
There was substantial vascular amyloid in many retinal blood vessels and, similar to the 
subpial deposits, there were small amyloid plaques and diffuse deposits along the retinal 
limiting membrane. No gross decrease in cell numbers could be discerned in any of the 
retinal  layers  and  the  photoreceptor outer  segments  and  retinal-pigmented  epithelial 
cells  appeared  identical  to  age  matched  control.  There  was  an  increase  in  GFAP 
expression in Muller’s glial cells.
3.3.7  Tau pathology in relation to ABri deposition
Severe involvement by NFTs and NTs of mediotemporal and other limbic structures, 
including  the  hippocampus,  subiculum,  entorhinal  and  transenthorhinal  cortices, 
amygala,  uncus,  cingulum  and  insular  cortex  was  readily  noted  using  AT8 
immunohistochemistry  (figure  3.3 A  and  3.3B).  Double  AT8  and  Ab338 
immunohistochemistry  also  revealed  that  the  amyloid  plaques,  occurring  in  these 
anatomical  areas,  tended to be  surrounded with ANs,  many of which were fine and 
thread like and were often incorporated within the large hippocampal amyloid plaques 
in  a radial  pattern.  ANs  clustering  around  an  occasional  blood  vessel  with  amyloid 
deposition were also seen in the hippocampus, amygdala and temporal neocortex. There 
was  a  strikingly  similar distribution  of AT8  positive  structures  and  Ab338  positive 
amyloid plaques within the amygdala in that both pathologies affected the basal nucleus 
more  severely than the  lateral  nucleus.  Occasional NFTs  and NTs were  seen  in the 
parvopyramidal clusters of the pre and parasubiculum. In the entorhinal cortex, which 
was rich in non-fibrillar ABri and contained only relatively few amyloid plaques, the 
Pre-a and Pri-a neurons were  severely  affected  containing frequent NFTs and NTs, 
which because of their large numbers, produced darkly stained bands in both cell layers.
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The Pre-P and Pre-y neurons also contained moderate numbers  of NFTs.  In the six- 
layered fusiform gyrus, there were numerous NFTs and NTs. These gradually decreased 
in number toward the neighbouring third temporal gyrus, which, similar to the first and 
second temporal gyri contained only sparse NFTs and NTs. Other neocortices, except 
the  cingulum  and  insular  cortex,  were  unaffected.  The  hypothalamus,  claustrum, 
midbrain  tectum,  periaqueductal  gray  and  locus  coeruleus  contained  sparse  and the 
pontine  raphe  moderate  numbers  of NFTs.  The  cerebellum  and  spinal  cord  were 
unaffected by tau pathology (table 12 -14).
3.3.8  Correlation between Ab338, CD68 and GFAP staining and lesion types
A prominent microglial reaction was demonstrated with CD68 immunohistochemistry 
in different brain regions. Microglial cells were also stained with the CR3/43 antibody 
suggesting  that  microglia  were  activated  (figure  3.3C).  Such  cells  localized  around 
amyloid laden (Ab338 positive) blood vessels and amyloid plaques, which were also 
permeated  by  microglial  processes.  A  similar  picture  was  seen  with  GFAP 
immunohistochemistry showing severe gliosis in all regions affected by amyloid lesions 
(figure 3.3D).  Sections stained with CD68 and counterstained with Congo red (figure 
3.3E and 3.3F) proved the close association of microglia with the  amyloid structures. 
Tissue  sections  double  stained  with  Ab338  and  CD68  and  examined  by  confocal 
microscopy  showed  a  good  co-localization  between  cells  of microglial/macrophage 
lineage  and  both  amyloid  plaques  (figure  3.4A  and  3.4B)  and  vascular  amyloid. 
However such cells were few in areas in which diffuse deposits were predominant. A 
similar relationship between GFAP positive astrocytes and Ab338 positive  structures 
was  seen  on  preparations  double  labelled with  Ab338  and  GFAP  (figure  3.4C  and 
3.4D).
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Figure 3.3: Tau, GFAP, CD68 and CR3-43 immunohistochemistry in FBD. A
& B: AT8 immunohistochemistry showing numerous NFTs, NTs and ANs in the 
hippocampus (arrows pointing to large plaques permeated by abnormal neurites). 
C:  CR3/43  immunohistochemistry  demonstrating  reactive  microglia  response 
associated  with  ABri  deposits.  D:  Extensive  astrocytic  reaction  in  the 
hippocmapus affected by severe ABri deposition.  E & F (viewed  in polarized 
light)  CD68 immunhistochemistry and Congo red staining shows clustering of 
microglia around amyloid parenchymal deposits (double arrow) and an amyloid­
laden  vessel  (arrow).  Extensive  GFAP  immunohistochemistry  in  the 
hippocampus. Bar in panel A represents 100pm in A, B and D, 45pm on panels E 
and F, 28pm on panel C.
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3.3.9  Immunoelectron Microscopy
Ultrathin sections from the hippocampus and temporal neocortex, labelled with Ab338 
using  immunogold method,  were examined.  Tissue preservation was  such that blood 
vessels, neurons, astrocytes and both neuronal and glial processes could be identified. In 
the hippocampus frequent amyloid plaques were present and many small blood vessels 
had amyloid fibrils deposited within their walls thus confirming the findings of light 
microscopy.  Amyloid  plaques varied  in  size  and were  composed  of short fibrils  of 
~10nm diameter, which were randomly distributed but varied in density, some plaques 
being  composed  of  loosely  arranged  fibrils  were  consistently  heavily  labelled  by 
Ab338.  Glial  processes  containing  intermediate  filaments  were  often  seen  within 
plaques (figure 3.5A and 3.5B).  Regions of the temporal neocortex in which Ab338 
positive,  but  thioflavine-S  negative  diffuse  deposits  had  been  identified  in  semithin 
sections  were  selected  for  iEM.  In  these  areas  amyloid  plaques  were  identified 
ultrastructurally; however, extracellular immunogold labelling was seen to be associated 
with  amorphous  electrondense  material  that  was  sometimes  accompanied  by  small 
numbers of loosely arranged fibrils resembling the amyloid fibrils of plaques (figure 
3.5C).  Such electron dense  material was  not found  in association with  hippocampal 
amyloid plaques.
Small  blood vessels  showed  labelling of the  basal  lamina by  Ab338.  Several  blood 
vessels had normal segments of basal lamina adjacent to areas in which a low level of 
labelling was present in its central part. The basal lamina then often became expanded 
into regions with a greater labelling density, in which amyloid fibrils became apparent. 
In some blood vessels the intensity of labelling was greatest on the abluminal aspect of 
the basal lamina reflecting the accentuation of Ab338 staining  seen around the outer 
perimeter of some blood vessels using light microscopy.
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Figure 3.4: Microglial and astrocytic response in FBD. Confocal images
A  &  B;  Ab338  (green)  and  CD68  (red)  double  immunohistochemistry 
showing a marked microglial response around hippocampal amyloid plaques 
(A), but a sparse reaction in the entorhinal cortex where the protein deposits 
are predominantly non-fibrillar (B). C & D; Ab338 (green) and GFAP (red) 
double  immunohistochemistry  showing  a  similar  pattern  of  astrocytic 
reaction in the same areas. Original magnifications xlO (A and C ), x40 (B 
and D).
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Figure  3.5:  Ab338  immunoelectron  microscopy.  B:  Bundles  of  labelled  fibrils  in  a 
hippocampal plaque. An astrocyte process (a) is unlabelled. Insert A showing labelled fibrils 
with high magnification. C: Amorphous electron-dense material together with sparse fibrils is 
decorated with Ab338 in a  thioflavine-S negative area of temporal neocortex. D: Small vessel 
showing labelling of the basal lamina (b), which is focally disrupted by amyloid fibrils. E: A 
vessel  showing  extensive  deposition  of  labelled  fibrils  in  the  basal  lamina.  D  and  E: 
Endothelial cells (e) are unlabeled. Original magnifications: xl6,000 (A); x6,600 (B); xl0,000 
(C); x8,300 (D); and xl3,000 (E).
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The  accumulation  of  amyloid  fibrils  within  the  basal  lamina  produced  increased 
expansion and eventual disruption of the abluminal surface whereas the luminal aspect 
of the basal lamina remained intact (figure 3.5D and 3.5E). NFTs composed of paired 
helical filaments were frequently found in both neuronal cell bodies and processes but 
these were unlabelled by Ab338. No labelling was found using the preimmunization 
rabbit serum or when the primary antibody was omitted.  The antibody that had been 
previously absorbed using the immunizing peptide showed some residual labelling of 
amyloid fibrils but this was greatly reduced in comparison with untreated Ab338.
3.4  Discussion
Of 5  cases of FBD Ab338 stained a large number of pathological lesions of different 
morphological  types  throughout  the  CNS.  The  pathological  lesions  included  blood 
vessels  affected by  amyloid deposition,  amyloid  (fibrillar) plaques  and diffuse (non- 
fibrillar)  parenchymal  ABri  deposits.  This  immunohistochemical  study  confirms 
findings of previous pathological examinations (Plant et a l,  1990; Revesz et al,  1999), 
showing that in FBD the hippocampus and cerebellum are among the anatomical areas 
most severely affected by amyloid deposition in both blood vessels and parenchymal 
plaques. It was also possible to show that ABri is widely deposited throughout the CNS 
and  that  it  deposits  in  anatomically  well  defined  structures  such  as  the  amygdala, 
hypothalamic nuclei, inferior olive, dentate nucleus and parvopyramidal cell clusters of 
the pre- and parasubiculum. Using the same antibody (Ab338) for iEM examination we 
confirmed that bundles of amyloid fibrils in both plaques and blood vessel walls were 
also strongly labelled. In areas with diffuse parenchymal deposits, non-fluorescent with 
thioflavine-S, Ab338 decorated amorphous, electron dense extracellular material, which 
was interspersed with sparse fibrils, but not with bundles of fibrils. As such tinctorial,
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optical  and ultrastmctural  appearances  are thought to represent protein deposits in  a 
nonfibrillar configuration,  or pre-amyloid,  the presence of such lesions  demonstrates 
that ABri deposits in both fibrillar and nonfibrillar forms throughout the CNS in FBD. 
With  the  use  of  the  AT8  antibody,  which  recognises  phosphorylated  serine 
202/threonine 205 epitopes of tau (Su et al., 1994) it was possible to show that there is a 
rich network of fine thread-like processes permeating the large amyloid plaques  and 
also that tau positive dystrophic neurites are also present in relation to the ABri amyloid 
plaques.
When the conformational state of ABri was taken into account it was established that 
while NFTs and NTs occurred in association with both amyloid plaques and diffuse 
deposits, ANs only occurred in association with amyloid lesions, mostly around plaques 
but occasionally in relation to amyloid-laden blood vessels.  A number of NFTs with 
appearances of extracellular tangles were stained with Ab338 in the hippocampus and 
subiculum, which are among the structures with the highest parenchymal ABri load. It 
has been shown that in AD A0 deposition within extracellular tangles, taking place in 
the vicinity of senile plaques,  is a secondary phenomenon (Yamaguchi et al,  1991a; 
Schwab et al, 1998) and it is likely that a similar mechanism is found in FBD.
The  predominantly  limbic  distribution  of  the  tau  pathology  together  with  mild 
involvement of the temporal cortex would suggest that the NFT pathology corresponds 
to stage IV in the system recommended by Braak and Braak for staging NFT pathology 
in AD (Braak & Braak,  1991). However, in FBD the severity of the limbic involvement 
exceeds that expected in stage IV of AD and the presence of NFTs in structures such as 
the granular cell layer of the dentate fascia and substania nigra suggests that in FBD the 
progression of NFT pathology may be different from that  seen in AD.  Although the 
mechanism of NFT formation in FBD remains to be investigated, the close topographic
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association  of both  fibrillar  and  nonfibrillar  ABri  with  neurofibrillary  pathology  in 
limbic  structures  may  support  the  notion  that  NFTs  are  present  because  of  ABri 
mediated neurotoxicity and not because of conformational differences. This hypothesis 
is supported by our finding of colocalization of reactive astrocytes and microglial with 
ABri  in  p-sheet  conformation,  which  is  strikingly  similar to the  findings  in  AD,  in 
which a relationship between the presence of these cell types and the neurodegenerative 
events have been suggested (el Hachimi et a l,  1991; Pike et al,  1995; Selkoe,  1999). 
Despite the close association between neurofibrillary pathology and ABri deposition in 
limbic structures, the absence of apparent neurodegeneration in some other well defined 
protein bearing regions  such as the  dentate nucleus  and  inferior olive,  points to the 
importance of other biological variables in this process.
Ab338  positive congophilic angiopathy of variable severity was widespread and was 
only absent in the striatum, globus pallidus and  substantia nigra.  In FBD the overall 
patterns of amyloid  deposition in cerebral blood vessels  are similar to those  seen in 
congophilic angiopathies related to other amyloid peptides,  in particular Ap,  in which 
arteries and arterioles are more frequently affected than veins.
FBD  with  CAA,  parenchymal  amyloid  plaques,  and  diffuse  deposits  as  well  as 
neurofibrillary degeneration mimics important morphological features of AD, although 
there are distinct features in both diseases. Limbic structures are severely affected by 
both  parenchymal  amyloid  deposition  and  neurofibrillary  degeneration  in  both 
conditions,  although in AD neocortical  involvement is much more prominent than  in 
FBD. The cytoskeletal pathology in FBD, immunohistochemically, ultrastructurally and 
biochemically, is indistinguishable from that found in AD.  The morphology of limbic 
plaques  shows  some  similarities  with  AD  as  the  large  plaques  of FBD  noticeably 
resemble the cotton wool plaques seen in variant AD with spastic paraparesis associated
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with PS1A9 or PS1  exon 4 DellM mutations. However, there are differences between 
the two lesions as the cotton wool plaques are mainly Congo-red negative, whereas the 
large  hippocampal  plaques  of FBD  are  Congo  red  and  thioflavine-S  positive.  CAA 
resulting in white matter degeneration is not a unique feature of FBD as this can be 
associated with a similar pathological picture in AD.
It  is  also  possible  that  the  immunoreactivity  detected  by  Ab338  does  not  solely 
represent the presence of ABri because the specific epitope (TVKKNIEEEN) is shared 
by  ABri,  its  precursor  ABriPP  and  potential  truncated  fragments  generated  by  the 
proteolytic processing of either species.  The heterogeneity of the ABri peptide within 
the  different  lesion  types  has  not  previously  been  studied.  Since  antibodies  to 
differentiate N- and C-terminally truncated ABri species are not yet available we used a 
biochemical approach to differentiate ABri species as described in chapter 7.
These morphological  studies have also provided observations that may be relevant to 
the understanding of the origin of the amyloid peptide ABri. Further investigations into 
the orgin of ABri were carried out in Chapter 8.
Therefore  the  study  of FBD,  including  future  development  of different  transgenic 
animal  models,  may  result  in  a  better  understanding  of the  link  between  amyloid 
deposition and neurodegeneration.
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Chapter 4
Regional distribution of  ADan and 
Ap deposition and its association with 
neurofibrillary degeneration in FDD
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Chapter 4  -  Hypothesis and specific questions
In this chapter, I hypothesised that, similar to ABri in FBD, the deposition of the 
ADan  peptide  is  closely  related  to  the  neurodegenerative  process  in  FDD.  The 
specific questions I wished to concentrate on included: 1) What is the distribution 
and  conformational  patterns  of  ADan  deposition  in  FDD?;  2)  Is  there  a 
relationship  between  ADan  deposition  and  neurofibrillary  pathology,  astroglial 
and microglial responses?
To  answer  these  questions  the  topographical  distribution  of ADan  deposition  was 
studied in FDD  cases using immunohistochemistry.  To determine the conformational 
state  of  the  protein  deposits,  ADan  immunohistochemistry  was  combined  with 
thioflavine-S and evaluated by confocal microscopy. The distribution and relationship 
of  neurofibrillary  degeneration  to  ADan  deposits  were  investigated  by  tau 
immunohistochemistry. The astrocytic and microglial responses to ADan deposits were 
studied by a double immunohistochemical approach. The ultrastructural characteristics 
of the ADan deposits were analysed by immunoelectron microscopy.
4.1  Introduction
FDD, previously described as heredopathia ophthalmo-oto-encephalica by Stromgren et 
al (1970, 1981), is a rare, dominantly inherited neurodegenerative disease. The original 
description  of  the  disease,  as  described  in  section  1.3,  provided  only  scanty 
neuropathological  data  based  on  the  examination  of a  single  case.  Suggesting  the 
presence  of a  uniform,  diffuse  atrophy  of the  brain,  thin  and  demyelinated  cranial 
nerves,  as  well  as  ‘histological  involvement’  including  a  vasculopathy  of  the 
cerebellum, cerebral cortex and white matter (Stromgren, 1981).
Like  FBD  it  has  been  shown  to  be  associated  with  a  mutation  in  the  BRI2  gene; 
however FDD is associated with a decamer duplication occurring between codons 265 
and 266 (Vidal et al., 2000b), resulting in a ffameshift abolishing the normal stop codon 
and the production of a 277 amino acid long precursor protein (ADanPP), from which a 
34  amino  acid  peptide  (ADan)  is  cleaved  by  a  furin-like  proteolysis  from  the  C- 
terminus.  The  amyloidogenic  subunit  ADan  has  been  shown  to  be  deposited  in 
leptomeningeal  and  cerebral  blood  vessels  and  also  as  the  major  component  of 
parenchymal lesions.  The hippocampal deposits found within FDD are mainly Congo 
red negative suggesting that the protein deposited is predominantly in a nonfibrillary
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structure. As well as the deposition of ADan within FDD, Ap co-depositing has also 
been found mainly in a perivascular postion (Vidal et al., 2000b).
Because  FDD  combines  severe  vascular  amyloid,  perivascular  and  parenchymal 
plaques,  as  well  as  NFT  formation,  the  study  of the  disease  may  provide  useful 
information leading to the understanding of the relationship between cerebrovascular 
amyloidogenesis  and  neurodegeneration.  After  the  identification  of  ADan  the 
production  of a  specific  antibody  (Ab5282)  raised to  C-terminal  amino  acids of the 
ADan protein (CFNLFNSQEKHY) was produced (Vidal et al., 2000b).
With  this  anti-ADan  antibody  available,  it  would  now  be  possible  to  study  the 
distribution  of  ADan  and  the  correlation  between  protein  deposition  and  the 
conformational state of the protein.
Tau  immunoreactive  structures  were  found to be  numerous  within the  hippocampus 
where ANs mostly around amyloid affected blood vessels, NFTs and NTs were seen in 
large numbers (Vidal et al., 2000b). A study of their correlation to the ADan peptide 
could also be undertaken.
The  purpose  of this  study  was  to  investigate  the  distribution  and  patterns  of ADan 
deposition  using  immunohistochemistry  with  the  antibody  Ab5282.  Using  antibody 
Ab5282  the  visualisation  of both  conformational  states  of ADan,  amyloid  and pre­
amyloid,  could  be  undertaken  using  immunohistochemistry  in  combination  with 
thioflavine-S or Congo red. The distribution and relationship of NFTs, NTs and ANs to 
ADan deposits was investigated using the AT8 antibody.
The  astrocytic  response  to  ADan  deposits  was  studied  using  GFAP 
immunohistochemistry  and  the  microglial  response  was  addressed  using  CD68  and 
CR3/43  antibodies.  Ultrastructural  characteristics  of amyloid  and diffuse  deposits  as 
well as NFTs were studied by EM and iEM.
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4.2  Material and Methods
4.2.1  Tissue
Brain and spinal cord samples from 3 cases of FDD, 5 sporadic AD cases, diagnosed by 
using standard criteria (Mirra et al., 1991), and 3 normal control cases were collected at 
post mortem (table  15).  For routine  stains  and immunohistochemistry tissue  samples 
were  fixed  in  10%  formalin  in  PBS.  For  EM,  selected  tissue  samples  from  the 
hippocampal  formation  from  case  1   were  fixed  in  3%  buffered  glutaraldehyde  after 
fixation in 10% formalin.
Case Age Sex Cause of Death Diagnosis
1 43 M Bronchopneumonia FDD
2 60 F Bronchopneumonia FDD
3 58 M Not recorded FDD
4 69 F Acute tracheobronchitis AD
5 92 F Pneumonia AD
6 88 M Bronchopneumonia AD
7 89 F AD AD
8 85 F Acute tracheobronchitis AD
9 56 M Cardiac failure Control
10 33 M Acute bronchopneumonia Control
11 75 F Head injury Control
Table 15: Cases used in FDD pathological study
4.2.2  Antibodies
The antibodies used for this study are listed in table 16. Immunohistochemical analysis 
was carried out at the light microscopy level using standard protocols (section 2.2). To 
determine the conformational state of the protein deposits sections were double stained 
with  Ab5282  and  thioflavine-S  as  described  in  section  2.6.2  and  with  Ab5282  and 
Congo  red  as  described  in  section  2.5.1.  Tissue  sections  from  the  hippocampal 
formation, amygdala, and cerebellum including the dentate nucleus, cerebral cortex and
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white  matter were used  for double  staining with  Ab338  and  either GFAP  or CD68 
(section 2.7.2).
Antibody Source Species Pretreatment Dilution
5282 Dr J Ghiso Polyclonal Formic acid 12000
5282 Abs Dr J Ghiso Polyclonal Formic acid 12000
5282 PI Dr J Ghiso Polyclonal Formic acid 12000
AT8 Autogen Bioclear Monoclonal Microwave 1600
GFAP Dako Polyclonal Tyrpsin 1 1000
CD68 Dako Monoclonal Trypsin 1200
CR3/43 Dako Monoclonal Pressure cook 1200
Table 16: Antibodies used  for pathological study of  FDDAbs: Antibody 
preabsorbed with synthetic peptide used  for immunisation, PI: Pre-immune
4.2.3  Immunnoelectron microscopy
Ultrathin sections were prepared from case 1  as described in section 2.8.1. The sections 
were  then  immunostained  as  described  in  section  2.8.3  and  viewed  under  a  JOEL 
1200EX electron microscope.
4.2.4  Semi-quantitation of CAA
The presence and frequency of Ab5282 positive plaques and CAA were evaluated in 
different  anatomical  regions  using  a  semi-quantitative  approach  as  used  for  the 
evaluation in FBD (section 2.9.1).
4.2.5  Semi-quantitation of parenchymal deposits
For the quantitation of Ab5282 positive parenchymal deposits amyloid plaques were 
defined as Ab5282-, Congo red-, and thioflavine-S positive structures with or without 
an  associated  blood vessel,  whereas diffuse  deposits were  often  ill-defined,  Ab5282 
positive, but Congo red negative structures, which were only weakly stained, if at all, 
with thioflavine-S.  The  semi-quantitative approach was used  as  described  in  section
2.9.2  for FBD.
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4.2.6  Semi-quantitation of tau pathology
The  severity  of NFT,  NT  and  AN  pathologies  was  evaluated  separately  in  a  semi- 
quantitative manner as described in section 2.9.3.
43  Results
4.3.1  Macroscopic description
The brain weights of cases 1  and 2 were l,438g and l,220g respectively; the weight of 
case 3 was not recorded. The leptomeninges were thick and opaque and the degree of 
atheroma in the blood vessels at the base of the brain varied from absent in case 3, mild 
in case 1  to severe in case 2. On slicing, the lateral ventricles were found to dilated and 
there was thinning  of the  cortical  ribbon and  reduction  in the white  matter bulk.  In 
addition,  case  1   showed focal perivascular gray translucent areas in the white matter. 
The hippocampi were reduced in bulk. The brainstem and cerebellum were atrophic and 
the cranial nerve roots of case 3 were noted to be thin. The spinal cord was examined in 
cases  1   and 2 and found to narrowed in the antero-posterior dimension and on slicing 
showed yellow discolouration. The spinal nerve roots were thin and firm.
4.3.2  Histological examination
All cases showed similar features and, although the severity of the disease varied, will 
be  described  together.  The  histological  examination  revealed  widespread  vascular 
pathology  affecting  small  arteries,  arterioles  and  capillaries  in  the  parenchyma  and 
leptomeninges  throughout  the  CNS.  The  blood  vessels  affected  had  thickened, 
eosinophilic  walls  with  fine  spicules  of  eosinophilic  material  radiating  into  the 
parenchyma  surrounding  the  blood  vessels.  This  finding  was  common  in  the 
hippocampal  CA1  region,  subiculum  and the  cerebellar  cortex where  the  lumina  of
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capillaries were often occluded.  Congo red staining with apple green birefringence in 
polarized  light  and thioflavine-S  positivity  confirmed that  ADan was  in  an amyloid 
conformational state (figure 4.1C-J). This congophilic material was also present in the 
parenchyma but the majority was associated with affected blood vessels (figure 4.1C-F) 
and perivascular plaques (figure 4.1G and 4.1H). These were found to be most common 
in the CA1 region of the hippocampus as well as the subiculum, entorhinal cortex and 
neocortex. Whereas they were relatively uncommon in the cerebellar cortex despite the 
amount of vascular pathology seen in this region.
In addition  to  vascular  pathology,  the  CA1  sub-region  of the  hippocampus  and the 
subiculum  showed  marked  abnormalities with  neuronal  loss,  NFTs  and  extracellular 
ghost  tangles.  Silver  staining  revealed  the  presence  of  NFTs  and  fine  NTs 
predominantly in limbic structures (figure 4.1 A and 4. IB).  Bulbous ANs were found 
around amyloid bearing blood vessels most frequently  in the CA1  sub-region of the 
hippocampus and the subiculum, but neuritic plaques were not a feature. Extracellular 
NFTs (ghost tangles) were confirmed in the hippocampal CA1 region and subiculum.
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Figure  4.1:  Pathological  findings  in  FDD.  A:  Numerous NFTs  shown on the 
Bielschowsky’s  silver  stain  in  the  CA1  subregion  of  the  hippocampus.  No 
argyrophilic plaques are present.  B:  Abnormal neurites  (arrows) cluster around 
amyloid-laden  blood  vessels  (asterisks).  C  &  D:  Congo  red  staining  of the 
hippocampal  formation  showing  amyloid  deposition  within  the  blood  vessels 
(arrows) but on Congo red reactivity observed corresponding to the severe ADan 
parenchymal deposition (C, inset). E & F: Hippocampal blood vessel with amyloid 
deposition.  G & H:  Some vessels are surrounded by loose perivascular amyloid 
deposits.  I  &  J:  Congo  red positivity mainly  restricted to  blood  vessels  in the 
cerebellum. Bar in panel A represents 500pm in A; 1000 pm in C and D; 250pm in 
B; 100pm in G,H,I and J represents 100pm and 45pm in E and F.
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The neocortex showed no spongiosis and only mild neuronal loss. The hemispheric and 
deep cerebellar white matter was rarified with patchy myelin pallor and axonal loss with 
occasional axonal retraction balls, and the perivascular spaces were frequently enlarged. 
Several small areas of infarction of varying age were found in the hemispheric white 
matter in addition to other regions such as the deep gray nuclei, cerebellum and pons.
The cerebellum was severely affected by amyloid angiopathy and was atrophic with loss 
of volume in the molecular layer, granule cell depletion, and marked loss of basket and 
Purkinje  cells,  the  latter frequently  displaying  axonal torpedoes.  Bergman glia were 
increased  in number.  The deep white  matter showed  similar changes to those of the 
hemispheric white matter,  although folial white matter was less affected.  The dentate 
nucleus was well preserved although mild neurofibrillary pathology was found in one 
case.
Examination of the brainstem showed widespread amyloid angiopathy. The substantia 
nigra and locus ceruleus were well populated by neurons with only small amounts of 
free pigment indicative of cell loss. Occasional NFTs were seen in the substantia nigra 
in one case.  The pontine base contained small areas of old infarction in 2 cases.  The 
inferior olive in case 2 had a region of cell loss and gliosis, which was most likely to be 
secondary to the vascular lesion noted in the pons.
The spinal cord was affected by amyloid angiopathy in all areas throughout its length. 
Silver impregnation demonstrated circumferential peripheral axonal loss. Anterior horn 
cells  were  well  preserved  and the  nerve  roots  available  for examination  showed  no 
significant pathology.
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4.3.3  Ab5282  immunohistochemistry,  Congo  red  and  thioflavine-S  staining  of 
blood vessels.
All three cases showed widespread vascular pathology. Many small arteries, arterioles 
and  capillaries  in  the  leptomeninges  (figure  4.2G,  inset),  gray  and  white  matter 
throughout the CNS had thickened, eosinophilic walls frequently with fine spicules of 
eosinophilic  material  radiating  into  the  parenchyma  surrounding  capillaries.  Small 
arteries with a diameter of up to 1mm were labelled by Ab5282 (figure 4.21), although 
the majority of the blood vessels were smaller than 300 pm. Some of the small arteries 
and arterioles showed an accentuation of Ab5282 labelling in the outer perimeter, while 
in severely affected blood vessels Ab5282 was seen throughout the full thickness of the 
blood  vessel  wall  (figure  4.2G,  inset).  The  glia  limitans  and  the  perivascular 
parenchyma around some of the affected blood vessels were also labelled with Ab5282 
(figure 4.21).
Preparations double stained with Ab5282 and thioflavine-S and examined by confocal 
microscopy  confirmed  a  close  overlap  between  ADan  and  amyloid  deposits  within 
blood  vessels  (figure  4.3D-F).  The  severity  of  CAA  varied  considerably  between 
anatomical areas and was entirely absent only in the globus pallidus in all three cases 
(tables  17  and  18).  CAA was  mild  in  the  striatum,  nucleus  basalis  of Meynert  and 
substantia nigra and was moderate in structures such as the amygdala, entorhinal cortex, 
different  neocortical  areas,  thalamus,  subthalamus,  red  nucleus,  pontine  base,  spinal 
cord, and both cerebral and cerebellar white matter.  Severe CAA was observed in the 
hippocampus, cerebellar cortex and the retina.
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4.3.4  ADan immunohistochemistry, Congo red and thioflavine-S staining
of parenchymal lesions.
Semi-quantitative  analysis  showed  that  the  hypothalamus,  midbrain  tectum  and
periaqueductal gray, locus ceruleus, retina and the hippocampal formation were severely
affected by parenchymal ADan deposits (figure 4.2A-C), other limbic structures such as
amygdala and anterior thalamus, and cerebellum (figure 4.2G and 4.2H). Other regions
were less severely affected and there was no involvement of the optic nerve, cingulate
gyrus,  globus  pallidus,  nucleus  basalis  of Meynert,  thalamus,  subthalamic  nucleus,
substantia nigra, red nucleus and gray matter of the lumbar and sacral cord (tables  17
and 18). Congo red and thioflavine-S staining of adjacent sections demonstrated that the
majority of the  parenchymal  lesions were  negative  or weakly positive  and therefore
largely represent protein deposition in the non-fibrillar or pre-amyloid form, for which
the term of diffuse deposits was used in this study (figure 4.1C and 4. ID). This finding
was confirmed by  studies using double labelling with Ab5282 and thioflavine-S  and
confocal  microscopy  (figure  4.3A-C).  Diffuse  deposits  were  morphologically  of 2
types:  compact  deposits  of varying  size that  showed  some similarity with the cotton
wool plaques of variant AD with spastic paraparesis (Crook et a l,  1998c; Houlden et
a l, 2000b) (figure 4.2E),  and ill-defined, cloudy or loose deposits which often had a
peri-neuronal disposition (figure 4.2A and 4.2B). Both types of diffuse deposits were
frequent  in the  hippocampal  formation where ghost tangles  sometimes  labelled with
Ab5282  were  found.  In  the  parasubilculum,  the  parvopyramidal  cell  clusters  were
occupied by Ab5282 positive, ill-defined diffuse lesions.
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Figure  4.2:  Distribution  of  ADan  in  FDD  shown  by  Ab5282
immunohistochemistry.  A:  Plaque-like  and  ill  defined  parenchymal  deposits 
outlining the anatomical regions of the hippocampus. B: Ill-defined deposits in the 
CA1  subregion.  C:  Parenchymal  deposits  near  to  the  GCL  are  better  defined 
(arrow), while the deposits in the CA4 are large and confluent (double arrow). D: 
The  staining pattern  is bilaminar  in the  entorhinal  cortex (asterisk)  and the two 
bands become united towards the transentorhinal cortex (arrow). E:  Well-defined 
plaques are found in the subiculum. F: Subpial deposition of ADan (arrow) is also 
found in the frontal cortex. G:  Severe CAA found in the cerebellum, inset showing 
leptomingeal vessels.  H: Diffuse ADan plaques in the cerebellar dentate nucleus. 
I:  A  large  perivascular  deposit  found  in  the  frontal  cortex.  Bar  in  panel  A
represents 1000pm in A and D; 500 pm on C and G; 250pm on B, F and H; 100pm 
on E; 45 pm on I and G (inset).
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In the entorhinal cortex, ADan was most commonly found as compact diffuse deposits 
and formed a bilaminar pattern with relative sparing of the middle cortical laminae, in a 
manner similar to that seen in FBD (figure 4.2D). Neocortical deposits were mostly of 
the diffuse type and were only mild to moderate in severity. The cerebellar cortex also 
contained  mild  to  moderate,  loose,  diffuse  deposits  of ADan  predominantly  in  the 
granular cell layer, and there were similar deposits occasionally found in the molecular 
layer  and  white  matter.  Subpial  deposition  of ADan  was  also  characteristic  in  the 
cerebellum.  In  one  case  (case  3)  compact diffuse  ADan  deposits  were  found in the 
dentate  nucleus  (figure  4.2H).  The  midbrain tectum,  periaqueductal  gray matter and 
IVth  nerve  nucleus  were  variably,  but  often  severely  affected  by  diffuse  peptide 
deposits, although there were no such deposits in the substania nigra. In the pons the 
locus  ceruleus  contained moderate to  severe  diffuse  deposits.  While  elsewhere these 
were only mild.
Normal  and  AD  controls  were  negative  with  Ab5282  and  no  staining  of vascular 
amyloid  or  parenchymal  deposits  was  found  in  the  FDD  cases  when  Ab5282  was 
replaced with the pre-immune serum or the primary antibody was ommitted.
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Figure 4.3:  ADan  and  thioflavine-S  double labelling for  confocal 
microscopy  (ADan:  red  (A  &  D),  thioflavine-S:  green  (B  &  E), 
combined  images  C  &  F).  A  -C:  The well-defined  ADan  deposits 
adjacent  to  the  hippocampal  granular  cell  layer  are  in  part  also 
thioflavine-S  positive  while  those  in  the  CA4  subregion  are  mainly 
thioflavine-S negative. There is a good overlap between ADan (D) and 
thioflavine-S  (E)  staining  of  blood  vessels  (arrow)  in  the  CA4 
subregion,  whereas  the  Ab5282  positive  parenchymal  deposits  are 
mainly thioflavine-S negative (double arrow) (F) (Obj xlO).
166Type of Lesion
Amyloid plaques Diffuse deposits Amyloid angiopathy NFT AN NT
ADan AP ADan AP ADan AP
Retina (1) +++ 0 ++ 0 +++ 0 0 0 0
Optic nerve (2) 0 0 0 0 ++ 0 0 0- + 0
Optic tract (2) 0 0 0- + 0 ++ 0 N/A 0- + 0- +
Hippocampus (3) 0- + 0 +++ ++.+++ +++ ++-+++ +++ ++-+++ +++
Subiculum (3) 0 0 +++ + -++ ++ ++ + -+++ + -+++ ++_+++
Amygdala basal (2) + 0 +++ 0 -+++ ++ 0-++ ++  -+++ ++ ++-+++
Amygdala lateral (2) 0- + 0 + 0 -+++ ++ 0-++ + -++ 0-++ + -++
Amygdala (1) + 0 ++ ++ ++ ++ +++ ++ +++
Septum (2) 0 0 + -+++ + ++_+++ + + -++ + + -++
Uncus (2) 0 0 + -+++ 0 -+++ ++ + -++ ++-+++ + +++
Entorhinal cortex (3) + -++ 0 + -+++ ++-+++ + -++ ++-+++ + -+++ + -+++ ++-+++
Fusiformgyrus (3) 0 0 + + -+++ ++ + - ++ + -+++ + -+++ + -+++
1st, 2nd, S^emporal gyri (3)
+
+
1
o 0 0-++ + -++ ++ ++-+++ + -++ + -++ + -++
Frontal cortex (3) 0- + 0 0- + ++-+++ ++ ++ + + -++ + -++
Cingulum (1) 0 0 0 ++ ++ + + + +
Insular cortex  (2) 0 0 0- + ++-+++ ++ + -++ ++-+++ + -+++ ++-+++
Parietal cortex (2) 0 0 + ++-+++ ++ + -++ + -++ + -+++ + - +++
Occipital cortex (3)
+
+
1
o 0 0-++ + -+++ ++ ++ 0- + + 0 - +
Cerebral white matter (3) 0 0 + 0-++ ++ 0- + N/A ++ +
Hypothalamus (2) 0 0 + -+++ + ++ + -++ + -++ + -++ + -++
Caudate (3) 0 0 0 0 -+++ 0- + 0 0- + 0 0 - +
Putamen (3) 0 0 0 + -++ 0- + 0 0 0 0- +
Globus pallidus (3) 0 0 0 0 0 0 0 0 0
Claustrum (2) 0 0 0- + + + -++ 0- + + 0-++ + -++
Meynert nucleus (3) 0 0 0 0 -+++ + 0- + ++ 0- + ++
Thalamus (2) 0 0 0 0-++ + -++ 0-++ + -++ 0 +
Subthalamus (2) 0 0 0 0- + ++ 0 0 0 0
Table 17: Distribution of  different ADan and A/5 lesion types and tau pathology in familial Danish dementia 
_   Numbers in brackets refer to the number of cases, in which this area could be examined. NFT = neurofibrillary tangle, AN = abnormal neurite, NT = neuropil thread
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Type of Lesion
Amyloid plaques Diffuse deposits Amyloid angiopathy NFT AN NT
ADan A(3 ADan AP ADan AP
Tectum (3) 0-++ 0 + - +++ 0-++ ++ 0 -+++ 0-++ 0 -+++ 0-++
Periaqueductal gray (2) 0- + 0 + -+++ 0-++ + -++ 0 + -++ 0 +
Midbrain raphe  (2) 0 0 + 0- + + 0 0-++ 0 0 - +
Substantia nigra (3) 0 0 0 0 - + + 0 0- + 0 0 - +
Red nucleus. (1) 0 0 0 0 ++ 0 0 0 0
Cerebral peduncle (2) 0 0 0- + 0- + + -++ 0- + N/A 0 0
Locus coeruleus (3) 0- + 0 ++ - +++ 0 ++ - +++ 0 + -++ 0- + + -++
Pontine raphe (2) 0 0 0- + 0- + ++ 0 + -  ++ 0- + +
Pontine base (3) 0- + 0 0- + 0- + ++ 0- + 0 0 0
Inferior olive (3) 0- + 0 0-++ 0 + -++ 0 0 0 0
Pyramid (3) 0 0 0- + 0 0 0 N/A 0 0
Cerebellar cortex (3) 0- + 0 + -++ 0- + +++ + -++ 0 0 0
Cerebellar white m. (3) 0 0 0- + 0- + + -++ 0 N/A 0 0
Dentate nucleus (3) 0- + 0 0-++ 0 ++ 0 0- + 0- + 0- +
Cervical cord LC (2) 0 0 + 0 + -++ 0 N/A 0- + 0
Cervical cord PC (2) 0 0 + 0 + - ++ 0 N/A 0 0
Cervical cord VC (2) 0 0 + 0 + -++ 0 N/A 0- + 0
Cervical cord GM (2) 0 0 0- + 0 + -++ 0 0- + 0- + 0- +
Thoracic LC (3) 0 0 0- + 0 ++ 0 N/A 0-++ 0
Thoracic PC (3) 0 0 0- + 0 + -++ 0 N/A 0 0
Thoracic VC (3) 0 0 0- + 0 + -++ 0 N/A 0- + 0
Thoracic GM (3) 0 0 0- + 0- + + -++ 0 0- + 0- + 0- +
Lumbar LC (2) 0 0 0- + 0 0- + 0 N/A 0- + 0
Lumbar PC (2) 0 0 0- + 0 0- + 0 N/A 0 0
Lumbar VC (2) 0 0 0- + 0 + 0 N/A 0- + 0
Lumbar GM (2) 0 0 0 0 + 0 0- + 0 0 - +
Sacral LC (1) 0 0 + 0 + 0 N/A 0 0
Sacral PC (1) 0 0 + 0 + 0 N/A 0 0
Sacral VC (1) 0 0 + 0 + 0 N/A 0 0
Sacral GM (1) 0 0 0 0 0 0 0 0 +
Table 18: Distribution of  different ADan and Ap lesion types and tau pathology in familial Danish dementia
Numbers in brackets refer to the number of  cases, in which this area could be examined. NFT = neurofibrillary tangle, AN = abnormal neurite, NT = neuropil thread
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4.3.5  Ap immunohistochemistry of blood vessels
A proportion of the parenchymal  capillaries (figure 4.4C),  arterioles,  leptomeningeal 
blood vessels  (figure 4.4E)  and  veins  were  affected by  Ap  deposition,  although the 
number of blood vessels containing ADan exceeded those with Ap deposits.  Some of 
the blood vessels were affected with Ap deposition alone, but in a considerable number 
co-localization of both Ap and ADan was established using confocal microscopy (figure 
4.5A-C, 4.5D-F).  Such peptide co-localization was sometimes evident throughout the 
circumference of the blood vessel wall, but in other instances there were isolated foci 
within  the  blood  vessels  wall  containing  only  one  of  the  peptides.  Ap  amyloid 
angiopathy was most severe in the hippocampal formation, where capillaries of the CA1 
subregion (figure 4.4A)  and  subiculum were prominently  affected,  limbic  structures, 
neocortex (figure 4.4B), thalamus, and cerebellum, while there was little involvement of 
the blood vessels by Ap depostion in the brainstem and spinal cord (table 18).
4.3.6  Ap immunohistochemistry of parenchymal deposits
In the CNS  parenchymal  subpial  peptide deposits,  perivascular plaques (figure 4.4C, 
4.4D and 4.5G-I) and diffuse deposits were often found to contain Ap in addition to 
ADan. As many subpial and perivascular deposits were congophilic it was not possible 
to ascertain whether only  one or both of the component peptides was present in the 
fibrillar  conformation,  and  parenchymal  Ap  deposits  have,  therefore,  only  been 
classified as of diffuse type.  The hippocampus,  limbic structures and neocortex were 
most severely and consistently affected by parenchymal  Ap deposits,  which took the 
form of mainly perivascular lesions (figure 4.4A), compact diffuse deposits and loose or 
cloudy diffuse deposits sometimes surrounding neurons.
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Figure 4.4:  Ap immunohistochemistry in FDD. A:  Ap distribution 
in  the  hippocampal  formation.  B:  Well-defined  Ap  plaques  in  the 
parietal cortex, a mature plaque with core in the parietal cortex (inset) 
C: A capillary showing vascular and perivascular Ap deposition. D: A 
rare Ap deposit is found in the Purkinje cell layer of the cerebellum. 
E: An occasional leptomeningeal vessel with Ap is also found. Bar in 
panel A represents 250pm on panel A;  100pm on panel B;  55pm on 
panel D ; 28pm on panels C and E.
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Figure  4.5:  ADan  and  Ap  double  immunohistochemistry  and 
confocal  microscopy  (ADan:  red  (A,  D  and  G),  Ap:  green  (B,  E 
and H), combined images C, F and I). A-C: While ADan is found in 
both  parenchyma  (double  arrow)  and  blood  vessels  (arrow)  in  the 
parasubiculum, Ap is largely found in the blood vessels (arrow) (obj. 
x25).  D-F:  A  neocortical  blood  vessel  showing  deposition  of both 
ADan (red) and Ap (green), but the overlap is incomplete (obj.  x63). 
G-I:  A  further neocortical  blood  vessel  showing  ADan  and  Ap co­
deposition with the vessel wall primarily containing ADan (red), while 
the perivascular deposit is largely Ap (green) (obj. x63).
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In the parietal cortex of case 1  several lesions had the appearance of the classical cored 
plaques found in AD (figure 4.4B, inset), however, these were noted to be unstained by 
Congo red and did not contain ADan. In the hippocampus the CA1 subregion was most 
severely affected with diffuse and perivascular Ap deposits. The subiculum also showed 
marked  perivascular  deposition  and  Ap  peptide,  like  ADan,  was  also  found  to  be 
deposited on extracellular ‘ghost tangles’. The pre-a neuronal clusters of the entorhinal 
cortex were highlighted by diffuse deposition of Ap. In the neocortex, Ap deposits were 
found predominantly in superficial cortical laminae and were often found to be more 
numerous than those of ADan.  The occasional  Ap diffuse deposits were found in the 
cerebellum but these were very rare compared to the amount of ADan deposition.
Several areas of the CNS had parenchymal Ap deposition without ADan deposits; these 
included  the  cingulum,  striatum,  nucleus  basalis  of  Meynert,  thalamus,  and 
subthalamus. There were regions, notably the retina, optic nerve and tract, red nucleus, 
locus ceruleus,  dentate nucleus and the spinal cord, with the exception of the thoracic 
grey matter, in which ADan was found in either blood vessels and/or parenchyma in the 
absence of Ap.
4.3.7  AT8  immunohistochemistry  and  its  correlation  with  ADan  and  Ap 
deposition.
The hippocampus was consistently the region most severely affected by all three types 
of neurofibrillary  pathology  with  abundant  NFTs  (figure  4.6A  and  4.6B),  including 
ghost  tangles;  bulbous  ANs  and  fine  NTs  (figure  4.6B).  Abnormal  neurites  around 
amyloid deposits in blood vessel walls were frequent in the CA1  subregion and in the 
subiculum (figure 4.6C and 4.6D).
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Figure 4.6: Tau (AT8) immunohistochemistry in FDD. A & B: Numerous NFTs 
(double arrows) and NTs (arrow) in the hippocampus. C &  D: Abnormal neurites 
(arrows) are clustered around amyloid-laden blood vessels (asterisks). Bar in panel 
A represents 100pm in A and C; 28pm on panels D and B.
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Figure 4.7: Astrocytic and microglial response in FDD demonstrated by GFAP 
& CR3/43 immunohistochemistry.  A: Reactive astrocytes tend to cluster around 
amyloid  laden  blood  vessels  (arrow)  B:  Activated  microglia  cells  tend  to  be 
orientated towards subpial amyloid deposits (arrows). C: Activated microglial cells 
are  found  within  the  cortex,  inset  showing  an  activated  microglial  cell  in  the 
subiculum.  D  &  E:  Activated  microglia  tend  to  cluster  around  amyloid  laden 
vessels, as shown with a double Congo red and CR3/43 staining (arrows). Bar in 
panel A represents 100pm in A, B and C; 55pm on panels D and E .
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Neurons  showing  finely  granular  cytoplasmic  staining  representing pre-tangles  were 
also  observed.  Scanty NFTs  were  seen  in  the  dentate  fascia.  Although  other  limbic 
regions were also affected by these pathological structures, their involvement showed a 
greater  variation  between  cases.  All  neocortical  regions  examined  showed 
neurofibrillary pathology with NFTs most frequent in the parietal and temporal lobes, 
while  ANs  and NTs  were  most  commonly  found  in  the  parietal  cortex.  Neocortical 
vessel-related  neurites  were  often  more  commonly  seen  in  the  superficial  cortical 
laminae, while those related to subpial amyloid were more frequent in sulci than on the 
locus  ceruleus  both  showed  neurofibrillary  pathology,  but  the  substantia  nigra  was 
inconsistently  involved  by  NFTs  and  NTs  without  ANs.  Of  note  was  the  mild 
involvement of the dentate nucleus in 1  case by NFTs, ANs and NTs.
Abnormal neurites were only found in relation to ADan and/or Ap deposited as amyloid 
in blood vessel walls  (figure 4.6D)  or in  subpial  regions,  but they were not seen in 
association with diffuse ADan or Ap parenchymal deposits. The regions most severely 
affected by parenchymal ADan deposition were also severely affected by neurofibrillary 
pathology. The neocortex, in which diffuse ADan deposits were never more severe than 
*++’, but showed up to *+++’ diffuse Ap deposits, also had neurofibrillary pathology of 
all  3  types  graded up  to  ‘+++\  No  CNS  regions  were  observed  in which there was 
neurofibrillary pathology in the absence of either ADan or Ap deposits, although there 
were areas in which either peptide could be found without accompanying neurofibrillary 
pathology.
4.3.8  GFAP, CD68 and CR3/43 immunohistochemistry.
The astrocytic response demonstrated by GFAP immunohistochemistry showed some 
variation between cases. The relationship to amyloid deposits was confirmed by double
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labelling using an anti-GFAP antibody and Congo red. The hippocampus and subiculum 
displayed  severe  astrocytosis  with  reactive  astrocytes  and  numerous  processes 
distributed  evenly  within  the  parenchyma  (figure  4.7A)  and  in  increased  numbers 
around amyloid-laden blood vessels (figure 4.7A, arrow). The neocortex was involved 
by mild, patchy astrocytosis, which was accentuated around amyloid containing blood 
vessels and in the superficial cortex in relation to subpial amyloid deposition. There was 
moderate to severe fibrillary astrocytosis in the subcortical white matter that was most 
marked in the posterior frontal and parietal lobes.  The cerebellum  showed prominent 
Bergmann gliosis and diffuse astrocytosis of the cortex and white matter with relative 
sparing of the dentate nucleus.
Microglial distribution was assessed by CD68 immunohistochemistry and the antibody 
CR3/43 recognizing MHC class II antigen was used to assess the presence of reactive, 
activated microglia (figure 4.7B). Double labelling with each antibody and Congo red in 
the  hippocampus  and  temporal  lobe  was  used  to  assess  the  relationship  between 
microglia  and  amyloid  deposits.  Both  antibodies  showed  a  diffuse  distribution  of 
microglia throughout the hippocampus  and  subiculum with an increase  in density of 
cells  around  amyloid-bearing  blood  vessels  (figure  4.7C  and  4.7D)  and  around 
perivascular  plaques.  The  cortex  and  white  matter  showed  a  pattern  of microglia 
response similar to that observed for astrocytes. In the cerebellum, activated microglia 
were distributed throughout although they were more frequent in the white matter.
4.3.9  Immunoelectron microscopy with Ab5282
iEM was performed  on  a  sample from the  hippocampus of case  1   using  Ab5282  to 
localize ADan peptide.  Tissue preservation enabled the identification of blood vessels, 
cell  processes,  neurons  and  glial  cells.  Several  small  blood  vessels  had  deposits  of
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randomly  orientated  amyloid  filaments  of approximately  lOnm  diameter  within  the 
basement  membrane  and  extending  into  the  surrounding  parenchyma,  these  amyloid 
fibrils were recognized by Ab5282 (figure 4.8A and 4.8B). Amyloid laden blood vessels 
were also  found  covered with the  Ab5282  immunolabelling  (figure 4.8A).  Labelling 
was found  in association with amorphous electron dense material  in association with 
small  numbers  of lOnm  filaments representing parenchymal  preamyloid  (figure 4.8C 
and 4.8D). No labelling was found when the primary antibody was omitted or the pre- 
immune  serum  was  used.  NFTs  were  confirmed  to  be  composed  of PHFs  with  a 
maximum diameter of approximately 20 to 25 nm and periodic constrictions at about 80 
nm.
4.3.10  Double immunoelectron microscopy with Ab5282 and Ap
Double labelling for iEM was performed with Ab5282 and Ap antibodies, on a sample 
from the hippocampus of case 1, to determine the relationship of the two amyloidogenic 
peptides ADan and Ap peptide.  The two peptides were found to co-localize within the 
same lesions including parenchymal deposits and amyloid-laden blood vessels (figure 
4.9).  Ab5282  was  found  labelling  parenchymal  deposits  and  amyloid  affected  blood 
vessels  without  any  Ap  positive  staining,  but  Ap  labelling  was  only  found  in 
conjunction with Ab5282 labelling. No labelling was found when the primary antibody 
was omitted or the pre-immune serum was used.
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Figure  4.8:  Ab5282  im mu noelectron  microscopy  in 
FDD. A:  A blood vessel showing expanded basal lamina 
labelled  with  antibody  to  ADan.  B:  The  anti-ADan 
antibody  decorates  fibrillar  material  corresponding  to 
amyloid  in  an  affected  vessel.  C:  The  diffuse
parenchymal  deposits  are  composed  of  amorphous 
electron dense material with sparse filaments representing 
pre-amyloid.  Gold  particle  size  20  nm.  Original 
magnification in A x6,600; B and  C x!0,000; D xl6,000.
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Figure 4.9: Double ADan and Ap immunoelectron microscopy in FDD. A:
A  blood  vessel  showing  expanded  basal  lamina  labelled  with  antibodies  to 
ADan  and  Ap.  B:  Higher  magnification  of (A)  showing  the  two  amyloid 
peptides labelling the same amyloid deposit;  ADan shown with lOnm particles 
(red  arrows)  and  Ap  shown  with  20nm  particles  (blue  arrows).  Original 
magnification in A x 12,000; B x30,000.
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4.4 Discussion
The data presented in this chapter illustrated that FDD, which is an inherited form of 
CNS amyloidosis, is characterised by widespread CAA, parenchymal lesions and NFTs. 
These findings expand the spectrum of neurodegenerative diseases in which the major 
pathological changes include neurofibrillary pathology and nerve cell death occurring in 
combination with deposition of extracellular protein aggregates.
Using the phosphorylation dependent anti-tau antibody AT8 (Goedert et al.,  1993) we 
demonstrated extensive tau pathology, including NFTs, NTs and ANs. NFTs and NTs 
were  found  to  occur  in  limbic  structures,  neocortices,  and  some  of the  subcortical 
nuclei, corresponding to stage V-VI in the Braak and Braak system used for grading the 
severity of neurofibrillary degeneration in AD (Braak & Braak,  1991).  In all 3  cases, 
ANs were located around blood vessels with CAA, but not in association with either 
ADan  or  Ap  parenchymal  pre-amyloid  lesions  (defined  as  Congo  red  -negative, 
thioflavine-S  negative  or  weakly  positive  and  ultrastructurally  non-fibrillar  protein 
deposits  (Verga  et  al.,  1989;  Giaccone  et  al.,  1992).  Perivascular  clustering  of 
argyrophilic and tau immunoreactive abnormal neurites has been described in relation to 
CAA associated with Ap (Vidal et al., 2000a; Peers et al.,  1988), prion protein (Ghetti 
et  al.,  1996),  and  ABri  deposition  (Holton  et al.,  2002;  Revesz  et  al,  1999).  The 
presence of ANs around CAA of various origins and their absence in association with 
preamyloid  lesions  suggests  a  correlation  between  the  fibrillation  of amyloidogenic 
peptides and formation of ANs (Holton et al., 2002; Vickers et al., 1996).
Using Ab5282 specifically recognizing ADan, we demonstrated that this amyloidogenic 
peptide which is associated with the genetic defect in FDD,  is a major component of 
both the vascular and parenchymal lesions throughout the CNS. From the pathological 
data presented here, however it is not possible to ascertain whether full length ADan is
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the  only  significant  species  comprising  the  cerebral  vascular  amyloid  and  the 
parenchymal  lesions since the residues recognized by Ab5282  (CFNLFLNSQEKHY) 
are not exclusive to ADan, but are  also present in ADanPP  and potential C-terminal 
fragments that may be processed from either ADanPP or ADan. (studies in Chapter 7 
aim  to  identify  the  ADan  deposits  present  in vascular amyloid  and  species  that are 
present in the parenchymal lesions).
This  study  showed  that  in  FDD  the  majority  of the  hippocampal  and  neocortical 
parenchymal  ADan  lesions  often  have  ill-defined  boundaries  and  show  tinctorial, 
optical  and  ultrastructural  features  of preamyloid  rather than  amyloid  (Verga  et al., 
1989; Giaccone et al.,  1992). In contrast, in FBD (as has been demonstrated in chapter 
3) the majority of the hippocampal ABri  lesions are well-defined, plaque-like and of 
amyloid  nature,  although  pre-amyloid  lesions  are  predominant  in  some  of  the 
anatomical areas such as the entorhinal and transentorhinal cortices (Holton et al., 2002; 
Revesz  et  al.,  1999).  The  combination  of  preamyloid  lesions  and  neurofibrillary 
degeneration in FDD is analogous to that seen in variant AD with spastic paraparesis, 
which is also characterized by the pre-amyloid Ap plaques of the cotton wool-type in 
association with neurofibrillary degeneration (Crook et al.,  1998; Houlden et al., 2000; 
Steiner et al., 2001; Verkkoniemi et al., 2001). This observation adds further weight to 
the evidence that amyloid conformation per se is not a prerequisite for NFT formation. 
The experimental data currently available are not sufficient to explain the predominance 
of preamyloid  lesions  in  FDD.  One  possibility  is  that  due  to  the  difference  in  the 
primary sequence ADan forms amyloid fibrils less efficiently than ABri does, although 
conversion of multiconformational proteins into predominantly p-pleated fibrils is not 
thought to be significantly dependent only on sequence per se (Lansbury, Jr.,  1999). It 
is, however, possible that the difference in the amino acid sequence is sufficient to make
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ADan less able to attract and/or bind to amyloid associated components such as ApoE, 
HSPGs, SAP or ACT, which have been shown to modulate aggregation of Ap in vivo, 
which would be required, possibly in combination with other factors for efficient fibril 
formation.
In all 3 cases studied, we were able to demonstrate the presence of various degrees of 
Ap peptide deposition either in combination with ADan or alone, in blood vessels and in 
brain parenchyma. The Ap parenchymal deposition similar to that of ADan, was most 
severe in the limbic structures, but also occurred in neocortical areas where it was more 
severe than deposition of ADan. The significance of Ap deposition cannot be clarified 
at present. Co-deposition of ADan and Ap, as has been shown for Ap and cystatin C 
(Levy  et  al.,  2001),  is  a  possibility  although  the  presence  of Ap  alone  in  several 
anatomical  areas  makes  this  possibility  less  likely.  The  possibility  of  a  second 
hereditary neurodegenerative disease should be considered although in the absence of 
neocortical neuritic plaques the diagnosis of AD could not be made on morphological 
grounds.
The  presence  of two  amyloidogenic  peptides  has  also  been  observed  within  other 
diseases.  A  study  has  shown  in  four  cases  of GSS  the  presence  of Ap  deposits  co­
localised  with  PrP  protein  in  amyloid  plaques  (Miyazono  et al.,  1992).  The  results 
reported were the first evidence for colocalization of the two amyloidogenic peptides 
PrP and Ap protein in the same amyloid plaques at the light and electron microscope 
level. Although the amyloid plaques that were purified from the youngest GSS patient 
(aged 45) were immunolabelled by anti-PrP, but not by anti-Ap, suggesting that Ap is 
only observed in the older GSS patients and that it is a secondary event to the deposition 
of PrP (Miyazono et al.,  1992).  The Ap deposition found in this study is unlikely to 
represent an aging phenomenon as the youngest patient in our series was 43 years old at
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the  time  of death.  Several  studies  have  also  shown the  co-localisation  of two  other 
peptides a-synuclein and tau. The first study showed that some Lewy bodies (LBs) in 
the  substantia  nigra  from  diffuse  Lewy  body  disease  (DLBD),  but  not PD,  had tau 
immunoreactivity with a peripheral pattern of immunostaining (Galloway et al., 1988). 
This was followed by a study that demonstrated the presence of tau in LBs in a case of 
familial  PD  (Contursi  kindred)  due  to mutations  in  a-synuclein (Duda et al,  2002). 
More  recently  the  observations  have  been  extended  to  sporadic  Lewy body  disease 
where  the  location  of the  tau  immunoreactivity  was  detected  in  the  cytoplasm  of 
neurons with LBs, at the periphery of LBs, with a-synuclein immunoreactivity in the 
core of the LB, or throughout the LB. Although the most common location of the tau 
epitopes was at the periphery of the LB, suggesting the deposition of the tau in LBs is a 
secondary  process  to  a-synuclein  deposition  and  presenting  the  possibility  that  a- 
synuclein might serve as a seed for tau aggregation (Ishizawa et al, 2003). This is an 
interesting possibility that the formation of amyloid fibrils from one peptide may seed 
the formation of a second amyloidogenic peptide. In FDD the ADan deposits found in 
the blood vessels have been shown to form amyloid fibrils in this study, with occasional 
Ap  deposits.  The  parenchymal  deposits  on  the  other hand  are  pre-amyloid  deposits 
therefore if a seeding process was taking place here oligomers or protofibrils would be 
acting as the seeding agent and not the amyloid fibrils themselves.
With the detailed pathological analysis of FBD (see chapter 3) and FDD (this chapter) 
completed,  questions  could  now  start  to  be  answered.  The  mechanism  of peptide 
deposition,  whether  other  molecules  are  implicated  in  this  process.  For  example 
amyloid associated proteins, are they just innocent bystanders involved in the deposition 
of the  amyloid  forming  peptides  or  involved  in  converting  pre-amyloid  to  amyloid 
peptides.  Compelling  evidence  continues  to  accumulate  for  a  significant  role  of
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local  inflammatory  processes  in  the  progression  of  neurodegenerative  disorders, 
mechanisms  which  have  been  studied  extensively  in  AD  (Akiyama et al.,  2000).  In 
particular  complement  activation  and  its  proinflammatory  consequences  have  been 
demonstrated to contribute extensively to disease pathogenesis (Tenner, 2001). Most of 
the studies have been completed on AD cases, but with activated microglia expressing 
major histocompatibility class II antigens characteristic of inflammatory processes and 
reactive  astrocytes  present  around  amyloid  lesions,  an  investigation  of complement 
activation was completed in both FBD and FDD.
Although ABri and ADan only differ by 12 amino acids there is a remarkable difference 
in  the way  the  peptides  are  deposited  in  the  CNS.  ABri  primarily  forming  amyloid 
lesions (see chapter 3) and ADan forming amyloid lesions in affected blood vessels but 
only pre-amyloid deposits are found in the parenchyma. This difference must arise from 
the primary sequence of the peptides forming different secondary structures and making 
the  peptides  behave  in  different  ways.  To  try  and  understand  the  properties  of the 
peptides a biochemical study was undertaken to assess the solubility of the peptides and 
the degree to which the peptides would oligomerise. This was taken a step further and 
the heterogeneity of the peptides was investigated.
With all the subsequent investigations following this chapter, work was carried out not 
only  on  the  FBD  and  FDD  cases  but  also  sporadic  AD  cases  and  variant  AD  with 
spastic  paraparesis.  This  was  to  ensure  a  clear  comparison  between  the  two  novel 
amyloid peptides,  ABri and ADan, with Ap in both amyloid and pre-amyloid lesions. 
For a combination  of preamyloid  lesions  and  neurofibrillary degeneration  in FDD  is 
analogous to that seen in variant AD with spastic parapaesis.
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Chapter 5
Amyloid associated proteins in BRI2
gene-related dementias.
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Chapter 5 -  Hypothesis and specific questions
In  this  chapter.  I wished  to  investigate the  hypothesis  that AAPs  play  a  role in 
ABri and ADan fibrillogenesis. The specific questions I wished to investigate were; 
1) Are AAPs, which  are known to co-localise with Ap deposits in AD  and some 
other cerebral and systemic amyloidoses, present in ABri and ADan lesions in FBD 
and  FDD?;  2) Is the conformational state of these novel amyloidogenic peptides 
related to the deposition of AAPs?
As the presence of AAPs in Ap  lesions in AD has been linked to the process of Ap 
fibrillogenesis, this study aimed to establish whether such proteins are also associated 
with ABri and ADan lesions thus raising the possibility of a more general role for these 
proteins  in  amyloid  fibril  formation.  This  question  was  addressed  by  an 
immunohistochemical study investigating the distribution of Apolipoprotein E (ApoE), 
Apolipoprotein  J  (ApoJ),  a-l-antichymotrypsin  (ACT),  serum  amyloid  P  component 
(SAP),  cystatin  C  and  various  heparan  sulphate  proteoglycans  (HSPGs),  including 
agrin,  perlecan,  glypican-1  and  syndecans.  The  conformational  state  of  the 
amyloidogenic peptides in the different lesion types was established using thioflavine-S 
staining.
5.1  Introduction
Why  amyloid  fibrils  form  and  the  steps  involved  in  the  process  of amyloid  fibril 
formation  from  its  precursor  proteins  are  still  not  fully  understood.  After  the 
identification  of Ap,  as the  major component of cerebrovascular amyloid  and senile 
plaques in AD, evidence was found that a heterogenous group of proteins termed AAPs 
are  co-deposited  within  the  parenchymal  and vascular Ap  deposits  in  AD  and with 
amyloid  proteins  in  other  forms  of  cerebral  or  systemic  amyloid  diseases 
(Alexandrescu,  2005;  Calero et al.,  2000;  McLaurin et al.,  2000;  Wisniewski  et al., 
1995)  and  other  disorders  of protein  misfolding  (Ishii  &  Haga,  1984).  While  the 
deposition of some of these proteins may be a secondary event a series of in vitro data 
shows that several AAPs may influence the process of conversion of soluble amyloid 
proteins to both soluble and insoluble forms with high p-sheet content (Alexandrescu, 
2005;  McLaurin  et al.,  2000).  Such  molecules  include  ApoE  (introduced  in  section 
1.10.1), which is a major apolipoprotein in the brain,  produced mainly by astrocytes
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(Pitas et al,  1987). The ApoE gene is associated with altered risk of AD and CAA in 
that the possession of ApoE-s4 is associated with an increased risk for both pathologies 
(Greenberg et al,  1995; Nicoll et a l,  1997; Strittmatter & Roses,  1996) while that of 
ApoE-e2  decreases  the  risk  of  AD,  but  increases  the  risk  of  CAA-associated 
vasculopathy and intercerebral haemorrhage (McCarron et al,  1999). ApoE has been 
shown to co-localise with Ap in CAA and senile plaques and also NFTs in AD (Namba 
et a l,  1991;  Pitas  et al,  1987;  Wisniewski  &  Frangione,  1992).  ApoJ  (clusterin  or 
SP40-40)  is  a  complement  inhibitor,  which  converts  the  hydrophobic  MAC  into  a 
hydrophilic structure thus preventing its insertion into cell membranes. ApoJ can also be 
classed as an AAP and has been show to associate with Ap  lesions (Lidstrom et al., 
1998; McGeer et al, 1992).
Several proteases and protease inhibitors have been demonstrated in the amyloid lesions 
in AD. These include the decameric glycoprotein SAP (Coria et al,  1988; Rozemuller 
et al, 1989), a normal plasma glycoprotein synthesized exclusively in the liver (Kalaria 
&  Grahovac,  1990)  which  has  been  suggested  to  be  an  elastase  inhibitor  (Li  & 
McAdam,  1984)  (see  section  1.10.2).  ACT,  which  belongs  to  the  group  of serine 
protease inhibitors, has also been shown to be present (Rozemuller et al, 1991). ACT is 
an  acute-phase  reactant  and  member  of the  SERPIN  superfamily;  it  is  produced by 
hepatocytes in the liver, alveolar epithelial cells in the lung (Hood et al, 1980; Potter et 
al, 2001) and by astrocytes within the brain (Pasternack et al, 1989; Rozemuller et al, 
1991).  ACT has been shown to be associated with the Ap protein but not with other 
amyloidoses  (Abraham  et  al,  1990;  Rozemuller  et  al,  1991)  (see  section  1.10.3). 
Cystatin C, the mutated form of which causes HCHWA-I, has also been shown to be 
associated with amyloid deposits. Cystatin C belongs to a group of potent, non-covalent, 
competitive  inhibitors  of cysteine  proteinases  of the  papain  superfamily  (Bobek  & 
Levine,  1992).  The possibility that cystatin C may have a role in the pathogenesis of 
other amyloidoses was raised by the observation that it is present in Ap parenchymal 
and vascular amyloid lesions in AD (Levy et al, 2001) (see section 1.10.4).
HSPGs  are  another  major  class  of  AAPs  which  have  been  implicated  in  the 
pathogenesis of amyloid diseases (Snow et al,  1988). They have been shown with Ap 
deposits  which have been shown to accumulate  in both  senile plaques  and amyloid­
laden blood vessels in AD (Perlmutter et al, 1990; Snow et al, 1988), DS (Snow et al, 
1990)  and  HCHWA-D  (Maat-Schieman  et al,  2000)  (the  structure  and  function  of 
which are introduced in section 1.10.6)
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Although the presence of most of these AAPs within the amyloid lesions is unknown, it 
has  been  assumed  that  most  are  deposited  because  of  or  in  response  to  amyloid 
accumulation. ApoE, on the other hand, has been shown to bind to Ap in vitro forming 
an  SDS-stable  complex,  with ApoE4 forming  such a complex more rapidly than the 
ApoE3  (Strittmatter  et  al.,  1993b;  Strittmatter  et  al.,  1993a).  Several  studies  have 
examined  the  effect  of ApoE  on  Ap  conformation,  showing  that  lipid  free  ApoE 
increases Ap fibril formation (Ma et al., 1994; Sanan et al.,  1994; Soto et al.,  1996). In 
contrast other studies have shown that lipid free ApoE decreases fibrillogenesis through 
inhibiting Ap seeding or nucleation (Evans et al., 1995; Wood et al.,  1996), suggesting 
the ApoE influences the fibrillogenesis process in some way.
The majority of the  information about AAPs available within the  literature is linked 
with Ap. To date there is no data available about the AAPs present in the BRI2-gene 
related dementias and whether an association with ABri and ADan is observed. In this 
immunohistochemical  study we aimed to  investigate the distribution of ApoE,  ACT, 
SAP,  cystatin  C  and  various  HSPGs  that  had  been  studied  previously  in  AD  and 
HCHWA-D (van Horssen et al., 2001) and to establish whether they were present in 
both FBD and FDD amyloid and preamyloid lesions. By investigating the presence and 
distribution  of these  AAPs  in the  ABri  lesions  in  FBD  and ADan  lesions  FDD  we 
wished  to  study  whether their  association  with  Ap  lesions  in  AD  is  indeed protein 
specific, or may contribute to the fibrillogenesis of other proteins. We also wished to 
establish whether the conformational state of amyloid protein deposited influences the 
efficency of deposition of the AAPs.
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5.2  Material and methods
5.2.1  Tissue collection
Brain samples from 5 FBD, 3 FDD, 5 AD cases, including one familial case of variant 
AD with cotton wool plaques associated with the PS1 AI83/AM84 mutation (Houlden et 
a l, 2000b;  Steiner et al, 2001) and 4 normal controls were collected at post mortem. 
The criteria for the neuropathological diagnosis of FBD and FDD have been previously 
described (Holton et al, 2001c; Holton et al, 2002b; Plant et al,  1990; Revesz et al, 
1999),  while  for that  of AD  standard  criteria  were  used  (Mirra et al,  1991);  (The 
National  Institute  on  Aging  and  Reagan  Institute  Working  Group,  1997).  For 
immunohistochemistry,  carried  out  on paraffin-embedded tissue,  7pm  serial  sections 
were cut from the hippocampus, cerebellum and frontal cortex in all cases listed above. 
For immunohistochemistry, carried out on frozen tissue,  7pm serial sections were cut 
from the hippocampus and frontal cortex from one FBD case and three sporadic AD 
cases; frontal cortex from one variant AD case with cotton wool plaques.
5.2.1  Antibodies
The panel of antibodies used in this study (table 19 and table 20) to establish the pattern 
of deposition of the AAPs including:  ApoE, ApoJ, SAP, ACT, cystatin C and various 
HSPGs.  HSPGs  included  agrin,  perlecan,  syndecans,  glypican-1  and  HS  GAG  side 
chains.  The  antibodies  recognizing  amyloid  proteins  were  as  follows:  polyclonal 
antibody 338 (Ab338), polyclonal antibody 5282 (Ab5282) and antibodies to Ap (amino 
acids 17-26, Biosource International).
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Antigen/ antibody Dilution Pretreatment Source
AP (17-26) 1:4000 FA/PC Biosource
ABri, 338 (24-34) 1:2000 Formic Acid Dr J Ghiso
ADan, 5282 (21-34) 1:1000 Formic Acid Dr J Ghiso
Apo J (Clusterin) 1:600 FA /PC Santa Cruz Biotechnology Inc
Apo E 1:200 FA/PC Autogen Bioclear
Cystatin C 1:200 FA/PC Upstate biotechnology
Table 19: Antibodies used on paraffin embedded tissue in the AAPs study
Antigen/ antibody Dilution Source
Amyloid P component 1200 NovaCastra
a-1 -antichymotrypsin 1 500 NovaCastra
Agrin JM72 1500 Dr. M M Veibeek
AgrinBI31 1750 Dr. M M Veibeek
Perlecan 1948 1500 Dr. M M Veibeek
Pan-HSPG 3G10 1300 Dr. M M Veibeek
Syndecan 1,3 2E9 1 100 Dr. M M Veibeek
Syndecan 2 10H4 1300 Dr. M M Veibeek
Syndecan 1 1C7 1 300 Dr. M M Veibeek
Glypican 1 SI 1 500 Dr. M M Veibeek
Heparan sulphate side chains JM403 1 100 Dr. M M Veibeek
Heparan sulphate side chains JM13 1:50 Dr. M M Veibeek
Table 20: Antibodies used on  frozen tissue in the AAPs study
5.2.2  Immunohistochemistry
For this study, immunohistochemistry for paraffin sections was carried as described in 
section 2.2 and frozen section as described in section 2.4.
5.2.3  Semi-quantitative assessment
For each antibody the intensity and extent of the staining of amyloid plaques, vascular 
amyloid and parenchymal preamyloid lesions and/or cotton wool plaques were assessed 
and documented using a four-tiered scale. Absence of staining =  Patchy and weak 
staining = +; Weak, but extensive staining = ++; Extensive and strong staining = +++.
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5.3  Results
5.3.1  Deposition patterns and conformational state of amyloid proteins
Serial sections of the hippocampus, frontal cortex and cerebellum have confirmed our 
previous observations that in FBD Ab338 stained frequent amyloid-laden blood vessels 
(figure 5.1  Al and All) and also the different amyloid plaques (figure 5.1  BI and BII) 
and  preamyloid  parenchymal  deposits  (Chapter  3,  Holton  et al,  2001).  In  FDD,  in 
addition  to  cerebral  blood vessels  showing  CAA,  Ab5282  stained hippocampal  and 
other parenchymal ADan deposits in a manner indicative of preamyloid diffuse deposits 
(figure 5.1 DI and DII) (Chapter 4, Holton et al, 2002). In three of the four AD cases 
the Ap plaque morphology included plaques with an amyloid core as well as diffuse 
deposits. CAA (figure 5.1  Cl and CII) due to Ap deposition was also a feature. In the 
familial variant AD case and one of the  sporadic AD cases Ap-positive cotton wool 
plaques and CAA were prominent (figure 5.1 El and Eli).
5.3.2  Distribution of ApoE in FBD and FDD
Deposition  of ApoE  in  FBD  followed  a  similar pattern to that  of ABri  (Chapter 3, 
(Holton  et al,  2001).  Both  large  and  small  hippocampal  plaques  (figure  5.2A)  and 
preamyloid, diffuse deposits (figure 5.2B) were positively stained with the anti-ApoE 
antibody (table 21).  The dense amyloid plaque core and the looser radiating fibrillar 
area surrounding the core stained with equal  intensitiy.  All blood vessels affected by 
CAA in the hippocampus, frontal cortex and cerebellum (table 21) (figure 5.2C & 5.2D) 
stained for ApoE. It was also noted, although not part of the focus of this study, that all 
NFTs  found  in  all  subregions  of  the  hippocampus,  previously  stained  with  tau 
antibodies including the ghost tangles were also positive for ApoE (figure 5.2E).
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In FDD the parenchymal diffuse deposits were stained for ApoE (figure 5.3 A & 5.3B), 
although the staining intensity was less than that of the amyloid-laden blood vessels, 
which showed strong positivity (figure 5.3C & 5.3D). ApoE deposition was also found 
in the subpial and perivascular deposits. NFTs, which are also frequent in FDD showed 
strong positivity in the entorhinal cortex and the hippocampus (figure 5.3E).
In AD the staining pattern mirrored that seen within FBD and FDD with both plaque 
(figure 5.3F) and vascular amyloid (figure 5.3F, insert) showing strong staining with the 
anti-ApoE antibody. Diffuse deposits in AD and the cotton wool plaques in variant AD 
were also positive for ApoE in a manner similar to that seen in the preamyloid ADan 
lesions in FDD (figure 5.3G, double arrow). Amyloid-laden blood vessels within vAD 
showed an intense staining pattern with the anti-ApoE antibody (figure 5.3G, arrow). 
NFTs were frequently stained with the ApoE antibody in both AD and variant AD (data 
not shown).
191Amyloid associated protein FBD FDD Sporadic AD Variant AD
CAA Plaque Diffuse CAA Diffuse CAA Plaque Diffuse CAA CWP
Amyloid  protein  (ABri, 
ADan, AP)
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Apolipoprotein E + + + + + + + + + + + + + + + + + + + + + + + + + +
Apolipoprotein J + + + + + + + + + + + + + + + + + + + + + + + + ++
Serum amyloid P + + + + + + + + + + + + + + + + + + + + + + +
a-1 -antichymotrypsin + + + + + + + + + + + + + + + + + + + + + + +
Cystatin C + + + + + + + + + - + + + - + -
Agrin + + + + + + + + + + + + + + + + + + + + + + + + + +
Perlecan + + - + - - - - - -
Syndecan-1, -3 + + - + + - + - + +
Syndecan-2 + + + + + + + + + + + + + + + + +
Syndecan-3 + + + - + + + + + + + + + + + + +
Glypican-1 + + + + + + + + + + + + + + + + + + + + + + + +
HS GAG side chains JM403 + + + + + + + + + + + + + + + + + + + + +
HS GAG side chains JM13 + + + + + + + - + + + + + +
Pan-HSPG 3G10 + + + + + + + + - + + + + + + + + +
Table 21: Semi-quantitative analysis of the deposition of  AAPs in CAA, amyloid  plaques and diffuse deposits in FBD, FDD and AD.  FBD 
=familial British dementia; FDD = familial Danish dementia; AD = Alzheimer's disease; CAA cerebral amyloid angiopathy; CWP = 
cotton wool plaque
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Figure 5.1:  Amyloid  immunohistochemistry  and  thioflavine-S  staining in  FBD, 
FDD, AD  and  variant AD with  cotton  wool  plaques (vAD). Amyloid  lesions  in 
FBD  in  row  A  (CAA,  arrow)  and  row  B  (plaques,  arrowheads).  In  AD  amyloid 
plaques  are  shown  in  row  C  (arrowheads)  with  amyloid-laden  blood  vessels 
demonstrated  in  inserts.  In  FDD  CAA  (arrow)  and  diffuse  parenchymal  deposits 
(double  arrow)  are  illustrated  in  row  D.  In  variant  AD  (vAD:  row  E)  CAA  is 
demonstrated by an arrow while cotton wool plaques are indicated by double arrows. 
FBD is compared with AD as the lesion types (amyloid plaques and CAA) are similar. 
Likewise, FDD and vAD have similar features with CAA and parenchymal, largely 
preamyloid  deposits.  Thioflavine-S  staining  demonstrating  strong  fluorescence  in 
amyloid-laden blood vessels in all diseases. Amyloid plaques are strongly labelled in 
FBD and AD. Diffuse deposits are the main parenchymal lesion type in FDD showing 
weaker staining with thioflavine-S. The cotton wool plaques in variant AD show a 
similar weak staining pattern. Bar on panel A represents 100pm on A, B & C; 250pm 
on D&E. A xlO objective was used for the thioflavine-S images.
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Figure 5.2: ApoE immunohistochemistry in FBD; The anti-ApoE 
antibody  strongly  labelled  the  amyloid  plaques  (A:  large  amyloid 
plaques  (arrows)  in  the  granular  cell  layer  of the  dentate  fascia), 
preamyloid lesions (B: The parvopyramidal clusters of the pre- and 
parasubiculum,  arrows)  and  amyloid-laden  blood  vessels  (C 
leptomeningeal  arteriole  with  double  barrelling)  and  also 
perivascular amyloid plaques (D). E: NFTs in the hippocampus are 
strongly  positive  for  ApoE  (arrows).  Bar  on  panel  A  represents 
250pm in A; 500pm on B; 100pm on C & E and 28pm on D.
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Figure 5.3:  ApoE  immunohistochemistry  in  FDD (A-E), AD  (F)
and vAD (G); In FDD ApoE positive diffuse parenchymal deposits 
in  the  CA4  (A)  and  CA1  (B)  hippocampal  subregions.  Amyloid­
laden blood vessels of all sizes, including small arteries, arterioles (C, 
asterisk),  often with perivascular deposition (C, double arrow),  and 
capillaries  (D,  arrow)  were  also  strongly  labelled.  As  in  FBD,  the 
majority of the hippocampal NFTs (E, arrows) were stained with the 
anti-ApoE  antibody.  In  AD  both  amyloid  plaques  (F,  arrowheads) 
and blood vessels with CAA (F,  insert) were positive for ApoE.  In 
vAD  a  strong  intense  staining  pattern  was  observed  within  the 
amyloid-laden blood vessels (G, arrow) and a weaker staining pattern 
observed in the diffuse cotton wool plaques (G, double arrow). Bar in 
panel A represents 500pm in A; 250pm on panel B,F and G; 45pm 
on panels C and D; 28 pm in panel E.
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5.3.3  Distribution of ApoJ in FBD and FDD
In  the  FBD  cases  the  anti-ApoJ  antibody  strongly  labelled  the  blood  vessels  with 
amyloid  deposition,  in  addition  to  both  amyloid  plaques  and  ‘diffuse’  preamyloid 
deposits.  Therefore  the  staining  pattern  seen  in  ApoJ  immunohistochemistry  closely 
overlapped with that seen in Ab338 immunohistochemistry. In FDD the ApoJ staining 
pattern  also  closely  mimicked  that  seen  in  ADan  immunohistochemistry,  with  both 
amyloid-laden  blood  vessels  and  preamyloid  deposits  being  stained.  The  antibody 
recognizing ApoJ strongly labelled all affected amyloid-laden blood vessels of all sizes 
including capillaries in the AD cases, including the cotton wool plaques. In general, the 
staining pattern  seen  in  ApoJ  immunohistochemistry was  similar to that  seen in  Ap 
immunohistochemistry  in  that  the  anti-ApoJ  antibody  stained  all  plaques  types, 
perivascular lesions as well  as subpial  deposits,  irrespective of whether they were of 
amyloid or diffuse/preamyloid nature. Nevertheless, amyloid lesions were usually more 
strongly stained than the diffuse/preamyloid AP lesions were.
5.3.4  Distribution of SAP in FBD and FDD
In FBD, the amyloid structures that stained with Congo red and thioflavine-S were also 
strongly positive with the antibody to SAP. The large and small amyloid plaques were 
all positively stained with the anti-SAP antibody (table 21) (figure 5.5A). The intensity 
of the  SAP  immunoreactivity  varied  throughout the  plaque,  the  large  cored  plaques 
found within the CA4 had intensely stained cores, but the staining was weaker towards 
the outer limits of the plaques (figure 5.5A insert).  Within the CA1  subregion of the 
hippocampus,  all arteries and arterioles with CAA showed positivity for SAP (figure 
5.5B & 5.5C), with a small proportion of capillaries affected by amyloid deposition
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Figure 5.4:  ApoJ immunohistochemistry in FBD, FDD, AD and 
vAD; The anti-ApoJ antibody strongly labelled the amyloid plaques 
and amyloid-laden blood vessels (large amyloid plaques (arrows) in 
CA4 of the hippocampus and arteriole, insert). In FDD ApoJ positive 
diffuse parenchymal  deposits  in the CA1  (double arrows),  together 
with  amyloid-laden  blood  vessels  (arrows).  In  AD  the  amyloid 
plaques  are  shown  labelled  with  the  anti-ApoJ  antibody  (arrows) 
with amyloid-laden blood vessels demonstrated in the insert. In vAD 
the  CAA  showed  intense  labelling  (double  arrow)  with  the  cotton 
wool plaques showing a weaker labelling intensity (arrows). Bar on 
panel A represents 100pm in A and D; 250pm on B & C.
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were positive for SAP. The diffuse parenchymal lesions showed weak patchy positivity. 
The anti-SAP antibody stained the NFTs including ghost tangles in FBD, with the NFTs 
in the pre-a clusters of the entorhinal cortex showing a particularly strong staining (data 
not shown).
In FDD  all  amyloid  affected blood vessels,  including arteries (figure  5.5E,  asterisk), 
arterioles  and  capillaries  (figure  5.5D,  arrow),  showed  strong  immunoreactivity  for 
SAP.  The  perivascular  amyloid  deposits  around  arterioles  (figure  5.5E,  arrow)  and 
capillaries were also strongly stained.  The parenchymal diffuse deposits were weakly 
positive (figure 5.5D, double arrow). A small amount of positive staining was seen in 
the subpial regions, but the intensity of the staining did not match that seen within the 
blood vessels. No NFTs were found to be SAP immuno-positive in FDD.
In AD the staining pattern mirrored that seen within FBD and FDD with all amyloid 
structures, both plaque (figure 5.5F) and vascular (figure 5.5F, insert), showing strong 
staining with the  anti-SAP  antibody,  while  diffuse deposits were weakly  stained.  In 
variant AD the amyloid-laden blood vessels showed strong staining with the anti-SAP 
antibody (figure 5.5G, arrow), whereas a weaker staining pattern was observed in the 
cotton wool plaques (figure 5.5G, double arrow).  NFTs were also found to be positive 
in both the sporadic and variant AD cases (data not shown).
5.3.5  Distribution of ACT in FBD and FDD
In FBD amyloid plaques were positive for ACT (figure 5.6A) in both the CA1 and CA4 
subregions of the hippocampus (table 21). The large plaques of CA4 were stained with 
equal  intensity  in  the  core  and  the  periphery.  All  blood  vessels  affected  by  ABri 
deposition were positive for ACT (figure 5.6A, insert) (table 21). Perivascular plaques 
stained with ABri were positive for ACT (figure 5.6A, insert). The parenchymal diffuse
198Chapter 5- Amyloid associated proteins
deposits were weakly and patchily labelled with the anti-ACT antibody. In FBD NFTs 
were also positive for ACT, with the majority being in the CA1 subregion.
In FDD all blood vessels affected by ADan deposition were positive for ACT and the 
perivascular plaques were also positive for ACT (figure 5.6B, arrow). The parenchymal 
diffuse  plaques  showed  weak  positivity  (figure  5.6B,  double  arrow)  and  the 
hippocampal NFTs remained unstained.
In AD the staining pattern mirrored that seen within FBD and FDD with all amyloid 
structures,  both  plaque  (figure  5.6C,  arrowhead)  and  vascular  (figure  5.6C,  insert), 
showing  strong  staining  with  the  anti-ACT  antibody.  The  diffuse  deposits  usually 
showed  weaker  positivity  for  ACT,  although  the  cotton  wool  plaques  were  more 
strongly labelled (figure 5.6D, double arrow). The amyloid-laden blood vessels in vAD 
showed strong labelling for the anti-ACT antibody (figure 5.6D, arrow). No NFTs were 
shown to be positive with the anti-ACT antibody within the AD cases studied.
199Chapter 5- Amyloid associated proteins
FD©  E
\D   G
Figure  5.4:  Serum  amyloid  P  (SAP)  immunohistochemistry 
in FBD (A-C), FDD (D & E), AD (F) and vAD (G). In FBD
amyloid  plaques  (A,  arrow  and  insert  showing  a  large 
hippocampal  plaque with  higher magnification),  amyloid-laden 
blood vessels (B,  arrow)  and perivascular amyloid plaques  (C, 
arrow).  In  FDD  positive  staining  was  found  in  vascular  (D, 
arrow) and perivascular amyloid (E,  arrow).  Preamyloid ADan 
deposits  showed weak staining for  SAP  (D,  double  arrow).  In 
AD  both  amyloid  plaques  (F,  arrowheads)  and  amyloid-laden 
blood  vessels  (F,  insert)  were  positive  for  SAP.  In  vAD  an 
intense staining pattern was observed within the amyloid-laden 
blood vessels (G, arrow) and a weaker staining pattern observed 
in  the  diffuse  cotton  wool  plaques  (G,  double  arrow).  Bar  in 
panel A represent 250pm in A;  100pm in panel B, D, E and F; 
45pm in panels C and G.
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Figure 5.6:  ACT immunohistochemistry in FBD (A), FDD (B), 
AD  (Q   and  vAD  (D).  The  anti-ACT antibody  labelled the ABri 
amyloid  plaques  (A,  arrow),  amyloid-laden  blood  vessels  (A, 
insert).  In FDD ACT was present in amyloid-laden blood  vessels 
(B, arrow) and diffuse parenchymal deposits were weakly labelled 
(B,  double  arrow).  In  AD  amyloid  plaques  (C,  arrowheads)  and 
amyloid-laden  blood  vessels  (C,  insert)  are  positive  for  ACT.  In 
vAD both amyloid-laden blood vessels (D, arrow) and the diffuse 
deposits (D, double arrow)  showed an intense staining pattern for 
ACT.  Bar  in  panel  A  represents  250pm  in  A  and  C;  100pm  in 
panels B and D.
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5.3.6  Distribution of cystatin C in FBD and FDD
All the amyloid deposits that were positively stained with the anti-ABri antibody were 
also  stained  with the  anti-cystatin  C  antibody,  although the  overall  intensity  of the 
staining was slightly weaker with the latter. Cystatin C immunoreactivity was found in a 
significant proportion of the amyloid plaques of the CA1  and CA4 subregions of the 
hippocampus (table 21) (figure 5.7A) and in all blood vessels with CAA (figure 5.7C). 
Perivascular amyloid ABri deposits were also positive (figure 5.7C, double arrow), but 
the diffuse preamyloid deposits remained unstained.
In FDD cystatin C deposition was present in amyloid-laden blood vessels (figure 5.7D, 
double arrow) but no staining of the diffuse parenchymal deposits was detected.
In  AD the  anti-cystatin  C  antibody  labelled the  amyloid-laden blood vessels (figure 
5.7E,  insert)  along  with  a  few  weakly  positive  plaques  (figure  5.7E,  arrowheads). 
Amyloid-laden  blood  vessels  found  in  vAD  showed  strong  labelling  with  the  anti- 
cystatin  C  antibody (figure  5.7F,  arrow)  although the cotton wool  plaques remained 
unstained (data not shown).
No NFTs were found to be positive with anti-cystatin C antibody in any of the diseases 
studied.
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Figure 5.7:  Cystatin C immunohistochemistry in FBD (A- 
C),  FDD  (D),  AD  (E)  and  vAD  (F).  The  anti-cystatin  C 
antibody  strongly  labelled  the  ABri  amyloid  plaques 
demonstrated in the hippocampus (A, arrows and insert), and 
cerebellum  (B),  amyloid-laden  blood vessels  (C),  showing a 
perivascular  deposit  (C,  double  arrow).  In  FDD  only  blood 
vessels affected by ADan amyloid deposition were stained (D, 
double  arrow).  Cystatin  C  positive  amyloid  plaques  (E, 
arrowheads)  and  amyloid-laden  blood  vessels  (E,  insert)  in 
AD.  In  vAD  blood  vessels  with  CAA  (F,  arrow)  showed 
strong staining while the diffuse deposits were negative. Bar in 
panel  A  represents  250pm  in  A  &  D;  500pm  on  panel  B, 
100pm on panels C, E and F;
\
£
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5.3.7  Distribution of heperan sulphate proteoglycans in FBD and FDD
5.3.7.1  Distribution of agrin in FBD and FDD
JM-72  and  BI-31,  the two  antibodies  recognising the  core  protein  of agrin,  showed 
similar staining patterns and stained the same structures. As agrin is present in basement 
membranes all blood vessels regardless of size, whether unaffected or severely affected 
by  amyloid  deposition were positive.  However in FBD,  amyloid-laden blood vessels 
showed an increase in staining intensity and the staining pattern was clearly different 
from  that  seen  in  unaffected  blood  vessels  (figure  5.8A,  insert).  All  types  of 
hippocampal amyloid plaque were labelled with the anti-agrin antibodies (figure 5.8A, 
arrow).  The parenchymal diffuse deposits were extensively,  but usually less intensely 
stained than the  amyloid  lesions.  The  anti-agrin  antibody  stained  NFTs  and NTs  in 
FBD, including occasional ghost tangles.
In FDD the vascular amyloid deposits were positive with the anti-agrin antibody (figure 
5.8B arrow), but the diffuse deposits,  although positive, only showed a weak staining 
pattern (figure 5.8B, double arrow). NFTs were also found to be positive in FDD.
In AD including the cotton wool variants the amyloid-laden blood vessels (figure 5.8C 
insert,  5.8D,  arrow)  were  strongly  labelled  by  the  anti-agrin  antibodies  as  were  the 
amyloid  plaques  (figure  5.8C  double  arrow)  and  cotton  wool  plaques  (figure  5.8D 
double arrow). NFTs were found to be positive in both sporadic and variant AD.
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Figure  5.8:  Agrin  immunohistochemistry  in  FBD,  FDD,  AD 
and  vAD.  As  agrin  is  a  normal  component  of the  basement 
membrane,  all  blood  vessels  are  stained  with  the  anti-agrin 
antibody.  However,  agrin is also deposited in the ABri amyloid 
plaques  (A,  arrow) and  blood  vessels with  CAA  (A,  insert).  In 
FDD  blood  vessels  with  amyloid  deposition  were  positive  for 
agrin  (B,  arrow),  while  only  occasional  diffuse  deposits  were 
positive for agrin (B, double arrow). In AD both amyloid plaques 
(C,  double arrow) and blood vessels with CAA (C,  insert) were 
positive for agrin.  In vAD a strong intense  staining pattern was 
observed within both the amyloid-laden blood vessels (D, arrow) 
and the diffuse cotton  wool  plaques  (D,  double  arrow).  Bar  on 
panels A represents 45pm in panels A; 100pm on panels B and D; 
250 pm on panel C.
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Figure 5.9: Perlecan immunohistochemistry in FBD, FDD, AD 
and  vAD.  In FBD the anti-perlecan antibody weakly  labelled  a 
proportion of ABri amyloid plaques (A, arrow) and amyloid-laden 
vessels  of all  sizes  were weakly  stained  in FBD  (B,  arrow).  In 
FDD amyloid-laden blood vessels were positive for perlecan (C: 
arteriole-  double  arrow;  capillary  -   arrow).  The  parenchymal 
preamyloid  ABri  and  ADan  lesions  were  negative  in  both 
diseases. In AD amyloid plaques and amyloid-laden blood vessels 
were  negative perlecan, but positive staining was seen in vessels 
with normal morphology (D, arrow) A similar pattern was seen in 
vAD with only blood vessels with normal  morphology  showing 
positive  staining  for  perlecan  (E,  arrow).  Bar  on  panels  A 
represents 100pm in panels A, B C and E; 28pm on panel D.
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5.3.7.2  Distribution of perlecan in FBD and FDD
Similar to agrin, perlecan is present within the basement membrane and therefore, the 
majority of blood vessels were stained with this antibody. In addition, a small number 
of ABri amyloid plaques (figure 5.9A, arrow) and larger amyloid-laden blood vessels 
(figure 5.9B, arrow) showed patchy, weak staining with the anti-perlecan antibody, but 
the parenchymal diffuse deposits were always unstained.
In FDD a few blood vessels with amyloid were labelled (figure 5.9C) and parenchymal 
diffuse deposits were unstained
In the AD controls no staining was present in amyloid or preamyloid lesions (figure 
5.9D and 5.9E). No NFTs were found to be positive with anti-perlecan antibody in any 
of the diseases studied.
5.3.7.3  Distribution of syndecans in FBD and FDD
Three antibodies directed against different members of the syndecan family, 2E9 (anti- 
syndecan-1,  -3),  10H4  (anti-syndecan-2)  and  IC7  (anti-syndecan-3),  were  used  to 
investigate the expression of these cell membrane associated HSPGs.
In FBD both syndecan-2 and syndecan-3 were present in amyloid-laden blood vessels 
(figure  5.10A,  insert)  and  amyloid  plaques  (figure  5.10A,  double  arrow),  while  the 
parenchymal diffuse ABri deposits showed weak, patchy positivity for syndecan 2. The 
antibody recognizing syndecan-1, -3 showed some weak positivity in a proportion of the 
amyloid lesions, but did not stain the parenchymal diffuse lesions.
In  FDD,  in  a pattern  similar to that seen  in FBD,  syndecan-2  and  syndecan-3  were 
present in the blood vessels  with CAA (figure  5.1 OB,  arrow).  Syndecan-2 was  more 
consistently present in the parenchymal preamyloid lesions than syndecan-3. Syndecan-
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1,-3  immunohistochemistry  showed  mostly  a  similar  pattern  to  that  in  FBD,  but 
labelling of a proportion of the parenchymal diffuse deposits was also noted.
In  AD  the  pattern  of staining  for  syndecans  was  similar to that  seen  in  FBD  with 
syndecan-2  and  syndecan-3  being  present  in  the  vascular  (figure  5.IOC,  insert)  and 
parenchymal  amyloid  lesions  (figure  5. IOC,  arrowheads).  Syndecan-3  staining  was, 
however,  also  present  in  AJ3  parenchymal  diffuse  deposits,  but  not  in  similar  ABri 
lesions. The antibody to syndecan-1, -3 mostly stained amyloid plaques. In variant AD 
both the cotton wool plaques and blood vessels with CAA showed significant staining 
for syndecan-3, while they showed weaker and more patchy reactivity for syndecan-2 
(figure 5.10D) and syndecan-1,-3.
5.3.7.4  Distribution of glypican-l in FBD and FDD
Immunohistochemistry  with  the  SI  antibody  directed  against  the  glypican-l  core 
protein demonstrated that a significant proportion of blood vessels affected by amyloid 
deposition contained glypican-l in both FBD (figure 5.1 IB and 5.1 IB, insert) and FDD 
(figure  5.11C,  arrow and  5.1 ID)  as  did  the  amyloid plaques  in FBD  (figure  5.11 A, 
arrow). The diffuse parenchymal deposits were also stained in both FBD and FDD.
In  AD  all  vascular  (figure  5.11E,  insert)  and  parenchymal  amyloid  lesions  (figure
5.1  IE, arrowheads) were positive for glypican-l. The cotton wool plaques in the variant 
AD cases were positive for glypican-l  (figure 5.1 IF, double arrow) and the amyloid­
laden blood vessels showed a strong staining pattern with the anti-glypican-1 antibody 
(figure 5 .1 IF, arrow). A proportion of the NFTs were positive in the hippocampus the in 
FBD and AD cases.
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Figure  5.10:  Syndecan-2  immunohistochemistry  in 
FBD,  FDD,  AD  and  vAD.  In  FBD  syndecan-2  stained 
both amyloid plaques (A, double arrow) and amyloid-laden 
blood vessels (A,  insert asterisk), while the parenchymal 
diffuse ABri deposits showed weak patchy positivity (data 
not  shown).  In  FDD  anti-syndecan-2  antibody  stained 
amyloid-laden  blood  vessels  (B,  arrow),  but  not  the 
preamyloid parenchymal deposits (data not shown). In AD 
both  amyloid plaques (C,  arrowheads)  and blood vessels 
with CAA (C, insert) were positive for syndecan-2. In vAD 
staining  was  observed  within  the  amyloid-laden  blood 
vessels (D, insert) and the diffuse cotton wool plaques (D, 
double  arrow).  Bar  on panel  A  represents  100pm  on  A; 
45pm on panel B,C and D.
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5.3.7.5  Distribution of HS GAGs in FBD and FDD
Three  different  antibodies were used to  investigate the  expression of HS  GAG side 
chains:  the  JM403  and  JM13  antibodies  recognizing  different  epitopes  in  the  HS 
polysaccharide  side chain  and the pan-HSPG antibody 3G10 that was raised  against 
heparitinase-digested HSPGs.  The pan-HSPG and JM403  antibodies stained amyloid­
laden  blood  vessels  and  amyloid  plaques  in  FBD  (figure  5.12A,  arrow  and  5.12B, 
asterisk). Weak staining of some of the diffuse,  preamyloid ABri deposits was noted 
(data not shown).  A similar, but weaker staining pattern of amyloid lesions was seen 
with the JM13 antibody.
In FDD all three antibodies JM403, JM13 and 3G10 stained the amyloid-laden blood 
vessels (figure 5.12C, arrow and 5.12D, double arrow), although 3G10 showed weaker 
staining of fewer blood vessels than the other two antibodies. The parenchymal diffuse 
deposits  showed  patchy  weak  staining  for  JM403  and  3G10  (figure  5.12D,  double 
arrow).
In  AD,  including  variant  AD,  all  three  antibodies  labelled  the  amyloid-laden  blood 
vessels (figure 5.12F, arrow), but the intensity of labelling with JM13 in variant AD was 
less.  In AD amyloid plaques were labelled with variable intensity as were the diffuse 
Ap deposits (figure 5.12E, arrowheads).  The cotton wool plaques were labelled by all 
three antibodies (figure  5.12F,  double arrows),  although the staining seen with JM13 
and 3G10 was the weakest.
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Figure  5.11:  Glypican-l  immunohistochemistry  in 
FBD  (A &  B), FDD (C &  D), AD (E) and vAD  (F). 
The  anti-glypican  antibody  strongly  labelled  the  ABri 
amyloid plaques  (A,  arrows).  The  amyloid-laden blood 
vessels  of all  sizes  were  similarly  strongly  stained  in 
FBD  (B)  and  FDD  (C,  arrows  and  D).  In  FDD 
perivascular  deposits  were  also  positive  for  glypican-l 
(D, double arrow). In AD amyloid plaques were positive 
for  glypican-l  (E,  arrowheads)  as  were  amyloid-laden 
blood vessels (E, insert). In vAD both blood vessels with 
CAA (F, arrow) and diffuse deposits (D,  double arrow) 
showed  equal  intensity  of  staining.  Bar  in  panel  A 
represents 250pm on A;  100pm on panel C and E; 45pm 
on panel D and F; 28pm on panels B.
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Figure 5.12:  HS GAG (JM403)  immunohistochemistry  in  FBD 
(A&B),  FDD  (C&D),  AD  (E)  and  vAD  (F).  In  FBD  positive 
staining for JM403  (HS side chains) was seen in amyloid plaques 
(A,  arrows)  and  amyloid-laden  blood  vessels  (B:  double  arrow 
pointing to a perivascular plaque surrounding an arteriole, asterisk). 
In FDD JM403  immunoreactivity was seen in amyloid-laden blood 
vessels  (C:  affected  capillaries  highlighted  by  arrows;  D:  faintly 
labelled perivascular amyloid lesion). In AD amyloid plaques were 
positive  for  HS  GAG  side  chains  (E,  arrowheads).  In  vAD  both 
blood  vessels  with  CAA  (F,  arrow)  and  diffuse  deposits  were 
positive for HS  GAG (JM403) (F,  double  arrow).  Bar in panel A 
represents 250pm in A;  100pm in all other panels; 28 pm in panel 
E; 45 pm  in panel F.
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5.4  Discussion
It has been proposed that a significant number of AAPs or ‘pathological chaperones’ 
may have a prominent role in the pathogenesis of amyloid-linked cerebral diseases in 
vivo  in  that  they  are  able  to  influence  the  process  of amyloid  fibril  formation  by 
stabilizing amyloid fibrils once they have formed (Alexandrescu, 2005). This, together 
with recent in vitro data suggesting that the protofibrillary intermediates rather than the 
amyloid fibrils are the protein species that are linked to neurodegeneration, may have 
important  implications  for  our  understanding  of the  pathogenesis  of  a  number  of 
cerebral  amyloid  conditions  such  as  AD  (Caughey  &  Lansbury,  Jr.,  2003).  Of the 
cerebral  amyloid diseases most of the in  vitro  and in  vivo data about AAPs that are 
available in the literature relate to AD. In order to establish whether these findings are 
specific  to  AD  or  may  have  a  wider  implication  for  the  understanding  of  the 
pathogenesis of other cerebral amyloidoses, we systematically investigated the patterns 
of AAP deposition in the novel BR12 gene-related dementias, FBD and FDD.
The  data  from  the  current  study  demonstrated  that  a  number  of AAPs  are  closely 
associated with ABri and ADan amyloid and preamyloid parenchymal lesions and also 
CAA,  in FBD  and FDD  in a manner mostly similar to that seen in AD. A group of 
AAPs  including  ApoE,  ApoJ,  agrin,  glypican  and  HS  GAG  side  chains  rather 
extensively co-deposited  with  both  amyloid and preamyloid ABri  and ADan  lesions 
(figure  5.13).  The remainder was predominantly seen in relation to parenchymal and 
vascular amyloid lesions,  although most of the  anti-AAP  antibodies  labelled at least 
some  of the  diffuse  (preamyloid)  ABri  and  ADan  parenchymal  lesions.  The  rather 
significant co-deposition of some  of the AAPs  in diffuse ABri, ADan or Ap  lesions 
including the cotton wool plaques seen in variant AD may be interpreted in at least two 
ways. Either AAP binding to parenchymal or vascular protein deposits is not entirely
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dependent  on  amyloid  conformation  or,  alternatively,  the binding  of AAPs to  ABri, 
ADan and Ap preamyloid lesions, including the cotton wool plaques, reflects that such 
lesions  contain  variable  numbers  of amyloid  fibrils.  The  latter is  supported by their 
weak labelling with thioflavine-S  and the observation that preamyloid lesions in FBD 
and FDD and the cotton wool plaques in variant AD can be demonstrated by iEM to 
contain sparse amyloid fibrils, in addition to amorphous electron dense material (Holton 
et al., 2001a; Holton et al., 2002a).
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Figure 5.13: A  schematic diagram summarizing the deposition of AAPs in the BRI2- 
gene related dementias.  The AAPs are listed for the BRI2-gene related dementias, FBD 
and FDD,  AD  and  variant  AD  with  cotton  wool plaques.  The  diagram  shows  the 
progression  from  soluble  peptides  (ABri,  ADan  and  Ap)  through  prefibrillar 
intermediates to amyloid fibrils indicated with the red arrows.  The AAPs co-deposited 
with  the  prefibrillar  intermediates  (diffuse  deposits)  are  indicated  with  the  green 
arrows. AAPs which are co-deposited with the proteins in amyloid conformation,  either 
amyloid plaques or amyloid-laden blood vessels, are indicated with the blue arrows. In 
both AD and vAD perlecan not co-deposited with either prefibrillar intermediates or 
amyloidfibrils and is therefore not represented on the diagram.
ApoE and ApoJ have been previously shown to be present in Ap amyloid in AD and 
with other tested cerebral and systemic amyloids (Namba et al.,  1991; Wisniewski & 
Frangione,  1992).  The  current  investigations  have  shown that  ApoE  and  ApoJ  (see
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chapter 6)  are extensively associated with  ABri  and ADan amyloid  and pre-amyloid 
lesions, suggesting that the amyloid conformational state of ABri, ADan and AP is not a 
prerequisite of the co-deposition of apolipoprotein.  These findings are consistent with 
the notion the ApoE and ApoJ may exercise an early influence on the process of ABri 
and ADan fibril formation. In vitro and in vivo data indicate that both apolipoproteins 
have a major role in Ap fibrillogenesis in that it can interact with AP and facilitate the 
conversion  of soluble  into  fibrillar  AP  with  high  P-sheet  content  (Holtzman,  2004). 
Biochemical studies demonstrated the binding of ApoE to the Ap peptide occurs in the 
lOkDa carboxyl domain of ApoE, and residues 12 to 28 of AP are essential for the bond 
between ApoE and AP and also that the efficiency of the binding is isoform dependent 
(Yang et al.,  1997; Zhou et a l,  1996) as is the effect of ApoE on Ap fibrillogenesis or 
aggregation (Pillot et a l, 1997). ApoE is also implicated in the clearance of cerebral Ap 
(Zlokovic, 2004). The role of ApoE in amyloid formation has recently been investigated 
in a series of in vivo experiments that have shown it to be an amyloid promoter (Bales et 
a l,  1997; Holtzman et a l, 2000b). Transgenic ApoE knock out mice that also express 
human  APP  showed  a  variable  amount  and  speed  of amyloid  deposition  that  was 
dependent  on the  number  of copies  of the  ApoE  gene  (Bales et al,  1997).  Mature, 
fibrillar amyloid never formed in the ApoE' ' mice.  These results suggest that mouse 
ApoE was  influencing  Ap  metabolism promoting the conversion of soluble  Ap  to  a 
species  rich  in  P-sheet  conformation.  Our  results  correlate  with  these  in  vivo 
experiments and transgenic animal models in that we observed ApoE immunolabelling 
of all  lesion  types  regardless  of the  conformational  state  of the  respective  amyloid 
protein in FBD,  FDD  and  AD.  The diffuse parenchymal  deposits found in FBD and 
FDD were also equally and intensely stained, consistant with the hypothesis that ApoE 
binding is early and has a role in promoting amyloid formation. There are also data to
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suggest  that  ApoE  binding  also  protects  the  amyloid  formed  from  proteolytic 
breakdown (Wisniewski et al.,  1994a).  Studies also suggest that ApoJ is produced at 
similar levels to ApoE (May & Finch,  1992) and similarly acts as an Ap chaperone, 
regulating the conversion of Ap to insoluble forms (Oda et al.,  1995; Lambert et al.,
1998).  An  in  vivo  study  has  been  carried  out  to  assess  the  effects  of ApoJ  on  Ap 
metabolism and structure using knockout mice (DeMattos et al., 2004). PDAPP mice 
were  compared  with  PDAPP  ApoJ*7 '  and  PDAPP  ApoE*7 7ApoJ*7 * .  The  results  were 
interesting because the single knockout mice, PDAPP ApoJ'7 *  showed significantly less 
thioflavine-S positive material than would be seen with the ApoJ gene present.  Since 
both ApoE and ApoJ independently contribute to Ap fibril formation in vivo (Bales et 
al., 1997; Bales et al., 1999; Holtzman et al., 2000b), you might expect that there would 
be less fibril formation in the PDAPP ApoE*7 7ApoJ'7 *  mice. However, within these mice 
greater  levels  of  thioflavine-S  positive  deposits  were  found  than  in  the  normal 
genotypes. The magnitude of the effect of removing both molecules on Ap levels and 
onset of deposition was similar in extent to that described for overexpressing presenilin 
mutations in APP transgenic mice (Duff et al., 1996; Borchelt et al., 1997; DeMattos et 
al., 2004). This study shows that ApoE and ApoJ cooperatively suppress Ap deposition 
and that ApoE is contributing to this effect via directly influencing the metabolic fate of 
soluble, extracellular Ap (DeMattos et al., 2004).
No similar data are available as yet about the significance of ApoE and ApoJ in the 
regulation  of the  fibrillisation process  and/or  clearance  of ABri  and  ADan.  For this 
further  in  vitro studies,  and once  transgenic models  of FBD  and FDD have become 
available, in vivo experiments are required.
As in AD (Coria et al., 1988) SAP immunoreactivity was observed in all amyloid-laden 
blood  vessels  and  amyloid  plaques  within  the  FBD  and  FDD  and  the  diffuse
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parenchymal  deposits  were  only  weakly  labelled,  including  variant  AD  (PS1 
AI83/AM84)  with  cotton wool  plaques  showed positive  immunoreactivity  within the 
pre-amyloid structures. This observation is in keeping with previous investigations such 
as that demonstrated by using iEM that anti-SAP antibodies decorate amyloid fibrils, 
but are not associated with protofibrils (Holm et al., 2000). Although originally SAP 
was thought to be produced solely by the liver, more recent data suggest that it is also 
synthesized in the brain, particularly by pyramidal neurons, and that its synthesis is up- 
regulated in AD  (Yasojima et al.,  2000).  SAP has  a major role  in fibrillogenesis as 
under  experimental  conditions  it  stabilizes  and  protects  fibrils  from  phagocytic  and 
proteolytic degradation and amyloid deposition is reduced and delayed in SAP knockout 
mice  (Botto  et al.,  1997).  The  Ca2+-dependent protective  effect  of SAP  on amyloid 
fibrils may be due to its ability to enhance the strength and density of local amyloid 
inter-fibrillar interactions thus forming compact fibril networks with increased density 
of fibril entanglements (MacRaild et al., 2004). The presence of SAP in ABri and ADan 
amyloid lesions and its relative paucity in the diffuse lesions is in keeping with previous 
studies showing that SAP is ubiquitously associated with all types of amyloid while it 
has  little  or no affinity for amyloid proteins  in their native state (Coria et al.,  1988; 
Gallo etal., 1994; Hamazaki, 1995; Pepys etal., 1994).
These  observations  would  also  be  in  keeping  with  previous  investigations 
demonstrating  by  iEM  that  SAP  molecules  bind  to  and  coat  the  surface  of mature 
amyloid fibrils, but not that of protofibrils composed of A(3m2 (Holm et al., 2000). The 
high level of labelling obsevred in the cotton wool plaques is apparently contrary not 
only to these previous studies, but also to a morphological study of variant AD in which 
no immunoreactivity for SAP in the cotton wool plaques was seen, although that study 
employed formalin fixed paraffin sections (Verkkoniemi et al., 2001) while we used a
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different  antibody  on  frozen  sections.  The  relative  abundance  of  SAP  in  our 
preparations may suggest that the rather widely dispersed amyloid fibrils in the cotton 
wool plaques observed using Ap iEM (personnal observation) are capable of efficient 
binding of SAP.
In  this  study  we  demonstrated  that  the  acute  phase  protein  ACT  co-deposited  with 
vascular ABri  and ADan amyloids in FBD  and FDD and it was also found in CAA 
within the AD controls,  in addition to a significant proportion of amyloid plaques in 
both FBD and AD. ACT was also detected in ADan diffuse deposits and significantly in 
the  Ap  diffuse  lesions  and  cotton  wool  plaques.  ACT  can  bind  directly  to  the  Ap 
peptide in vitro and promote polymerization and fibrillization of synthetic Ap peptide 
(Ma  et  al.,  1994),  perhaps  by  initiating  or  catalyzing  the  self-assembly  process 
(Janciauskiene et al.,  1996).  Several in vivo observations also support the association 
between ACT and amyloid formation in AD: both amyloid and preamyloid lesions have 
been shown to contain ACT (Abraham et al.,  1988b; Picken et al.,  1990; Potter et al., 
1992), amyloid plaques are found in brain regions in which ACT mRNA and protein are 
over-expressed by astrocytes  in AD  (Potter et al.,  1992) and furthermore,  transgenic 
mice with both ACT and human APP transgenes exhibit elevated total Ap levels and 
increased  amounts  of  Ap  deposits  when  compared  with  mice  with  only  the  APP 
transgene (Nilsson et al., 2001). Genetic support for the involvement of ACT in AD was 
suggested by the  observation that the  inheritance  of ACT-A  allele,  in which alanine 
replaces threonine at position -15 in the signal peptide, correlates with an increased risk 
of developing  AD  in  ApoE  e4  carriers  (Kamboh  &  DeKosky,  1995),  although  this 
observation was not confirmed by subsequent studies (Muller et al., 1996;). Our finding 
of ACT  deposition  in  ABri  and  ADan  amyloid  lesions  is  of particular  interest  as 
previous studies have suggested a direct role for ACT in amyloid formation in AD, but
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not in other amyloid diseases (Abraham et al.,  1988a; Potter et al.,  1992; Abraham et 
al.,  1988b;  Potter et al.,  1992).  Further in  vitro  studies  are required to elucidate the 
biochemical mechanisms of ACT binding to ABri and ADan and the subsequent effects 
on the aggregation and fibrillization of these two amyloid peptides.
We demonstrated a variable degree of co-localization of cystatin C with both ABri and 
ADan vascular and parenchymal amyloid lesions. Previous studies showed that cystatin 
C is also present in vascular Ap in AD and also in senile plaques (Levy et al., 2001; 
Vinters et al., 1990). Whether the association of cystatin C with Ap plays a primary role 
in amyloidosis  of AD  or it is  a late  event,  in which cystatin C binds  to the already 
formed  Ap  amyloid  fibrils  is  still  unknown.  Since  cystatin  C  has  cysteine  protease 
inhibitory activity,  it may play a role in protecting Ap (or ABri and ADan) deposits 
from proteolytic degradation or together with ACT may be present as  a result of an 
ongoing anti-inflammatory response that is present in relation to the amyloid lesions 
(Akiyama et al., 2000; Eikelenboom et al., 1991; Rostagno et al., 2002).
We have found that HSPGs also co-deposit in ABri and ADan amyloid lesions, as has 
been shown for other forms of cerebral and systemic amyloidosis, supporting the view 
that one feature of all amyloids is the presence of highly sulphated proteoglycans (van 
Horssen  et  al.,  2003;  Ancsin,  2003)  which  may  directly  contribute  to  the  complex 
structure of the amyloid fibrils (Inoue et al.,  1999). Our data suggest that of the major 
HSPGs investigated agrin, glypican-l  and syndecans are significantly associated with 
both  ABri  and  ADan  vascular  and  parenchymal  amyloid  lesions  and  variably  with 
preamyloid lesions. Although perlecan was shown to be a potent facilitator of Ap fibril 
formation in vitro and it was initially described as a major HSPG in AD in vivo (Snow 
et al.,  1988;  Snow et al.,  1994), this  latter observation was not confirmed by recent 
studies  using  a  well-characterized  anti-perlecan  antibody  (van  Horssen  et al.,  2001;
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Verbeek et al.,  1999). Using the same anti-perlecan antibody we observed only weak 
staining of a relatively small proportion of ABri plaques and CAA in both FBD and 
FDD, but saw no immunoreactivity in the AD controls. These findings are consistent 
with  the  notion  that  the  HSPG  core  protein  perlecan  is  unlikely  to  play  a  major 
pathogenic role in either FBD, FDD or AD. We also demonstrated co-localization of HS 
GAG side chains with ABri parenchymal amyloid lesions, blood vessels with CAA due 
to  ABri,  ADan  or Ap  and  less  consistently  with  preamyloid  lesions.  HS  GAGs  are 
ubiquitously  expressed  in  basal  laminae  and  cell  surfaces  and  can  modulate  the 
functions of proteins, such as growth factors or protease inhibitors (Ancsin, 2003). HS 
GAG accumulation has been observed in a number of human amyloid diseases in vivo, 
including AD and prion diseases (Perlmutter et al.,  1990;  Snow et al.,  1988; Snow et 
al.,  1990).  Furthermore,  in  vitro  studies  demonstrated  that  HS  GAGs  are  able  to 
promote a shift in the structure of Ap from a predominantly random to a p-sheet-rich 
secondary structure and that they enhance fibril formation of a number of other proteins 
implicated in neurodegenerative diseases including prion protein, a-synuclein and tau 
(for review see Ancsin, 2003).
As deposition of the HSPG core protein agrin has previously been described only in 
relation to Ap in AD (Cotman et al., 2000; van Horssen et al., 2001; Verbeek et al.,
1999)  and in experimental AA amyloidosis (Wien et al., 2004), our findings indicate 
that this basement membrane associated HSPG may have a more generic role  in the 
pathogenesis of cerebral and systemic amyloid diseases. It has been shown that under 
experimental conditions agrin is able to bind, probably through its HS GAG side chains, 
to the fibrillar, but not to the soluble form of Ap and that it is also able to stabilize and 
protect Ap fibrils from proteolytic degradation (Cotman et al., 2000).
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The  presence  of AAPs  in  amyloid  lesions  in  different  diseases  suggests  a  general 
participation of these molecules in amyloid formation and it is tempting to  speculate 
that  they  may  play  a  similar  role  in  FBD  and  FDD  to  that  proposed  for  other 
amyloidoses. However, further experimental studies are required to establish how AAPs 
bind to ABri and ADan and what effect this binding may have on the fibrillization of 
these two amyloid proteins, which are capable of initiating a neurodegenerative cascade. 
It also remains to be investigated whether AAPs,  and,  in particular,  those which are 
normally  associated  with  cell  membranes,  could  influence  the  incorporation  of the 
amyloid  subunits  into  cell  membranes  and  modulate  the  formation  of the  recently 
described ion-channel-like structures, thus contributing to the mechanism of cell death 
in these diseases (Quist et a l, 2005).
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Chapter 6
Complement activation in BRI2 gene-
related dementias.
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Chapter 6  -  Hypothesis and specific questions
In  this  chapter,  I  wished  to  investigate  the  hypothesis  that  activiation  of  the 
complement pathways is implicated in the pathogenesis of both FBD and FDD. The 
specific  questions  I  wished  to  concentrate  on  were:  1)  Are  the  complement 
pathways (classical and alternative) fully activated in both FBD and FDD?: 2) Is 
there  a  correlation  between  the  conformational  state  of  ABri  and  ADan  and 
complement activation?
In  relation  to  Ap  deposition  activation  of  the  complement  pathways  has  been 
documented with implications for fibrillogenesis, host response and the mechanism of 
neurodegeneration.  This  study investigates by immunohistochemistry the presence of 
complement components of both the classical and alternative pathways and complement 
inhibitors  in  FBD  and  FDD,  and  seeks  to  establish  whether  the  binding  of  the 
recognition protein Clq to ABri and ADan is dependent on the conformational state of 
these  amyloid  proteins.  For  this  Clq  immunohistochemistry  was  combined  with 
thioflavine-S stain and evaluated by confocal microscopy.
6.1  Introduction
In the epidemiologically most important neurodegenerative disease, AD, the Ap protein 
forms extracellular plaques and can be deposited in blood vessels.  Evidence suggests 
that cerebral inflammation is associated with AD pathogenesis (Akiyama et al., 2000), 
and  inflammatory  mediators,  immunologic  factors  and activation of the  complement 
pathways have been implicated in this process (Vidal et al., 2000a). The complement 
proteins have been shown by previous studies to be associated with Ap amyloid plaques 
(Head et al., 2001; Stoltzner et al., 2000; Webster et al.,  1997),  amyloid laden blood 
vessels (Verbeek et a l,  1998) and NFTs (Shen et al., 2001; Schwab et al,  1996a) in 
vivo.
In brief the complement pathways,  classical (see section  1.9.2.1) and alternative (see 
section 1.9.2.2), consist of over 20 components that can be sequentially activated as an 
amplifying  cascade.  Antibody  dependent  and antibody  independent  activation of the 
complement system can lead to inflammation, opsonization and cytolysis. The classical 
pathway (Cl  to C9) can be activated principally by the binding of the first component, 
Clq  of Cl,  to  an  antibody  or  other  activator.  This  triggers  the  proteolytic  cascade 
culminating in the formation of the membrane attack complex (MAC or C5b-9), which
223Chapter 6- Complement activation
damages cells by forming transmembrane lytic pores, leading to cellular injury and the 
recruitment  and  activation  of  immune  cells  to  the  site  of  complement  activation 
(Strohmeyer et al., 2000). Ap has been shown to bind to Clq and activate the classical 
pathway (Afagh et al., 1996; Rogers et al., 1992a). The alternative pathway provides an 
antibody independent route of complement activation, which has also been shown to be 
activated by Ap (Strohmeyer et al., 2000). The initiation of this pathway occurs through 
the hydrolysis of circulating C3, activated in the absence of antibodies and is therefore a 
mechanism  of  innate  immunity.  In  addition  to  the  proteins  that  compose  the 
complement pathways there are also several regulatory proteins, of which Vn (Walker 
& McGeer,  1998; Schvartz et al.,  1999) and ApoJ (clusterin or SP40-40) (Lidstrom et 
al.,  1998;  McGeer  et  al,  1992)  are  complement  inhibitors,  which  convert  the 
hydrophobic MAC  into  a hydrophilic  structure thus preventing its insertion into  cell 
membranes.
As  demonstrated  in  chapters  3  and  4  the  BRI2  gene-related  dementias  are  also 
characterized pathologically by extracellular fibrillar and non-fibrillar protein deposition 
in combination with neurofibrillary degeneration (Stromgren et al., 1970; Holton et al., 
2001; Holton et al., 2002; Plant et al., 1990; Revesz et al., 1999). Chapters 3 and 4 also 
show that the overall patterns of deposition of ABri and ADan in the CNS of affected 
individuals  are  similar to those  of Ap  in AD  and that the parenchymal  deposits  are 
mostly of amyloid (fibrillar) nature in FBD, but are predominantly of the preamyloid 
(non-fibrillar) type in FDD.
This  study  aimed  to  investigate  in  vivo  whether,  as  in  AD,  complement  activation 
products  are  also  implicated in the pathogenesis  of FBD  and FDD.  To  answer this 
question  sequential tissue  sections  of FBD  and FDD  cases together with  appropriate 
controls were used for immunohistochemistry using antibodies to the classical pathway 
recognition  (Clq)  and  activation  (C3d,  C4d)  components,  an  alternative  pathway 
activation  product  (Bb),  a  proteolytic  derivative  (iC3b)  common  to  both  pathways, 
MAC representing the terminal stage of activation in either pathway, and its physiologic 
inhibitors  ApoJ  and  Vn.  In  order  to  establish  a  correlation  between  the 
activation/deposition of complement components  and inhibitors  on one hand and the 
conformational state of ABri and ADan on the other, tissue sections were also stained 
with  Congo  red  and  thioflavine-S.  Double  immunohistochemical  staining  with  an
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antibody to either of the amyloid proteins and thioflavine-S was also carried out and the 
results were evaluated with confocal microscopy.
6.2  Material and Methods
6.2.1  Tissue
Brain samples from 5 FBD, 3 FDD, 5 sporadic and 2 familial AD cases, and 4 normal 
controls were collected at post mortem and shown in table 22. The familial AD cases 
included  one  variant  AD  case  with  cotton  wool  plaques  due  to  PS1  AI83/AM84 
mutation (Houlden et al.,  2000;  Steiner et al.,  2001),  a case  caused by PS1  M233V 
mutation. The criteria for the neuropathological diagnosis of FBD and FDD have been 
previously described (Holton et al., 2001; Holton et al., 2002; Plant et al., 1990; Revesz 
et al., 1999), while for that of AD standard criteria were used (Mirra et al., 1991).
For immunohistochemistry carried out on paraffin embedded tissue sections were cut 
from  the  hippocampus,  cerebellum  and  frontal  cortex  in  all  cases  listed  above. 
Immunohistochemistry carried out on frozen tissue hippocampus and frontal cortex was 
used from one FBD and three sporadic AD cases; frontal cortex from one familial AD 
case and hippocampus from one FDD case.
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Case Case number Sex Age Cause of Death Diagnosis
1 PM 37-99 M 43 Bronchopneumonia FDD
2 PM 38-99 F 60 Bronchopneumonia FDD
3 PM 39-99 M 58 Not recorded FDD
4 PM 91-99 F 68 Bronchopneumonia FBD
5 PM 3319 F 65 Bronchopneumonia FBD
6 PM 111-95 M 60 Cardiac failure FBD
7 PM 6-00 N/A N/A N/A FBD
8 PM 49-76 F 56 Not recorded FBD
9 PM 100-95 F 46 Bronchopneumonia FAD
10 PM 8-00 N/A N/A N/A FAD
11 PM 69-99 F 92 Pneumonia AD
12 PM 32-97 F 91 Pneumonia AD
13 PM 73-98 M 86 Bronchopneumonia AD
14 PM 25-98 F 69 Acute tracheo Bronchtis AD
15 PM 83-98 F 84 Dementia AD
16 C 4-00 M 81 Chronic obstructive airway disease Control
17 C 5-00 F 88 Chronic obstructive airway disease Control
18 PM 84-98 M 56 Cardiac failure Control
19 PM 76-99 M 33 Acute bronchopneumonia Control
Table 22: Cases used in the complement study.
6.2.2  Antibodies
A panel of antibodies used in this study to establish the pattern of complement staining 
in relation to the amyloid proteins are shown in table 23.
Antibody Antigen Source Species Cone.
Ab338 ABri Dr. Jorge Ghiso Polyclonal 1 2000
Ab5282 ADan Dr. Jorge Ghiso Polyclonal 1 1000
A3 8-17 A3 Dako Monoclonal 1 100
A201 Clq Quidel Monoclonal 1 50
A207 C3d Quidel Monoclonal 1 100
A213 C4d Quidel Monoclonal 1 1000
A209 IC3b Quidel Monoclonal 1 100
A239 Sc5b-9 Quidel Monoclonal 1 100
A227 Factor Bb Quidel Monoclonal 1 50
Apolipoprotein J Apolipoprotein J Dr. Jorge Ghiso Polyclonal 1 200
A237 Vitronectin Quidel Monoclonal 1 200
CR3/43 M0775 HLA-DR Dako Monoclonal 1 200
Z0334 GFAP Dako Polyclonal 1 1000
Table 23: Antibodies used  for the complement study.
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6.2.3  Immunohistochemistry
For this study immunohistochemistry for paraffin sections was carried out as described 
in section 2.2; frozen sections as described in section 2.4; and free-floating sections as 
described in section 2.3. Staining for confocal microscopy was carried out as described 
in section 2.7.
63  Results
6.3.1  Clq expression in Ap, ABri and ADan lesions.
Clq immunoreactivity was observed  in all  amyloid affected blood vessels in the AD 
controls  (figure  6.6J-L)  including  those  with  cotton  wool  plaques  (figure  6.7A-C). 
Blood vessels of all sizes including capillaries, affected with amyloid deposition, were 
labelled with the anti-Clq antibody.  Strong Clq immunoreactivity was observed in the 
AP  amyloid  plaques,  including  those  containing  a central  core (figure  6.6A-C).  The 
thioflavine-S  and  Congo  red-negative  diffuse  plaques,  including  those  seen  in  the 
parvopyramidal clusters of the pre- and parasubiculum were negative or weakly positive 
for Clq compared with the amount of immunoreactivity found within the blood vessels. 
There  was  a  similar  pattern  in  variant  AD  in  that  while  the  strongly  thioflavine  S- 
positive blood vessels also showed a markedly positive reaction for Clq, the majority of 
the  cotton  wool  AP  plaques  with  weak  thioflavine-S  positivity,  were  also  weakly 
positive for Clq (figure 6.7C).  This staining pattern was mirrored in FBD with strong 
positivity for Clq in amyloid laden blood vessels (figure 6.1A-C) and in thioflavine-S 
positive  plaques.  The dense central  core of the  large hippocampal plaques were also 
strongly  labelled  with  the  anti-Clq  antibody  (figure  6.1D-F).  In  FDD  strong  Clq 
immunolabelling  was  found  in  association  with  blood  vessels  affected  by  ADan
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deposition (figure 6.1G-I), but only weak or no immunolabelling was seen in relation to 
the diffuse parenchymal lesions that are mainly negative with thioflavine-S staining.
In FBD Clq and thioflavine-S double staining revealed a close topographical overlap 
between the two staining patterns, confirming that the anti-Clq antibody stained ABri 
lesions in (3-pleated sheet conformation (figure 6.1A-F). Such preparations also showed 
that the Ab338-positive ‘diffuse’ thioflavine-S-negative or weakly positive lesions were 
either entirely  negative or only weakly reactive  for Clq (figure 6.1G-I).  A similarly 
close correlation between Clq immunoreactivity and thioflavine-S fluorescence of the 
parenchymal  lesions  was  noted  in  FDD  in  that  thioflavine-S  positive,  subpial  and 
perivascular ADan amyloid lesions were strongly labelled with the anti-Clq antibody, 
while the thioflavine-S-negative, parenchymal ‘diffuse deposits’ were negative or only 
weakly positive for Clq (data not shown).
Confocal microscopy was also undertaken to investigate the relationship between HLA- 
DR  positive  cells  and  amyloid  conformation  (thioflavine-S  positive)  and  HLA-DR 
positive cells and Clq reactivity.  In FBD HLA-DR positivity was found within cells 
closely associated with amyloid plaques (figure 6.2A-C), but were sparse in relation to 
preamyloid  lesions.  A  similar  association  of  the  glial  cellular  response  with  the 
conformational  state  of the  amyloid  proteins  was  confirmed  in  FDD,  as  activated 
microglia and astrocytes were mainly clustered around amyloid-laden blood vessels, but 
were sparse in relation to the diffuse preamyloid parenchymal lesions (data not shown). 
Amyloid plaques and amyloid-laden blood vessels in FBD (figure 6.2D-F) and FDD 
(figure  6.2G-I)  that  are  positive  with  Clq  showed  close  association  with  HLA-DR 
positive cells.
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Figure 6.1:  Clq deposition  in  FBD and  FDD.  (A, D and  G Clq- 
red; B,E and H thioflavine-S- green; C, F and I combined images).
Clq  is  deposited  in  amyloid-laden  blood  vessels  (A)  and  amyloid 
plaques (E), but was not found in preamyloid lesions (not shown) in 
FBD. In FDD Clq was also deposited in amyloid-laden blood vessels 
and parenchymal preamyloid lesions were unaffected (G and H). 
(Confocal  images;  Panels  A-F:  objective 20,  Panels  G-I:  objective 
10).
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Figure 6.2:  Microglial and astrocytic response in FBD and FDD.
Activated microglia expressing HLA-DR (red) are closely associated 
with  thioflavine-S  positive  (green)  amyloid  plaques  in  FBD  (A-C). 
(Confocal  images  panels  A-C:  objective  10  and  inset  objective  40, 
panels d-E: objective 63). HLA-DR positivity is in close proximity of 
Clq containing amyloid lesions (arrow- vessel, double arrow- plaque) 
in  both  FBD  (D-F)  and  FDD  (G-I).  (Confocal  images  Panels  G-I: 
objective 40, Panels J-L: objective 63).
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Figure  6.3:  Deposition  of  complement  components  in  amyloid 
plaques  in  FBD.  ABri-positive  amyloid  plaques  in  the  CA4 
subregion  of the  hippocampus  (A)  are  shown to  be  in  an  amyloid 
conformation by Congo red staining (B). Amyloid plaques  are  also 
decorated by the anti-Clq (C), anti-C3d (D), anti-iC3b (E), anti-C4d 
(F) anti-Sc5b-9 (G) and Bb antibodies (H). Plaques were also found 
to be strongly positive for ApoJ (I) and vitronectin (J). Arrows on all 
panels  are  pointing  towards  an  amyloid  plaque.  Bar  in  panel  A 
represents 100pm in all panels except H where it represents 45pm.
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6.3.2  C3d and C4d expression in Ap, ABri and ADan lesions
The antibodies to C3d and C4d, the presence of which indicates the activation of the 
classical complement pathway,  showed a staining pattern similar to that seen on Clq 
immunohistochemistry in both blood vessels and plaques in AD (figure 6.6D-E, 6.6M- 
N). In both FBD and FDD strong C3d and C4d immunoreactivity was also detected in 
amyloid-laden  blood  vessels  and  the  staining  patterns  with  these  antibodies  was 
comparable to those seen with antibodies to ABri,  ADan and Clq (figure 6.4D,  6.4F 
and figure 6.5E).  In addition, the C3d and C4d antibodies labelled the ABri amyloid 
plaques of all morphological types in FBD (figure 6.3D, 6.3F). While the subpial and 
perivascular parenchymal  amyloid  lesions were also  positively  stained with the anti- 
C3d  and  C4d  antibodies,  the  ‘diffuse  deposits’  remained unstained with these  latter 
antibodies.
6.3.3  IC3b expression in Ap, ABri and ADan lesions
The presence of iC3b can indicate the activation of either the classical or alternative 
complement  pathways,  is  formed  when  the  unstable  thioester  bonds  of the  newly 
generated  C3b  molecule  reacts  with  water  yielding  an  inactive  C3b  (iC3b).  The 
antibody  to  iC3b  strongly  stained  amyloid-laden  blood  vessels  and  parenchymal 
deposits  in  all  AD  cases  studied.  Including  the  familial  AD  cases  studied,  strong 
staining was found within the amyloid-laden blood vessels and weak staining was found 
within the  cotton wool  plaques  in which AP  is  in pre-amyloid  conformation (figure 
6.7E).  Immunohistochemistry with an antibody to iC3b showed that in FBD there was 
strong immunoreactivity of both vascular and parenchymal amyloid lesions (figure 6.3E 
and 6.4E) while ‘diffuse deposits’ showed a weak positivity.
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Figure  6.4:  Deposition  of  complement  components  in  blood  vessels  in  FBD. 
Amyloid-laden  blood  vessels  (B)  including  capillaries  (B,  inserts)  due  to  ABri 
deposition (A) in the frontal white matter. The anti-Clq (C), anti-C3d (D), anti-C4d (F), 
anti-iC3b  (E),  anti-SC5b-9  (G)  and  anti-Bb  (H)  antibodies  label  blood  vessels  and 
capillaries with ABri deposition.  ApoJ (I) and Vn (J) are similarly deposited in ABri 
containing vessel walls. Bar in panel A represents 45pm in all panels and inserts 22pm.
In FDD, in addition to the amyloid-laden blood vessels, iC3b positivity was associated 
with the subpial and perivascular amyloid lesions, but no or weak staining of the diffuse 
deposits was seen (figure 6.5E).
6.3.4  MAC expression in Ap, ABri and ADan lesions.
Immunoreactivity  for  MAC  was  visualized  using  anti-C5b-9  and  anti-Sc5b-9 
antibodies.  Both antibodies recognize the terminal complement complex consisting of 
C5b,  C6,  C7,  C8 and C9.  Anti-C5b-9 recognises the membrane-bound lytic complex 
and anti-Sc5b-9 recognises both the membrane-bound and fluid phase complex. In the 
current studies both antibodies gave similar results and, although the antibody to Sc5b-9 
gave a more intensive labelling than C5b-9 did, the two will be described together. In 
the AD cases MAC deposited in both amyloid-laden blood vessels (figure 6.60) and the 
staining of the blood vessels was especially strong in the variant AD cases,  in which 
CAA, also affecting capillaries, was especially severe (figure 6.7G). There were various 
amounts of MAC deposition in the AP plaques and a weak staining of the cotton wool 
plaques was also apparent (figure 6.6E and 6.7G).
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Figure 6.5:  Deposition of complement components in FDD. ADan deposits in both 
blood  vessels  and  parenchyma  (A,  vessel  arrow,  parenchyma  double  arrow),  while 
Congo  red  (B,  vessel  arrow)  mainly  stains  blood  vessels  suggesting  that  the 
parenchymal ADan lesions are mainly of preamyloid nature. Deposition of complement 
proteins, Clq (C), C3d (D), C4d (E), iC3b (F), Sc5b-9 (G) and Bb (H) taking place in 
amyloid-laden blood vessels (arrow) some of which with perivascular plaques (double 
arrow). Anti-ApoJ (I) and Vn (J) antibodies strongly stain vascular lesions (arrow), but 
the parenchymal  preamyloid lesions are more weakly labelled (double arrow).  Bar in 
panel A and in all panels represents 100pm and in panel H 28pm.
In FBD MAC immunoreactivity was present in both blood vessels affected by CAA and 
amyloid plaques (figure 6.3G and 6.4G).  In contrast in FDD, while the blood vessels 
affected by CAA were strongly labelled with the anti-MAC antibodies, the majority of 
the parenchymal lesions remained unstained (figure 6.5G).
6.3.5  Factor Bb in Ap, ABri and ADan lesions.
There was generally a small degree of staining of mainly the central cores of the senile 
plaques and also of the blood vessels with CAA in the AD cases (figure 6.6G and 6.6P). 
Immunoreactivity for factor Bb was seen in both larger blood vessels and capillaries in 
both FBD and FDD (figure 6.4H and 6.5H). Furthermore various degree of staining of 
the  ABri  amyloid  plaques  was  seen  in  FBD  (figure  6.3H)  while  the  parenchymal 
‘diffuse lesions’ remained unstained in both FBD and FDD.
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6.3.6  Complement inhibitors in AD, FBD and FDD lesions
An  antibody  recognizing  the  complement  inhibitor  ApoJ  strongly  labelled  all 
amyloid-laden lesions in FBD, FDD, AD and vAD cases. In general, the staining pattern 
seen  in  ApoJ  immunohistochemistry  was  similar  to  that  seen  with  the  amyloid 
antibodies used in each case (see section 5.3.3 for detailed results).
Vn strongly labelled ABri or ADan lesions with amyloid conformation; parenchymal 
amyloid plaques and  CAA in FBD (figure 6.3J and 6.4J),  and mostly  amyloid-laden 
blood  vessels  in  FDD  (figure  6.5J)  and  the  preamyloid  lesions  showed  a  weaker 
reaction for this antigen.
In the  AD  cases  studied the Vn  immunoreactivity followed  a pattern similar to that 
observed with ApoJ, although in general, the diffuse lesions showed a weaker reaction 
for this antigen than they did for ApoJ (figure 6.61, 6.6R, 6.7J).
6.3.7  Labelling of neurons by complement and complement inhibitor antibodies
in FBD and FDD
In AD anti-Clq labelled NFTs were found in the hippocampus, entorhinal cortex and 
frontal cortex (figure 6.8G). Positive staining was also found in neurons unaffected by 
NFTs  (figure  6.8M).  The  presence  of  C3d  (figure  6.8H)  and  C4d  (figure  6.81) 
immunoreactivity was also noted, but the number of labelled NFTs was fewer than that 
seen with Clq. IC3b immunoreactivity was found in NFTs throughout the hippocampus 
(figure  6.8J).  ApoJ  and  Vn  positivity  was  found  in  both  NFTs  and  ghost  tangles. 
However the anti-ApoJ antibody stained more NFTs than Vn did and also labelled NTs 
(figure 6.8L).
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Figure 6.6: Deposition of complement components in AD. Complement activation in 
AD, both amyloid plaques (A-I) and amyloid-laden vessels (J-R) are strongly labelled 
with Clq (C and L); C3d (D and M); C4d (E and N); Sc5b-9 (F and O); Bb (G and P). 
The expression of the two complement inhibitors ApoJ (H and Q) and Vn (I and R) 
were also positive. Panels A and J show Ap positive amyloid plaque and blood vessel 
with amyloid deposition, panels B and K show the Ap in the amyloid conformation state 
with Congo red staining. Bar in A represents 45pm; in panels B,D,E,F,G,H,I,J,K,N,Q,R 
represents 45 pm;  in panels C,L,M and O represents  100pm and in panel P represents 
22pm.
In FBD the anti-Clq antibody labelled NFT-containing neurons and also ghost tangles 
in the CA1  subregion of the hippocampus and in large numbers in the entorhinal cortex 
where NFTs are present in the pre-a neurons and also in the deeper cortical laminae in 
this disease (figure 6.8A).
The tangles, some of the ghost tangle type, were also positively labelled with both C3d 
(figure 6.8B) and C4d (figure 6.8C) in the hippocampus and entorhinal cortex. In FDD 
the  anti-Clq  antibody  labelled  many  neurons  with  NFTs  or  ghost  tangles  in  the 
entorhinal  cortex  and  a  similar  staining  pattern  was  seen  on  C3d  and  C4d 
immunohistochemistry.  In both FBD and FDD NFTs and ghost tangles were positive 
for iC3b (figure 6.8D) in the hippocampus and entorhinal cortex, and for Sc5b-9 in FBD 
(figure 6.8E).
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Figure  6.7:  Deposition  of  complement  components  in  cotton  wool  variant  of 
familial AD. The pattern of complement deposition reflects the difference in amyloid 
load between vessels and plaques.  Ap immunolabelling was found in CAA (A, arrow) 
as well as the pre-amyloid ‘cotton wool’ plaques (A, double arrow), where as Congo red 
positivity  was  only  found  within  CAA  (arrow).  Strong  immunolabelling  was  found 
within all amyloid affected vessels (arrows) with all complement components including 
Clq (C); C3d (D); iC3b (E); C4d (F); Sc5b-9 (G), the ‘cotton wool’ plaques were only 
weakly  stained  (double  arrows).  The  anti-Bb  antibody,  representing  the  alternative 
pathway,  stained  the  amyloid-laden  blood  vessels  (arrow)  and  weakly  stained  the 
‘cotton wool’ plaques (H, double arrow). The complement inhibitors ApoJ (I) and Vn 
(J)  positivity was found within amyloid affected vessels (arrows) of all sizes, plus weak 
staining  found within the cotton wool plaques (double arrows).  Bar in panel  A,  G-J 
represents 100pm, on panels D and E 250pm and on panels B, C and F 55pm.
The  anti-Sc5b-9  antibody  stained  relatively  few  NFTs  in  FDD.  In  FBD  ApoJ 
immunoreactivity  was  observed  in  numerous  neurons,  many  of which  possessed  an 
NFT (figure 6.8F). While some neurons showed a granular staining pattern, the majority 
of the  labelled  neurons with an NFT  demonstrated a filamentous  staining pattern.  A 
strong labelling of a proportion of the neurons,  often with an NFT,  by the anti-ApoJ 
antibody was  also  observed  in FDD.  Vn immunoreactivity in FBD and FDD gave a 
staining  pattern  similar  to  that  seen  in  ApoJ  immunohistochemistry,  although  the 
number  of  labelled  neurons  appeared  smaller  than  that  seen  in  ApoJ 
immunohistochemistry.
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Figure  6.8:  Deposition  of complement  components  in 
neurons  in  FBD  and  AD.  Full  activation  of  the 
complement cascade was  demonstrated  in FBD  (A-F) and 
AD  (G-L).  Panels  A  and  G  show  Clq  immunolabelling; 
panels B  and H C3d; panels C and I C4d; panels D and J 
iC3b; panels E and K Sc5b-9 and panels F and L Apo J. All 
panels were taken with original objective x40.
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6.4  Discussion
In this  study  we  demonstrated that  in  the BRI2 gene-related  dementias  complement 
proteins and activation fragments of the classical pathway (Clq, C3d and C4d) as well 
as the terminal MAC are present in parenchymal lesions and CAA, which are composed 
of ABri in FBD and ADan in FDD. These findings indicate not only that the classical 
complement pathway is activated, but also that it proceeds to its terminal stages in these 
diseases.  Furthermore,  we  demonstrated  that  lesions,  which  are  predominantly 
composed of ABri or ADan amyloid protein species in (3-pleated sheet conformation, 
showed  a  stronger  reaction  for  the  complement  components  than  those,  which 
ultrastructurally  are  composed  of sparse  amyloid  fibrils  (pre-amyloid  lesions).  This 
latter correlation is well illustrated by our finding a difference in complement deposition 
between  the  parenchymal  lesions  of  FBD  and  FDD.  The  majority  of  the  ABri 
parenchymal deposits, which are mainly of amyloid nature (Chapter 3) were strongly 
labelled with all the anti-complement antibodies, including those recognizing MAC in 
FBD, while there was a weak or no reaction in the ADan parenchymal deposits, which 
are  predominantly  of the  ‘diffuse’  or  preamyloid  type  in  FDD  (Chapter  4).  These 
observations  provide  strong  evidence  that  in  both BRI2  gene-related  dementias  the 
overall patterns of complement deposition closely resemble those observed in AD,  in 
which a similar correlation between the conformational  state of Ap and the degree of 
complement deposition has been demonstrated (Berkenbosch et al., 1992; Eikelenboom 
&  Stam,  1982;  Ishii  &  Haga,  1984;  McGeer  et  al,  1989;  Rogers  et  al.,  1992b; 
Rozemuller et al.,  1992; Verbeek et al.,  1998; Webster et al,  1997) and supported by 
data of the current study of AD cases. Interestingly we consistently found a variable and 
often weak staining of the cotton wool plaques with all the anti-complement antibodies, 
including MAC, in the variant AD cases.  These latter findings suggest that weak, but
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full  activation  of the  complement  pathway  also  takes place  in  variant  AD.  We  also 
observed  that  immunolabelling  with  the  complement  antibodies,  similar  to  the 
parenchymal  ADan lesions,  shows a good correlation with the weak positivity of the 
cotton wool plaques for thioflavine-S and also the presence of sparse amyloid fibrils, 
which can be found with EM (data not shown).  These findings at first seem to be at 
variance with data of a previous  study,  which  suggested that only negligible plaque- 
related labelling for Clq, C3d and C9 is present in the cotton wool plaques (Crook et 
al.,  1998b).  It  is,  however,  possible  that  this  difference  in  the  observations  can  be 
explained  by  the  different  methodological  approaches  employed  in  the  two  studies. 
Twenty micrometer thick free floating paraffin sections were used for Clq and frozen 
tissue sections for downstream complement components in the current study, while 4pm 
paraffin  sections  were  used  in  the  above  cited  study.  This  latter  method  in  our 
experience  can  underestimate  the  level  of complement  deposition  in  Ap  and  other 
amyloid lesions (data not shown).
Extensive  investigations  have  been  undertaken  to  prove  that  the  presence  of 
complement proteins are harmful and that they are an important component of the AD 
pathogenesis.  Recent  studies,  however,  showed  that  increased  clearance  of Ap  can 
improve cognitive function in mouse models of AD (Janus et al., 2000; Morgan et al,
2000).  Clearance of Ap in these experiments was achieved by immunizing mice with 
synthetic  Ap,  which  can  prevent  or  reduce  AP  accumulation  (Schenk  et al.,  1999). 
However, a recent study provides evidence for a role of complement and innate immune 
responses in AD-like mice and supports the concept that certain inflammatory defense 
mechanisms in the brain may be beneficial in neurodegenerative diseases (Wyss-Coray 
et  al.,  2002).  This  study  demonstrated  that  expression  of  a  complement  inhibitor 
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in  mice  expressing  human  amyloid  precursor  protein  (hAPP),  whereas  increased 
complement C3 production was associated with reduced AP deposition in hAPP/ TGF- 
pi  transgenic  mice.  These  data  support  that  complement  activation  products  may 
protect  against  Ap-induced  toxicity  and  reduce  the  accumulation  or  promote  the 
clearance  of amyloid.  In  addition to  direct  neuroprotective  effects  (Fishelson et a l,
2001),  complement  may  stimulate clearance and reduce the  accumulation of Ap  and 
degenerating neurons via complement receptors on phagocytic microglia.
In vitro studies have shown that aggregated Ap peptides, especially Ap]_4 2 , are able to
directly activate the classical complement pathway by their binding to the recognition 
component Clq.  Several studies have shown that the Clq binding site of Ap is located
in the region of the N-terminal  1-11  amino acids and that residues Asp^ and/or Glu* *  
are  essential  in  this  process  (Velazquez  et  al,  1997;  Webster  et  al,  1997).  It  is 
noteworthy, however, that a synthetic peptide composed of the N-terminal  1-16 amino 
acids  of Apj_ 4 2  alone,  which  is  unable  to  form  amyloid  fibrils  due to  lack  of the
C-terminal  region,  is  not  sufficient  for  complement  activation.  This  observation 
provides experimental support to the hypothesis that formation of the fibrillar structure, 
leaving  the  essential  N-terminal  region  of Ap  to  adopt  the  necessary  conformation 
and/or to provide the appropriate charge pattern for an efficient recognition by Clq, is 
also an essential precondition of complement activation (Tacnet-Delorme et al, 2001). 
A  recent  biochemical  study  has  demonstrated  that  ABri  and  ADan,  which  form 
spontaneous p-pleated sheet rich structures and show very fast aggregation kinetics, are 
also  able  to  form  stable  complexes  with  Clq  and  can  fully  activate  the  classical 
complement  cascade in  vitro.  ABri  and  ADan  have  also  been  shown  to  be  able  to 
produce  complements  at  levels  that  are  comparable  to  those  produced  by  Apj_ 4 2
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(Rostagno  et  al.,  2002).  This  latter  study  has  demonstrated  that  the  complement- 
activating site of ABri and ADan is localized to the N-terminal region of these amyloid 
peptides.  However,  no information is available about the precise Clq binding sites of 
ABri  and  ADan  peptides  as  yet,  and to  answer these questions further experimental 
investigations would be required.  The current study has also demonstrated in vivo the 
presence  of  the  alternative  complement  pathway  activation  product  factor  Bb  in 
association with ABri, ADan and Ap amyloid lesions. Although previously no evidence 
was found for the occurrence of components of the alternative complement pathway in 
AD,  our in vivo  findings  are  supported by  data of recent  studies demonstrating that 
some activation or amplification of the alternative pathway does occur in AD (Bradt et 
al,  1998;  Strohmeyer  et  al,  2000c).  Furthermore  there  is  also  now  experimental 
evidence showing that the alternative pathway can be activated using synthetic ABri and 
ADan peptides (Rostagno et al., 2002).
The  current  investigations  also  demonstrated that  ApoJ  and  Vn  are  present  in  both 
amyloid and preamyloid ABri and ADan lesions.  The significance of these findings is 
that  both  ApoJ  and  Vn  are  inhibitors  of  the  complement  systems  and  the 
neuroprotective role attributed to ApoJ in AD may be due to this activity (Calero et al., 
2000).  Experimental data suggest that the complement inhibitor activity of both ApoJ 
and Vn is related to their ability to interact with the terminal complement components. 
ApoJ inhibits the complement cascades by binding to the C5b-7 complex inhibiting its 
insertion  into  the  cell  membrane,  hence  inhibiting  the  formation  of MAC  with  the 
addition of C8 and C9 (Tschopp et al,  1993).  This interaction between ApoJ and the 
terminal complement components makes the complex hydrophilic and lyrically inactive 
(Tschopp  et  al.,  1993).  Vn,  acting  at  the  stage  of C5b-9  and  neutralizing  the  lytic 
activity of the complex, also binds to C8 and C9. Although both ApoJ and Vn are able
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to interact with C9, the former binds to the C9b while the later to the C9a fragment, 
therefore  simultaneous  binding  is  possible.  This  could  more  efficiently  reduce  the 
impact  of  complement  attack  (Tschopp  et  al.,  1993).  ApoJ  not  only  acts  as  a 
complement inhibitor, but can also be classified as an AAP influencing aggregation and 
fibrillization of amyloidogenic proteins (Calero et al., 2000). ApoJ acting as an AAP is 
discussed in chapter 5.
In both FBD and FDD there was a significant reaction by HLA-DR-positive microglia 
and also astrocytes, which also occasionally expressed HLA-DR, in relation to the ABri 
and ADan parenchymal and vascular amyloid lesions. Such a reaction (see also chapters 
3  and 4) was sparse or absent in relation to preamyloid lesions.  Microglial cells and 
astrocytes are both known to produce inflammatory mediators, including complement 
proteins (McGeer & McGeer,  1995; McGeer & McGeer, 2001). Furthermore light and 
confocal  microscopy  data  of this  study  also  suggest  that  ABri  and  ADan  fibrillar 
deposits can be in close contact with microglial cells and/or astrocytes. The widespread 
expression  of MHC  class  II  antigens  by  microglia,  which  is  a  consistent  marker of 
activation (Tooyama et al., 1990), is consistent with a phagocytic role and suggests that 
microglia may contribute to the clearance of cerebral ABri and ADan deposits. This is 
comparable to AD, in which it had also been documented that activated microglia are in 
close contact with Ap plaques and also that they are able to internalize Ap (Stalder et 
al., 1999). In this regard complement activation may facilitate the phagocytosis of ABri 
and ADan amyloid fibrils in a manner similar to that suggested for Ap fibrils (Stalder et 
al.,  1999). In order to elucidate the biological functions of microglia and astrocytes in 
FBD and FDD, further experimental investigations are required.
The  importance  of inflammation in neurodegenerative processes  and,  in particular in 
AD has become clear over recent years. Dementia has been shown to correlate with the
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detection  of  inflammatory  markers,  activated  microglia,  reactive  astrocytes  and 
increased  levels  of cytokines and  complement  products around  amyloid plaques  and 
dystrophic neurites (Emmerling et al., 2000), with the use of anti-inflammatory drugs in 
epidemiological  studies  being  associated  with  a  reduced  risk  of AD  (Rogers  et al.,
1996).  These  findings  together  with  the  in  vitro  demonstration  that  complement 
activation can lead to cell death in both rat hippocampal and neuronal cell lines (Schultz 
et al.,  1994; Shen et al.,  1995), point to the importance of chronic inflammation in the 
pathogenesis of AD and other neurodegenerative diseases.
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Chapter 7
Biochemical and 
immunohistochemical analysis of  ABri 
in FBD andADan and Ap in FDD.
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Chapter 7-Hypothesis and specific questions
In  this  chapter,  I  wished  to  investigate  the  hypothesis  that  biochemical 
heterogeneity of ABri and ADan exists in different lesion types in FBD and FDD 
respectively.
As correlation exists between the N- and C- terminal heterogeneity of the Ap peptide 
species and different lesion types in AD, the question was addressed whether similar 
heterogeneity occurs in FBD and FDD. In this study, ABri and ADan species deposited 
in  blood  vessels  and  parenchymal  lesions  were  isolated  and  biochemically 
characterised.  In  addition,  the  heterogeneity  of the  Ap  species  co-deposited  in  the 
parenchyma and CAA in FDD was also studied by immunohistochemistry, utilising a 
panel of antibodies specific for N- and C-terminally modified Ap species.
7.1  Introduction
The Ap peptide is the major component found within senile plaques (Dickson,  1997) 
and CAA (Kalaria & Hedera, 1996) in AD. This 4kDa peptide produced by proteolytic 
cleavage  of  the  APP  by  p-secretase  (cleaving  at  the  N-terminus)  and  y-secretase 
(cleaving at the C-terminus) (Checler, 1995). The mechanism by which Ap is deposited 
in the CNS may be affected by several factors 1) N- and C-terminal modifications of the 
Ap peptide, 2) Mutations within the Ap region of the APP gene, 3) Mutations in PS1 
and PS2 genes, 4) Change in ratio between Apx-40/ APx-42, 5) Clearance of Ap from 
the CNS.
Biochemical and immunohistochemical analysis  of the Ap deposits demonstrated the 
presence of N- and C-terminally heterogeneous peptide species (Iwatsubo et al., 1994b; 
Saido et al., 1995; Saido et al., 1996), in addition to the full length Apl-42. In sporadic 
AD cases Apx-42 has been shown to be both the earliest and the most abundant peptide 
identified in plaques, whereas Apx-40 predominates in blood vessels (Iwatsubo et al., 
1994b; Iwatsubo et al.,  1995; Wisniewski et al.,  1994b). In vitro truncation of the C- 
terminus  reduces  the  aggregation properties  and toxicity of the peptide,  for example 
Api-40 is less toxic than Api-42 (Pike et al.,  1995).  Several isoforms of Ap42 have 
been found truncated at the N-terminus (Ap4-42, Ap8-42, Ap 12-42 and Ap 17-42) and 
such peptides aggregate more readily and are more toxic than the full-length Api-42
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(Pike et al.,  1995). Interestingly, N-terminally truncated isoforms of Apx-40 (Ap4-40, 
Ap8-40, Ap 12-40) have also been found to be more toxic than the full-length peptide 
(Apl-40)  (Pike  et al.,  1995).  Biochemical  in  vivo  studies  have  demonstrated the L- 
aspartates present at positions 1  and 7 of Ap, can be isomerized or stereoisomerized and 
the glutamates present at positions 3  and  11  can undergo intramolecular dehydration 
forming Ap species that begin with pyroglutamate (pE) (Mori et al., 1992; Russo et al.,
1997).  The  pyroglutamate  modifications  confer  enhanced  resistance  to  most 
aminopeptidases,  therefore  the  abundance  of Ap3(pE)-x  likely reflects  a decrease in 
clearance.  Ap in AD plaques has been shown to stain with antibodies specific for N- 
terminal Ap3(pE), and such species have been shown to be an important component of 
the total Ap load in AD, as assessed by immunoblotting (Saido et al.,  1995). The N- 
terminally  truncated  Ap  species  Apll-x  has  also  been  shown  to  be  generated  by 
transgenic rodent neurons supporting the notion that truncated species may play a role 
in AD pathogenesis (Gouras et a l,  1998). These observations raise the posibility that 
the  different Ap  species  may  interact differently with the  extracellular  environment, 
making Ap movement through the different local environments in the CNS an important 
determinant of cerebral amyloid pathology (Herzig et al., 2004).
The potential for aggregation and toxicity of Ap species found, can be influenced by 
mutations of the APP and PSJ genes. Missense mutations within or in close proximity 
of the Ap  coding region of the APP gene are associated with familial  forms of AD. 
Approximately  18 mutations of the APP gene have been reported,  five of which, the 
Dutch E693Q causing HCHWA-D (Levy et a l,  1990a), Flemish A692G (Hendriks et 
al.,  1992), Artie E693G (Nilsberth et al., 2001), Italian E693K (Miravalle et al., 2000) 
and  Iowa D694N (Van Nostrand et al., 2001)  are  located in the mid-part of the Ap 
sequence.  In HCHWA-D  (E693Q)  the  major pathological  findings  include  extensive 
CAA  in  the  leptomeningeal  small  arteries  and  cortical  arterioles,  but unlike  in AD, 
parenchymal  amyloid  deposition  is  minimal  and  NFTs  are  not  a  feature  (Maat- 
Schieman et al.,  1996). In HCHWA-D Ap40 predominates in the leptomeningeal and 
cortical blood vessel walls  with  limited labelling  in the parenchyma (Castano et al,
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1996). The Flemish mutation (A692G) affecting the amino acid immediately before that 
affected by  the  Dutch mutation,  also  has prominent CAA with predominantly Ap40 
deposits (Kumar-Singh et al., 2002).  APP mutations flanking the Ap region interfere 
with  the  normal  processing  of APP,  enhancing  the  formation  of P-amyloid peptides 
ending  at  residue  42  (Teller  et  al.,  1996;  Selkoe,  1998).  For  example  the  double 
Swedish mutation [KM670/671NL] affects the two residues located just before the N- 
terminus of Ap,  immediately preceding the  p-secretase cleavage site (Johnston et al., 
1994; Axelman et al.,  1994).  The pathological phenotype of the Swedish mutation is 
AD  with Ap plaques  as well as extensive NFT pathology (Bogdanovic et al., 2002). 
Mutations  occurring  around  the  y-secretase  cleavage  site,  including  the  London 
mutation (V717I) and the Florida mutation (1716V)  enhance the production of Ap42 
(Hardy,  1997;  Selkoe, 2001).  The phenotypes of these mutations are that of classical 
AD including extensive NFT pathology.
Mutations,  including point mutations and deletions,  found in the PS1  gene have also 
been  shown  to  increase  the  brain  burden  Apx-42,  but  not  Apx-40  resulting  in 
parenchymal amyloid deposition (Citron et al., 1997; Duff et al., 1996). Deletions in the 
PS1  gene  may  show  a  unique  morphological  phenotype  with  large  ‘cotton  wool’ 
plaques unlike those observed in AD (Mann et al., 2001b; Houlden et al., 2000; Crook 
etal., 1998)
The  ratio  of  Apx-40/Apx-42  may  be  a  critical  factor  in  the  pathogenesis  and  a 
determinant of the morphological phenotype. Studies with transfected cell cultures have 
shown that cells expressing the double Swedish mutation release approximately 7 times 
more  Ap  than  their  wild  type  counterparts  (Johnston  et  al.,  1994).  This  mutation 
increases the total amount of Ap, leaving the ratio between Apx40/Apx-42 unchanged. 
Whereas  in  HCHWA-D  individuals  enhanced  deposition  of Apx-40  shifts  the  ratio
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towards  Apx-40  and towards  a more vascular pathology (Ozawa et al., 2002). In an 
effort to understand the mechanism of Ap deposition, transgenic mouse models have 
been constructed that express the genes implicated in AD: mutant APP, PS1 and ApoE, 
tau as well as wildtype APP.  Recent work has yielded many lines of transgenic mice 
that show Ap deposition and cognitive impairment (Janus et al., 2000). The effect of the 
overall  ratio  between  Apx40/Apx-42  has  been  examined  in  transgenic  mice.  For 
example in the APPDutch mice the vast majority of Ap is Apx-40 with approximately 
12  times  more  ApDutch40  than  ApDutch42  (Herzig  et al.,  2004).  Furthermore,  the 
double APPDutch-PS45 mice, produced by crossbreeding the APPDutch mice with the 
PS45  mice  overexpressing  mutant  PS1  (G384A),  resulted  in  increased  Apx-42 
production with the development of parenchymal amyloid lesions (plaques) composed 
of ApDutch42  rather  than  vascular pathology  (Herzig  et al.,  2004).  Thus,  although 
ApDutch  preferentially  accumulates  Ap  in  and  around  cerebral  blood  vessels,  by 
genetically shifting the ApDutch40/ApDutch42 ratio to favour ApDutch42 is sufficient 
to alter the distribution of the resulting amyloid pathology from the vasculature to the 
parenchyma (Herzig et al, 2004).
The accumulation of Ap in the brain is determined not only by the rate of Ap generation 
but also by its clearance. Evidence suggests that both the LRP and RAGE receptors are 
involved  in  receptor  mediated  bidirectional  flux  of Ap  across  the  BBB  (Zlokovic, 
2004).  While LRP appears to mediate Ap movement from brain to periphery, RAGE 
has been strongly implicated in the influx of Ap into the CNS. In addition, evidence 
exists to suggest that  10%-15% Ap can enter into the CSF from the brain and onward 
into the blood stream (Shibata et al., 2000). LRP, located at the BBB, has been shown to 
favour  the  clearance  of Ap40  over  the  more  amyloidogenic  species  Ap42  and  the
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mutant form of Ap containing two APP gene mutations (Dutch and Iowa) (Deane et al., 
2004). These data suggest that the mutations not only render Ap more prone to amyloid 
formation, but may also impede efflux out of the brain via the LRP receptor (Deane et 
al., 2004). Different proteases (neprilysin, endothelin-converting enzyme, angiotensin- 
converting  enzyme,  plasmin  and insulin degrading  enzyme)  have been implicated in 
proteolysis-related clearance of Ap from the CNS (Carson & Turner, 2002; Morelli et 
al, 2003; Morelli et al, 2002; Farris et al, 2004). Clearance experiments in rats showed 
that after infusion of radiolabelled Ap  peptides  into the  lateral ventricle, 40% of the 
injected radioactivity was present in the blood and urine and taken up by the liver and 
kidneys, indicating a clearance mechanism and involvement of systemic organs in the 
catabolism of Ap (Ghersi-Egea et al, 1996).
FBD  has  been  previously  shown  to  be  pathologically  characterised  by  CAA  and 
amyloid plaques, which are composed of ABri (Holton et al, 2001; Vidal et al, 1999). 
ABri is a 4kDa peptide cleaved by a furin-like proteolysis from the C-terminus of the 
mutated  precursor  protein  ABriPP  (Vidal  et  al,  1999).  ABri  isolated  from 
leptomeningeal  fibrillar deposits  shows  a high  degree  of polymerization  and  a post- 
translationally modified N-terminus (pyroglutamate) at position  1   (Vidal et al,  1999). 
In contrast,  soluble ABri from sera of FBD patients consistently revealed monomeric 
forms  of ABri  with  no  obvious  N-or  C-terminal  heterogeneity  (Ghiso  et al,  2001). 
However,  little  is known about the heterogeneity of the  amyloidogenic peptide ABri 
composing the different CNS lesions and whether these ABri species differ when they 
deposit in in the parenchyma or blood vessels. FDD is pathologically similar to FBD, 
but both the vascular and parenchymal deposits are composed of ADan (see chapter 4; 
(Holton et al, 2002; Vidal et al, 2000b). The first 22 residues of ADan and ABri are 
identical  and  biochemically  ADan  has  also  been  demonstrated to  possess  N-teminal
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modifications  described  in relation to  ABri  with pyroglutamates  found  at position  1  
(Vidal et al., 2000b). An interesting finding of all FDD cases, so far examined, is the 
presence of widespread co-deposition of Ap.
As a correlation exists between the N- and C- terminal heterogeneity of the Ap peptide 
species  and different lesion types  in AD, the question addressed here was whether a 
similar heterogeneity  of ABri,  ADan  and  Ap  occurs  in  FBD  and  FDD  respectively. 
To  address  this  question  ABri  and  ADan  species  deposited  in  blood  vessels  and 
parenchymal  lesions were isolated and biochemically characterised in FBD and FDD 
respectively, along with the co-depositing Ap in FDD. Several regions were taken from 
frozen material for the  study,  including the hippocampus,  entorhinal cortex, occipital 
cortex and thalamus. The extraction strategy took advantage of the differential solubility 
properties  of soluble  peptides  (soluble  in  PBS),  pre-amyloid  (insoluble  in  PBS  but 
soluble  in  SDS)  and the amyloid fractions  (insoluble in PBS  or SDS, but soluble in 
formic  acid).  From each extraction step several techniques were undertaken to reveal 
the amyloid species contained in the tissue, including mass spectrometry and western 
blot analysis. The availability of a panel of antibodies specific for N- and C-terminally 
modified Ap species made it possible to study the heterogeneity of the Ap species co­
deposited  in the parenchyma and CAA  in FDD and AD using immunohistochemical 
techniques.  The  immunohistochemical  investigation  was  used  to  confirm  mass 
spectrometry results  or add  additional  information about the heterogeneity of the Ap 
species present in FDD and AD.
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7.2  Material and methods
7.2.1  Tissue
Brain from two FBD cases (1&2), one FDD case (3), two sporadic AD cases (6&7), two 
familial AD cases, which included one case with variant AD with cotton wool plaques 
due to PS1 AI83/AM84 mutation (4) (Houlden et al., 2000b; Steiner et al., 2001), a case 
caused by PS1  M233V mutation (5) and two  age-matched controls were collected at 
post  mortem  (8&9)  (table  24).  The  pathological  diagnosis  of AD  was  made  using 
standard criteria (Mirra et al.,  1991).
Case Case number Age Sex Cause of death Diagnosis
1 PM 91-99 68 F Bronchopneumonia FBD
2 PM 3319 65 F Bronchopneumonia FBD
3 PM 37-99 43 M Bronchopneumonia FDD
4 PM 100-95 46 F Bronchopneumonia FAD
5 PM132-99 N/A N/A N/A FAD
6 A96/95 86 M Bronchopneumonia AD
7 A104/95 81 M N/A AD
8 C8-99 79 M Ca. prostate Control
9 C4-99 91 M Bronchopneumonia Control
Table 24: Cases used in biochemical analysis of  amyloid and  preamyloid species.
From case  1   frontal, occipital, cerebellum including the dentate nucleus were dissected 
and  used  for  biochemical  analysis;  from  case  2  occipital  and  parietal  lobes  were 
available for use;  from case 3  frontal,  posterior frontal, temporal, thalamus,  occipital, 
dura vessels, hippocampus, entorhinal cortex and leptomeninges were used; from cases 
4, 6, 8 and 9 frontal cortex was used; from case 5 occipital cortex was used; from case 7 
the hippocampus was used.
7.2.2  Protein extraction
Crude protein extraction was undertaken as described in section 2.9.1. From these crude 
extracts the protein was further purified as described in section 2.9.2.
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7.2.2.1  Mass spectrometry
All  cases  and  all  samples  of protein  extract  were  subjected  to  mass  spectrometry 
analysis as described in section 2.10.
7.2.2.2  Immunoblotting
Aliquots  from  the  samples  extracted  were  subjected  to  western  blot  analysis  using 
antibodies specific to ABri, ADan and Ap as described in section 2.12. Antibodies used 
for western blot analyses are listed in table 25.
Antibody Source Species Dilution
A3 1-17 Biosource Monoclonal 1:4000
A3 17-26 Biosource Monoclonal 1:4000
Ab338 Gift Dr J Ghiso Polyclonal 1:3000
Ab5282 Gift Dr J Ghiso Polyclonal 1:3000
Table 25: Antibodies used  for western blot analysis of  non-fibriallar andfibrillar ADan, 
ABri and Aft species in FDD, FBD and AD.
7.2.2.3  Immunoprecipitation
Samples from the FDD case (case 3) underwent immuoprecipitation to extract only the 
ADan or Ap species from the samples before analysis with MS. Experimental 
procedures are described in section 2.12.
7.2.3  Immunohistochemistry
7.2.3.1  Tissue
Brain from three cases of FDD (1-3),  six sporadic AD cases (7-12) and three familial 
AD cases (4-6) were collected at post mortem (table 26). The pathological diagnosis of 
AD was  made using  standard  criteria (Mirra et al.,  1991).  For immunohistochemical 
analysis the hippocampus, frontal cortex and cerebellum were used from cases 1-4 and
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7-12. From case 6 only hippocampus and frontal cortex were available and from case 5 
only frontal cortex was available for immunohistochemical analysis.
Case Case number Age Sex Cause of death Diagnosis
1 PM37-99 43 M Bronchopneumonia FDD
2 PM38-99 60 F Bronchopneumonia FDD
3 PM39-99 58 M Not recorded FDD
4 PM 100-95 46 F Bronchopneumonia FAD
5 PM8-00 N/A N/A N/A FAD
6 PM 3385 35 F FAD FAD
7 PM69-99 92 F Pneumonia AD
8 PM32-97 91 F Pneumonia AD
9 PM93-99 76 F AD AD
10 PM73-98 86 M Bronchopneumonia AD
11 PM25-98 69 F Acute tracheobronchitis AD
12 PM83-98 84 F Dementia AD
Table  26:  FDD,  familial  AD  and  sporadic  AD  cases  used  in  N-terminal  Ap 
immunohistochmeical study.
1.2.3.2  Antibodies
Immunohistochemical  analysis  was  carried  out  at  light  microscopy  level  using  the 
standard protocol (section 2.2) and the antibodies listed in table 27.
Antibody Source Species Pretreatment Dilution
A3 1-17 Biosource Monoclonal FA + PC 1 4000
A3 17-26 Biosource Monoclonal FA + PC 14000
A3 8-15 Dako Monoclonal FA + PC 1 100
A3 x-40 Biosource Polyclonal FA + PC 1 100
A3 x-42 Biosource Polyclonal FA + PC 1 100
A3 l(rD) Gift from Dr T Saido Polyclonal FA + PC 1 1000
A3 1(D) Gift from Dr T Saido Polyclonal FA + PC 1 500
A3 3(pE) Gift from Dr T Saido Polyclonal FA + PC 1 100
A3 ll(pE) Gift from Dr T Saido Polyclonal FA + PC 1 1000
Table 27: Antibodies used  for N-terminal immunohistochemical Ap study in FDD and 
AD. FA; Formic Acid, PC; Pressure Cook.
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13  Results
7.3.1  Biochemical analysis
7.3.1.1  Direct western blot analysis of FBD
Western blot  analysis was  carried  out on the PBS-soluble;  SDS-soluble;  formic acid 
fractions for ABri using the anti-Ab338 antibody. A summary of the results are shown 
in table 28, showing the monomeric, dimeric and trimeric ABri species present in each 
analysed fraction.
Case Region Subregion
PBS-soluble
fraction
SDS-soluble
fraction
Formic acid 
fraction
ABri ABri ABri
M D T M D T M D T
1 Frontal cortex Gray matter + + + + + - + + +
1 Frontal cortex White matter + + + + + - + + -
1 Frontal cortex Blood vessels + + - + + + + + +
1 Occipital cortex Gray matter + + + + - - + + +
1 Occipital cortex White matter + + + + - - + - -
1 Occipital cortex Blood vessels + + - + + - + + +
1 Cerebellum Blood vessels + + - + + + + + +
1 Cerebellum - + + - + - - + - -
1 Cerebellum Dentate nucleus - - - + - - + + -
2 Occipital cortex Gray matter + - - + + - + + -
2 Occipital cortex White matter + - - + + - + + -
2 Occipital cortex Blood vessels + - - + + - + + +
2 Parietal cortex Gray matter + + - + + - + + -
2 Parietal cortex White matter + + - + + - + + -
2 Parietal cortex Blood vessels + + - + + - + + +
Table  28:  Direct  western  blot  analysis  o f non-fibrillar  and fibrillar ABri  species  in 
FBD. Identified in PBS-soluble, SDS-soluble andformic acidfractions from case 1 and 
case 2 showing monomeric (M), dimeric (D) and trimeric (T) species present.
Samples from case  1   are shown in figure 7.1  with bands clearly visible that represent 
the monomeric (3.4 kDa), dimeric (6.8 kDa) and trimeric (10.2 kDa) forms of ABri. The 
monomeric form of ABri was present in all PBS-soluble fractions obtained apart from 
the dentate nucleus. In case 2 the monomeric form was found in all areas investigated 
(table 28).
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The dimeric form of ABri was present in the PBS-soluble fractions of all FBD tissue 
apart from the occipital cortex from case 2.  The trimeric form was only present in the 
PBS-soluble fraction in the white and gray matter of the frontal and occipital cortices 
from  case  1   (figure 7.1).  The blood vessels extracted from the  same regions did not 
show any ABri trimers.
The fraction collected after re-suspension in SDS was investigated for the presence of 
pre-amyloid/SDS-soluble peptides. All samples studied had visible monomeric bands in 
the pre-amyloid (SDS-soluble fraction). As summarised in table 28 and shown in figure
7.1  for case  1. Dimeric species were found in the frontal (gray and white matter, and 
blood vessels) cortex of case 1  (figure 7.1) and occipital and parietal cortices from case 
2 (table 28), along with the blood vessels found in the cerebellum. Trimers were found 
in the blood vessels extracted from the frontal and occipital cortices from case 1  (figure 
7. IB lanes 6&7), but not the parenchyma.
The  amyloid  fraction,  the  fraction  remaining  after  extraction  by  PBS  and  SDS  and 
treated with formic acid, showed a greater amount of ABri than the previous fractions. 
Especially in the blood vessels extracted from all regions from case 1  (figure 7.1C lanes 
5-7) and the blood vessels from the occipital and parietal cortices from case 2 (table 28). 
A similar pattern was observed in the parenchymal extracts with the white matter from 
all the cortices only producing a monomeric band (figure 7.1C lanes 2&4), while in the 
gray matter monomeric,  dimeric and trimeric bands were observed (figure 7.1C lanes 
1&3).
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Figure  7.1:  Direct  western  blot  analysis  of ABri  in  FBD  (Case  1).  Western blot 
analysis  of  PBS-soluble,  SDS-soluble  and  formic  acid  extracted  fractions  from 
different  regions  of FBD  (case  1),  showing  monomeric  (Mo),  dimeric  (Di)  and 
trimeric (Tri) ABri species. In the PBS-soluble fraction the majority of ABri species 
present was monomeric in all samples with a faint  band shown in the dimeric region. 
In the SDS-soluble fraction stronger bands were seen in the monomeric bands, along 
with stronger bands in the dimeric region in the frontal and cerebellum blood vessels. 
In the formic acid  fraction monomeric bands were visible  in all regions and strong 
dimeric bands were seen in all blood vessel samples and gray matter samples, whereas 
white matter samples did not appear to contain any dimeric species. Lane  1  frontal 
(gray  matter),  lane  2  frontal  (white  matter),  lane  3  occipital  (gray  matter),  lane  4 
occipital (white matter), lane 5 occipital (blood vessels), lane 6 frontal (blood vessels), 
lane 7 cerebellum blood vessels, lane 8 cerebellum, lane 9 dentate nucleus (M-marker 
and C- synthetic control).
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7.3.1.2  Direct mass spectrometry analysis of FBD extracts
Although western blot analysis showed (figure 7.1) that ABri species were present in all 
fractions Matrix-assisted laser desorption ionisation-time-of-flight MS (MALDI-TOF) 
analysis of the  purified samples  from the PBS-soluble,  SDS-soluble and formic acid 
fractions  indicated  the  presence  of various  ABri  species  only  in  the  formic  acid 
fractions.  Figure  7.2  shows representative MS  results  obtained from the  formic  acid 
fraction from the frontal cortex obtained from case  1.  The peaks shown in figure 7.2 
correspond to monomeric species of ABri in either full length, truncated or modified 
peptides. The ABri species that correspond to the major peaks shown on figure 7.2 are 
shown in table 29, showing the expected mass of the ABri species against the observed 
mass obtained experimentally.
Region ABri
Sequence Expected mass 
[M+H]
Observed mass 
[M+H]
Frontal gray matter 3-34 3754.3 3753.8
l-34pE 3936.5 3936.6
l-34pE* 3964.5 3962.0
1-34* 3982.5 3986.9
l-34pE** 3992.5 3988.5
Frontal white matter 3-34 3754.3 3753.8
l-34pE 3937.5 3936.6
l-34pE* 3964.5 3964.6
1-34* 3983.5 3986.9
Frontal blood vessels 3-34 3754.3 3753.8
3-34* 3782.3 3782.4
3-34** 3810.3 3810.8
l-34pE 3936.5 3936.8
l-34pE* 3964.5 3964.6
l-34pE** 3992.5 3992.6
Table 29: Direct mass spectrometry analysis o f  fibrillar ABri.  Theoretical average and 
observed ABri  molecular  masses  bearing  a  single  disulphide-bond between  cysteine 
residues 5 and 22, are shown in the table from the frontal gray matter, white matter and 
extracted blood vessels  (case  1).  Formylated species are  indicated by  * and species 
containing a pyroglutamate are indicated with pE. M+H; protonated molecular ions.
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Figure  7.2:  Direct  mass  spectrometry  analysis  of  fibrillar 
ABri. For MALDI-TOF analysis, ABri molecules were desalted 
by  ZipTip  micro-reverse phase  column,  eluted with  90%  (v/v) 
acetonitrile-0.1% trifluroacetic acid in water, as described in the 
material and methods. Panel A: Frontal gray matter FA-extracts 
from microvessel-depleted cortex after PBS and SDS extractions. 
Panel B: Frontal white matter FA extracts and Panel C:  Blood 
vessel  extracts  from  frontal  cortex  in FA-isolated vessels  after 
PBS  and  SDS  extractions.  See  table  29  for  detailed  listing  of 
ABri  species  present,  m/z;  used  to  denote  the  dimensionless 
quantity  formed by  dividing the mass number of an ion by  its 
charge number [mass to charge ratio].
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7.3.1.3  Analysis of non-fibrillar ABri species in FBD extracts after
immunoprecipitation.
Although ABri species were seen on the western blot anaylsis from the PBS and SDS 
extraction without immunoprecipitation no species were found when MS analysis was 
undertaken. Therefore the additional immunoprecipitation step was introduced to obtain 
a concentrated ABri sample for MS analysis.
Western blot analysis was carried out on the FBD samples after immunoprecipitation, 
although  the  blots  obtained  without  immunoprecipitation  showed  the  presence  of 
monomeric and multimeric species (figure 7.1). Western blots were repeated to confirm 
their  presence  after the  immunoprecipitation  step  (figure  7.3).  The  PBS-soluble  and 
SDS-soluble fractions clearly showed the monomer, dimeric and trimeric ABri species 
(figure 7.3).
MALDI-TOF MS analysis was carried out after immunoprecipitation. The PBS-soluble 
fractions  were  composed  of a mixture  of two  ABri  full  length  species  (ABri  1-34) 
differing in 18 mass units, a difference equivalent to the mass of one molecule of water, 
corresponding to a pyroglutamate N-terminal modification. The SDS-extracted fractions 
contained the  same two ABri  species when  analysed with MS to those  found in the 
PBS-soluble fractions. The experimental masses found for ABri  1-34 and ABri  l-34pE 
were in good agreement with the expected masses of the post-translationally modified 
species, with a single disulphide bond between cysteine residues 5  and 22  (table 30, 
figure 7.3).
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Figure  7.3:  Western  blot  and  MALDI-TOF  MS  analysis  of 
PBS-soluble  and  SDS-extracted  fraction  from  FBD  after 
immunoprecipitation.  ABri  species  were  immunoprecipitated 
with Dynabeads coated with Ab338. Bound peptides were eluted 
and analysed either by western blot using Ab338 or by MALDI- 
TOF  MS.  Theoretical  average  masses  and  experimental  ABri 
molecular  masses  are  shown  in  table  30.  Mo,  monomers;  Di, 
dimers; Tri, trimers.
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ABri Species Observed Mass [M+H] Expected mass [M+H]
PBS SDS
l-34pE 3935.6 3936.5 3936.5
1-34 3951.5 3953.8 3954.5
Table  30:  Mass  spectrometry  analysis  o f  non-fibrillar  ABri  deposits  after 
immunoprecipitation.  ABri  molecules  were  immunoprecipitated  using  Dynabeads 
coated with Ab338 and subsequently eluted in  Tris-Tricine sample buffer. MS analysis 
via  MALDI-TOF  revealed  full-length  ABri  (1-34)  and  full-length  ABri  with 
pyroglutamate  (pE)  modification  in  both  PBS  and  SDS  soluble  fractions.  M+H; 
protonated molecular ions.
7.3.1.4  Direct western blot analysis of FDD
Samples  were  analysed  from  the  PBS-soluble,  SDS-soluble/pre-amyloid  and  formic 
acid/ amyloid fractions. Western blots were run for each fraction and blotted using both 
Ab5282 to recognise ADan peptides and a cocktail of Ab4G8 and Ab6E10 antibodies to 
recognise Ap peptide species. A summary of the findings from all regions are shown in 
table 31.
Blood vessels extracted from the leptomeninges showed a monomeric band (-3.4 kDa) 
corresponding to ADan in the PBS-soluble fraction, but no band corresponding to Ap 
was present (figure 7.4, lane 3). No other bands in any other region studied showed any 
positivity  in  the  PBS-soluble  fractions  for either  ADan  or Ap  (table 31).  The  SDS- 
soluble fractions analysed yielded a monomeric and dimeric forms of ADan from the 
blood vessels extracted from the leptomeninges, but no Ap was found (figure 7.4, lane 
3).
All  formic  acid  fractions  from all  regions  studied  (table 31)  showed the  monomeric 
form  of ADan,  although  the  intensity  of the  staining  varied  between  samples.  For 
example, the amount of monomeric ADan seen in the thalamus (figure 7.5, lane 15) was 
substantially less than that observed in the blood vessels separated from the temporal 
lobe (figure 7.5, lane 25). All samples showed a dimeric form of ADan, apart from the
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thalamus, third temporal gyrus gray matter (figure 7.5, lane  11) and entorhinal cortex 
(figure  7.4,  lane  2).  The  trimeric  form  of ADan was  found  in  a  limited  number of 
samples where the amount of ADan was greatly increased.  These included the blood 
vessels  extracted  from the  leptomeninges,  blood vessels  that  underwent  only  formic 
acid  extraction  (those  blood  vessels  not  previously  undergone  PBS  and  SDS 
extractions),  first  temporal  gyrus  gray  matter  and  blood  vessels  extracted  from  this 
region.
Region
PBS-soluble fraction
ADan
M   D M   D
M
SDS-soluble fraction
ADan
M   D M   D
M
Formic acid fraction
ADan
M D M M
D
P osterior fron tal  g ra y  m atter + + + +
P osterior fron tal w h ite  m atter + +
P osterior fron tal b lo o d  v e s se ls + +
S eco n d  fron tal  g y ru s gray m atter + + +
S eco n d  fron tal  g y ru s w h ite  m atter + +
S eco n d  fron tal g y m s  b lo o d  v e s se ls + + +
T hird tem p oral g y r o s g ra y  m atter + + +
T hird tem p oral  g y r o s w h ite  m atter + +
T hird tem p oral  g y ru s b lo o d  v e s se ls +
S eco n d  tem p o ra l  g y r o s g ra y  m atter
S eco n d   tem p o ra l  g y r o s  w h ite 
m atter
+ + + +
S eco n d   tem p o ra l  g y r o s  b lo o d  
v e sse ls
+ +
O ccip ital  g ra y  m atter +
O ccip ital w h ite  m atter
O ccip ital b lo o d  v e s se ls +
First tem p oral  g y r o s g ra y  m atter + + +
First tem p oral g y ru s w h ite  m atter + +
First tem p oral  g y ru s b lo o d  v e sse ls + + + +
T h alam us +
T h alam us b lo o d  v e s se ls
D ura b lo o d  v e s se ls + + + + + + + +
H ip p ocam p u s + +
E ntorhinal +
L ep to m en in g es b lo o d  v e s se ls + + + + +
Table  31:  Direct  western  blot  analysis  o f non-fibrillar  and fibrillar ADan  and Ap 
species in FDD.  Identified in PBS-soluble,  SDS-soluble and  formic acid  fractions from 
case 3, showing monomeric (M), dimeric (D) and trimeric (T) species.
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Figure  7.4:  Direct  western  blot  analysis  of  ADan  and  Ap  from  hippocampus, 
entorhinal  cortex  and  leptomeningeal  blood  vessels.  Western  blot  analysis  ADan 
(detected  with  Ab5282)  and  Ap  (detected  with  Ab4G8  and  Ab6E10)  from  the  PBS- 
soluble,  SDS-soluble  and  formic  acid  extracted  fractions  from  hippocampus  (lane  1), 
entorhinal cortex (lane 2) and blood vessels extracted from the leptomeninges (lane 3) of 
FDD,  showing monomeric  (Mo)  and  dimeric  (Di) ADan  and Ap  species.  Monomeric 
ADan  species  were  found  in  the  leptomeningeal  blood  vessels  in  the  PBS-soluble 
fraction,  whereas  monomeric  and  dimeric  species were  found  in the SDS-soluble  and 
formic  acid  fraction.  With  a  greater  amount  found  in  the  formic  acid  fraction.  The 
hippocampal  sample  showed  only  monomeric  and  dimeric  species  in the  formic  acid 
insoluble fraction, whereas only a monomeric band was found from the entorhinal cortex 
sample. Ap monomeric and dimeric species were only found in the formic acid insoluble 
fraction in the hippocampal and leptomeningeal blood vessels. The absence of ADan and 
Ap  from  the  PBS  and  SDS  fractions  were  the  main  reason  for  introducing  the 
immunoprecipitation step necessary to visualize soluble ADan and Ap. (M-marker and C- 
synthetic control).
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Figure 7 .5 : A regional western blot analysis of ADan from formic acid insoluble 
fraction: Western blot analysis of ADan from the formic acid insoluble fraction from 
FDD (case 3). Each lane representing a different anatomical region and subregion e.g 
white matter, gray matter or blood vessels. The majority of the regions contained both 
monomeric  and  dimeric  species  with  the  blood  vessel  samples  from  the  different 
regions  showing  a  higher  concentration  of  the  two  ADan  species.  The  regions 
investigated are as follows lane 1  third temporal gyrus (blood vessels), lane 2  second 
temporal  gyrus (gray matter),  lane 3  second temporal  gyrus  (white matter),  lane  4 
second temporal gyrus (blood vessels), lane 5 posterior frontal (blood vessels), lane 6 
posterior frontal (gray matter), lane 7 posterior frontal (white matter), lane 8  second 
frontal gyrus (gray matter), lane 9  second frontal gyrus (white matter), lane 10 second 
frontal gyrus (blood vessels), lane 11 third temporal gyrus (gray matter), lane 12 third 
temporal  gyrus  (white  matter),  lane  13  dura blood  vessels,  lane  14 thalamus  blood 
vessels, lane 15 thalamus, lane 16 occipital (gray matter), lane 17 first temporal gyrus 
(white matter), lane 18  formic acid vessels, lane 19  thalamus, lane 20  occipital (white 
matter), lane 21  occipital (gray matter), lane 22  occipital (blood vessels), lane 23  first 
temporal gyms (white matter), lane 24  first temporal gyrus (gray matter), lane 25 first 
temporal gyrus (blood vessels), C  control, M marker.
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Figure 7.6: A regional western blot analysis of AP from formic acid insoluble 
fraction: Western blot analysis of Ap (detected using Ab4G8 and Ab6E10) from 
the formic acid insoluble fraction from FDD (case 3). Each  lane representing a 
different anatomical region and subregion e.g white matter, gray matter or blood 
vessels.  Monomeric  (Mo)  and  dimeric  (Di)  species  were  found  within  the 
temporal  and  frontal regions and  dura vessels.  The  regions  investigated  are  as 
follows  lane  1  third  temporal  gyrus  (blood vessels),  lane  2  second temporal 
gyrus (gray matter), lane 3  second temporal gyrus (white matter), lane 4  second 
temporal  gyrus  (blood vessels),  lane  5  posterior frontal  (blood  vessels),  lane  6 
posterior  frontal  (gray  matter),  lane  7  posterior  frontal  (white  matter),  lane  8 
second frontal gyrus (gray matter),  lane 9  second frontal gyrus (white matter), 
lane  10 second frontal gyrus (blood vessels), lane 11 third temporal gyrus (gray 
matter), lane 12 third temporal gyrus (white matter), lane 13 dura blood vessels, 
lane 14 thalamus blood vessels, lane 15 thalamus, lane 16 occipital (gray matter), 
lane 17 first temporal gyrus (white matter), lane 18  formic acid vessels, lane 19 
thalamus, lane 20  occipital (white matter), lane 21  occipital (gray matter), lane 
22  occipital (blood vessels), lane 23  first temporal gyrus (white matter), lane 24 
first temporal gyrus (gray matter), lane 25 first temporal gyrus (blood vessels), C 
control, M marker.
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The  formic  acid  fractions were  also  investigated using two  Ap  antibodies combined 
together (Api-16 and Ap 17-26), in order to ensure that all Ap species were detected, 
including any N-terminally truncated species. Samples that did not contain any Ap were 
the  second  temporal  gyrus  gray  matter,  blood  vessels  extracted  from  the  thalamus, 
thalamus and the occipital white and gray matter and blood vessels (figure 7.6). Most of 
the  samples that  were  positive  for Ap  showed both monomeric and dimeric  species 
(table 31), although the third temporal gyrus gray matter and first temporal gyrus white 
matter showed only the dimeric species and not the monomeric species (figure 7.6).
7.3.1.5  Direct mass spectrometry analysis of FDD extracts
Western blot analysis of the parenchymal samples and cerebral blood vessels showed 
that  ADan  species  were  present  in  PBS-soluble,  SDS-soluble  and  formic  acid 
sequentially extracted fractions. As, expected the majority of ADan was recovered from 
the amyloid extracts and it was not possible to evaluate the direct MS results for the 
PBS and SDS samples as no peaks corresponded to any ADan species.
Analysis of the formic acid fractions revealed complexity in terms of composition of 
ADan  species.  The  interpretation  of the  MS  analysis  was  challenging  due  to  the 
additional presence of mono-, di-, and tri-formylated species likely on the lysine and/or 
serine  residues  (Duewel  &  Honek,  1998) artificially generated due to the  extraction 
procedure (additional mass of 28 for each formylation). Both parenchymal and vascular 
lesions were composed of a heterogenous mixture of post-translationally modified and 
N- and C-terminally truncated ADan species.  The predominant species were ADanl- 
33pE,  ADanl-28pE  and  ADanl-34pE  although the  presence  of ADan3-28,  ADanl- 
27pE,  ADanl-30pE,  ADan3-33,  ADan3-34,  ADan 1-33  and  ADan 1-34  were 
consistently demonstrated (table 32, figure 7.7).
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ADan species Expected Mass 
[M+Hl
Observed mass 
in parenchyma
Observed mass 
in vessels
3-28 3090.6 3091.5 3091.3
l-27pE 3158.7 3158.8 3159.1
l-28pE 3272.8 3272.9 3272.7
l-30pE 3488.0 3489.2 3489.3
3-33 3700.2 3700.7 3701.3
3-34 3863.4 3863.7 3864.8
l-33pE 3882.4 3883.3 3883.4
1-33 3900.4 3903.2 3900.4
l-34pE 4045.6 4045.6 4046.5
1-34 4063.6 4063.6 4063.7
Table 32:  Direct  mass  spectrometry analysis  o f fibrillar ADan.  Mass spectrometry 
analysis  via  MALDI-TOF  revealed full-length  ADan  (1-34),  C-  and  N-terminally 
truncated species along with N-terminally modified species with pyroglutamate  (pE). 
Peaks  were  also found corresponding  to formylated species as  shown  in figure  7.7. 
M+H; protonated molecular species.
7.3.1.6  Analysis of ADan species in FDD extracts after immunoprecipitation
An immunoprecipitation step was carried out on the samples for the same reason as the 
FBD samples.  When analysed previously without prior immunoprecipitation, gray and 
white matter were separated from each other and the blood vessels. Because the results 
obtained  from  the  gray  and  white  matter  were  similar  for  the  immunoprecipitation 
experiments parenchyma was separated from the blood vessels. Using a combination of 
immunoprecipitation  and  western  blot/  mass  spectrometry  it  was  possible  to  detect 
ADan species in the PBS and SDS soluble fractions. There were noticeable differences 
in  terms  of degree  of aggregation,  in  the  PBS-soluble  fraction  ADan  species  were 
mainly monomeric, with some dimers barely visible in both parenchymal and vascular 
fractions (figure 7.8).
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Figure  7.7:  Direct  mass  spectrometry  analysis  of fibrillar  ADan 
deposits.  Formic  acid  fractions  from  blood  vessel  depleted  frontal 
cortex and leptomeningeal blood vessels after PBS and SDS extractions 
contain  various  ADan  species.  Both  C-  and  N-terminally  truncated 
species  were  found  with  and  without  modifications.  The  theoretical 
average masses and experimental  ADan molecular masses are shown 
in  table  34.  Peaks  corresponding  in  mass  to  fonnylated  species  are 
indicated by  asterisks  (*,  single formylation:  **,  double  formylation: 
***, triple formylation: pE pyroglutamate modification)
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Figure  7.8:  Western  blot  analysis  o f ADan  species  extracted from  PBS  and  SDS 
fractions after  immunoprecipitation.  ADan molecules were  immunoprecipitated using 
Dynabeads  with  anti-ADan  Ab5282  and subsequently  eluted  in  Tris-Tricine  sample 
buffer for  Western  blot  analysis.  Mo,  monomers;  Di,  Dimers;  P,  parenchyma;  V, 
vessels.
Whereas  the  SDS-soluble  fractions  showed  a  higher  tendency  to  aggregate.  The 
presence  of  dimeric  ADan  species  in  the  parenchymal  extracts  showed  an  equal 
intensity to the monomeric species, although the vascular samples still showed a higher 
monomeric content (figure 7.8).
MALDI-TOF MS was carried out after immunoprecipitation showing the PBS-soluble 
fractions were composed of a mixture of two ADan species differing in  18 mass units
4045.2  for parenchyma / 4045.3  for blood vessels  (expected 4045.2)  and 4063.5  for 
parenchyma / 4062.7 for blood vessels (expected 4063.6), a difference equivalent to the 
mass of one molecule of water and likely corresponding to ADan-pE and ADan species 
(table  33,  figure  7.9).  The  SDS-extracted  fractions  contained  the  same  two  ADan 
species  when  analysed  with  MS  to  those  found  in  the  PBS-soluble  fractions.  The 
experimental masses 4043.6 for parenchymal /4045.6 for blood vessels and 4062.0 for 
parenchymal  /4063.6  for  blood  vessels  were  in  good  agreement  with  the  expected 
masses of the post-translationally modified ADan-pE (4045.6) and the wild-type ADan 
(4063.6),  with a  single disulphide-bond between cysteine residues 5 and 22 (table 33, 
figure 7.9).
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ADan
species
PBS SDS Expected 
mass [M+H] Parenchymal Vessel Parenchymal Vessel
l-34pE 4045.2 4045.3 4043.6 4045.6 4045.6
1-34 4063.5 4062.7 4062.0 4063.6 4063.6
Table  33:  Mass  spectrometry  analysis  o f  non-fibrillar  ADan  deposits  after 
immunoprecipitation.  ADan  molecules  were  immunoprecipitated  using  Dynabeads 
coated  with  anti-ADan  Ab5282  and  subsequently  eluted  with  a  4:4:1  mixture  of 
isopropyl  alcohol/water/formic  acid.  Mass  spectrometry  analysis  via  MALDI-TOF 
revealed  full-length ADan (1-34) and  full-length ADan with pyroglutamate modification 
(pE)  in both the PBS-soluble and SDS-soluble fractions. M+H; protonated molecular 
species.
7.3.1.7  Direct analysis of Ap species in FDD extracts
The western blot analysis of the PBS-soluble,  SDS-soluble and formic acid fractions 
from the  leptominenges,  hippocampus  and  entorhinal  cortex  showed that AP  species 
were only present in detectable amounts in the formic acid fraction. However, the direct 
MS results from the formic acid fraction showed no Ap species to be present. The MS 
readings  showed  an  array  of peaks  none  of which  corresponded  to  any  known  Ap 
species (data not shown). Further analysis using immunoprecipitation was carried out to 
identify the Ap species found present on the western blot analysis.
7.3.1.8  Analysis of Ap species in FDD after immunoprecipitation.
Using  a combination  of immunoprecipitation and western blot/ mass  spectrometry  it 
was possible to detect AP species in the PBS and  SDS soluble fractions.  There were 
noticeable differences in terms of degree of aggregation, in the PBS-soluble Ap species 
were  mainly  dimeric,  with  some  monomers  barely  visible  in  both  parenchymal  and 
vascular fractions (figure 7.10). The SDS-soluble fractions also showed a high tendency 
to aggregate, with dimeric Ap species in the parenchymal and vascular extracts showing 
a greater intensity than the monomeric species (figure 7.10).
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Figure 7.9: Mass spectrometry analysis of non-flbrillar ADan deposits after 
immunoprecipitation.  ADan  molecules  were  immunoprecipitated  using 
Dynabeads  coated  with  anti-ADan  Ab5282  and  subsequently  eluted  in 
water/isopropyl alcohol/formic acid (4:4:1) for mass spectrometry via MALDI- 
TOF.  PBS-soluble  fractions  from  blood  vessel  depleted  frontal  cortex  and 
leptomeningeal  blood vessels are  shown to contain both the  full  length ADan 
species (1-34) and the full length with a pyroglutamate modification at the N- 
terminus.  SDS-soluble fractions from the same regions showed the same ADan 
species  present.  The  theoretical  average  masses  and  experimental  ADan 
molecular masses are shown in table 33.
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Figure 7.10:  Western blot analysis of  Ap species extracted from PBS and SDS fractions 
after  immunoprecipitation.  Ap molecules  were  immunoprecipitated using Dynabeads 
with anti-Ap antibody  4G8 and subsequently eluted in  Tris-Tricine sample  buffer for 
Western blot analysis. Mo, monomers; Di, Dimers; P, parenchyma;  V, vessels.
In parenchymal extracts MALDI-TOF MS analysis after immunoprecipitation revealed 
a small peak that corresponded to the A04-34 fragment (experimental 3473.5; expected 
3472.9) no other peaks corresponded to any other Ap  species (table 34,  figure 7.11). 
Vascular extracts,  on the  other hand,  showed  major peaks corresponding to  Api-42, 
Ap4-42 and Api-40, the latter being a minor component (table 34, figure 7.11).
When the SDS-extracts were analysed by the  same procedures, MS indicated that the 
parenchymal  and blood vessel  extracts mainly contained Api-42  and its N-terminally 
truncated derivative AP4-42 whereas Apl-40 was a minor component (table 34, figure 
7.11). The double peak obtained in this sample is due to the presence of Ap peptides 
bearing  oxidized  Met35  (Met  Sulpoxide  +16  mass  units)  most  probable  a  technical 
artefact due to the use of formic acid to process this sample for MS.
Ap species PBS soluble fraction SDS soluble fraction Expected mass 
[M+H] Parenchymal Vessels Parenchymal Vessels
4-34 3473.5 - - - 3472.9
4-42 - 4199.4 4200.0 4198.1 4199.8
1-40 - 4329.3 4331.1 4331.1 4330.9
1-42 - 4513.9 4514.9 4515.6 4515.1
Table  34:  Mass  spectrometry  analysis  o f  non-fibrillar  Ap  in  FDD  after 
immunoprecipitation. Ap species were immunoprecipitated with Dynabeads coated with 
a mixture o f anti-Ap 1-17 and anti- Ap 17-26 antibodies. Bound peptides were eluted and 
analysed  by  MS.  PBS-soluble  and  SDS-soluble fractions  of the frontal  cortex  and 
leptomeningeal blood vessels were analysed.
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When the formic acid extracts were analysed by MS for both parenchymal and vascular 
samples the most prominent signal corresponded to an experimental mass  of 4200.0, 
consistent with the theoretical protonated mass of 4199.8 for Ap4-42. Both Apl-42 and 
Apl-40 were also present in the sample, although Apl-40 was a minor contributor to 
the formic acid extract. Two additional peaks differing in +16 and +28 mass units with 
AP4-42 were also observed. Both experimental masses matched the expected values for 
AP4-42 (Met Sulphoxide) and AP4-42 (formylated) (table 35, figure 7.11).
Since samples were exposed to formic acid during the extraction procedure and prior to 
the  MS  analysis,  these  Ap  derivatives  may  well  represent  undesirable  secondary 
products  of the  specimen  treatment  rather  then  actual  post-translationally  modified 
components  present  in  the  lesions.  Alternatively,  these  oxidised  Ap42  species  may 
represent  existent  in  vivo  neurotoxic  subproducts  of oxidative  stress,  as  previously 
proposed (Butterfield, 2002).
AP species Parenchymal Vessels Expected mass [M+Hl
4-42 4200.0 4200.2 4199.8
4-42 OX 4215.9 4216.3 4215.8
4-42* 4228.1 4228.4 4227.8
1-40 4330.0 4330.3 4330.9
1-42 4514.9 4515.9 4515.1
Table  35:  Mass  spectrometry  analysis  o f fibrillar  Ap  in  FDD.  MS  analysis  of 
parenchymal FA-extracts from micro-vessel depleted frontal cortex after PBS and SDS 
extractions.  Along  with  FA  fractions  from  leptomenigeal  blood  vessels.  M+H; 
protonated molecular ions.
It is interesting to note that the Apl-40 species was found to be a minor species in FDD 
when  the  pathological  eveidence  of AD  suggests  the  major  species  of Ap  found  in 
vascular structures  is Api-40.  Further immunohistochemical investigations have been 
carried out to confirm this finding (section 7.3.2).
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Figure 7.11: Mass spectrometry analysis of Ap in FDD alter immunoprecipitation. Ap species were 
immunoprecipitated with Dynabeads coated with a mixture of A01-17 and Ap 17-26. Bound peptides were 
eluted and analysed by MALDI-TOF MS as described in material and methods. PBS extracted fractions of 
microvessel-depleted frontal cortex (parenchyma) and isolated microvessels from frontal cortex (vessels) 
(panel  A),  SDS-extracted  fractions  (panel  B)  and formic acid extracted fraction (panel C).  Theoretical 
average masses and experimental Ap molecular masses are shown in tables 36 & 37. Peaks of MS indicated 
by # were present in the negative controls (without brain extracts) and considered to be non-specific. Peaks 
notated by a were also obtained in negative controls (using brain extracts but uncoated Dynabeads) and 
considered non-specific.
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7.3.1.9  Western blot analysis of sporadic AD, FAD and normal controls
In  the  PBS-soluble  fractions,  no  monomeric  Ap  species  were  found  in  any  region 
studied.  Ap  dimers  were  found in the  frontal  gray matter of FAD  (case 4)  and the 
frontal blood vessels of sporadic AD (case 6) (table 36). No Ap species were detected in 
the  SDS-soluble fractions  in any AD, FAD or normal control cases. The formic acid 
extraction samples showed an abundance of Ap in both monomeric and dimeric forms 
in both sporadic AD and FAD (table 36). Of the two normal controls used, one (case 8) 
showed  no  Ap  species  which  was  predictable,  but  the  other  control  used  (case  9) 
showed both monomeric and dimeric species of Ap. This may be due to the age of the 
control case (91 years) (table 36).
Case Diagnosis Region Subregion
PBS-soluble
fraction
SDS-soluble
fraction
Formic acid 
fraction
AP Ap Ap
M D T M D T M D T
4 FAD Frontal cortex White matter + + -
4 FAD Frontal cortex Gray matter - + - - - - + + -
4 FAD Frontal cortex Blood vessels + + -
5 FAD Occipital cortex White matter + + -
5 FAD Occipital cortex Gray matter + + -
5 FAD Occipital cortex Blood vessels + + -
6 AD Frontal cortex White matter + + -
6 AD Frontal cortex Gray matter + + -
6 AD Frontal cortex Blood vessels - + - - - - + + -
7 AD Hippocampus -
8 Control Frontal cortex White matter
8 Control Frontal cortex Gray matter
8 Control Frontal cortex Blood vessels
9 Control Frontal cortex White matter + + -
9 Control Frontal cortex Gray matter + + -
9 Control Frontal cortex Blood vessels + + -
Table 36:  Western blot analysis o f non-fibrillar and fibrillar A p  species in sporadic AD, 
FAD and normal controls.  Distribution  o f A P species  in  extracted supernatants from 
cases 4 and 5  (familial AD),  cases  6 and  7 (sporadic AD) and cases 8 and 9 normal 
controls. Showing monomeric (M), dimeric (D) and trimeric (T) Ap species.
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7.3.1.10  Mass spectrometry analysis of Ap species in sporadic AD, FAD 
and normal controls
Mass spectrometry analysis was carried out on PBS-soluble,  SDS-soluble and formic 
acid  fractions  collected  from  the  sporadic  AD,  FAD  and  normal  control  cases.  In 
sporadic AD and FAD major AP species in both the gray and white was both Api-42 
and Apl-40.  Whereas in the blood vessels Api-40 species without any modifications 
were dominant (data not shown).
7.3.2  Immunohistochemical study of Ap species in FDD, AD and FAD
7.3.2.1  Ap immunohistochemistry in FDD
Antibodies to Apl-16,  Ap 17-26  and AJ38-15  gave a similar staining pattern and will 
therefore  be  described  together  and  referred  to  as  Ap  (figure  7.12).  Ap 
immunohistochemistry  revealed  that  a  large  number  of  blood  vessels  including 
capillaries  and  arterioles  (figure  7.12F)  were  positive  in  the  CA1  subregion  of the 
hippocampus and subiculum (figure 7.12C). The majority of the labelling in this region 
was vascular,  but an occasional perivascular Ap deposit (figure 7.12B) was found. In 
addition,  sparse  diffuse  deposits  were  weakly  stained.  In the  CA4  subregion  of the 
hippocampus  no  vascular  Ap  was  found,  but  diffuse  deposits  were  present  in  the 
parenchyma (figure 7.12E, 7.12H). A similar pattern of diffuse staining was present in 
the CA2 and CA3  subregions.  In the parahippocampus, entorhinal and transentorhinal 
cortices  Ap  deposits  were  seen  in  capillaries  and  arterioles.  In  addition,  prominent 
perivascular deposits were detected. Such deposits were found around blood vessels that 
were affected by Ap deposition and also around blood vessels that were negative for 
Ap, but were obviously affected by amyloid deposition, therefore by ADan deposition 
(figure  7.12B).  The  fusiform  gyrus  showed  prominent  vascular  and  perivascular
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deposits, but an increase in the number of compact parenchymal diffuse plaques was 
observed  (figure  7.12H).  Affected  blood  vessels  tended  to  be  more  frequent  in  the 
superficial laminae and parenchymal deposits in the deeper laminae. Dense staining was 
also  found  the  subpial  region  of the  fusiform  gyrus  (figure  7.12A).  The  neocortical 
regions showed a similar staining pattern to that observed in the fusiform gyrus showing 
an increase in the number a compact Ap positive ill-defined plaques and the occasional 
leptomeningeal blood vessel affected by the deposition of the peptide was seen.
7.3.2.2  Heterogeneity of Ap species in FDD
The three FDD cases (cases  1-3) studied showed varying degrees of staining intensity 
with the different N- and C-terminal Ap antibodies.  Although the intensity varied the 
structures  stained  by  each  antibody  were  the  same,  so  will  be  described  together. 
Immunohistochemistry  was  carried  out  using  antibodies  recognising  different  N- 
terminal  amino  acids  N1(D),  Nl(rD),  N3(pE)  and Nll(pE)  (Saido  TC  et  al  1995). 
N1(D),  Nl(rD)  and  N3(pE)  stained  Ap  affected  blood  vessels  throughout  the 
hippocampus  and  subiculum  (figure  7.13  C-E),  although  the  diffuse  parenchymal 
plaques  stained  weakly.  The  staining  pattern  found  in  the  fusiform  gyrus  and 
neocortices was similar to that seen with Ap.  Nll(pE) on the other hand  stained all 
structures  shown  to  be  positive  with  Ap,  including  capillaries,  arterioles,  diffuse 
deposits,  compact  plaques,  perivascular plaques  and  subpial  deposits but the  overall 
staining intensity was weaker than that observed with the other N-terminal antibodies 
(figure 7.13F).
C-terminal  heterogeneity of the Ap  species were also investigated using Apx-40 and 
Apx-42  end  specific  antibodies.  APx-42  showed  strong  immunolabelling  of  all 
structures  labelled  with  Ap  deposition  (figure  7.13H).  The  anti-Apx-40  antibody
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showed  a  staining  pattern  with  scanty  immunolabelling  present  in  capillaries  and 
arterioles, including leptomeningeal vessels (figure 7.13G). Weak staining was found in 
a few perivascular plaques and there was some diffuse deposits stained, but the number 
Ap deposits stained was considerably lower than that seen with anti-Apx-42 antibody. 
These  findings  confirmed  the  observations  seen  using  mass  spectrometry,  although 
differing from what one would expect from the data relating to Ap, Api-42 was found 
to be the major Ap species over Apl-40 using immunohistochemistry.
7.3.2.3  Ap immunohistochemisty in FAD
As in FDD, the staining pattern for the Ap antibodies Api-16, Ap 17-26 and AP8-15 
was  very  similar  so  will  all  be  described  together  and  referred  to  as  Ap.  In  the 
superficial cortical layers cotton wool plaques were found in the subpial region (figure 
7.14B, arrow), which was followed by a layer of diffuse deposits (figure 7.14B, double 
arrow).  Cotton wool plaques were found throughout the deeper cortical layers (figure 
7.14A). In the hippocampus all cotton wool plaques were found to be positive with Ap. 
Blood vessels, including capillaries and arterioles were positive in the hippocampus but 
reduced in number compared to that seen in the cortical regions. Diffuse deposits with 
no definite structures were found in the parvopyramidal clusters (figure 7.14C). In the 
entorhinal cortex all lesion types were stained including diffuse deposits (figure 7.14D, 
arrow),  cotton wool  plaques  (figure  7.14G,  7.14H)  and  blood  vessels  (figure  7.14E 
arrow,  7.141),  but  here  the  positive  staining  in  the  capillaries  became  prominent. 
Positive staining was also found in the white matter in the blood vessels and a small 
amount of diffuse staining, along with a large amount of subpial staining (figure 7.14F).
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Figure 7.12: Immunohistochemical study of Ap deposition 
in  FDD.  Panels  A-F  are  immunostained  with  Ap  1-16 
antibody (Biosource International).  Subpial deposits stained 
with Ap (A, arrows). Perivascular staining (B, double arrow) 
was seen around blood vessels affected with ADan amyloid 
(B,  asterisk).  Vascular  Ap  staining  was  observed  in  the 
periphery  of  ADan  amyloid-laden  capillaries  (C,  arrow), 
along  with  arterioles  showing  patchy  Ap  deposition  (D, 
arrow).  Plaques  positively  stained  with  Ap  were  found 
throughout  the  parenchyma  in  various  forms  including 
diffuse deposits (E) and compact ill-defined plaques (F). Bar 
in panel A represents 100pm on panel A; 55pm on panel B,F; 
28pm on panels C, D and E
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Figure  7.13:  N-terminal  Ap  immunohistochemistry  in  FDD 
blood vessels. In FDD positive Ap staining was found in all types 
of blood  vessels  from  small  capillaries,  to  arterioles  and  arteries. 
Serial  sections  were  used  and the  pathological  lesions  recognised 
using Apl-16  (A),  AP17-26  (B), N1(D)  (C), Nl(rD)  (D), N3(pE) 
(E),  Nll(pE)  (F),  Apx-40  (G),  Apx-42  (H).  Bar  in  panels  A-H 
represents 55pm.
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Figure  7.14:  Ap  deposition  in  FAD.  AP17-26  immunohistochemistry  in  FAD 
showing the  pathological  lesions  stained.  The  dense  staining  of the  cotton  wool 
plaques  in the deep cortical layers is  shown in A.  The different types of diffuse 
plaques  are  shown the cortical  layers  in B,  with traditional cotton wool plaques 
found towards the subpial (arrow), and more diffuse cloudy deposits found in the 
cortical  layers below (double  arrow).  The  diffuse  deposit  of the  parvopyrmaidal 
clusters  of the  entorhinal  cortex  are  shown  in  C,  arrows.  Panel  D  shows  the 
looseness  of the  diffuse  deposits  compared to the  cotton  wool plaques.  Panel  E 
(arrow)  shows  the  intensity  of the  vascular  staining  in  the  capillaries.  Panel  F 
(arrows) shows the amount of Ap deposited in the subpial. Panels G and H show 
two  plaques  at  higher  magnification.  Panel  I  (arrow)  shows  a  large  arteriole 
positively stained with Ap.  Bar in panel A represents 250 pm in A-D; 55  pm in 
panels E,F and I; 28 pm in panels G and H.
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13,2.4  Heterogeneity of Ap species in FAD
Strong  N1(D)  immunolabelling  was  found  in  the  blood  vessels  throughout  the 
hippocampus whereas the parenchymal staining in the cotton wool plaques was very 
weak (figure 7.15C). The diffuse Ap structures with no defined boundaries, like those 
found in the parvopyramidal clusters, remained negative with N1(D) staining. Whereas 
with Nl(rD)  the  blood  vessels  were  equally as  strong  as  that  seen  with N1(D)  the 
parenchymal  staining  was  more  intense  than  seen  with the  N1(D)  antibody  (figure 
7.15D).  N3(pE)  and Nll(pE)  antibodies  showed  weak  staining  of the  cotton  wool 
plaques  and the  diffuse  deposits  of the  parvopyramidal  clusters.  Whereas  all  blood 
vessels were stained with anti-N3(pE) and anti-Nl l(pE) antibodies the staining was not 
as prominent as with AP or the antibodies starting at position 1  (figure 7.15E).
The distribution of two C-terminal antibodies APx-40 and APx-42 were investigated in 
the FAD cases. Apx-40 gave strong staining in all amyloid affected blood vessels with 
the  occasional  perivascular  plaque  being  positive.  A  small  portion  of cotton  wool 
plaques found in the parenchyma was weakly stained but a large proportion remained 
unstained (figure 7.15G). APx-42 gave a contrasting staining pattern to that seen with 
Apx-40.  Apx-42  gave  occasional  positive  staining  in  the  capillaries  and  arterioles 
(figure  7.15H,  inset).  The  cotton  wool  plaques  were  strongly  stained  with  Apx-42 
(figure 7.15H).
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Figure  7.15:  Distribution  of  AP  staining  in  FAD.  Parenchymal 
cotton wool plaques and an amyloid-laden capillary immunolabelled 
with a panel of Ap antibodies. Serial sections that were stained with 
Apl-16  (A),  AP 17-26  (B),  N1(D)  (C),  Nl(rD)  (D),  N3(pE)  (E), 
N1 l(pE) (F), Apx-40 (G), APx-42 (H). Inset shows a cortical arteriole 
immunostained with the same panel of Ap antibodies. Bar in panel A 
represents 100pm in panels B-H. In insets bar represents 45 pm.
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7.3.2.5  Ap immunohistochemistry in sporadic AD
The Ap antibodies Apl-16, Ap 17-26 and AP8-15  showed similar staining patterns so 
will all be described together and referred to as Ap. Occasional blood vessels, including 
capillaries and arterioles were positive in those AD cases containing CAA. Cored and 
compact plaques were found in all AD cases and were positive with the Ap antibodies. 
Diffuse deposits with no definite structures were occasionally found and were positive 
with the Ap antibodies (data not shown).
7.3.2.6  Heterogeneity of Ap species in sporadic AD
In all the sporadic AD cases investigated the four antibodies recognising N-terminally 
truncated species (N1(D); Nl(rD); N3(pE); Nll(pE)) all showed positive reactivity in 
all  the  amyloid  and  preamyloid  structures.  All  blood  vessels  regardless  of size,  if 
affected by amyloid deposition, were positive with the N-terminally truncated species. 
The same is true for the amyloid plaques and preamyloid lesions. Although the intensity 
of the staining patterns seen varied from case to case all peptide species were present 
(data not shown).  The distribution of two C-terminal antibodies Apx-40 and Apx-42 
was investigated in the sporadic AD cases. The staining pattern observed followed the 
same pattern as that seen in the FAD cases. Apx-40 gave strong staining in all amyloid 
affected blood vessels with the occasional perivascular plaque being positive and Apx- 
42 gave occasional positive staining in the capillaries and arterioles with plaques being 
strongly stained with Apx-42 (data not shown).
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7.4 Discussion
The  data  from  this  study  showed that in both FBD  and FDD  the  complexity of the 
extracted  peptides  (ABri  and  ADan)  increased  as  the  solubility  of  the  deposits 
diminished,  as  reflected  in  the  degree  of  oligomerisation,  predominant  amyloid 
subunits, extent of post-translational modifications and magnitude of N- and C- terminal 
proteolytic degradations. In general terms, non-fibrillar deposits appeared less complex 
than  the  fibrillar  counterparts,  perhaps  reflecting  the  presence  of early  intermediate 
states of the fibrillisation process (table 37).
Analysis Fraction
PBS-soluble SDS-soluble Formic Acid
F Western Blot M D T M D  T M D  T
B Mass Spectrometry l-34pE* l-34pE* 3-34*
D 1-34 1-34 l-34pE
1-34
F Western Blot M D - M D M D  T
D Mass Spectrometry l-34pE* l-34pE* l-34pE*
D 1-34 1-34 1-34
l-33pE
1-33
3-34
3-33
l-30pE
l-28pE
Table 37: Summary of  findings in FBD and FDD for the peptides ABri and ADan. The 
table summarises the peptide species observed with western blot analysis in the PBS- 
soluble, SDS-soluble and formic acid fractions. The mass spectrometry results show the 
major species present in the three fractions in order from the species with the major 
peak  (*)  to  the  speices  with  the  smallest  peak  being  less  abundant  in  the  sample 
analysed. M; monomer, D; dimer, T; trimer.
The Ap species with a more restricted pattern of heterogeneity were also retrieved in all 
the FDD  extracts but not from FBD tissue. This study confirmed previous studies, in 
FAD and sporadic AD, in that Apx-40 was found to be the principal component of Ap 
vascular deposits whereas Apx-42 the main component of parenchymal lesions.  This 
was  confirmed  with  both  mass  spectrometry  and  immunohistochemical  studies.
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Suprisingly  in  FDD  the  principal  component  found  in  vascular  and  parenchymal 
deposits,  with mass  spectrometry  and confirmed by the  immuohistochemical  studies, 
was Apx-42, alongside its N-terminal degradation derivative Ap4-42. This latter finding 
could  not  be  confirmed  with  immunohistochemical  analysis  for  no  antibodies 
recognising peptide species starting at position 4 are available at present. Interestingly 
the N-terminally truncated AP4-42 has been shown to aggregate more readily and be 
more toxic than the full length Apl-42 (Pike et al., 1995).
Analysis Fraction Immuno.
PBS-
soluble
SDS-
soluble
Formic
Acid
F Western Blot -  D  - M  D  - M  D  -
D Mass 4-34* 4-42* 4-42* 1-42**
D Spectrometry 4-42 1-42 1-42 N1(D)
1-42 1-40 1-40 Nl(rD)
1-40 N3(pE)
Nll(pE)
1-40
F Western Blot -  D  - - M  D  -
A Mass 1-40* 1-40* 1-40* 1-40**
D Spectrometry 1-42 1-42 1-42 1-42
N1(D)
Nl(rD)
N3(pE)
Nll(pE)
A Western Blot -  D  - - M  D  -
D Mass 1-40* 1-40* 1-40* 1-40**
Spectrometry 1-42 1-42 1-42 1-42
N1(D)
Nl(rD)
N3(pE)
Nll(pE)
Table 38:  Summary of  findings  of the Ap peptide  in FDD,  FAD and AD.  The  table 
summarises  the  Ap  species  observed  with western blot  analysis  in  the  PBS-soluble, 
SDS-soluble and formic acid fractions. The mass spectrometry results show the major 
species present in the three fractions in order from the species with the major peak (*) to 
the  speices  with  the  smallest  peak  being  less  abundant  in  the  sample  analysed. 
Immunohistochemical results show the N- and C-terminal truncated species present in 
the  three  diseases  in  order  of staining  intensity  -  **  representing the most abundant 
species. M; monomer, D; dimer, T; trimer.
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Interestingly  using  both  mass  spectrometry  and  immunohistochemistry  the  Apx-40 
species were found to be negligible in FDD (table 38). It is also informative to note that 
the immunohistochemical studies showed the presence of several Ap species that were 
not revealed by mass spectrometry analysis (N1(D); Nl(rD); N3(pE); Nll(pE)). This 
may  be  explained  by  the  methodologies  used  in  the  mass  spectrometry  procedures, 
where the tissue is processed and the N-terminally truncated species may be diluted out 
to an undetectable amount, while with immunohistochemistry the peptides are detected 
in-situ.  One  possible  way  around  this  would  be  to  immunoprecipitate  with  the  N- 
terminal  antibodies  followed by mass spectrometry to investigate the presence of the 
peptide with this methodology.
The non-fibrillar deposits extracted from PBS-soluble and SDS-soluble fractions in the 
FBD cases showed that the ABri isolated formed mainly monomeric species, but ABri 
oligomeric  species  were  present  in  smaller  amounts.  Both  C-  and  N-terminally 
truncated ABri  species were  found.  However, if no truncation was present at the N- 
terminus  of  ABri  a  pyroglutamate  modification  was  likely  to  be  present.  Cyclic 
pyroglutamate has been previously found in truncated forms of the Ap peptide in AD 
(Mori  et  al.,  1992;  Saido  et  al.,  1996;  Tekirian  et  al.,  1998),  along  with  early 
observations  in  FBD  (Vidal  et al.,  1999).  Pyroglutamate modification has  also been 
found  in  some  hormones  and  neuropeptides  including  neurotensin,  thyrotropin  and 
gonadotropin-releasing hormones in which their biological activities largely depend on 
the existence of the N-terminal pyroglutamate (Sykes et al.,  1999). Although the final 
pyroglutamate product is the same, neuropeptides and amyloids differ in the amino acid 
that serves as a substrate  for the post-translational modification.  In the neuropeptides 
and peptide hormones the post-translational modification occurs at a glutamine residue 
and cyclization involves the nucleophilic attack of the a-amino group on the aminidated
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carboxyl  group and the release of NH3 catalyzed by glutaminyl  cyclase at neutral pH 
(Busby, Jr. et al.,  1987; Fischer & Spiess,  1987). Few examples are known of the post- 
translational modification from glutamic acid to pyroglutamate, involving a dehydration 
reaction losing a molecule of water instead of a deamination reaction. Examples of this 
post-translational  modification  are bovine  and  ovine  (3-lipotropin  and joining  peptide 
derived  from  the  proteolytic  processing  of  their  common  precursor  pro­
opiomelanocortin  (Bateman  et  al.,  1990;  Yamashiro  &  Li,  1976),  Af  N-terminal 
truncated derivatives A03pE and Api IpE in AD (Mori et al.,  1992; Saido et al.,  1996), 
along with the recently  identified ABri and ADan (Tomidokoro et al.,  2005; Vidal et 
al.,  1999).  Whether  the  same  glutaminyl  cyclase  is  responsible  for  the  dehydration 
process in all these cases remains to be investigated. Since this N-terminal modification 
was not detected in the soluble circulating ABri and ADan species, it is conceivable that 
cyclization occurs at the sites of ABri and ADan deposition.
ABri  species extracted with formic acid (amyloid fraction) showed a range of species 
from  the  monomeric  form  to  species  with  a  high  degree  of  oligomerization. 
Interestingly the gray matter from the different cortical regions showed a high degree of 
oligomerization along with the blood vessels  from the different regions.  Whereas the 
white  matter  regions  only  showed  monomeric  species.  The  monomeric  ABri  species 
were  found  to  be  full  length  and  heavily  modified  at  the  N-terminus  with  a 
pyroglutamate modification.
The non-fibrillar deposits extracted from PBS-soluble and  SDS-soluble fractions from 
the FDD case appeared less complex than the fibrillar counterparts found in the formic 
acid extract, perhaps reflecting the early intermediate states of the fibrillization process. 
The degree of oligomerization was limited only to the dimeric forms and the degree of 
heterogeneity was highly restricted in the soluble fractions.  After immunoprecipitation
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ADan species were found in small quantities within the soluble fractions and consisted 
of full-length species with the occasional N-terminal pyroglutamate modification. 
Analysis  of  the  PBS  and  SDS  soluble  fractions  for  Ap  deposits  without  prior 
immunoprecipitation  showed  no  Ap  deposits  when  western  blot  analysis  was  used. 
However,  with the  incorporation of the immunoprecipitation step N-  and C-terminal 
truncated  species  were  found  in  the  soluble  fractions.  Api-42  and  N-terminally 
truncated AP4-42 were the major species whereas Api-40 and Ap derivatives ending at 
position  34  were  minor  components.  Although  the  predominant  species  ending  at 
position  42  were  expected  in  the  parenchymal  extracts,  their  abundance  in  vascular 
components was suprising.  Limited  studies indicate that Ap-related parenchymal pre­
amyloid lesions are enriched in species ending at position 42. The a-secretase fragment 
Ap 17-42, in particular, was previously identified as the main component of pre-amyloid 
lesions  in  AD  (Gowing  et  a l,  1994),  DS  (Lalowski  et  al,  1996)  and  aged  dogs 
(Wisniewski et al,  1996) with Apl-42 an AP4-42 being minor components in the last 
two cases. In FDD extracts Ap 17-42 was not detected in any fraction, whereas Ap4-42 
was the major species of the pre-amyloid lesions.
ADan  and  Ap  species  extracted  with  formic  acid  from  amyloid  deposits were  more 
heterogenous.  ADan  was  fully  post-translationally  modified  at  the  N-terminus 
(pyroglutamate), partially N- and C-terminally degraded at positions 3, 28 and 33  and 
heavily  oligomerized.  These  findings  have  been  confirmed  by  a  recent  N-terminal 
sequence  anaylsis  in  both  parenchymal  and  vascular  extracts.  The  minor  sequences 
retrieved,  SNXFAIR and EASNXF correspond to ADan starting at positions 3  and  1  
respectively,  in  3:1  ratio  (Tomidokoro  et  al,  2005).  Ap,  on  the  other  hand,  was 
composed of Apl-42  and AP4-42 (with negligible Apl-40),  showed higher degree of 
oligomerization.  Whether,  extensive  proteolytic  degradation  and  heavier
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oligomerization  reflect  critical  necessary  steps  in  the  process  of  ADan  amyloid 
formation or simply a futile  cellular effort to end and clear the formation of fibrillar 
deposits in still under investigation. In die case of Ap, the N-terminal degraded AP4-42 
is known to have a faster aggregation kinetics than the intact Api-42 (Pike et al., 1995). 
As well  as  analysing the  Ap  species present in FDD,  sporadic AD and familial AD 
cases were examined.  Using western blot analysis of the Ap species showed that the 
formic acid fraction contained the majority of the Ap peptides. The samples from the 
familial  AD  cases  showed  both  monomeric  and  dimeric  Ap  species,  whereas  the 
sporadic AD case showed a predominance of the dimeric Ap species. The MS results 
revealed that the major species in both the familial and sporadic AD cases were both N- 
and  C-terminally  truncated  Ap  species  modified  with  a  pyroglutamate  at  the  N- 
terminus. Whereas the samples obtained from the blood vessels contained more of the 
full-length species and less modified with the pyroglutamate residue. This finding is in 
contrast to the Ap species found within FDD where no species were found with MS to 
contain the pyroglutamate species.
The existence of other Ap species was also previously identified in pre-amyloid lesions 
based  on  classical  immunohistochemical  stainings  and  their  reactivity  with  specific 
antibodies.  Apl-42  and  Ap3-42pE  were  reported  to  be  major  components  in  AD, 
Downs syndrome and normal aging preamyloid lesions whereas antibodies recognizing 
position  17  were  only  weakly  positive  (Iwatsubo  et  al.,  1996).  Anti-Ap 
immunoreactivity  was  found  prevalent  in  parenchymal  pre-amyloid  deposits  in  the 
Dutch variant of familial AD (Castano et al., 1996). Ap immunohistochemistry in FDD, 
with  antibodies  raised  against  different  residues  of the  Ap  peptide,  confirmed  MS 
analysis results showing the presence of Ap42 in the amyloid lesions, with little Ap40
295Chapter 7-Biochemical analysis
positivity  found in the amyloid lesions.  For comparison immunohistochemistry using 
anti-Ap antibodies was also carried out on sporadic AD and familial AD cases. All Ap 
antibodies showed positive staining in both sporadic AD and familial AD. Both N3(pE) 
and N1 l(pE) stained all structures as observed in FDD. Although this study did not find 
the  presence  of Nll(pE)  species  in  sporadic AD using MS,  a study has shown the 
presence  of both Ap peptides  beginning at position 3  and  11  as prominent bands in 
familial AD carrying presenilin 1  mutations (Russo et al., 2000). N- and C-terminal Ap 
isoforms are consistently present in AD (Harigaya et al., 2000), but were found to a 
lesser extent in normal aging (Piccini et al., 2005).
From looking at three different amyloid peptides a pattern emerged suggesting that the 
full  length  species  could be  produced either locally  or systemically and modified in 
transit or at the site of cerebral deposition.  The formation of a pyroglutamate residue 
heightens  the  state  of  degradation  resistance,  presumably  rendering  cells  in  and 
surrounding a plaque unable to clear the amyloid peptide, as they are resistant to major 
aminopeptidases  and  have  a  higher  p-sheet  to  a-helical  stability  compared  to 
unmodified Ap peptides  (He  & Barrow,  1999).  Pyroglutamate containing N-terminal 
truncated peptides form p-sheet structure and aggregate more readily than the full length 
forms. It has also been shown that pyroglutamate modified Ap peptides remain in the p- 
sheet conformation at all pH values.
Analysis of the Ap peptide in both AD and ADan showed that the modified peptides 
were  found  in  all  pathological  lesions,  suggesting  that  extracellular  components 
influence the  formation of the  different lesions.  More  information could be  obtained 
about ABri and ADan with the introduction of antibodies raised against the N-terminus 
of these peptides and the modified N-terminus.
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In sporadic and familial AD as well as in other Ap related disorders, amyloid deposits in 
cerebral blood vessels are primarily constituted of fibrillar forms of AJ340 although the 
presence  of Ap42  in  detectable  amounts  is  considered  a  common  finding  in  these 
lesions (Ghiso & Frangione, 2002).  Similarly AP40 is the main component of vascular 
deposits (Van Dorpe et a l, 2000a; Kuo et al., 2001), including the recently published 
APP-Dutch mouse (Herzig et al, 2004). The fact that the main Ap components of the 
vascular  FDD  lesions  are  AP42  species  was  an  unexpected  finding  of unknown 
connotations for the disease pathogenesis.  It is also not known at present whether the 
colocalization  of  ADan  and  Ap  reflects  important  aspects  of  the  mechanism  of 
amyloidogenesis or simply a conformational mimicry. However it is important to note 
that AP was not detected in parenchymal or vascular ABri lesions in FBD (Ghiso et al, 
1995;  Revesz et al,  1999)  in  spite of sharing the  first 22  amino  acid residues with 
ADan.  If amyloid is indeed necessary for the development, of dementia it is certainly 
not exclusive for AP nor dependent on the presence of compact plaques. Therefore, we 
can propose that these disorders, FBD and FDD, are suitable models to study early steps 
in peptide fibrillization and the role of pre-amyloid and vascular amyloid in the process 
of neurodegenration.
Footnote:  The immunoprecipitation steps described in this chapter were completed by 
Yasushi Tomidokoro after I had left New York Universtiy due to time constraints. The 
work however was carried out on the samples I had already prepared.
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Chapter 8
Expression ofBRI2 mRNA, BRI 
precursor protein and  furin in normal
human brain and FBD
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Chapter 8 —  Hypothesis and specific questions.
In this chapter I wished to investigate the hypothesis that cellular components of 
the CNS are a major source of ABri and ADan deposited in the CNS in FBD and 
FDD, respectively.
Understanding  the  origin  of  the  ABri  and  ADan  peptide  could  provide  further 
information about the evolution of the parenchymal and vascular lesions.  To test the 
above hypothesis that the brain is a major source of these amyloid peptides a study was 
undertaken  to  establish  the  cerebral  distribution  of BriPP  and  the  enzyme  (furin) 
implicated in its processing. For this study in-situ hybridisation, immunohistochemistry 
and biochemical methods were used.
8.1  Introduction
The function of the BRI2 gene is mainly unknown, although it has become recognised 
that  it belongs  to  a  family  of genes,  which  also  includes  the BR11  and BRI3  genes, 
encoding  integral  transmembrane  proteins  (Deleersnijder  et  al.,  1996;  Pittois  et  al, 
1998). The mechanism of cleavage of the wild type and mutated BRI precursor proteins 
has  been  investigated  using  in  vitro  studies.  These  have  shown  that  the  ubiquitous 
prohormone convertase (PCo) furin is able to cleave wild type BriPP between Arg243 
and Glu244 to generate an N-terminal 243-amino-acid-long and a C-terminal 23-amino- 
acid-long fragment. The mutated precursor proteins ABriPP and ADanPP can also be 
cleaved  at  the  same  site  producing  the  amyloidogenic  peptides  ABri  and  ADan. 
Cleavage of the mutated precursor proteins was found to be more efficient than that of 
the wild type and furin was more effective in producing this cleavage than other PCos 
expressed in brain (Kim et al., 1999; Kim et al., 2002). Furin is a member of the family 
of  subtilisin-like  calcium-dependent  serine  proteases,  a  group  of  enzymes,  which 
function as proprotein and prohormone convertases generating a wide range of bioactive 
molecules.  Furin is a type  1   transmembrane protein, which is synthesized as profurin 
and, during progression from the ER to the trans-Golgi network, undergoes activation 
by two sequential autoproteolytic cleavages, the second of which permits dissociation of 
the propeptide providing the final step in enzyme activation (Nakayama, 1997; Thomas, 
2002).  A  secreted  form  of furin has  also been described in experimental models,  in 
which  cells  are  transfected  with  furin  and  also  in  cell  lines  derived  from malignant
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glioma (Denault et al., 2002; Leitlein et al., 2001; Vey et al.,  1994; Vidricaire et al., 
1993).
The origin and mechanism of deposition of ABri in plaques and blood vessel walls is 
not known.  One of the hypotheses is that ABri is produced by cellular components of 
the  CNS.  In  support  of  this  possibility  are  the  morphological  investigations 
demonstrating  a perineuronal  distribution of ABri.  The  association  of neuronal  cells 
with Ap  production in AD  has been  shown previously,  therefore the possibility that 
neurons may be one of the cell types involved in cerebral ABri production can be raised. 
Such a hypothesis is further supported by previous Northern blot studies, demonstrating 
that BRI2  mRNA  is expressed throughout the human brain and is  expressed at high 
levels in a number of areas, which include the hippocampus, amygdala, and cerebellum 
(Vidal etal., 1999).
Only  limited  information  is  available  about  the  cellular  origin  and  potential  furin 
processing  of ABri  in  the  human  brain.  Both  BriPP  protein  and  furin  have  been 
demonstrated in neurons and furin was also localised in both reactive astrocytes and in 
ABri parenchymal amyloid lesions in FBD (Akiyama et al., 2004; Schwab et al., 2003). 
In this study we wished to investigate these issues further by analysing the distribution 
of  BRI2  mRNA  using  non-radioactive  in-situ  hybridisation  in  parallel  with 
immunohistochemical studies of the protein localisation and to compare these with the 
distribution of furin. We explored these in control brain tissue and in both FBD and AD 
to determine whether there was any relationship between parenchymal amyloid and pre­
amyloid lesions and either BriPP or furin expression.
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8.2  Material and Methods
8.2.1  Tissue
Samples of brain tissue which had been flash frozen and stored at -80°C following brain 
removal at autopsy were obtained from four normal controls, one case of FBD, four AD 
cases and one case of variant AD with cotton wool plaques (table 39).
Number Age Sex Diagnosis Post mortem delay
1 43 M Heart attack 15 hrs
2 63 M Congestive heart disease 42 hrs
3 75 M Pulmonary embolism 64 hrs
4 81 M Chronic obstructive airway disease 40 hrs
5 68 F FBD 6.5 hrs
6 79 M AD 27 hrs
7 73 F AD 18 hrs
8 78 M AD 38 hrs
9 43 F AD 75 hrs
10 46 F Variant AD with cotton wool plaques 26 hrs
Table 39: Cases used  for immunohistochemistry; western blotting and in situ
hybridisation.
For western blot analysis, the cerebellum was used from the control cases and frontal 
lobe from the FBD and four AD cases (cases 6-9). To study the distribution of furin and 
BriPP  in  the  normal  brain  using  immunohistochemistry  and  in-situ  hybridisation 
sections were cut from the frontal cortex, basal ganglia, hippocampus and cerebellum in 
all control cases; temporal and occipital cortices in two of the cases and thalamus and 
pons in one of the cases.  The hippocampus and frontal cortex were available from the 
FBD case. Temporal cortex was available in all AD cases.
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8.2.2  Immunohistochemical staining
Antibody Source Dilution for IB Dilution for IH
Ab338 Dr J Ghiso 1:2000 1:2000
Furin convertase Affinity Bioreagents 1:1000 1:50
Ab340 Dr J Ghiso 1:500 1:500
GFAP Chemicon - 1:1000
NeuN Chemicon - 1:1000
Prohormone convertase  1 Affintiy Bioreagents 1:500 -
Prohormone convertase 2 Affinity Bioreagents 1:2500 -
Ab340 Pre-immune (Pi) Dr J Ghiso 1:500 1:500
Ab340 Blocked Dr J Ghiso 1:500 1:500
Table 40: Antibodies usedfor expression of  BriPP study.
IB- Immunoblotting and IH- immunohistochemistry.
Sections from the above regions were cut from flash frozen tissue and immunostained 
as described in section 2.4. The antibodies used in this study are listed in table 40. 
Ab340,  which  recognises  the  wild  type  and  mutant  precursor  proteins,  was  raised 
against the CHDKETYKLQR sequence of BriPP that is 10 residues N-terminal of the 
furin cleavage site.  For negative controls the pre-immune rabbit serum (Ab340 Pi) or 
immuno-absorbed Ab340 (Ab340 Abs - see section 8.2.3) were used. Experiments in 
which the primary antibodies were omitted were also carried out.
8.2.3  Immuno-absorption of Ab340
Immuno-absorption of Ab340 was carried out using frill length immunizing synthetic 
peptide (lOOpg of peptide per 50pl of antibody). Incubation was carried out for 1   hour 
at 37°C and 16 hour at 4°C, followed by centrifugation at 14,000g for 5 mins.
302Chapter 8- Expression of  BRI  mRNA
8.2.4  Double immunohistochemical staining for furin/GFAP and furin/NeuN
For the double immunohistochemical staining with light microscopy, the protocol was 
followed  as  described  in  section  2.2.2.  Using  the  glucose  oxidase  method  as  the 
chromogen for furin (section 2.14.7) and Novored (Vector) as the chromogen for GFAP 
and NeuN.
8.2.5  Double immunohistochemical staining for BriPP/GFAP and BriPP/NeuN
For double immunohistochemistry with BriPP and GFAP or NeuN, the protocol was 
followed  as  described  in  section  2.2.  Using  the  glucose  oxidase  method  as  the 
chromogen for furin (section 2.14.7) and Novored (Vector) as the chromogen for GFAP 
and NeuN.
8.2.6  Western blot analysis
Frozen cerebellum from four control cases and frontal cortex from the FBD case were 
used in the western blot analysis, and the protocol was followed as described in section 
2.15.
8.2.7  Northern blot analysis
Northern  blot  analysis  was  carried  out  on  a  normal  control  case  and the  FBD  case 
primarily to check the integrity of the RNA in the samples.  The protocol followed is 
given in detail in section 2.13.
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8.2.7  BRI2  mRNA in-situ hybridisation
In-situ  hybridisation  was  carried  out  in  the  control  cases,  FBD  and  AD  cases  as 
described above and the protocol followed is described in  section 2.15.  The negative 
controls used for this study were a  1 :1 0 0 dilution of the labelled probe and omitting the 
labelled probe completely. Three oligonucleotide probes were used in this study which 
are listed in table  15  in section 2.15.2. Although in a pilot experiment all three probes 
labelled the  same  structures,  probe  1  labelled the structures more intensely and was, 
therefore, chosen for this study.
8J  Results
8.3.1  Northern blot analysis
Northern  blot  analysis  of  mRNA  showed  good  preservation  of  mRNA  with 
hybridisation  of the  probe  for  the  control  housekeeping  gene  GAPDH  producing  a 
strong 1.4Kb band. A 2.0Kb species representing BriPP mRNA was identified using the 
BriPP probe (figure 8.1). The integrity of RNA, used in the northern blot analysis, was 
assessed by visualizing 28S and 18S ribosomal RNA bands on a denaturing agarose gel 
(figure 8.2). The integrity of the RNA was good as two bands were clearly visible. The 
upper 28S band appeared stronger than the lower 18S band and there was no smearing 
that would indicate degradation.
8.3.2  Western blot analysis
Immunoblotting  from  four controls  and  one FBD  case with Ab340  showed a strong 
band  at  34kDa  (figure  8.3),  which  was  absent  when  the  pre-immune  serum  or the 
Ab340 absorbed with immunising peptide, were used (figure 8.4). The presence of furin
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was confirmed in three control cases (1-3) using three different commercially available 
antibodies (figure 8.5). All of the antibodies demonstrated bands at 90kDa and 96kDa 
corresponding with the zymogen form and the cleaved lower molecular weight active 
form of furin, but two of the antibodies also showed multiple bands at lower molecular 
weights (figure 8.5). Therefore the antibody furin convertase (Affinity Bioreagents) was 
chosen to demonstrate the presence of furin in the four control cases (1-4), the FBD case 
(5)  using  western  blot  analysis  (figure  8 .6)  before  proceeding  onto  the 
immunohistochemical analysis.
8.3.3  Distribution of BRI2 mRNA assessed by in-situ hybridisation
A summary of the cases used in this study are given in table 41 and the major findings 
of the study are summarized in table 41.
BRI2 mRNA BriPP Furin
Control
Brain
Neurons + + +
Glia + - +
Vessels - - +
FBD Neurons + + +
Glia + - +
Normal vessels - - +
Preamyloid lesions - - -
Amyloid lesions V + + +
P + + +
AD Neurons + + +
Glia + - +
Normal vessels - - +
Preamyloid lesions - - -
Amyloid lesions V + - -
p - - -
Table 41: Summary of the  findings normal controls, FBD and AD.
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9.49 Kb — 
7.46 Kb —
4.40 Kb —
2.37 Kb- 
1.35 Kb-
A  B
Figure 8.1: Northern blot analysis of RNA extracted from the cerebellum 
of a normal control showing a 2.0kB band corresponding to BriPP (A) and 
a 1.4Kb band corresponding to GAPDH (B).
28s 
18s
A  B   C D
Figure 8.2: A denaturing gel showing the quality of the RNA used for the 
northern blot analysis. Two clear 28s and 18s rRNA bands can be seen in all 
four samples, A and C extracted from control cerebellum; B and D extracted 
from  control  frontal  cortex.  The  ratio  of approximately 2:1  (28s: 18s)  is  a 
good indication that the RNA is intact. Partially degraded RNA would have 
a smeared appearance and would lack sharp rRNA bands.
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39 kDa  -----
28 kD a-----
19 kDa-----
1  2  3  4  5
Figure  8.3:  Western blot  analysis  for BriPP,  using the  Ab340 
antibody demonstrates a band of 34kDa corresponding to BriPP 
in  the  cerebellum  of normal  controls  (cases  1-4)  and  in  the 
frontal cortex in the case of FBD (case 5).
Ab340 Pi  Ab340 Abs
191 kDa _
97 kDa —
64 kDa —
51 kDa —
39 kDa —
28 kDa —
14 kDa —
6 kDa —
3 kDa —
1 2   3  1 2   3
Figure  8.4:  Western  blot  analysis  using  Ab340  pre-immune 
serum (Ab340 Pi) and immunoabsorbed Ab340 (Ab340 Abs) in 
the cerebellum  of three control cases (1-3) demonstrating that 
the 34kDa band corresponding to BriPP is abolised.
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Prohormone  Furin  Prohormone
convertase  convertase  convertase 1
191 kDa  -----
97  kDa  -----——
64  kDa ----
51  kDa  -----
39  kDa ----
28  kDa----
1  2  3  1  2  3  1  2  3
Figure 8.5: Western blot analysis with three different anti-furin 
antibodies, in three normal controls (1-3). All three antibodies 
show  two  bands  at  96kDa  and  90kDa  corresponding  to  the 
zymogen form and the cleaved lower molecular weight active 
form  of  furin.  All  three  antibodies  were  purchased  from 
Affinity Bioreagents.
191  kDa  — 
97 kDa -   T
Figure  8.6 :  Western  blot  analysis  for  furin,  using  furin 
convertase  antibody  demonstrating  the  expected  two  bands 
around  of 90  and  96kDa  in  the  normal  controls  (1-4)  and the 
frontal cortex of a case of FBD (5). The higher molecular weight 
bands  represent  the  zymogen  form  of  furin,  while  the  lower 
molecular weight species corresponds to the active form of furin.
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The findings were similar in all the control brains so they will be described together. In 
all areas  examined  neurons of all  sizes  showed strong cytoplasmic labelling with the 
BRI2 probe (figure 8.7A and 8.7B). Not only was BRI2 mRNA expression seen in the 
cytoplasm  it  also  extended  into the  apical  dendrites  of pyramidal  cells  (figure  8.7C, 
arrow).  Labelling was easily identified in all regions and this was particularly marked 
in  the  granule  cells  of the  dentate  fascia  (figure  8.7E).  The  cerebellar  granule  cells 
showed a narrow rim of staining around the nucleus (figure 8.71, double arrow), while 
the  Purkinje  cells  expressed  BRI2  mRNA  in  proportion  to  the  volume  of  their 
cytoplasm  (figure  8.7H  and  8.71).  Positive  staining  was  shown to  be present  in the 
neurons of the cerebellar dentate nucleus (figure 8.7G). The neurons of the substantia 
nigra  (figure  8.7F)  were  similarly  strongly  labelled,  which despite the neuromelanin 
pigment  (brown)  could  be  unequivocally  established  (figure  8.7F).  No  labelling  of 
vascular  smooth muscle or endothelial  cells  (figure  8.7A,  arrow and  8.7D)  of blood 
vessels  of different  sizes  was  seen.  In  the  white  matter  glial  cells  showed  a  small 
amount of cytoplasmic staining (figure 8.7J) and the majority of the positively stained 
cells had an astrocytic morphology.  Control sections in which the labelled probe was 
diluted  1 0 0-fold  with  unlabelled  probe  or  when  the  probe  was  ommitted  from  the 
experiment showed no positive ISH staining (data not shown).
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Figure  8.7:  BRI2  in-situ  hybridisation  in  normal  human  brain.  In-situ 
hybridisation  for  BRI2  mRNA  demonstrated  strong  expression  in neurons  in  all 
areas of the normal brain as shown in the occipital cortex (A) and frontal cortex (B). 
Neurons of all types expressed the mRNA, this included an extension into the apical 
dendrite of the pyramidal cells (C, arrow). Arterioles found in the cortex remained 
negative (D,  arrow). The granule cells of the hippocampal dentate fascia strongly 
express BRI2 mRNA (E, arrow), as a narrow rim around the nuclei is clearly visible. 
The neurons in the substania nigra were also positive (F) as were the neurons in the 
dentate nucleus (G). In the cerebellum the Purkinje cells were strongly stained (H 
and I, arrow), while the granule cells showed a narrow rim of staining around the 
nucleus (I, double arrow). For comparison the granule cells from a negative control 
stained by omitting the probe is also shown (I, inset). Glial mRNA expression was 
demonstrated in the cerebellar white matter (J). Bar in A and B represents 250pm; 
on G and H represents 500pm; on D and F represents  100pm;  on G, E, I and K 
represents 45 pm; J represents 20pm.
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8.3.4  Distribution and staining pattern of BriPP in normal human brain
The distribution of the full-length precursor protein BriPP was demonstrated using the 
antibody  Ab340,  which was  raised  against  a  region  of BriPP  proximal  to  the  furin 
cleavage site. This showed strong diffuse cytoplasmic labelling in neurons of all sizes in 
all  regions  of the  brain  examined  (figure  8 .8A and  inset).  The Purkinje  cells  of the 
cerebellum  showed  strong  labelling  reflecting the  amount  of cytoplasm (figure  8 .8E 
double arrow,  8 .8F arrow) compared to the thin rim of staining seen around the granule 
cells (figure 8 .8F and insert). Strong staining was visible in the cytoplasm of the granule 
cells  of the  dentate  fascia  of the  hippocampus  (figure  8 .8B)  and  all  other  regions 
studied, including the pons (figure  8 .8C), cerebellar dentate nucleus (figure  8 .8D) and 
the substantia nigra (figure 8 .8D, inset).
Blood  vessels  were  consistently  unstained  by  Ab340  (figure  8 .8E,  arrow).  Neuronal 
staining was confirmed by double immunohistochemical labelling using an antibody to 
the  neuronal  marker NeuN  used  in  combination  with  the  Ab340  antibody (data  not 
shown).  It  was  not  possible  to  demonstrate  BriPP  expression  in  glial  cells  by 
immunohistochemical means in the normal controls (data not shown).
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Figure  8 .8 :  BriPP  immunohistochemistry  in  normal  human 
brain.  BriPP  expression  was  observed  in  all  neuronal  types 
demonstrated  in  cerebral  cortex  (A),  with expression extended  into 
the  apical  dendrites  (A,  inset),  granule  cells  of the  hippocampal 
dentate fascia (B), pons (C),  cerebellar dentate nucleus (D) and the 
substantia  nigra  (D,  insert).  The  cerebellar  Purkinje  cells  show 
abundant  cytoplasmic  staining  (E)  and  there  is  a narrow  band  of 
staining around the nucleus in the granule cells  (F): Inset on F shows 
a negative control in which the primary antibody was omitted. Blood 
vessels  were  found to  be  negative  (E,  arrow).  Bar  in A  represents 
100pm; on panels C and D represents 250pm; on panels D (inset), F 
and  F  (inset)  represents  100pm;  on  panels  A  (inset),  B  and  E 
represents 30pm.
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8.3.5  Distribution and staining pattern of furin in normal human brain
In all of the brain regions examined a pattern of immunohistochemical staining for furin 
similar to that of BriPP was seen. Neurons of all sizes in all cortical (figure 8.9A), sub- 
cortical,  brainstem  (figure  8.9F)  and  cerebellar (figure  8.9E)  regions  examined were 
strongly positive for furin with a punctate cytoplasmic staining pattern. The cytoplasmic 
positivity  also  extended  into the apical  dendrite  of pyramidal  cells  (figure  8.9A and 
inset).  Similar to the pattern seen with BRI2  mRNA in situ hybridisation and BriPP 
immunohistochemistry,  furin immunohistochemistry showed a narrow rim of staining 
around the nucleus of the cerebellar granule cells, which is in keeping with the volume 
of the cytoplasm of these cells (figure 8.9E,  double arrow). A similar staining pattern 
was  observed  when  the  granule  cells  of  the  hippocampal  dentate  fascia  were 
investigated (figure 8.9B). Leptomeningeal vascular smooth muscle cells were positive 
for furin (figure 8.9G, arrows).
Double  immunohistochemical  staining with  antibodies to  furin  and NeuN confirmed 
neuronal  cytoplasmic  furin  expression  but  also  showed  that  in both grey  and  white 
matter  small  NeuN  negative  cells  showed variable  positivity  for  furin  and  therefore 
represent  glia  (figure  8.9H,  arrows).  Using  double  labelling  with  GFAP  to  identify 
astrocytes it was  not  possible to  demonstrate that  such positively  labelled  cells were 
astrocytes.
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Figure  8.9:  Furin  immunohistochemistry  in  normal  human 
brains. Furin expression could be demonstrated in all neuronal types 
in different regions including the frontal cortex (A) granule cells of 
the hippocampal dentate fascia (B), dentate nucleus (C), substantia 
nigra (D), cerebellar Purkinje cells and granule cells (E) and pontine 
neurons (F). Blood vessels were also positive (G). Glial  cells were 
also labelled in white matter (H). Bar in A, C represents 100pm; on 
panel F represents  500pm;  on panels B, E, D, G and H represents 
45 pm.
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8.3.6  Distribution of BRI2 mRNA assessed by in-situ hybridisation in FBD
In a case of FBD in-situ hybridisation showed a BRI2 mRNA expression pattern similar 
to that observed in the normal human brain with strong staining in neurons throughout 
the cortical layers of the frontal cortex (figure 8.10A and insert), the hippocampal CA1 
subregion and the dentate fascia (figure 8.1 OB). Normal blood vessels without amyloid 
deposition  were  negative,  whereas  vascular  structures  affected  by  ABri  amyloid 
deposition showed strong positive staining (figure 8.10A arrow and 8 .IOC). In addition, 
parenchymal  amyloid  lesions were also found to contain BRI2  mRNA (figure  8.10D 
and 8.10E), but the pre-amyloid ABri lesions remained unstained. Positive staining of 
glial cells with an astrocytic morphology was found in the white matter of the frontal 
cortex (figure 8 .10F). In sections from FBD in which the probe was omitted no staining 
was seen.
8.3.7  Distribution and staining pattern of BriPP in FBD
In  the  FBD  case  immunohistochemical  labelling  for BriPP  in the  hippocampus  and 
frontal cortex showed the same staining pattern as described in the normal human brain. 
Neurons  throughout  the  cortical  layers  of the  frontal  cortex  (figure  8.11 A)  and  the 
hippocampal  subregions were strongly stained.  Strong staining was also visible in the 
dentate  fascia  of the  hippocampus  (figure  8.1 IB).  ABri  amyloid  plaques  and  blood 
vessels  with  amyloid  deposition  were  also  positively  labelled  (figure  8 .11E).  Large 
hippocampal  plaques that had distinct central  cores (figure 8.11C) were  stained with 
equal intensity,  along with the plaques that were less well defined in appearance and 
lacked the central core,, but were still classed as amyloid plaques (figure 8.1 ID).
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Figure  8.10:  BRI2  in-situ  hybridisation  studies  in  FBD.  BRI2 
mRNA  expression  demonstrated  in  the  frontal  cortex  (A),  and  at 
higher magnification (A, insert) The granule cells of the hippocampal 
dentate  fascia  strongly  express  BRI2  mRNA  (B).  Positive  staining 
was  also  seen  in  all  amyloid  structures  in  FBD  including  amyloid­
laden blood vessels (A, arrow and C), cored plaques (D) and less well 
defined plaques (E). Glial mRNA expression was demonstrated in the 
white matter of the  frontal cortex (F,  arrow), the majority of which 
had astrocytic morphological appearance. Bar in A represents 500pm; 
on  panels  B  and  C  represents  100pm;  on  panels  D  -  F  represents 
55pm.
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Figure  8.11:  BriPP  immunohistochemistry  in  an  FBD  case.
Immunohistochemical staining using the Ab340 which recognises the 
full  length wild-type BriPP and N-terminal fragments of both wild- 
type and mutant precursor proteins produced by furin-like cleavage. 
All neurons were positive in the frontal cortex (A) and throughout the 
hippocampus, including the dentate fascia (B). Positive staining was 
also  seen  in  all  structures  containing  amyloid,  including  cored 
plaques found in the CA4 (C), ill defined white matter ABri deposits 
(D, arrow) and amyloid-laden blood vessels (E). Bar in panel A and 
C represents 45pm: on panels B, D and E represents 100pm.
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8.3.8  Distribution and staining pattern of furin in FBD
Immunohistochemical staining for furin showed similar staining patterns to those found 
in the normal human brain (figure 8.12A and 8.12B). Blood vessels affected by amyloid 
deposition  (figure  8.12E,  double  arrow)  were  intensely  stained  with  the  anti-furin 
antibody,  as were  amyloid  plaques with  or without  a dense  core  (figure  8.12C  and 
8.12D).  Glial  cells were  stained throughout the frontal cortex and hippocampus with 
their morphology suggesting that they were astrocytes (figure 8.12F).
8.3.9  Distribution of BRI2 mRNA, BriPP and furin in AD
In both sporadic AD and variant AD with cotton wool plaques the distribution of BRI2 
mRNA, BriPP and furin was similar in neurons and glia to that found in controls and in 
FBD.  In variant AD with cotton wool plaques,  in which cerebral  amyloid angiopathy 
(CAA) is a prominent feature, BRI2 mRNA was found in the walls of amyloid laden 
blood vessels although the cotton wool plaques, which are largely composed of Ap in 
preamyloid  conformation,  did  not  contain  the  mRNA.  In  sporadic  AD  the  amyloid 
plaques and amyloid laden blood vessels did not contain BRI2 mRNA although CAA 
was sparse in the cases available for study (results not shown). No deposition of BriPP 
or furin was found in either amyloid or preamyloid lesions in sporadic or variant AD.
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Figure  8.12:  Furin  immunohistochemistry  in  an  FBD  case. 
Immunohistochemical  staining  for  furin  was  used  to  determine  the 
distribution of protein expression. Expression was seen in all neuronal 
cells throughout the hippocampus CA1  (A)  and the  granule cells of 
the dentate fascia (B).  ABri plaques with (C) or without a core (D) 
were also positive with furin. Panel E shows the expression of furin in 
an  arteriole alongside a neuron with expression spreading down the 
apical dendrite. Glial cells with clear astrocytic morphology are also 
shown  to  be  positive  with  furin  immunohistochemistry.  Bar  in  A 
represents  100pm;  on  D  and  C  represents  100pm;  on  B,  E  and  F 
represents 45 pm.
319( hapier 8- Expression o f BRI  mRNA
8.4  Discussion
This study demonstrated that BRI2 mRNA is widely expressed by neurons and also by 
glial cells throughout the normal brain. Immunohistochemistry showed that both BriPP 
and furin are also widely  expressed,  mainly by  neurons,  in the normal human brain. 
Vascular smooth muscle cells were found to have detectable levels of furin but neither 
BRI2  mRNA nor BriPP were  identified in this  site.  The cellular expression of BRI2 
mRNA, BriPP and furin was similar to controls in cases of FBD and AD although in the 
former  glial  cells  with the  morphology  of reactive  microglia were  found to  express 
BRI2 mRNA and in both diseases reactive astrocytes contained  furin. In FBD vascular 
and parenchymal amyloid lesions, but not preamyloid deposits contained BRI2 mRNA, 
BriPP and furin.  In contrast in AD BRI2 mRNA was found only in vascular amyloid 
deposits and there was no lesional deposition of either BriPP or furin.
In  the  present  investigations,  the  polyclonal  Ab340  antibody,  recognising  the 
CHDKETYKLQR amino acid sequence that is present in both the wild type BriPP and 
the mutated precursor protein was used to demonstrate BriPP and ABriPP in both the 
immunohistochemical and in immunoblotting studies.  The antibody was characterised 
by  immunoblotting  and  was  found to  recognise  a  band with  an expected molecular 
weight  for  BriPP  of approximately  34kDa  which  was  absent  when  the  preimmune 
serum or the antibody absorbed with synthetic peptide was used for immunoblotting. 
Furthermore,  no  staining  was  observed  in  control  tissue  sections  when  the  same, 
absorbed antibody was used for immunohistochemistry. From the data presented here it 
can be established that BriPP  is  expressed by all  neuronal  cell  types throughout the 
normal human brain and in both FBD and AD, but no unequivocal staining of glial cells 
was  established  despite  the  presence  of BRI2  mRNA  in the  latter.  The  amino  acid 
sequence recognized by Ab340 is  10 residues upstream of the furin cleavage site (Kim
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et a l, 1999; Vidal et a l, 1999; Vidal et a l, 2000b). Therefore this antibody is expected 
to  recognise  not  only  the  full-length,  but  also  the  243-amino-acid-long  N-terminal 
fragment generated by furin-like processing of both the wild type BriPP and mutated 
precursor  protein  ABriPP  making  it  possible  that  the  presence  of  both  of  these 
fragments  have  contributed to the positive  immunohistochemical  results (Kim et a l, 
1999;  Vidal  et  a l,  1999;  Vidal  et  a l,  2000b).  Using  three  commercially  available 
antibodies for furin immunoblotting in the control brains and the FBD case which were 
used  for BriPP  and  ABriPP  immunoblotting,  we  demonstrated two bands  at  90  and 
96kDa, corresponding to the zymogen form of the enzyme (Denault & Leduc,  1996). 
Using the furin convertase antibody for furin immunohistochemistry we were able to 
show that both  neurons and glial  cells are  involved  in  furin expression and this can 
widely be observed in the normal human brain.
The findings of BriPP immunoblot and immunohistochemical studies are supported by 
the  current  in-situ  hybridisation  investigations  for BRI2  mRNA,  which  confirmed  a 
widespread mRNA expression with strong labelling of the hippocampal/dentate fascia 
neurons  and  cerebellar  Purkinje  cells.  We  were  able  demonstrate  BRI2  mRNA 
expression  by  glial  cells  in  the  white  matter,  although  no  protein  expression  was 
detected  immunohistochemically.  There  may  be  several  reasons  for  the  absence  of 
immunohistochemically detectable BriPP in glial cells;  1) the mRNA is not translated 
into protein;  2) the protein has a rapid turnover;  3) that the precursor protein may be 
present in  such small amounts that it is not detectable with the immunohistochemical 
method used in the current study. Further studies are required to clarify these issues.
A study using in-situ hybridisation and immunoblotting for the demonstration of mouse 
BRI2 mRNA and BriPP,  has also  suggested that both mRNA and protein are widely 
expressed in both grey and white matter of the mouse brain with greatest expression in
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the cerebellum, granular layer of the hippocampus, and olfactory bulb (Pickford et al., 
2003).  This  latter  study also  emphasised that  structures with a high level  of mRNA 
expression  are  among  those  in  which  neurogenesis takes  place  in  adult  mammalian 
brain  (Taupin  &  Gage,  2002),  which  is  interesting  in  view  of the  role  of the BRI2 
homologue BRII  gene  in  differentiation  (Deleersnijder et  al.,  1996;  Pickford  et al, 
2003).
Previous  studies have suggested that the hippocampus and cerebellum are among the 
structures with a high level of BRI2 mRNA expression (Pickford et a l, 2003; Vidal et 
a l,  1999).  Corresponding protein  expression  may  help to  explain  an especially  high 
degree  of  ABri  or  ADan  deposition  with  subsequent  neurodegeneration  in  these 
structures in FBD and FDD (Chapters 3 and 4, Holton et al., 2001a; Plant et al,  1990; 
Revesz et a l,  1999; Holton et a l,  2002a).  That mRNA and protein expression alone 
may not be the sole factor that determines the development of pathological, preamyloid 
and  amyloid  lesions  in  different  cerebral  anatomical  areas  may  be  supported by the 
current observation showing strong positivity in both BRI2 mRNA in-situ hybridisation 
and  BriPP  immunohistochemical  studies  in  structures  such  as  the  striatum  and  the 
substantia nigra, which are not, or only mildly, affected in FBD (Holton et al., 2001a; 
Holton et al., 2002a).
This  study  has  also  shown that  in FBD  both the vascular and parenchymal  amyloid 
lesions contain furin, BRI2 mRNA and BriPP. Furin, which has been suggested to be 
involved in the processing of BriPP (Kim et al.,  1999a), has also been implicated in the 
proteolytic processing of the precursors of several molecules associated with cerebral 
amyloid deposition. These include BACE, which mediates cleavage of (3APP to produce 
the N-terminus of the A0 peptide in AD; ADAM 10 and AD  AM 17 (Lopez-Perez et al., 
2001), which have been implicated in a-secretase activity leading to cleavage within the
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Ap  sequence  of pAPP;  gelsolin,  the precursor protein for the  amyloidogenic peptide 
AGel, deposition of which results in a form of familial cerebral amyloid angiopathy and 
the  recently described protein,  CLAC,  which  co-localises  to  amyloid plaques  in AD 
(Benjannet et al., 2001; Bennett et al., 2000; Chen et al., 2001; Creemers et al., 2001; 
Hashimoto et al., 2002).
The  findings  of this  current  study  show  that  furin  and  BriPP  (and/or  ABriPP)  are 
present in the  amyloid lesions  of FBD.  This points to the possibility that proteolytic 
processing may occur in lesions. Furin and BriPP deposition in ABri amyloid lesions is 
unlikely to be due to non-specific binding to amyloid peptides as neither were identified 
in  Ap  amyloid  lesions  in  AD.  This  could  be  supported  by  those  in  vitro  data 
demonstrating that furin, which is a membrane bound protein and localised in the Golgi 
apparatus, also has a secreted form, which having been released via post-translational 
modifications of the membrane associated form, maintains enzymatic properties that are 
similar  to  those  of  the  wild-type  enzyme  (Vidricaire  et  a l,  1993).  Our  in-situ 
hybridisation studies showed BRI2 mRNA is also present in vascular and parenchymal 
amyloid deposits in FBD and in vascular amyloid in AD. Previous studies analysing the 
non-proteinaceous  components  of senile  plaques  have  identified  about  50  different 
mRNA  species,  including  ApPP,  tau  and  furin  and  it has  been  suggested  that  both 
normal and degenerating neurons and their processes, which are in close contact with 
the  amyloid  plaques  in  AD,  are  a  source  of the  mRNAs  in  the  amyloid  lesions 
(Ginsberg et a l,  1998; Marcinkiewicz, 2002). The current findings that BRI2 mRNA 
deposition takes place in ABri amyloid lesions, which as Ap neuritic plaques in AD, are 
surrounded with abnormal neurites in FBD, but is absent in the non-neuritic preamyloid 
lesions  of FBD  and  cotton  wool  plaques  in  variant  AD  are  also  in  keeping  with  a 
dendritic origin of deposited BRI2 mRNA. The significance of previous and our current
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observation of association of mRNA in amyloid lesions is not clear. However, recent in 
vitro  studies  demonstrated  that  conversion  of  cellular  prion  protein  (PrPc)  to  the 
pathological,  protease-resistant  form  (PrPS c)  is  stimulated  by  the  presence  of RNA 
(Deleault et a l, 2003). It remains to be investigated whether RNA is a cofactor in the 
conversion of other soluble, native proteins to forms with high p-sheet content.
This  study  shows  that,  although  there  is  local  furin  protein  expression,  there  is  no 
significant BRI2 mRNA and BriPP protein expression in vivo by the cellular elements, 
including  smooth  muscle  cells  of the walls  of cerebral  arteries  and arterioles,  which 
have been implicated in the pathogenesis of CAA related to Ap deposition (Frackowiak 
et al.,  1994). The importance of this current observation is at least twofold:  1.) it could 
provide  evidence  that  CAA  may  not  be  due  to  local  production  of  ABri  by 
cerebrovascular  smooth  muscle  or  other  vascular  cells  in  FBD  and  2.)  it  may  lend 
indirect support to the drainage hypothesis of CAA pathogenesis put forward by Weller 
et  al.  (1998).  According  to  this  proposal  Ap  produced  primarily  by  CNS  cellular 
elements,  is  drained  along  the  perivascular  spaces  of the  brain  parenchyma  and 
leptomeninges and CAA occurs due to deposition of the amyloid proteins along these 
drainage pathways. It remains possible that a small amount of BRI2 mRNA and BriPP 
at levels below the threshold of the methods used in this study could be expressed by 
vascular components. Should this be the case it seems likely that this would represent a 
minor contribution to the deposition of protein in CAA. Theoretically it is also possible 
that in FBD the mutated precursor protein is drained along the drainage pathways and 
processed by furin produced by cerebrovascular smooth muscle cells and released in the 
extracellular  space.  This  possible  mechanism,  even  if  future  experimental  studies 
supported its feasibility, would not explain amyloid deposition in capillaries, which do 
not possess smooth muscle cells,  and also that,  similar to AD, larger arteries are less
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affected by CAA than small arteries and arterioles in FBD. It is also of note that in FBD 
the amyloid peptides ABri has been shown to be present in the plasma at levels 20 times 
higher than that of AP and, in at least FBD, amyloid deposition in systemic organs has 
also  been  documented  (Ghiso  et al.,  2001).  It  remains,  however,  to be  investigated, 
perhaps  with  the  help  of future  transgenic  animal  models  and  other  experimental 
approaches, how efficient the separation of the central and peripheral pools of ABri and 
ADan  is by the blood brain barrier, and thus determine the role systemically produced 
ABri species may play in the pathogenesis of cerebral amyloid lesions in FBD.
In  conclusion  this  study  has  presented  evidence  that  BRI2  mRNA  is  produced  by 
neurons  and  glia in  normal  human brain.  The presence of furin  in  neurons  and glia 
suggests that cleavage of the wild type and mutated precursor proteins can take place in 
these cells, resulting in the generation of C-terminal fragments, including ABri.  These 
findings confirm previous suggestions for a cerebral, neuronal and possibly glial origin 
of these  amyloid  peptides.  The  absence  of BRI2  mRNA  in  cerebrovascular  cells 
suggests that local production of ABri by vessels is unlikely to represent a significant 
source of these peptides and gives indirect support to the drainage hypothesis of CAA.
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9  Conclusions
9.1  Comparisons between FBD and FDD
FBD  and  FDD,  collectively  referred to  as the BR12  gene-related or chromosome  13 
dementias,  constitute alternative models for studying the role of amyloid deposition in 
neurodegeneration. The studies presented in this thesis have shown that the novel ABri 
and ADan amyloid peptides extensively deposit in the brain parenchyma in FBD and 
FDD,  respectively.  Both  diseases  also  demonstrate  severe  CAA  with  perivascular 
plaque formation occurring throughout the CNS. Despite the complete homology of the 
first 22 amino acids of ABri and ADan, significant differences were demonstrated in the 
morphological  manifestation  of  the  two  diseases.  In  FBD  the  majority  of  the 
parenchymal ABri lesions are well-defined, plaque-like and of amyloid nature, although 
pre-amyloid  lesions  are  also  present.  In  contrast,  in  FDD  the  majority  of  the 
parenchymal ADan lesions have ill-defined boundaries and show features of preamyloid 
rather than  amyloid  conformation.  In FDD,  but not  in FBD,  Ap  deposition either in 
combination with ADan or alone was also demonstrated in blood vessel walls and in 
brain parenchyma, the significance of which remains to be investigated.
Importantly despite these differences in ABri and ADan parenchymal lesion types, both 
diseases have a common end point - severe neurofibrillary pathology. Whether the pre­
amyloid lesions represent the oligomeric assemblies, which have recently emerged as a 
major  pathogenic  factor  in  a  number  of neurodegenerative  diseases  characterised  by 
protein misfolding (Klein et al., 2001), remains to be determined.
As previously  shown in AD, this study demonstrated a close association between the 
conformational  state of ABri  and  ADan  and  the  degree  of astrocytic and  microglial 
response (el Hachimi et al., 1991; Pike et al., 1995; Selkoe, 1999).
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9.2  Amyloid associated proteins, including complement components in FBD 
and FDD.
This study established that AAPs and complement proteins, that have been shown to be 
associated with  Ap  deposits  in AD,  are  also  present in ABri and ADan lesions thus 
supporting  the  notion  that  these  proteins  may  have  a  general  role  in  amyloid  fibril 
formation. In general, AAPs co-deposited with both amyloid and preamyloid ABri and 
ADan  lesions;  ApoE,  ApoJ,  agrin,  glypican-1  and  HS  GAG  side  chains  were 
extensively  associated with  both  lesion types whereas  syndecans,  HSPGs,  ACT  and 
SAP were predominantly seen in relation to amyloid lesions.  It was hypothesised that 
binding of some AAPs to proteins in preamyloid conformation is due to the presence of 
variable numbers of amyloid fibrils that can be found in these lesions. The experimental 
data currently  available are not sufficient to explain the predominance of preamyloid 
lesions in FDD. One possibility is that due to the difference in the primary amino acid 
sequence  ADan  forms  amyloid  fibrils  less  efficiently  than  ABri  does,  although 
conversion of multiconformational proteins into predominantly p-pleated fibrils is not 
thought to be significantly dependent only on sequence (Lansbury, Jr.,  1999). However, 
the difference in the amino acid sequence could be sufficient to make ADan less able to 
attract and/or bind to AAPs such as ApoE, ApoJ, proteoglycans,  SAP or ACT.  These 
have been shown to modulate aggregation of Ap in vivo and would be required, possibly 
in combination with other factors for efficient fibril formation.  To test this hypothesis 
further biochemical investigations are required.
The importance of inflammation in neurodegenerative processes has become clear over 
recent  years.  Amyloid  fibrils  are  believed  to  result  from  a  change  in  the  native 
conformation  of  amyloidogenic  peptides  resulting  in  insoluble  structures,  which 
accumulate in the form of either intra- or extracellular aggregates. In turn, these deposits 
trigger a complex set of inter-linking pathways usually associated with the local release
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of inflammatory  mediators,  complement  activation,  cell  toxicity  and  alterations  in 
membrane permeability.
This  study  demonstrated  in  vivo  that  both the  classical  and  alternative  complement 
pathways are fully activated in FBD and FDD and that complement inhibitors are also 
present  in  the  ABri  and  ADan  lesions.  This  activation  was  dependant  on  the 
conformational state of these amyloid peptides as Clq, the recognition components of 
the classical pathway, was shown to co-localise strongly with vascular and parenchymal 
ABri and mainly with vascular ADan amyloid lesions while no, or only weak, staining 
of the preamyloid lesions was found. This observation also explains the different levels 
of activation of downstream components of the classical pathway that was demonstrated 
in this study in relation to amyloid and preamyloid parenchymal lesions. As it has been 
suggested for AD (Eikelenboom P et al 1982), activation of complement pathways may 
be a factor in the neurodegenerative process in both FBD and FDD.
Microglial  cells  and  astrocytes  are  both  known  to  produce  inflammatory  mediators, 
including  complement  proteins  (McGeer  and  McGeer  1995,  2001).  Complement 
deposition was  also  associated with  significant activated microglial  response in FBD 
and FDD.  Co-localization of reactive astrocytes and microglial  cells with ABri  in (3- 
conformation is strikingly similar to the findings in AD, in which a relationship between 
the presence of these cell types and the neurodegenerative events has been suggested (el 
Hachimi etal.,  1991; Pike etal., 1995; Selkoe, 1999)
9.3  Comparison between ABri and ADan
The complexity and heterogeneity of FBD and FDD tissue deposits was assessed using 
biochemical  and  immunohistochemical  approaches.  For  biochemical  analysis  a 
differential  solubility  strategy  was  used;  water-based  buffers  for  the  extraction  of
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soluble  peptides,  detergent  for the removal  of non-fibrillar pre-amyloid deposits  and 
strong acid to solubilise fibrillar amyloid deposits. In both diseases, the complexity of 
the extracted material increased as the solubility of the deposits decreased, as reflected 
in the degree of peptide oligomerisation, predominant amyloid subunits, and extent of 
post-translational  modifications  and  magnitude  of  N-  and  C-terminal  proteolytic 
degradations.  In general, non-fibrillar deposits appeared less complex in the degree of 
polymerisation  and  the  extent  of post-translational  modifications  than  their  fibrillar 
counterparts.  The post-translational modification of the N-terminus from glutamate to 
the  cyclic  pyroglutamate  observed  in  both  ABri  and  ADan  is  interesting  and 
mechanistically informative,  since the formation of pyroglutamate is chemically stable 
and poorly reversible.  The presence of the N-terminal pyroglutamate,  previously also 
found in other CNS amyloids is thought to increase the p-sheet content of the ABri and 
ADan peptides as well  as their tendency to aggregate and polymerise and may offer 
protection against in vivo proteolysis by amino peptidases (Saido et al 1995).
Using the same biochemical approaches the major Ap amyloid deposits were found to 
be  AP4-42  and  Apl-42  in FDD,  whereas those  ending at position 40 were found  in 
negligible amounts. Immunohistochemical studies confirmed the findings observed with 
MS, that Apx-42 is a major Ap species with Apx-40 shown in negligible amounts. The 
immunohistochemical  studies  also  showed  the  presence  of additional,  including  N- 
terminally modified Ap species [Nl, Nl(rD), N3(pE) and N1 l(pE)] that were present in 
all lesion types. The predominance of the Apx-42 in blood vessels is in striking contrast 
to previous studies, also confirmed by the current investigations,  showing that Apx-40 
peptides  isolated  from  blood vessels  in  sporadic  AD  and  FAD  are the predominant 
peptide species in CAA (Alonzo NC et al 1998). Whether the predominance of AP4-42 
in FDD, which has been shown to be more toxic than the Apl-40 species (Pike et al
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1995), represents an event that could have a major implication on the pathogenesis of 
this disease or reflects specific conformational mimicry requires further studies.
9.4  The  BRI2  protein  (BriPP)  and  the  brain  with  implications  on  the 
understanding of the origin of ABri and ADan.
To  determine  the  cell  types  implicated  in  the  cerebral  production  of BriPP  control 
human  and  FBD  brain  tissue  was  probed  by  in-situ  hybridisation, 
immunohistochemistry  and  biochemical  methods.  The  presence  and  distribution  of 
furin,  which  has  been  implicated  in  the  processing  of the  BriPP,  was  studied  by 
immunohistochemistry. BRI2 mRNA was detected in neurons and glial cells but not in 
cerebrovascular smooth muscle cells or other blood vessel cellular components. BriPP 
was  expressed  by  neurons,  but  not  significantly  by  glia  or  cerebrovascular  smooth 
muscle cells. Furin was found in both neurons and glia and, in contrast to BriPP, also in 
smooth  muscle  cells.  In  FBD  both  the  vascular  and  parenchymal  amyloid  lesions 
contained BRI2 mRNA, BriPP and furin. These studies have confirmed that the cellular 
elements of the CNS are a major source of BRI2 mRNA, BriPP and furin and that the 
preconditions for processing the precursor protein are present.
The finding of this study that neurons are a major source of BriPP and also produce 
furin,  together with the  observation that  BRI2  mRNA  or BriPP  is  not  detectable  in 
cerebrovascular smooth muscle cells, could have an implication on our understanding 
the pathomechanism of CAA. These findings lend indirect evidence for the support of 
the  drainage  hypothesis  which  has  been  proposed  as  a  major  mechanism  of CAA 
production  in  AD  (Weller  et  al  1998).  The  findings  of this  study  do  not  exclude, 
however that circulating, systemically produced ABri and ADan could also be a source 
of the cerebral amyloid lesions in FBD and FDD.
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9.5  Future investigations
1)  The  co-existence  of BriPP  and  furin  in  neurons,  as  demonstrated  in  this  thesis, 
indicated that these cells are a likely source of ABri and ADan amyloid. However this 
study  was  unable  to  detect  intracellular  ABri  and  ADan  in  these  cases.  Further 
investigations into the potential intracellular accumulation of ABri and ADan in nerve 
cells  would  be  important  to  further  our  understanding  of  neurodegeneration. 
Immunofluorescence experiments using thioflavine S, anti-oligomer specific antibodies 
in  conjunction  with  ABri,  ADan  and  NeuN  would  allow  identification  of neurons 
containing  ABri  and  ADan  species.  If  such  neurons  are  found,  additional 
immunohistochemistry  using  commercially  available  antibodies  to  various  organelle 
markers could be used to assess the subcellular localisation.
2) Genetically modified laboratory animals that recapitulate the degenerative disorders 
of FBD and FDD could provide an invaluable tool to investigate the molecular 
mechanisms of neurodegeneration and may result in a better understanding of the link 
between amyloid deposition and neurodegeneration.
Animal models which have been shown to have circulating ABri and ADan may soon 
be available, but to date there is no information about the deposition of ABri and ADan 
in the CNS of such animals (J Ghiso, unpublished data). The morphological evolution 
of the cerebral lesions would be explored and correlated with biochemical analysis by a 
time course study. The impact of ABri, ADan cerebral amyloidosis on tau aggregation 
could  be  studied  by  crossing these  animals with  those  having  mutated or wild-type 
human tau.
3)  The role  of microglia and astrocytic involvement in the pathogenesis of FBD and 
FDD,  has been shown to be similar to that observed in AD. Numerous studies in AD
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have described how microglial lineage cells secrete neurotoxic factors upon stimulation 
with  A|3  peptides,  including  soluble,  oligomeric  and  ADDLs.  It  would  therefore  be 
interesting  to  investigate  the  effects  of the  different  forms  of the  ABri  and  ADan 
peptides on cultured microglia and astrocytic cell lines. Whether the activation of the 
glial  cells would result in the production neurotoxic factors that kill primary cultures 
neurons would be interesting and informative as to the neurotoxic species in these two 
diseases.
4) In FDD,  but not in FBD,  Ap deposition either in combination with ADan or alone 
was  also  demonstrated  immunohistochemically  in  blood  vessel  walls  and  in  brain 
parenchyma.  The  biochemical  analysis  carried  out  in  this  study  demonstrated  the 
presence of AP4-42 in FDD, which has been shown to be more toxic than the Apl-40 
species (Pike et al 1995). Further studies to refine the extraction techniques using laser- 
capture  microdissection  method  to  extract  blood  vessels  and  parenchymal  deposits 
containing amyloid species in FDD and subject them to similar biochemical techniques 
carried out in this thesis. Further double immunoelectron microscopy would be carried 
out on more regions to validate the interaction between the two amyloidogenic peptides.
5) Recent studies support that CAA is likely to be a cofactor of dementia in AD. The 
effect of CAA on brain parenchyma would be studied by determining synaptic loss in 
relation to amyloid laden blood vessels in brain areas less affected by amyloid plaque 
formation. For this synaptophysin immunohistochemistry would be used and the density 
of the  synaptic  staining  pattern  measured with  density  measurements  and  compared 
between regions around the glial limitans.
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In parallel the effect of ABri and ADan/Ap on vascular smooth muscle and endothelial 
cells will be determined by assessing blood vessel cell lining integrity using confocal 
microscopy  with  anti-CD31  and  anti-smooth  muscle  actin  in  conjuction  with  the 
corresponding anti-amyloid antibody. Results can then be correlated with the severity of 
CAA.
9.6  Concluding remarks
FBD and FDD are two cerebral amyloid diseases and without ABri and ADan sharing 
any structural identity with Ap, show important similarities in their neuropathological 
features to AD. These include widespread CAA, perivascular plaques, neuritic and non- 
neuritic parenchymal plaques and NFTs with the classical paired helical filaments. The 
parenchymal plaques in FDD are primarily of the preamyloid type and co-deposition of 
Ap also takes place in this disease. In both FBD and FDD the patterns of co-deposition 
of AAPs, complement components and inhibitors is similar to that seen in AD. The bl­
and C-terminal heterogeneity, post-translational modifications and oligomerisation of 
ABri and ADan increase as the solubility decreases. ABri and ADan may derive from 
several sources, but it is likely that cerebral cellular elements, primarily neurons play an 
important or crucial role in the production of these two amyloid peptides. Previous data 
and those described in this thesis, support the notion that different amyloid peptides, 
irrespective of their primary structure, can trigger similar pathological pathways 
resulting in neurodegeneration. FBD and FDD are proposed to be valuable alternative 
models for the study of the mechanisms of cerebral protein aggregation/amyloid 
formation and neurodegeneration, and it is anticipated that future studies of these 
diseases will be able to provide further important insight into the pathogenesis of a wide 
range neurodegenerative diseases.
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Al  Reagents for immunohistochemistry 
A 1.1  0.05M Phosphate buffered saline (PBS)
To 20 litres of distilled H2O add 142.4g di-sodium hydrogen orthophosphate (Na2HPC>4, 
BDH), 27.6g sodium dihydrogen orthophosphate dehydrate (NaH2Po4, BDH) and 180g 
NaCl (BDH). Adjust pH to 7.4.
A1.2  Citrate buffer i5
To 2 litres of distilled water, add 29.4g tri-sodium citrate (BDH) and 2.25g citric acid 
(BDH). Adjust pH to 6.0.
A2  Reagents used for RNA extraction
A2.1  DEPC water
Add 0.5ml of diethyl pyrocarbonate (Sigma D5758) to 500ml water, leave overnight in 
a fiime hood and then autoclave.
A2.2  10% (w/v) Sarcosyl
Dissolve lOg of N-lauroylsarcosine (Sigma L5125) in 100ml water; treat with 0.1% 
(v/v) DEPC and autoclave.
A2.3  Sodium citrate (0.75 M; pH7.0)
Dissolve 22.06g citric acid tri-sodium (Sigma C8532) in 80ml water pH7 with HCL and 
make volume to 100ml. Treat with 0.1% (v/v) DEPC and autoclave.
A2.4  Denaturing solution (solution D)
(4M guanidium thiocyanate, 25mM sodium citrate, pH7, 0.5% sarcosyl and 0.1M 2- 
mercaptoethanol). To 250g guanidium thiocyanate (Sigma G6639) add 293ml DEPC 
treated water, 17.6 ml 0.75M sodium citrate pH7 and 26.4ml 10% sarcosyl. Dissolve at 
65°C. Store at room temperature for upto 3 months. Prepare working solution by 
addition of 0.36ml 2-mercaptoethanol (Sigma M3148) per 50ml stock solution -  stable 
for 1  month at RT.
A2.5  Sodium acetate (2M; pH 4.0)
14.04ml acetic acid made up to 80ml with water then pH to 4.0 with NaOH and make 
up to 100ml. Treat with DEPC and autoclave.
A2.6  Chloroform:isoamyl alcohol (49:1)
To 2ml isoamyl alcohol (Sigma 11885) add 98ml chloroform (BDH)
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A2.7  SDS (0.5%)
Dissolve 0.5g SDS (Lauryl sulphate, sodium salt) in 90ml water. Add 0.1 ml DEPC and 
make volume to 100ml with water. Leave overnight in the fume cupboard then 
autoclave.
A3  Reagents for Northern blot analysis 
A3.1  EDTA (0.5%)
Add 18.6g EDTA (Sigma) to 80ml water. Adjust the pH to 8 with 10M NaOH, make to 
100ml with water after addition of 0.1ml DEPC. Leave overnight in the fume hood then 
autoclave.
A3.2  MOPS-acetate-EDTA buffer
(5x MAE: 0.1M MOS, 40mM NA+ acetate, 5mM EDTA, pH 7-7.5). Dissolve 20.6g 3- 
(N-morpholino) propanesulphonic acid (MOPS) (Sigma) and 3.28g sodium acetate 
(Sigma) in 800ml DEPC water. Adjust the pH to 7 with 2M NaOH. Add 10ml 0.5 M 
EDTA and make to 1  litre with DEPC water.
A3.3  Sample Mix
To 66(j,l 10X MOPS (Sigma, pH 7.0) add 232|il formaldehyde, 666pl formamide -  care 
suspected carcinogen  make up in the fume hood.
A3.4  Gel loading solution
(0.25% (w/v) Bromophenol blue, 0.25% (w/v) Xylene cyanole FF, 40% (w/v) sucrose 
in water) (Sigma).
A4  Reagents for Northern transfer
A4.1  Blotting buffer: Saline-sodium phosphate-EDTA buffer (SSPE)
20X concentrate (0.2M phosphate buffer, pH 7.4, containing 2.98 M NaCL and 0.02 M 
EDTA). To 174.15g NaCL (Sigma), 24g sodium phosphate (monobasic, anhydrous; 
Sigma) and 7.44g EDTA (Sigma) add 800ml water. Adjust the pH to 7.4 with 10M 
NaOH to dissolve.  After addition of 1ml DEPC make the volume up to 1  litre with 
water. Leave overnight and autoclave.
A5  Solutions used for Protein Extraction:
A5.1  TBS: lOx stock (Tris 20mM/ 150mM NaCl pH 7.5)
Add 24.2g trizma base (BDH) and 87.66g NaCl to 1000ml distilled water. Adjust to pH
7.5  with HCL. Dilute 1:10 with distilled water to use.
A5.2  Collagenase Buffer (50mM Tris, lOmM CaCh, 3mM NaN3, pH7.5)
Add 5ml 1M Tris pH7.5 to 150mg CaCl2.2H20 and 20ng of NaN3 and make up to 
100ml with distilled water. Adjust the pH to 7.5.
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A5.3  SDS Buffer (20mM Tris pH7.5, 2% SDS)
Add 24.2g trizma base (BDH) and 20g SDS (BDH) to 1000ml of distilled water.
AS.4  Coomasie Blue Staining (0.05% Coomasie Blue, 52% Methanol, 47.3% 
H20, 0.1% HAc)
Add 500mg Coomasie Blue to 520ml Methanol, 473ml distilled water and 1ml HAc.
A5.5  Coomasie Blue Destaining (52% Methanol, 47.3% H20 ,0.1% HAc)
Add 520ml methanol to 473ml distilled water and 1ml HAc.
A5.6  Anode Buffer (xlO; 2M Tris-HCL)
Add 242g trizma base to 1000ml of distilled water adjust with HCL to pH 8.9
A5.7  Cathode Buffer (xlO; 1M Tris-HCL, 1M Tricine, 1% SDS)
Add 12 lg trizma base to 179g tricine and lOg SDS, dissolve in 1  litre of distilled water 
and adjust pH to 8.25.
A5.8  Gel Buffer (3M Tris-HCL, 0.3% SDS)
Add 363.5g trizma base to 3g SDS and make up to 1  litre with distilled water. Adjust 
pH to 8.45.
A5.9  Acrylamide Stock
40% Acrylamide/Bis 29:1 (3.3%C) (Biorad # 161-0146)
A5.10  Composition of Gels
For slab gels Hoefer/ Pharmacia (12 x 10 x 1.5mm) -  16.5 % gels
4 Gels Stacking Gel Running Gel
Aciylamide/Bis  (ml) (40%T,3.3%C) 2.5ml 20ml
Gel Buffer 6.2ml 20ml
Glycerol
— 6.4ml
Water 16.8ml 13.6ml
15% APS 148fxl 300jil
TEMED 12.8|il 30^1
Total volume 25.66ml 60.33ml
Run at 25 V for 1  hour and 90V for 5 hours or overnight at 20V for 12-14 hours.
A5.ll  Rainbow Marker (amersham pharmacia biotech)
Low molecular weight range (2500-45000)
Supplied in 50% glycerol containing the following 
Ovalbumin 
Carbonic anhydrase 
Trypsin inhibitor 
Lysozyme 
Aprotinin 
Insulin (b) chain 
Insulin (a) chain
MW 45000 Yellow
MW 30000 Orange
MW 20100 Blue
MW 14300 Magenta
MW 6500 Blue Black
MW 3500 Blue
MW 2500 Blue
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A6  Reagents for EM
A6.1  Sodium Cacodylate Buffer
Dissolve 42.8g sodium cacodylate (BDH) in 1 litre of distilled water. Add 15ml NaCl to 
give a pH between 7.2 -  7.4. Store in a stopped bottle at 4°C.
A6.2  25% Uranyl Acetate
Dissolve 25g uranyl acetate (BDH) in 100ml methanol. This is a saturated solution and 
will take time to dissolve. During preparation the solution must be protected from the 
light, as uranyl acetate is light sensitive.
A6.3  Lead citrate
Dissolve 1.33g lead nitrate (BDH), 1.76g sodium citrate (BDH) in 30ml distilled water. 
Shake vigorously for one minute. Leave to stand for 30 minutes shaking occasionally. 
Add 8ml NaOH solution and make up to 50ml with distilled water. Store in a stoppered 
bottle at 4°C.
A6.4  Sodium ethoxide
Add 30.5g sodium hydroxide pellets (BDH) to 400ml absolute alcohol. Dissolve the 
pellets in the alcohol overnight.
A6.5  Sodium periodate solution
Add 4.7g sodium periodate (BDH) to 100ml distilled water, mix until dissolved.
A6.6  Tris-buffered saline (TBS) (0.5M)
Dissolve 60.57g tris (BDH) and 8.77g NaCl (BDH) in 800ml distilled water. Adjust pH 
to 7.0-7.4 with HCL, make up to 1L with distilled water.
A7  Glucose oxidase nickel DAB method.
Ref: Shu et al 1988 Neurosci Lett Feb29; 85(2) 169-71
A7.1  0.1M acetate buffer (pH 6.0)
A: 0.1M glacial acetic acid 200ml [1.2ml AA + 200ml cttLO]
B: 0.1M sodium acetate 3800ml [51.68g CH3C00Na(H20)3 +3 800ml cttLO]
Mix A and B, 2000ml kept for acetate buffer and 2000ml used to make reaction 
solution.
A7.2  Reaction buffer (pH 6.0)
To 2000ml acetate buffer (section A7.2) add 50g nickel ammonium sulfate and 0.8g 
ammonium chloride.
A7.3  Reaction solution (pH 6.0)
To 100ml of reaction buffer (section A7.3) add 150mg of (3-D-glucose, 50mg DAB and 
lOjul of glucose oxidase (add the enzyme just before you are ready to start the reaction). 
The reaction should take a minimum of 6 minutes.
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